cancer management and research

Treatment Research

When it comes to cancer drugs, researchers are moving away from a paradigm called the maximum tolerated dose. Instead, they’re focusing more on identifying doses that produce fewer side effects but are still effective against a person’s cancer.

Reshaping the cancer clinical trials infrastructure to overcome key bottlenecks will involve embracing technology and collaboration, and inviting innovation, explain NCI Director Dr. W. Kimryn Rathmell and NCI Special Advisor Dr. Shaalan Beg.

In a new study in mice, researchers showed they could enhance radiation therapy by boosting levels of the BAMBI protein in MDSC immune cells in the tumor microenvironment. After radiation, T cells flooded into the tumor and killed tumors elsewhere in the body.

In a clinical trial, people being treated for cancer who participated in virtual mind–body fitness classes were less likely to be hospitalized, and had shorter stays when they were hospitalized, than people who did not take the classes.

NCI’s James H. Doroshow, M.D., reflects on the accomplishments of NCI-MATCH, a first-of-its-kind precision medicine cancer trial, and gives an overview of three new successor trials: ComboMATCH, MyeloMATCH, and iMATCH.

A new study, conducted largely in mice, may help explain why a currently used molecular marker—called mismatch repair deficiency—doesn’t always work to predict which patients will respond to immunotherapies called immune checkpoint inhibitors.

New approach may increase the effectiveness of T-cell-based immunotherapy treatments against solid tumors.

A cancer-infecting virus engineered to tamp down a tumor’s ability to suppress the immune system shrank tumors in mice, a new study shows. The modified oncolytic virus worked even better when used along with an immune checkpoint inhibitor.

Despite recommendations, a new analysis shows few people with cancer undergo germline testing to learn if their cancer may have been caused by gene changes inherited from a parent. Germline testing can help doctors determine the best treatments for a patient and help identify people whose family members may be at higher risk of cancer.

ComboMATCH will consist of numerous phase 2 cancer treatment trials that aim to identify promising drug combinations that can advance to larger, more definitive clinical trials.

A new study has compared three formulations of an mRNA vaccine designed to treat cancers caused by human papillomavirus (HPV) infections. All three vaccines showed promise in mice.

Researchers have identified a mechanism by which cancer cells develop specific genetic changes needed to become resistant to targeted therapies. They also showed that this process, called non-homologous end-joining (NHEJ), can potentially be disrupted.

For some people with cancer, is 6 months of immunotherapy the only treatment they might ever need? Or 4 weeks of immunotherapy followed by minor surgery? Results from several small clinical trials suggest these scenarios may be bona fide possibilities.

Two research teams have developed ways of overcoming barriers that have limited the effectiveness of CAR T-cell therapies, including engineering ways to potentially make them effective against solid tumors like pancreatic cancer and melanoma.

In people with cancer treated with immune checkpoint inhibitors, a rare, but often fatal, side effect is inflammation in the heart, called myocarditis. Researchers have now identified a potential chief cause of this problem: T cells attacking a protein in heart cells called α-myosin.

Researchers have modified a chemo drug, once abandoned because it caused serious gut side effects, so that it is only triggered in tumors but not normal tissues. After promising results in mice, the drug, DRP-104, is now being tested in a clinical trial.

Two research teams have developed a treatment approach that could potentially enable KRAS-targeted drugs—and perhaps other targeted cancer drugs—flag cancer cells for the immune system. In lab studies, the teams paired these targeted drugs with experimental antibody drugs that helped the immune system mount an attack.

Inflammation is considered a hallmark of cancer. Researchers hope to learn more about whether people with cancer might benefit from treatments that target inflammation around tumors. Some early studies have yielded promising results and more are on the horizon.

NCI researchers are developing an immunotherapy that involves injecting protein bits from cytomegalovirus (CMV) into tumors. The proteins coat the tumor, causing immune cells to attack. In mice, the treatment shrank tumors and kept them from returning.

FDA has approved the combination of the targeted drugs dabrafenib (Tafinlar) and trametinib (Mekinist) for nearly any type of advanced solid tumor with a specific mutation in the BRAF gene. Data from the NCI-MATCH trial informed the approval.

People with cancer who take immunotherapy drugs often develop skin side effects, including itching and painful rashes. New research in mice suggests these side effects may be caused by the immune system attacking new bacterial colonies on the skin.

Researchers have developed tiny “drug factories” that produce an immune-boosting molecule and can be implanted near tumors. The pinhead-sized beads eliminated tumors in mice with ovarian and colorectal cancer and will soon be tested in human studies.

Women are more likely than men to experience severe side effects from cancer treatments such as chemotherapy, targeted therapy, and immunotherapy, a new study finds. Researchers hope the findings will increase awareness of the problem and help guide patient care.

Research to improve CAR T-cell therapy is progressing rapidly. Researchers are working to expand its use to treat more types of cancer and better understand and manage its side effects. Learn how CAR T-cell therapy works, which cancers it’s used to treat, and current research efforts.

Experts say studies are needed on how to best transition telehealth from a temporary solution during the pandemic to a permanent part of cancer care that’s accessible to all who need it.

Removing immune cells called naive T cells from donated stem cells before they are transplanted may prevent chronic graft-versus-host disease (GVHD) in people with leukemia, a new study reports. The procedure did not appear to increase the likelihood of patients’ cancer returning.

A specific form of the HLA gene, HLA-A*03, may make immune checkpoint inhibitors less effective for some people with cancer, according to an NCI-led study. If additional studies confirm the finding, it could help guide the use of these commonly used drugs.

The success of mRNA vaccines for COVID-19 could help accelerate research on using mRNA vaccine technology to treat cancer, including the development of personalized cancer vaccines.

Aneuploidy—when cells have too many or too few chromosomes—is common in cancer cells, but scientists didn’t know why. Two new studies suggest that aneuploidy helps the cells survive treatments like chemotherapy and targeted therapies.

New research suggests that fungi in the gut may affect how tumors respond to cancer treatments. In mice, when bacteria were eliminated with antibiotics, fungi filled the void and impaired the immune response after radiation therapy, the study found.

FDA has approved belumosudil (Rezurock) for the treatment of chronic graft-versus-host disease (GVHD). The approval covers the use of belumosudil for people 12 years and older who have already tried at least two other therapies.

In lab studies, the antibiotic novobiocin showed promise as a treatment for cancers that have become resistant to PARP inhibitors. The drug, which inhibits a protein called DNA polymerase theta, will be tested in NCI-supported clinical trials.

A drug called avasopasem manganese, which has been found to protect normal tissues from radiation therapy, can also make cancer cells more vulnerable to radiation treatment, a new study in mice suggests.

While doctors are familiar with the short-term side effects of immune checkpoint inhibitors, less is known about potential long-term side effects. A new study details the chronic side effects of these drugs in people who received them as part of treatment for melanoma.

Cholesterol-lowering drugs known as PCSK9 inhibitors may improve the effectiveness of cancer immune checkpoint inhibitors, according to studies in mice. The drugs appear to improve the immunotherapy drugs’ ability to find tumors and slow their growth.

Researchers have developed a nanoparticle that trains immune cells to attack cancer. According to the NCI-funded study, the nanoparticle slowed the growth of melanoma in mice and was more effective when combined with an immune checkpoint inhibitor.

A comprehensive analysis of patients with cancer who had exceptional responses to therapy has revealed molecular changes in the patients’ tumors that may explain some of the exceptional responses.

Researchers are developing a new class of cancer drugs called radiopharmaceuticals, which deliver radiation therapy directly and specifically to cancer cells. This Cancer Currents story explores the research on these emerging therapies.

FDA has recently approved two blood tests, known as liquid biopsies, that gather genetic information to help inform treatment decisions for people with cancer. This Cancer Currents story explores how the tests are used and who can get the tests.

Cancer cells with a genetic feature called microsatellite instability-high (MSI-high) depend on the enzyme WRN to survive. A new NCI study explains why and reinforces the idea of targeting WRN as a treatment approach for MSI-high cancer.

Efforts to contain the opioid epidemic may be preventing people with cancer from receiving appropriate prescriptions for opioids to manage their cancer pain, according to a new study of oncologists’ opioid prescribing patterns.

The gene-editing tool CRISPR is changing the way scientists study cancer, and may change how cancer is treated. This in-depth blog post describes how this revolutionary technology is being used to better understand cancer and create new treatments.

FDA’s approval of pembrolizumab (Keytruda) to treat people whose cancer is tumor mutational burden-high highlights the importance of genomic testing to guide treatment, including for children with cancer, according to NCI Director Dr. Ned Sharpless.

Patients with acute graft-versus-host disease (GVHD) that does not respond to steroid therapy are more likely to respond to the drug ruxolitinib (Jakafi) than other available treatments, results from a large clinical trial show.

NCI is developing the capability to produce cellular therapies, like CAR T cells, to be tested in cancer clinical trials at multiple hospital sites. Few laboratories and centers have the capability to make CAR T cells, which has limited the ability to test them more broadly.

An experimental drug may help prevent the chemotherapy drug doxorubicin from harming the heart and does so without interfering with doxorubicin’s ability to kill cancer cells, according to a study in mice.

In people with blood cancers, the health of their gut microbiome appears to affect the risk of dying after receiving an allogeneic hematopoietic stem cell transplant, according to an NCI-funded study conducted at four hospitals across the globe.

A novel approach to analyzing tumors may bring precision cancer medicine to more patients. A study showed the approach, which analyzes gene expression using tumor RNA, could accurately predict whether patients had responded to treatment with targeted therapy or immunotherapy.

Bone loss associated with chemotherapy appears to be induced by cells that stop dividing but do not die, a recent study in mice suggests. The researchers tested drugs that could block signals from these senescent cells and reverse bone loss in mice.

Some experts believe that proton therapy is safer than traditional radiation, but research has been limited. A new observational study compared the safety and effectiveness of proton therapy and traditional radiation in adults with advanced cancer.

In people with cancer, the abscopal effect occurs when radiation—or another type of localized therapy—shrinks a targeted tumor but also causes untreated tumors in the body to shrink. Researchers are trying to better understand this phenomenon and take advantage of it to improve cancer therapy.

An experimental drug, AMG 510, that targets mutated forms of the KRAS protein completely shrank tumors in cancer mouse models and data from a small clinical trial show that it appears to be active against different cancer types with a KRAS mutation.

Researchers have engineered an oncolytic virus to kill cancer cells and boost the immune response against tumors. In a new study, the virus provided T cells around tumors with a hormone they need for their own cell-killing functions.

FDA has approved entrectinib (Rozlytrek) for the treatment of children and adults with tumors bearing an NTRK gene fusion. The approval also covers adults with non-small cell lung cancer harboring a ROS1 gene fusion.

A new NCI-supported study showed that altering cancer cell metabolism by feeding mice a diet very low in the nutrient methionine improved the ability of chemotherapy and radiation therapy to shrink tumors.

An NCI-funded clinical trial is testing the immunotherapy drug nivolumab (Opdivo) in people who have advanced cancer and an autoimmune disease, such as rheumatoid arthritis, lupus, or multiple sclerosis, who are often excluded from such trials.

Researchers have identified a protein called CD24 that may be a new target for cancer immunotherapy. The protein is a ‘don’t eat me’ signal that prevents immune cells called macrophages from engulfing and eating cells.

Injecting cells undergoing necroptosis, a form of cell death, into tumors in mice kickstarted an immune response against the tumors, researchers have found. When combined with immunotherapy, the treatment was effective at eliminating tumors in mice.

Researchers have identified proteins that may play a central role in transforming T cells from powerful destroyers to depleted bystanders that can no longer harm cancer cells. The findings could lead to strategies for boosting cancer immunotherapies.

Did you know that NCI supports clinical trials of new treatments for pet dogs with cancer? Learn more about NCI’s comparative oncology studies and how they may also help people with cancer.

Researchers have discovered a potential way to turn on one of the most commonly silenced tumor-suppressor proteins in cancer, called PTEN. They also found a natural compound, I3C, that in lab studies could flip the on switch.

New findings from a clinical trial suggest that a single dose of radiation therapy may control painful bone metastases as effectively as multiple lower doses of radiation therapy.

The expanding use of cancer immunotherapy has revealed a variety of side effects associated with this treatment approach. Researchers are now trying to better understand how and why these side effects occur and develop strategies for better managing them.

The investigational immunotherapy drug bintrafusp alfa (also called M7824), a bifunctional fusion protein, shrank the tumors of some patients with advanced HPV-related cancers, according to results from a phase 1 clinical trial.

A new study provides insight into how cancer immunotherapy works and suggests ways to enhance the treatment’s effectiveness. The NCI-led study, published in Science, examined the effect of high potassium levels on T cells.

Pain is a common and much-feared symptom among people with cancer and long-term survivors. As more people survive cancer for longer periods, there is a renewed interest in developing new, nonaddictive approaches for managing their chronic pain.

Alzheimer's disease & dementia
Arthritis & Rheumatism
Attention deficit disorders
Autism spectrum disorders
Biomedical technology
Diseases, Conditions, Syndromes
Endocrinology & Metabolism
Gastroenterology
Gerontology & Geriatrics
Health informatics
Inflammatory disorders
Medical economics
Medical research
Medications
Neuroscience
Obstetrics & gynaecology
Oncology & Cancer
Ophthalmology
Overweight & Obesity
Parkinson's & Movement disorders
Psychology & Psychiatry
Radiology & Imaging
Sleep disorders
Sports medicine & Kinesiology
Vaccination
Breast cancer
Cardiovascular disease
Chronic obstructive pulmonary disease
Colon cancer
Coronary artery disease
Heart attack
Heart disease
High blood pressure
Kidney disease
Lung cancer
Multiple sclerosis
Myocardial infarction
Ovarian cancer
Post traumatic stress disorder
Rheumatoid arthritis
Schizophrenia
Skin cancer
Type 2 diabetes
Full List »

Cancer Management and Research

An international, peer-reviewed, open access journal focusing on cancer research and the optimal use of preventative and integrated treatment interventions to achieve improved outcomes, enhanced survival and quality of life for the cancer patient. This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE).

Some content from Wikipedia , licensed under CC BY-SA

Date 6 hours 12 hours 1 day 3 days all
Rank Last day 1 week 1 month all
LiveRank Last day 1 week 1 month all
Popular Last day 1 week 1 month all

High levels of depression found among Canadian older adults with cancer during the COVID-19 pandemic

Older adults who have had cancer had a high risk of experiencing symptoms of depression during the early months of the COVID-19 pandemic according to a study published in Cancer Management and Research.

Sep 7, 2023

Nomogram may help predict survival in primary intestinal non-Hodgkin lymphoma

(HealthDay)—A nomogram can assist clinicians in predicting cancer-specific survival in patients with primary intestinal non-Hodgkin lymphoma (PINHL), according to a study published online Dec. 20 in Cancer Management and ...

Jan 20, 2022

Ovarian cancer surgery outcomes studied

The introduction of optimal surgery in the treatment of advanced ovarian cancer in order to achieve complete cytoreduction has had the main objective of increasing survival and providing a definitive diagnosis for patients ...

Jan 20, 2021

Researchers make breakthrough on immune system and brain tumors

In what could be a breakthrough in the treatment of deadly brain tumors, a team of researchers from Barrow Neurological Institute and Arizona State University has discovered that the immune system reacts differently to different ...

Sep 27, 2012

E-mail newsletter

This website uses cookies to ensure you get the best experience. Learn more about DOAJ’s privacy policy.

Hide this message

You are using an outdated browser. Please upgrade your browser to improve your experience and security.

The Directory of Open Access Journals

Quick search, cancer management and research.

1179-1322 (Online)

ISSN Portal

Publishing with this journal

The journal charges up to:

as publication fees (article processing charges or APCs).

There is a waiver policy for these charges.

Look up the journal's:

Aims & scope
Instructions for authors
Editorial Board
Anonymous peer review

→ This journal checks for plagiarism .

Expect on average 16 weeks from submission to publication.

Best practice

This journal began publishing in open access in 2009 . What does DOAJ define as Open Accesss?

This journal uses a CC BY or a CC BY-NC license.

Attribution Attribution Non-Commercial

→ Look up their open access statement and their license terms .

The author does not retain unrestricted copyrights and publishing rights.

→ Learn more about their copyright policy .

Articles digitally archived in:

→ Find out about their archiving policy .

Deposit policy with:

Sherpa/Romeo

Permanent article identifier:

Journal metadata

Publisher Dove Medical Press , United Kingdom Manuscripts accepted in English

LCC subjects Look up the Library of Congress Classification Outline Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens Keywords epidemiology cancer anticancer agents cancer screening palliative care

WeChat QR code

Cancer Management and Research

Subject Area and Category

Dove Medical Press Ltd.

Publication type

Information.

How to publish in this journal

The set of journals have been ranked according to their SJR and divided into four equal groups, four quartiles. Q1 (green) comprises the quarter of the journals with the highest values, Q2 (yellow) the second highest values, Q3 (orange) the third highest values and Q4 (red) the lowest values.

Category	Year	Quartile
Oncology	2011	Q3
Oncology	2012	Q2
Oncology	2013	Q2
Oncology	2014	Q2
Oncology	2015	Q1
Oncology	2016	Q1
Oncology	2017	Q1
Oncology	2018	Q2
Oncology	2019	Q3
Oncology	2020	Q2
Oncology	2021	Q2
Oncology	2022	Q2
Oncology	2023	Q3

The SJR is a size-independent prestige indicator that ranks journals by their 'average prestige per article'. It is based on the idea that 'all citations are not created equal'. SJR is a measure of scientific influence of journals that accounts for both the number of citations received by a journal and the importance or prestige of the journals where such citations come from It measures the scientific influence of the average article in a journal, it expresses how central to the global scientific discussion an average article of the journal is.

Year	SJR
2011	0.324
2012	0.770
2013	0.778
2014	1.224
2015	1.386
2016	1.455
2017	1.519
2018	0.892
2019	0.797
2020	1.024
2021	0.729
2022	0.754
2023	0.675

Evolution of the number of published documents. All types of documents are considered, including citable and non citable documents.

Year	Documents
2010	32
2011	31
2012	47
2013	43
2014	43
2015	31
2016	16
2017	88
2018	635
2019	939
2020	1198
2021	826
2022	290
2023	116

This indicator counts the number of citations received by documents from a journal and divides them by the total number of documents published in that journal. The chart shows the evolution of the average number of times documents published in a journal in the past two, three and four years have been cited in the current year. The two years line is equivalent to journal impact factor ™ (Thomson Reuters) metric.

Cites per document	Year	Value
Cites / Doc. (4 years)	2010	0.000
Cites / Doc. (4 years)	2011	1.594
Cites / Doc. (4 years)	2012	2.556
Cites / Doc. (4 years)	2013	2.291
Cites / Doc. (4 years)	2014	3.157
Cites / Doc. (4 years)	2015	3.622
Cites / Doc. (4 years)	2016	3.768
Cites / Doc. (4 years)	2017	4.338
Cites / Doc. (4 years)	2018	3.163
Cites / Doc. (4 years)	2019	2.952
Cites / Doc. (4 years)	2020	3.694
Cites / Doc. (4 years)	2021	3.779
Cites / Doc. (4 years)	2022	3.561
Cites / Doc. (4 years)	2023	2.931
Cites / Doc. (3 years)	2010	0.000
Cites / Doc. (3 years)	2011	1.594
Cites / Doc. (3 years)	2012	2.556
Cites / Doc. (3 years)	2013	2.291
Cites / Doc. (3 years)	2014	3.504
Cites / Doc. (3 years)	2015	4.060
Cites / Doc. (3 years)	2016	4.248
Cites / Doc. (3 years)	2017	4.800
Cites / Doc. (3 years)	2018	2.600
Cites / Doc. (3 years)	2019	2.940
Cites / Doc. (3 years)	2020	3.700
Cites / Doc. (3 years)	2021	3.750
Cites / Doc. (3 years)	2022	3.497
Cites / Doc. (3 years)	2023	2.820
Cites / Doc. (2 years)	2010	0.000
Cites / Doc. (2 years)	2011	1.594
Cites / Doc. (2 years)	2012	2.556
Cites / Doc. (2 years)	2013	2.333
Cites / Doc. (2 years)	2014	3.889
Cites / Doc. (2 years)	2015	4.698
Cites / Doc. (2 years)	2016	4.689
Cites / Doc. (2 years)	2017	3.979
Cites / Doc. (2 years)	2018	2.327
Cites / Doc. (2 years)	2019	2.942
Cites / Doc. (2 years)	2020	3.701
Cites / Doc. (2 years)	2021	3.493
Cites / Doc. (2 years)	2022	3.248
Cites / Doc. (2 years)	2023	2.532

Evolution of the total number of citations and journal's self-citations received by a journal's published documents during the three previous years. Journal Self-citation is defined as the number of citation from a journal citing article to articles published by the same journal.

Cites	Year	Value
Self Cites	2010	0
Self Cites	2011	0
Self Cites	2012	2
Self Cites	2013	2
Self Cites	2014	1
Self Cites	2015	5
Self Cites	2016	0
Self Cites	2017	10
Self Cites	2018	16
Self Cites	2019	123
Self Cites	2020	179
Self Cites	2021	219
Self Cites	2022	60
Self Cites	2023	8
Total Cites	2010	0
Total Cites	2011	51
Total Cites	2012	161
Total Cites	2013	252
Total Cites	2014	424
Total Cites	2015	540
Total Cites	2016	497
Total Cites	2017	432
Total Cites	2018	351
Total Cites	2019	2173
Total Cites	2020	6150
Total Cites	2021	10394
Total Cites	2022	10361
Total Cites	2023	6526

Evolution of the number of total citation per document and external citation per document (i.e. journal self-citations removed) received by a journal's published documents during the three previous years. External citations are calculated by subtracting the number of self-citations from the total number of citations received by the journal’s documents.

Cites	Year	Value
External Cites per document	2010	0
External Cites per document	2011	1.594
External Cites per document	2012	2.524
External Cites per document	2013	2.273
External Cites per document	2014	3.496
External Cites per document	2015	4.023
External Cites per document	2016	4.248
External Cites per document	2017	4.689
External Cites per document	2018	2.481
External Cites per document	2019	2.774
External Cites per document	2020	3.593
External Cites per document	2021	3.671
External Cites per document	2022	3.477
External Cites per document	2023	2.817
Cites per document	2010	0.000
Cites per document	2011	1.594
Cites per document	2012	2.556
Cites per document	2013	2.291
Cites per document	2014	3.504
Cites per document	2015	4.060
Cites per document	2016	4.248
Cites per document	2017	4.800
Cites per document	2018	2.600
Cites per document	2019	2.940
Cites per document	2020	3.700
Cites per document	2021	3.750
Cites per document	2022	3.497
Cites per document	2023	2.820

International Collaboration accounts for the articles that have been produced by researchers from several countries. The chart shows the ratio of a journal's documents signed by researchers from more than one country; that is including more than one country address.

Year	International Collaboration
2010	9.38
2011	9.68
2012	6.38
2013	13.95
2014	11.63
2015	16.13
2016	18.75
2017	15.91
2018	12.28
2019	9.69
2020	5.01
2021	4.96
2022	7.59
2023	10.34

Not every article in a journal is considered primary research and therefore "citable", this chart shows the ratio of a journal's articles including substantial research (research articles, conference papers and reviews) in three year windows vs. those documents other than research articles, reviews and conference papers.

Documents	Year	Value
Non-citable documents	2010	0
Non-citable documents	2011	0
Non-citable documents	2012	0
Non-citable documents	2013	2
Non-citable documents	2014	2
Non-citable documents	2015	5
Non-citable documents	2016	3
Non-citable documents	2017	5
Non-citable documents	2018	2
Non-citable documents	2019	4
Non-citable documents	2020	5
Non-citable documents	2021	9
Non-citable documents	2022	11
Non-citable documents	2023	9
Citable documents	2010	0
Citable documents	2011	32
Citable documents	2012	63
Citable documents	2013	108
Citable documents	2014	119
Citable documents	2015	128
Citable documents	2016	114
Citable documents	2017	85
Citable documents	2018	133
Citable documents	2019	735
Citable documents	2020	1657
Citable documents	2021	2763
Citable documents	2022	2952
Citable documents	2023	2305

Ratio of a journal's items, grouped in three years windows, that have been cited at least once vs. those not cited during the following year.

Documents	Year	Value
Uncited documents	2010	0
Uncited documents	2011	8
Uncited documents	2012	11
Uncited documents	2013	24
Uncited documents	2014	19
Uncited documents	2015	22
Uncited documents	2016	14
Uncited documents	2017	12
Uncited documents	2018	25
Uncited documents	2019	144
Uncited documents	2020	261
Uncited documents	2021	399
Uncited documents	2022	461
Uncited documents	2023	445
Cited documents	2010	0
Cited documents	2011	24
Cited documents	2012	52
Cited documents	2013	86
Cited documents	2014	102
Cited documents	2015	111
Cited documents	2016	103
Cited documents	2017	78
Cited documents	2018	110
Cited documents	2019	595
Cited documents	2020	1401
Cited documents	2021	2373
Cited documents	2022	2502
Cited documents	2023	1869

Evolution of the percentage of female authors.

Year	Female Percent
2010	33.70
2011	36.70
2012	41.62
2013	33.13
2014	36.36
2015	50.00
2016	43.94
2017	32.46
2018	39.17
2019	40.30
2020	40.78
2021	40.47
2022	40.06
2023	44.11

Evolution of the number of documents cited by public policy documents according to Overton database.

Documents	Year	Value
Overton	2010	2
Overton	2011	0
Overton	2012	0
Overton	2013	0
Overton	2014	0
Overton	2015	0
Overton	2016	0
Overton	2017	0
Overton	2018	0
Overton	2019	0
Overton	2020	0
Overton	2021	0
Overton	2022	0
Overton	2023	0

Evoution of the number of documents related to Sustainable Development Goals defined by United Nations. Available from 2018 onwards.

Documents	Year	Value
SDG	2018	591
SDG	2019	874
SDG	2020	1091
SDG	2021	760
SDG	2022	263
SDG	2023	105

Name * Required

Email (will not be published) * Required

* Required Cancel

The users of Scimago Journal & Country Rank have the possibility to dialogue through comments linked to a specific journal. The purpose is to have a forum in which general doubts about the processes of publication in the journal, experiences and other issues derived from the publication of papers are resolved. For topics on particular articles, maintain the dialogue through the usual channels with your editor.

Cookie settings

Cookie Policy

Legal Notice

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

View all journals
Explore content
About the journal
Publish with us
Sign up for alerts
Published: 19 June 2024

Why do patients with cancer die?

Adrienne Boire ORCID: orcid.org/0000-0002-9029-1248 1 na1 ,
Katy Burke 2 na1 ,
Thomas R. Cox ORCID: orcid.org/0000-0001-9294-1745 3 , 4 na1 ,
Theresa Guise 5 na1 ,
Mariam Jamal-Hanjani 6 , 7 , 8 na1 ,
Tobias Janowitz ORCID: orcid.org/0000-0002-7820-3727 9 , 10 na1 ,
Rosandra Kaplan 11 na1 ,
Rebecca Lee ORCID: orcid.org/0000-0003-2540-2009 12 , 13 na1 ,
Charles Swanton ORCID: orcid.org/0000-0002-4299-3018 7 , 8 , 14 na1 ,
Matthew G. Vander Heiden ORCID: orcid.org/0000-0002-6702-4192 15 , 16 na1 &
Erik Sahai ORCID: orcid.org/0000-0002-3932-5086 12 na1

Nature Reviews Cancer ( 2024 ) Cite this article

7056 Accesses

1 Citations

449 Altmetric

Metrics details

Cancer models
Cancer therapy

Cancer is a major cause of global mortality, both in affluent countries and increasingly in developing nations. Many patients with cancer experience reduced life expectancy and have metastatic disease at the time of death. However, the more precise causes of mortality and patient deterioration before death remain poorly understood. This scarcity of information, particularly the lack of mechanistic insights, presents a challenge for the development of novel treatment strategies to improve the quality of, and potentially extend, life for patients with late-stage cancer. In addition, earlier deployment of existing strategies to prolong quality of life is highly desirable. In this Roadmap, we review the proximal causes of mortality in patients with cancer and discuss current knowledge about the interconnections between mechanisms that contribute to mortality, before finally proposing new and improved avenues for data collection, research and the development of treatment strategies that may improve quality of life for patients.

This is a preview of subscription content, access via your institution

Access options

Access Nature and 54 other Nature Portfolio journals

Get Nature+, our best-value online-access subscription

24,99 € / 30 days

cancel any time

Subscribe to this journal

Receive 12 print issues and online access

195,33 € per year

only 16,28 € per issue

Buy this article

Purchase on Springer Link
Instant access to full article PDF

Prices may be subject to local taxes which are calculated during checkout

The changing landscape of cancer in the USA — opportunities for advancing prevention and treatment

Causes of death among people living with metastatic cancer

Deceptive measures of progress in the NHS long-term plan for cancer: case-based vs. population-based measures

Dillekås, H., Rogers, M. S. & Straume, O. Are 90% of deaths from cancer caused by metastases? Cancer Med. 8 , 5574–5576 (2019).

Article PubMed PubMed Central Google Scholar

Seyfried, T. N. & Huysentruyt, L. C. On the origin of cancer metastasis. Crit. Rev. Oncog. 18 , 43–73 (2013).

Schnurman, Z. et al. Causes of death in patients with brain metastases. Neurosurgery 93 , 986–993 (2023).

Article PubMed Google Scholar

Gallardo-Valverde, J. M. et al. Obstruction in patients with colorectal cancer increases morbidity and mortality in association with altered nutritional status. Nutr. Cancer 53 , 169–176 (2005).

Swanton, C. et al. Embracing cancer complexity: hallmarks of systemic disease. Cell 187 , 1589–1616 (2024).

Article CAS PubMed Google Scholar

Wheatley-Price, P., Blackhall, F. & Thatcher, N. The influence of sex in non-small cell lung cancer. Onkologie 32 , 547–548 (2009).

Abu-Sbeih, H. et al. Immune checkpoint inhibitor therapy in patients with preexisting inflammatory bowel disease. J. Clin. Oncol. 38 , 576 (2020).

Neugut, A. I. et al. Duration of adjuvant chemotherapy for colon cancer and survival among the elderly. J. Clin. Oncol. 24 , 2368–2375 (2006).

Sullivan, D. R. et al. Association of early palliative care use with survival and place of death among patients with advanced lung cancer receiving care in the Veterans Health Administration. JAMA Oncol. 5 , 1702–1709 (2019).

Sallnow, L. et al. Report of the Lancet Commission on the value of death: bringing death back into life. Lancet 399 , 837–884 (2022).

Abdel-Karim, I. A., Sammel, R. B. & Prange, M. A. Causes of death at autopsy in an inpatient hospice program. J. Palliat. Med. 10 , 894–898 (2007).

Pautex, S. et al. Anatomopathological causes of death in patients with advanced cancer: association with the use of anticoagulation and antibiotics at the end of life. J. Palliat. Med. 16 , 669–674 (2013).

Khorana, A. A., Francis, C. W., Culakova, E., Kuderer, N. M. & Lyman, G. H. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J. Thromb. Haemost. 5 , 632–634 (2007).

Levi, M. & Scully, M. How I treat disseminated intravascular coagulation. Blood 131 , 845–854 (2018).

Cines, D. B., Liebman, H. & Stasi, R. Pathobiology of secondary immune thrombocytopenia. Semin. Hematol. 46 , S2 (2009).

Ghanavat, M. et al. Thrombocytopenia in solid tumors: prognostic significance. Oncol. Rev. 13 , 43–48 (2019).

Article CAS Google Scholar

Anker, M. S. et al. Advanced cancer is also a heart failure syndrome: a hypothesis. J. Cachexia Sarcopenia Muscle 12 , 533 (2021).

Asdahl, P. H. et al. Cardiovascular events in cancer patients with bone metastases — a Danish population-based cohort study of 23,113 patients. Cancer Med. 10 , 4885–4895 (2021).

Sinn, D. H. et al. Different survival of Barcelona clinic liver cancer stage C hepatocellular carcinoma patients by the extent of portal vein invasion and the type of extrahepatic spread. PLoS ONE 10 , e0124434 (2015).

Zisman, A. et al. Renal cell carcinoma with tumor thrombus extension: biology, role of nephrectomy and response to immunotherapy. J. Urol. 169 , 909–916 (2003).

Suárez, C. et al. Carotid blowout syndrome: modern trends in management. Cancer Manag. Res. 10 , 5617 (2018).

Lin, A. L. & Avila, E. K. Neurologic emergencies in the cancer patient: diagnosis and management. J. Intensive Care Med. 32 , 99 (2017).

Gamburg, E. S. et al. The prognostic significance of midline shift at presentation on survival in patients with glioblastoma multiforme. Int. J. Radiat. Oncol. Biol. Phys. 48 , 1359–1362 (2000).

Mokri, B. The Monro-Kellie hypothesis: applications in CSF volume depletion. Neurology 56 , 1746–1748 (2001).

Mastall, M. et al. Survival of brain tumour patients with epilepsy. Brain 144 , 3322–3327 (2021).

Steindl, A. et al. Neurological symptom burden impacts survival prognosis in patients with newly diagnosed non-small cell lung cancer brain metastases. Cancer 126 , 4341–4352 (2020).

Girard, N. et al. Comprehensive histologic assessment helps to differentiate multiple lung primary nonsmall cell carcinomas from metastases. Am. J. Surg. Pathol. 33 , 1752–1764 (2009).

Lee, P. et al. Metabolic tumor burden predicts for disease progression and death in lung cancer. Int. J. Radiat. Oncol. Biol. Phys. 69 , 328–333 (2007).

Kookoolis, A. S., Puchalski, J. T., Murphy, T. E., Araujo, K. L. & Pisani, M. A. Mortality of hospitalized patients with pleural effusions. J. Pulm. Respir. Med. 4 , 184 (2014).

PubMed PubMed Central Google Scholar

Cousins, S. E., Tempest, E. & Feuer, D. J. Surgery for the resolution of symptoms in malignant bowel obstruction in advanced gynaecological and gastrointestinal cancer. Cochrane Database Syst. Rev . https://doi.org/10.1002/14651858.CD002764 (2016).

Baker, M. L. et al. Mortality after acute kidney injury and acute interstitial nephritis in patients prescribed immune checkpoint inhibitor therapy. J. Immunother. Cancer 10 , e004421 (2022).

Bhave, P., Buckle, A., Sandhu, S. & Sood, S. Mortality due to immunotherapy related hepatitis. J. Hepatol. 69 , 976–978 (2018).

Lameire, N. H., Flombaum, C. D., Moreau, D. & Ronco, C. Acute renal failure in cancer patients. Ann. Med. 37 , 13–25 (2005).

Ries, F. & Klastersky, J. Nephrotoxicity induced by cancer chemotherapy with special emphasis on cisplatin toxicity. Am. J. Kidney Dis. 8 , 368–379 (1986).

Wong, J. L. & Evans, S. E. Bacterial pneumonia in patients with cancer: novel risk factors and management. Clin. Chest Med. 38 , 263–277 (2017).

Lee, L. Y. W. et al. COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study. Lancet 395 , 1919–1926 (2020).

Article CAS PubMed PubMed Central Google Scholar

Williamson, E. J. et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature 584 , 430–436 (2020). This study used a platform of 17.4 million pseudo-anonymized health-care records to determine risk factors for COVID-19.

Pelosof, L. C. & Gerber, D. E. Paraneoplastic syndromes: an approach to diagnosis and treatment. Mayo Clin. Proc. 85 , 838–854 (2010).

Donovan, P. J. et al. PTHrP-mediated hypercalcemia: causes and survival in 138 patients. J. Clin. Endocrinol. Metab. 100 , 2024–2029 (2015).

Burtis, W. J. et al. Immunochemical characterization of circulating parathyroid hormone-related protein in patients with humoral hypercalcemia of cancer. N. Engl. J. Med. 322 , 1106–1112 (1990). First study to show that patients with cancer-associated hypercalcaemia had elevated concentrations of plasma parathyroid hormone-related protein .

Ellison, D. H. & Berl, T. The syndrome of inappropriate antidiuresis. N. Engl. J. Med. 356 , 2064–2072 (2007).

Okabayashi, T. et al. Diagnosis and management of insulinoma. World J. Gastroenterol. 19 , 829–837 (2013).

Giometto, B. et al. Paraneoplastic neurologic syndrome in the PNS Euronetwork database: a European study from 20 centers. Arch. Neurol. 67 , 330–335 (2010).

Wang, D. Y. et al. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol. 4 , 1721 (2018).

Feng, S. et al. Pembrolizumab-induced encephalopathy: a review of neurological toxicities with immune checkpoint inhibitors. J. Thorac. Oncol. 12 , 1626–1635 (2017).

Coustal, C. et al. Prognosis of immune checkpoint inhibitors-induced myocarditis: a case series. J. Immunother. Cancer 11 , e004792 (2023).

Kuderer, N. M., Dale, D. C., Crawford, J., Cosler, L. E. & Lyman, G. H. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 106 , 2258–2266 (2006).

Agarwal, M. A. et al. Ventricular arrhythmia in cancer patients: mechanisms, treatment strategies and future avenues. Arrhythm. Electrophysiol. Rev . 12 , e16 (2023).

Zafar, A. et al. The incidence, risk factors, and outcomes with 5-fluorouracil-associated coronary vasospasm. JACC CardioOncol. 3 , 101–109 (2021).

Polk, A. et al. Incidence and risk factors for capecitabine-induced symptomatic cardiotoxicity: a retrospective study of 452 consecutive patients with metastatic breast cancer. BMJ Open 6 , e012798 (2016).

Safdar, A., Bodey, G. & Armstrong, D. Infections in patients with cancer: overview. Princip. Pract. Cancer Infect. Dis. https://doi.org/10.1007/978-1-60761-644-3_1 (2011).

Foster, D. S., Jones, R. E., Ransom, R. C., Longaker, M. T. & Norton, J. A. The evolving relationship of wound healing and tumor stroma. JCI Insight 3 , e99911 (2018).

Park, S. J. & Bejar, R. Clonal hematopoiesis in cancer. Exp. Hematol. 83 , 105 (2020).

Liebman, H. A. Thrombocytopenia in cancer patients. Thromb. Res. https://doi.org/10.1016/S0049-3848(14)50011-4 (2014).

Chakraborty, R. et al. Characterisation and prognostic impact of immunoparesis in relapsed multiple myeloma. Br. J. Haematol. 189 , 1074–1082 (2020).

Allen, B. M. et al. Systemic dysfunction and plasticity of the immune macroenvironment in cancer models. Nat. Med. 26 , 1125–1134 (2020).

Munn, D. H. & Bronte, V. Immune suppressive mechanisms in the tumor microenvironment. Curr. Opin. Immunol. 39 , 1–6 (2016).

Kochar, R. & Banerjee, S. Infections of the biliary tract. Gastrointest. Endosc. Clin. N. Am. 23 , 199–218 (2013).

Valvani, A., Martin, A., Devarajan, A. & Chandy, D. Postobstructive pneumonia in lung cancer. Ann. Transl. Med. 7 , 357–357 (2019).

Rolston, K. V. I. Infections in cancer patients with solid tumors: a review. Infect. Dis. Ther. 6 , 69–83 (2017).

Wu, X. et al. The association between major complications of immobility during hospitalization and quality of life among bedridden patients: a 3 month prospective multi-center study. PLoS One 13 , e0205729 (2018).

The clinicopathological and prognostic role of thrombocytosis in patients with cancer: a meta-analysis. Oncol. Lett . 13 , 5002–5008 (2017).

Kasthuri, R. S., Taubman, M. B. & Mackman, N. Role of tissue factor in cancer. J. Clin. Oncol. 27 , 4834 (2009).

Wade, J. C. Viral infections in patients with hematological malignancies. Hematology 2006 , 368–374 (2006).

Article Google Scholar

Ersvaer, E., Liseth, K., Skavland, J., Gjertsen, B. T. & Bruserud, Ø. Intensive chemotherapy for acute myeloid leukemia differentially affects circulating TC1, TH1, TH17 and TREG cells. BMC Immunol. 11 , 1–12 (2010).

Kuter, D. J. Treatment of chemotherapy-induced thrombocytopenia in patients with non-hematologic malignancies. Haematologica 107 , 1243 (2022).

Rodgers, G. M. et al. Cancer- and chemotherapy-induced anemia. J. Natl Compr. Canc. Netw. 10 , 628–653 (2012).

Nesher, L. & Rolston, K. V. I. The current spectrum of infection in cancer patients with chemotherapy related neutropenia. Infection 42 , 5–13 (2014).

Blijlevens, N. M. A., Logan, R. M. & Netea, M. G. Mucositis: from febrile neutropenia to febrile mucositis. J. Antimicrob. Chemother. 63 , i36–i40 (2009).

Petrelli, F. et al. Association of steroid use with survival in solid tumours. Eur. J. Cancer 141 , 105–114 (2020).

Bolton, K. L. et al. Cancer therapy shapes the fitness landscape of clonal hematopoiesis. Nat. Genet. 52 , 1219–1226 (2020). This study identified the molecular characteristics of clonal haematopoiesis that increased risk of therapy-related myeloid neoplasms, with different characteristics associated with different treatment exposures.

Bhatia, R. et al. Do cancer and cancer treatments accelerate aging? Curr. Oncol. Rep. 24 , 1401 (2022).

Eisenstein, T. K. The role of opioid receptors in immune system function. Front. Immunol. 10 , 485158 (2019).

Böll, B. et al. Central venous catheter-related infections in hematology and oncology: 2020 updated guidelines on diagnosis, management, and prevention by the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO). Ann. Hematol. 100 , 239 (2021).

Ruiz-Giardin, J. M. et al. Blood stream infections associated with central and peripheral venous catheters. BMC Infect. Dis. 19 , 1–9 (2019).

Lee, D. W. et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood 124 , 188–195 (2014).

Brahmer, J. R. et al. Safety profile of pembrolizumab monotherapy based on an aggregate safety evaluation of 8937 patients. Eur. J. Cancer 199 , 113530 (2024). Analysis of the toxicity profile of anti-PD1 therapy in more than 8,000 patients.

Larkin, J. et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N. Engl. J. Med. 381 , 1535–1546 (2019).

Vozy, A. et al. Increased reporting of fatal hepatitis associated with immune checkpoint inhibitors. Eur. J. Cancer 123 , 112–115 (2019).

Palaskas, N., Lopez-Mattei, J., Durand, J. B., Iliescu, C. & Deswal, A. Immune checkpoint inhibitor myocarditis: pathophysiological characteristics, diagnosis, and treatment. J. Am. Heart Assoc. 9 , e013757 (2020).

Janssen, J. B. E. et al. Immune checkpoint inhibitor-related Guillain–Barré syndrome: a case series and review of the literature. J. Immunother. 44 , 276–282 (2021).

Camelliti, S. et al. Mechanisms of hyperprogressive disease after immune checkpoint inhibitor therapy: what we (don’t) know. J. Exp. Clin. Cancer Res. 39 , 236 (2020).

Kitamura, W. et al. Bone marrow microenvironment disruption and sustained inflammation with prolonged haematologic toxicity after CAR T-cell therapy. Br. J. Haematol. 202 , 294–307 (2023).

Seano, G. et al. Solid stress in brain tumours causes neuronal loss and neurological dysfunction and can be reversed by lithium. Nat. Biomed. Eng. 3 , 230 (2019).

Madhusoodanan, S., Ting, M. B., Farah, T. & Ugur, U. Psychiatric aspects of brain tumors: a review. World J. Psychiatry 5 , 273 (2015).

Gerstenecker, A. et al. Cognition in patients with newly diagnosed brain metastasis: profiles and implications. J. Neurooncol. 120 , 179 (2014).

Krishna, S. et al. Glioblastoma remodelling of human neural circuits decreases survival. Nature 617 , 599–607 (2023). This study demonstrated that high-grade gliomas remodel neural circuits in the human brain, which promotes tumour progression and impairs cognition.

Taylor, K. R. et al. Glioma synapses recruit mechanisms of adaptive plasticity. Nature 623 , 366–374 (2023). This study showed that brain-derived neurotrophic factor (BDNF)–tropomyosin-related kinase B (TRKB) signalling promotes malignant synaptic plasticity and augments tumour progression.

Hanahan, D. & Monje, M. Cancer hallmarks intersect with neuroscience in the tumor microenvironment. Cancer Cell 41 , 573–580 (2023).

Ahles, T. A. & Root, J. C. Cognitive effects of cancer and cancer treatments. Annu. Rev. Clin. Psychol . 14 , 425–451 (2018).

Allexandre, D. et al. EEG correlates of central origin of cancer-related fatigue. Neural Plast. 2020 , 8812984 (2020).

Büttner-Teleagă, A., Kim, Y. T., Osel, T. & Richter, K. Sleep disorders in cancer — a systematic review. Int. J. Environ. Res. Public Health 18 , 11696 (2021).

Walsh, D. & Nelson, K. A. Autonomic nervous system dysfunction in advanced cancer. Support. Care Cancer 10 , 523–528 (2002).

Ghandour, F. et al. Presenting psychiatric and neurological symptoms and signs of brain tumors before diagnosis: a systematic review. Brain Sci. 11 , 1–20 (2021).

Akechi, T. et al. Somatic symptoms for diagnosing major depression in cancer patients. Psychosomatics 44 , 244–248 (2003).

Nho, J. H., Kim, S. R. & Kwon, Y. S. Depression and appetite: predictors of malnutrition in gynecologic cancer. Support. Care Cancer 22 , 3081–3088 (2014).

Thaker, P. H. et al. Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. Nat. Med. 12 , 939–944 (2006). This study linked chronic behavioural stress to higher levels of tissue catecholamines and tumour angiogenesis, resulting in greater tumor burden and invasion in ovarian cancer.

Chang, A. et al. Beta-blockade enhances anthracycline control of metastasis in triple-negative breast cancer. Sci. Transl. Med . 15 , eadf1147 (2023).

Magnon, C. et al. Autonomic nerve development contributes to prostate cancer progression. Science 341 , 1236361 (2013). This study showed that the formation of autonomic nerve fibres in the prostate gland regulates prostate cancer development and dissemination in mouse models.

Baracos, V. E., Martin, L., Korc, M., Guttridge, D. C. & Fearon, K. C. H. Cancer-associated cachexia. Nat. Rev. Dis. Prim. 4 , 17105 (2018).

Fearon, K. et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 12 , 489–495 (2011). International consensus definitions of cancer cachexia.

Bossi, P., Delrio, P., Mascheroni, A. & Zanetti, M. The spectrum of malnutrition/cachexia/sarcopenia in oncology according to different cancer types and settings: a narrative review. Nutrients 13 , 1980 (2021).

Farkas, J. et al. Cachexia as a major public health problem: frequent, costly, and deadly. J. Cachexia Sarcopenia Muscle 4 , 173–178 (2013).

Dennison, E. M., Sayer, A. A. & Cooper, C. Epidemiology of sarcopenia and insight into possible therapeutic targets. Nat. Rev. Rheumatol. 13 , 340–347 (2017).

Farasat, M. et al. Long-term cardiac arrhythmia and chronotropic evaluation in patients with severe anorexia nervosa (LACE-AN): a pilot study. J. Cardiovasc. Electrophysiol. 31 , 432–439 (2020).

Mehler, P. S., Anderson, K., Bauschka, M., Cost, J. & Farooq, A. Emergency room presentations of people with anorexia nervosa. J. Eat. Disord. 11 , 16 (2023).

Ferrer, M. et al. Cachexia: a systemic consequence of progressive, unresolved disease. Cell 186 , 1824–1845 (2023).

Bourke, C. D., Berkley, J. A. & Prendergast, A. J. Immune dysfunction as a cause and consequence of malnutrition. Trends Immunol. 37 , 386–398 (2016).

Tisdale, M. J. Biology of cachexia. J. Natl Cancer Inst. 89 , 1763–1773 (1997).

Babic, A. et al. Adipose tissue and skeletal muscle wasting precede clinical diagnosis of pancreatic cancer. Nat. Commun. 14 , 4754 (2023).

Waning, D. L. et al. Excess TGF-β mediates muscle weakness associated with bone metastases in mice. Nat. Med. 21 , 1262 (2015). This study showed that bone metastases cause TGFβ to be released from the bone marrow, resulting in leakage of calcium from skeletal muscle cells contributing to muscle weakness.

Greco, S. H. et al. TGF-β blockade reduces mortality and metabolic changes in a validated murine model of pancreatic cancer cachexia. PLoS ONE 10 , e0132786 (2015).

Johnen, H. et al. Tumor-induced anorexia and weight loss are mediated by the TGF-beta superfamily cytokine MIC-1. Nat. Med. 13 , 1333–1340 (2007). This study showed that GDF15 was elevated in patients with cancer-associated weight loss and that this was a central regulator of appetite and therefore a potential therapeutic target.

Al-Sawaf, O. et al. Body composition and lung cancer-associated cachexia in TRACERx. Nat. Med. 29 , 846–858 (2023). This study showed an association among lower skeletal muscle area, subcutaneous adipose tissue and visceral adipose tissue and decreased survival in patients with non-small-cell lung cancer and these were associated with higher levels of circulating GDF15.

Ahmed, D. S., Isnard, S., Lin, J., Routy, B. & Routy, J. P. GDF15/GFRAL pathway as a metabolic signature for cachexia in patients with cancer. J. Cancer 12 , 1125–1132 (2021).

Rebbapragada, A., Benchabane, H., Wrana, J. L., Celeste, A. J. & Attisano, L. Myostatin signals through a transforming growth factor β-like signaling pathway to block adipogenesis. Mol. Cell. Biol. 23 , 7230 (2003).

Queiroz, A. L. et al. Blocking ActRIIB and restoring appetite reverses cachexia and improves survival in mice with lung cancer. Nat. Commun. 13 , 1–17 (2022).

Loumaye, A. et al. Role of activin A and myostatin in human cancer cachexia. J. Clin. Endocrinol. Metab. 100 , 2030–2038 (2015).

Barton, B. E. & Murphy, T. F. Cancer cachexia is mediated in part by the induction of IL-6-like cytokines from the spleen. Cytokine 16 , 251–257 (2001).

Webster, J. M., Kempen, L. J. A. P., Hardy, R. S. & Langen, R. C. J. Inflammation and skeletal muscle wasting during cachexia. Front. Physiol. 11 , 597675 (2020).

Strassmann, G., Masui, Y., Chizzonite, R. & Fong, M. Mechanisms of experimental cancer cachexia local involvement of 11-1 in colon-26 tumor. J. Immunol. 150 , 2341–2345 (1993).

Stovroff, M. C., Fraker, D. L., Swedenborg, J. A. & Norton, J. A. Cachectin/tumor necrosis factor: a possible mediator of cancer anorexia in the rat. Cancer Res. 48 , 4567–4572 (1988).

CAS PubMed Google Scholar

Wyke, S. M. & Tisdale, M. J. NF-κB mediates proteolysis-inducing factor induced protein degradation and expression of the ubiquitin–proteasome system in skeletal muscle. Br. J. Cancer 92 , 711 (2005).

Cai, D. et al. IKKβ/NF-κB activation causes severe muscle wasting in mice. Cell 119 , 285–298 (2004). This study showed that activation of NF-κB, through muscle-specific transgenic expression of activated inhibitor of NF-κB kinase subunit β (IKKβ), causes profound muscle wasting in mice.

Patel, H. J. & Patel, B. M. TNF-α and cancer cachexia: molecular insights and clinical implications. Life Sci. 170 , 56–63 (2017).

Mergenthaler, P., Lindauer, U., Dienel, G. A. & Meisel, A. Sugar for the brain: the role of glucose in physiological and pathological brain function. Trends Neurosci. 36 , 587 (2013).

Sillos, E. M. et al. Lactic acidosis: a metabolic complication of hematologic malignancies case report and review of the literature. Cancer 92 , 2237–46 (2000).

Rampello, E., Fricia, T. & Malaguarnera, M. The management of tumor lysis syndrome. Nat. Clin. Pract. Oncol. 3 , 438–447 (2006).

Delano, M. J. & Moldawer, L. L. The origins of cachexia in acute and chronic inflammatory diseases. Nutr. Clin. Pract. 21 , 68–81 (2006).

Lombardi, A., Villa, S., Castelli, V., Bandera, A. & Gori, A. T-cell exhaustion in Mycobacterium tuberculosis and nontuberculous mycobacteria infection: pathophysiology and therapeutic perspectives. Microorganisms 9 , 2460 (2021).

Moldawer, L. L. & Sattler, F. R. Human immunodeficiency virus-associated wasting and mechanisms of cachexia associated with inflammation. Semin. Oncol. 25 , 73–81 (1998).

von Kobbe, C. Targeting senescent cells: approaches, opportunities, challenges. Aging 11 , 12844 (2019).

Shafqat, S., Chicas, E. A., Shafqat, A. & Hashmi, S. K. The Achilles’ heel of cancer survivors: fundamentals of accelerated cellular senescence. J. Clin. Invest. 132 , e158452 (2022).

Wang, L., Lankhorst, L. & Bernards, R. Exploiting senescence for the treatment of cancer. Nat. Rev. Cancer 22 , 340–355 (2022).

Terry, W., Olson, L. G., Ravenscroft, P., Wilss, L. & Boulton-Lewis, G. Hospice patients’ views on research in palliative care. Intern. Med. J. 36 , 406–413 (2006).

White, C. & Hardy, J. What do palliative care patients and their relatives think about research in palliative care? A systematic review. Support. Care Cancer 18 , 905–911 (2010).

Foster, B., Bagci, U., Mansoor, A., Xu, Z. & Mollura, D. J. A review on segmentation of positron emission tomography images. Comput. Biol. Med. 50 , 76–96 (2014).

Bera, K., Braman, N., Gupta, A., Velcheti, V. & Madabhushi, A. Predicting cancer outcomes with radiomics and artificial intelligence in radiology. Nat. Rev. Clin. Oncol. 19 , 132–146 (2022).

Kaczanowska, S. et al. Immune determinants of CAR-T cell expansion in solid tumor patients receiving GD2 CAR-T cell therapy. Cancer Cell 42 , 35–51.e8 (2024).

Dutta, S. & Sengupta, P. Men and mice: relating their ages. Life Sci. 152 , 244–248 (2016).

Alpert, A. et al. A clinically meaningful metric of immune age derived from high-dimensional longitudinal monitoring. Nat. Med. 25 , 487–495 (2019).

Gyawali, B., Hey, S. P. & Kesselheim, A. S. Evaluating the evidence behind the surrogate measures included in the FDA’s table of surrogate endpoints as supporting approval of cancer drugs. eClinicalMedicine 21 , 100332 (2020).

Hong, W. et al. Automated measurement of mouse social behaviors using depth sensing, video tracking, and machine learning. Proc. Natl Acad. Sci. USA 112 , E5351–E5360 (2015).

Johnson, D. E., O’Keefe, R. A. & Grandis, J. R. Targeting the IL-6/JAK/STAT3 signalling axis in cancer. Nat. Rev. Clin. Oncol. 15 , 234–248 (2018).

Bowden, M. B. et al. Demographic and clinical factors associated with suicide in gastric cancer in the United States. J. Gastrointest. Oncol. 8 , 897–901 (2017).

Zaorsky, N. G. et al. Suicide among cancer patients. Nat. Commun. 10 , 1–7 (2019).

CAS Google Scholar

Hu, X. et al. Suicide risk among individuals diagnosed with cancer in the US, 2000 – 2016 . JAMA Netw. Open 6 , e2251863 (2023).

Google Scholar

Abdel-Rahman, O. Socioeconomic predictors of suicide risk among cancer patients in the United States: a population-based study. Cancer Epidemiol. 63 , 101601 (2019).

Pinquart, M. & Duberstein, P. R. Depression and cancer mortality: a meta-analysis. Psychol. Med. 40 , 1797–1810 (2010).

Fitzgerald, P. et al. The relationship between depression and physical symptom burden in advanced cancer. BMJ Support. Palliat. Care 5 , 381–388 (2015).

Chida, Y., Hamer, M., Wardle, J. & Steptoe, A. Do stress-related psychosocial factors contribute to cancer incidence and survival? Nat. Clin. Pract. Oncol. 5 , 466–475 (2008).

He, X. Y. et al. Chronic stress increases metastasis via neutrophil-mediated changes to the microenvironment. Cancer Cell 42 , 474–486.e12 (2024). This study found that chronic stress shifts the normal circadian rhythm of neutrophils resulting in increased neutrophil extracellular trap (NET) formation via glucocorticoid release, resulting in a metastasis-promoting microenvironment.

Fann, J. R., Ell, K. & Sharpe, M. Integrating psychosocial care into cancer services. J. Clin. Oncol. 30 , 1178–1186 (2012).

Jacobsen, P. B. & Wagner, L. I. A new quality standard: the integration of psychosocial care into routine cancer care. J. Clin. Oncol. 30 , 1154–1159 (2012).

Gorin, S. S. et al. Meta-analysis of psychosocial interventions to reduce pain in patients with cancer. J. Clin. Oncol. 30 , 539–547 (2012).

Li, M. et al. Systematic review and meta-analysis of collaborative care interventions for depression in patients with cancer. Psychooncology 26 , 573–587 (2017).

Bova, G. S. et al. Optimal molecular profiling of tissue and tissue components: defining the best processing and microdissection methods for biomedical applications. Mol. Biotechnol. 29 , 119–152 (2005).

Gundem, G. et al. The evolutionary history of lethal metastatic prostate cancer. Nature 520 , 353–357 (2015). This study found that metastasis-to-metastasis spread was common in prostate cancer evolution and that lesions affecting tumour suppressor genes occurred as single events, whereas mutations in genes involved in androgen receptor signalling commonly involved multiple, convergent events in different metastases.

Turajlic, S. et al. Tracking cancer evolution reveals constrained routes to metastases: TRACERx renal. Cell 173 , 581–594.e12 (2018). This study examined evolutionary trajectories of 100 renal cancers and found that metastasis competence was driven by chromosome complexity, not by driver mutation load, and that loss of 9p and 14q was a common driver.

Spain, L. et al. Late-stage metastatic melanoma emerges through a diversity of evolutionary pathways. Cancer Discov. 13 , 1364–1385 (2023). This study examined evolutionary trajectories of melanoma metastasis and observed frequent whole-genome doubling and widespread loss of heterozygosity, often involving antigen-presentation machinery.

Download references

Acknowledgements

A.B. is funded by National Institutes of Health/National Cancer Institute P30 CA008748 and R01-CA245499. K.B. is employed by the UK National Health Service. T.R.C. acknowledges funding support from the National Health and Medical Research Council (NHMRC) Ideas (2000937), Project (1129766, 1140125), Development (2013881) and Fellowship (1158590) schemes, a Cancer Institute NSW Career Development Fellowship (CDF171105), Cancer Council NSW project support (RG19-09, RG23-11) and Susan G. Komen for the Cure (CCR17483294). T.G. is funded by the Cancer Prevention and Research Institute of Texas Grant 00011633. M.J.-H. has received funding from CRUK, NIH National Cancer Institute, IASLC International Lung Cancer Foundation, Lung Cancer Research Foundation, Rosetrees Trust, UKI NETs and NIHR. T.J. acknowledges funding from Cancer Grand Challenges (NIH: 1OT2CA278690-01; CRUK: CGCATF-2021/100019), the Mark Foundation for Cancer Research (20-028-EDV), the Osprey Foundation, Fortune Footwear, Cold Spring Harbour Laboratory (CSHL) and developmental funds from CSHL Cancer Center Support Grant 5P30CA045508. R.K. is funded by the Intramural Research Program, the National Cancer Institute, NIH Clinical Center and the National Institutes of Health (NIH NCI ZIABC011332-06 and NIH NCI ZIABC011334-10). R.L. is supported by a Wellcome Early Career Investigator Award (225724/Z/22/Z). E.S. is supported by the Francis Crick Institute, which receives its core funding from Cancer Research UK (CC2040), the UK Medical Research Council (CC2040) and the Wellcome Trust (CC2040) and the European Research Council (ERC Advanced Grant CAN_ORGANISE, Grant agreement number 101019366). E.S. reports personal grants from Mark Foundation and the European Research Council. C.S. is a Royal Society Napier Research Professor (RSRP\R\210001). His work is supported by the Francis Crick Institute that receives its core funding from Cancer Research UK (CC2041), the UK Medical Research Council (CC2041) and the Wellcome Trust (CC2041) and the European Research Council under the European Union’s Horizon 2020 research and innovation programme (ERC Advanced Grant PROTEUS Grant agreement number 835297). M.G.V.H. reports support from the Lustgarten Foundation, the MIT Center for Precision Cancer Medicine, the Ludwig Center at MIT and NIH grants R35 CA242379 and P30 CA1405141.

Author information

These authors contributed equally: Adrienne Boire, Katy Burke, Thomas R. Cox, Theresa Guise, Mariam Jamal-Hanjani, Tobias Janowitz, Rosandra Kaplan, Rebecca Lee, Charles Swanton, Matthew G. Vander Heiden, Erik Sahai.

Authors and Affiliations

Memorial Sloan Kettering Cancer Center, New York, NY, USA

Adrienne Boire

University College London Hospitals NHS Foundation Trust and Central and North West London NHS Foundation Trust Palliative Care Team, London, UK

Cancer Ecosystems Program, The Garvan Institute of Medical Research and The Kinghorn Cancer Centre, Darlinghurst, New South Wales, Australia

Thomas R. Cox

School of Clinical Medicine, St Vincent’s Healthcare Clinical Campus, UNSW Medicine and Health, UNSW Sydney, Sydney, New South Wales, Australia

Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Theresa Guise

Cancer Metastasis Laboratory, University College London Cancer Institute, London, UK

Mariam Jamal-Hanjani

Department of Oncology, University College London Hospitals, London, UK

Mariam Jamal-Hanjani & Charles Swanton

Cancer Research UK Lung Centre of Excellence, University College London Cancer Institute, London, UK

Cold Spring Harbour Laboratory, Cold Spring Harbour, New York, NY, USA

Tobias Janowitz

Northwell Health Cancer Institute, New York, NY, USA

Paediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA

Rosandra Kaplan

Tumour Cell Biology Laboratory, The Francis Crick Institute, London, UK

Rebecca Lee & Erik Sahai

Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK

Rebecca Lee

Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK

Charles Swanton

Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA

Matthew G. Vander Heiden

Dana-Farber Cancer Institute, Boston, MA, USA

You can also search for this author in PubMed Google Scholar

Contributions

All authors researched data for the article. A.B., K.B., T.R.C., T.G., T.J., C.S., M.G.V.H, R.K., M.J.-H. and E.S. contributed substantially to discussion of the content. T.C., R.L. and E.S. wrote the article. All authors reviewed and/or edited the manuscript before submission.

Corresponding authors

Correspondence to Thomas R. Cox or Erik Sahai .

Ethics declarations

Competing interests.

A.B. is an inventor on pending patents 63/449,817, 63/052,139 as well as awarded patents 11,305,014 and 10,413,522; all issued to the Sloan Kettering Institute. She has received personal fees from Apelis Pharmaceuticals and serves as an unpaid member of the Evren Technologies SAB. K.B., T.R.C., T.G., T.J. and R.K. declare no competing interests. M.J.-H. reports support from Achilles Therapeutics Scientific Advisory Board and Steering Committee, Pfizer, Astex Pharmaceuticals, Oslo Cancer Cluster and Bristol Myers Squibb outside the submitted work. R.L. reports personal fees from Pierre Fabre and has research funding from BMS, Astra Zeneca and Pierre Fabre outside the submitted work. E.S. reports grants from Novartis, Merck Sharp Dohme, AstraZeneca and personal fees from Phenomic outside the submitted work. C.S. reports grants and personal fees from Bristol Myers Squibb, AstraZeneca, Boehringer-Ingelheim, Roche-Ventana, personal fees from Pfizer, grants from Ono Pharmaceutical, Personalis, grants, personal fees and other support from GRAIL, other support from AstraZeneca and GRAIL, personal fees and other support from Achilles Therapeutics, Bicycle Therapeutics, personal fees from Genentech, Medixci, China Innovation Centre of Roche (CiCoR) formerly Roche Innovation Centre, Metabomed, Relay Therapeutics, Saga Diagnostics, Sarah Canon Research Institute, Amgen, GlaxoSmithKline, Illumina, MSD, Novartis, other support from Apogen Biotechnologies and Epic Bioscience outside the submitted work; in addition, C.S. has a patent for PCT/US2017/028013 licensed to Natera Inc., UCL Business, a patent for PCT/EP2016/059401 licensed to Cancer Research Technology, a patent for PCT/EP2016/071471 issued to Cancer Research Technology, a patent for PCT/GB2018/051912 pending, a patent for PCT/GB2018/052004 issued to Francis Crick Institute, University College London, Cancer Research Technology Ltd, a patent for PCT/GB2020/050221 issued to Francis Crick Institute, University College London, a patent for PCT/EP2022/077987 pending to Cancer Research Technology, a patent for PCT/GB2017/053289 licensed, a patent for PCT/EP2022/077987 pending to Francis Crick Institute, a patent for PCT/EP2023/059039 pending to Francis Crick Institute and a patent for PCT/GB2018/051892 pending to Francis Crick Institute. C.S. is Co-chief Investigator of the NHS Galleri trial funded by GRAIL. He is Chief Investigator for the AstraZeneca MeRmaiD I and II clinical trials and Chair of the Steering Committee. C.S. is cofounder of Achilles Therapeutics and holds stock options. M.G.V.H. is a scientific adviser for Agios Pharmaceuticals, iTeos Therapeutics, Sage Therapeutics, Faeth Therapeutics, Droia Ventures and Auron Therapeutics on topics unrelated to the presented work.

Peer review

Peer review information.

Nature Reviews Cancer thanks Vickie Baracos, Clare M. Isacke, who co-reviewed with Amanda Fitzpatrick and Erica Sloan and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

An autoimmune encephalitis characterized by complex neuropsychiatric features and the presence of immunoglobulin G (IgG) antibodies against the NR1 subunit of the NMDA receptors in the central nervous system.

Partial collapse or incomplete inflation of the lung.

Pressure-induced movement of brain tissue.

An ageing-associated process in which haematopoiesis becomes dominated by one or a small number of genetically distinct stem or progenitor cells. Clonal haematopoiesis is linked to an increased risk of haematological malignancies.

Inability of the heart to pump blood properly.

Constriction of the arteries that supply blood to the heart.

(CRH). One of the major factors that drives the response of the body to stress.

(DIC). A rare but serious condition in which abnormal blood clotting occurs throughout the blood vessels of the body.

Inflammation of the brain.

An abnormal connection that forms between two body parts, such as an organ or blood vessel and another often unrelated structure in close proximity.

A rare disorder in which the immune system of a body attacks the nerves, which can lead to paralysis.

The stopping of flow of blood, typically associated with the bodies response to prevent and stop bleeding.

A build-up of fluid within the cavities of the brain.

Elevated calcium levels in the blood, often caused by overactive parathyroid glands. Hypercalcaemia is linked to kidney stones, weakened bones, altered digestion and potentially altered cardiac and brain function.

(HPD). Rapid tumour progression sometimes observed during immune checkpoint inhibitor treatment.

The condition that occurs when the level of sodium in the blood is low.

Harm, which is often unavoidable, caused by cancer treatments.

The marked suppression of polyclonal immunoglobulins in the body.

(LEMS). A neuromuscular junction disorder affecting communication between nerves and muscles, which manifests as a result of a paraneoplastic syndrome or a primary autoimmune disorder. Many cases are associated with small-cell lung cancer.

When cancer cells spread to the tissue layers covering the brain and spinal cord (the leptomeninges).

Also known as pulmonary oedema is a condition caused by excess fluid in the lungs. This fluid collects in the alveoli compromising function and making it difficult to breathe.

The observation of displacement of brain tissue across the centre line of the brain, suggestive of uneven intracranial pressure.

Decreased blood flow to the myocardium, commonly called a heart attack.

Inflammation specifically of the middle layer of the heart wall.

A group of rare disorders that occur when the immune system reacts to changes in the body triggered by the presence of a neoplasm.

A dense network of nerves that transmit information from the brain (efferent neurons) to the periphery and conversely transmit information from the periphery to the brain (afferent neurons). A component of the peripheral nervous system is the autonomic nervous system.

A build-up of fluid between the tissues that line the lungs and the chest wall.

A condition characterized by loss of skeletal muscle mass and function.

The lodging of a circulating blood clot within a vessel leading to obstruction. Thromboembolisms may occur in veins (venous thromboembolism) and arteries (arterial thromboembolism).

A key component of the pathway regulating blood clotting, specifically the receptor and cofactor for factor VII/VIIa.

A syndrome occurs when tumour cells release their contents into the bloodstream, either spontaneously or more typically, in response to therapeutic intervention.

Devices worn on the body, typically in the form of accessories or clothing, that incorporate advanced electronics and technology to monitor, track or enhance various aspects of human life. Examples include smartwatches and fitness trackers.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Cite this article.

Boire, A., Burke, K., Cox, T.R. et al. Why do patients with cancer die?. Nat Rev Cancer (2024). https://doi.org/10.1038/s41568-024-00708-4

Download citation

Accepted : 15 May 2024

Published : 19 June 2024

DOI : https://doi.org/10.1038/s41568-024-00708-4

Share this article

Anyone you share the following link with will be able to read this content:

Sorry, a shareable link is not currently available for this article.

Provided by the Springer Nature SharedIt content-sharing initiative

This article is cited by

The road less travelled.

Nature Reviews Cancer (2024)

Quick links

Explore articles by subject
Guide to authors
Editorial policies

Cancer Management and Research

Number of papers	2300
H4-Index
TQCC
Average citations	6.849
Median citations
Impact Factor	3.300 (based on 2022)

( API-Link )

Impact Factor : 3.300 (based on Web of Science 2022)

# 51 / 223 (Q1) in Oncology

Partner: • University Press Alert

Cancer treatment has come far, fast: Better prevention, early detection, new treatment

Cayden Addison was 3 when he was diagnosed with leukemia and doctors began hammering his small body with chemotherapy.

Despite the terrible side effects and a near-death experience, two years of chemo only bought him about nine treatment-free months before his cancer returned in February.

By then, though, doctors had another tool.

Instead of blasting him with powerful chemotherapy, they were able to direct treatment to his immune system, turning its specialized cells into targeted missiles to attack the tumor cells. Other than a few days of nausea, he had almost no symptoms, his mother, Courtney told a Washington, D.C., audience Wednesday, gathered to hear an update on progress against cancer from the American Association for Cancer Research.

A half century of taxpayer-funded research is paying off for families like the Addisons, of Chesapeake, Virginia, the AACR noted in its annual progress report .

Not only can the Addisons hope that this time their cancer nightmare may truly have an end date but the latest round of treatment doesn't seem to have left Cayden, who turns 7 next week , with any additional health problems.

"We should not have to trade off having long-term side effects for the rest of their lives just to save our babies," Addison said. "They deserve better."

Blood cancer multiple myeloma: Once a death sentence, is now highly treatable. Here's why

Using the immune system to fight cancer

Progress against cancer has been remarkable.

More than 70% of children with cancer now survive long term and among adults, death rates have fallen by one-third since 1991, avoiding an estimated 3.8 million deaths, thanks to prevention, early detection and new treatments.

Progress has picked up momentum in recent years with advances in immunotherapy, basic tumor biology and genetics, said AACR President Dr. Philip Greenberg.

In the past year alone, 14 new cancer drugs have won federal approval and the uses of an additional 12 have been expanded to new tumor types or cancer stages.

"It's just a time of such enormous opportunity," said Greenberg, who heads the program in immunology at the Fred Hutchinson Cancer Research Center in Seattle.

One of the biggest advances has been in immunotherapy: turning a person's own immune system against their cancer.

A decade ago there was just one checkpoint inhibitor approved to treat one type of cancer, melanoma. Checkpoint inhibitors essentially remove the brake that cancer put on the immune system, allowing it to fight off tumors. Now there are 11 approved checkpoint inhibitors addressing 20 different tumor types.

A different type of immune therapy called CAR-T , which was first approved in 2017, is now used to treat six different forms of blood cancer and "more are coming," Greenberg said in an interview after the formal briefing. In some cases, CAR-T, which stands for chimeric antigen receptor T-cell, is so good at teaching the immune system to recognize and kill off cancer cells that cancer disappears never to return.

On Thursday, Dr. Carl June, of the University of Pennsylvania, and Dr. Michel Sadelain, of Memorial Sloan Kettering Cancer Center, credited with developing CAR-T therapy, were one of three groups awarded a 2024 Breakthrough Prize in life sciences . The prizes, which are billed as the "Oscars of Science," honor "impactful scientific discoveries" and come with $3 million awards.

Now that CAR-T has proven itself, June said Wednesday, there has been an explosion of interest, with hundreds of companies running more than 1,000 human trials in many tumor types, along with auto-immune conditions, heart disease and even infections.

"It's all pretty gratifying to see that happening," said June, who has not decided how to spend his share of the prize money.

As with other cancer treatments, challenges remain.

With blood cancers there were obvious targets to train the immune system against, but with other tumor types, it's harder to find "dream targets" that are just on the cancer cells and not also on healthy cells, June said. Killing them would cause unacceptable side effects. Scientists are working to find ways to be as specific as possible.

In solid tumors, CAR-T cells seem to get tired out quickly, working for only a short time, instead of the months or years that they work in blood cancers.

The approach also needs to be made cheaper and by a more mechanized process to make treatments more accessible, June said. "They're all solvable. It's a matter of the timescale," he said. "But (we've had) a lot of progress in the first 10 years of CAR-T cells and and we're going to see these things all get solved."

The same mRNA technology used in COVID-19 vaccines is also proving promising in early cancer trials, offering another potential new way to use the immune system against cancer.

Moderna announced Wednesday that it plans to start a late-stage trial in melanoma and a mid-stage trial in lung cancer along with its partner Merck.

Just as COVID-19 vaccines train the immune system to identify a protein on the surface of the infectious virus and destroy it, an mRNA vaccine can identify proteins made by mutated cancer cells , Moderna CEO Stéphane Bancel said in Tuesday interview.

"What we code is those mutations to teach them to your immune system so your immune system can eat them like Pac-Man," he said.

Enlisting the immune system: mRNA cancer treatment new target for Biden administration

Persistent challenges

Such scientific advances have dramatically improved outcomes for some cancer types. Breast cancer deaths fell by 43% between 1989 and 2020, saving roughly 460,000 lives. Lung cancer deaths declined just under 1% a year between 1995 and 2005 but fell 5% annually between 2014 and 2020, thanks to a drop in smoking along with the development of new treatments.

But some other cancers, particularly pancreatic cancer and glioblastoma brain tumors, "still have horrible 5-year rates," Greenberg said. "It is changing. It can change, but it won't change unless there's continued support to drive investment in cancer research."

In the U.S., this year, nearly 2 million people will be newly diagnosed with cancer and more than 600,000 are expected to die. Some cancer types are increasing in frequency, including early-onset colon cancer, pancreatic cancer and uterine cancer, in part because of rising rates of obesity, according to AACR.

In 2019, American cancer patients paid more than $16 billion out of pocket for cancer care and lost an additional $5 billion in “time costs," AACR reported.

Disparities in care remain an ongoing issue. Greenberg particularly highlighted disparities among people living in rural areas who do not have access to clinical trials. "The rural community has been very ineffectively reached by progress in cancer," he said.

The AACR announced Wednesday that it will form an alliance with the nation's cancer centers to address issues such as disparities in care, clinical and basic scientific research, training and public communication.

"One of the failures of the scientific community has been communicating to all these populations what the opportunities are, what the advantages are and to create trust in the cancer research enterprise," Greenberg said. "What people need to recognize is how incredible the opportunities are."

Cancer Moonshot

President Joe Biden has said he wants to cut cancer deaths in half within 25 years, a project called the White House Cancer Moonshot .

On Wednesday, the president's Cancer Cabinet met to announce new actions federal agencies are taking toward that goal, along with related commitments from the private sector. The new actions include:

$240 million in additional investment this year to accelerate cancer prevention, detection and treatment.
Establishment of a nationwide health network to bring cancer clinical trials to underserved communities.
Investments to reduce the impact of smoking and promote smoking cessation.
A push to collect more data on cancers that strike military veterans and to provide more virtual care for veterans.

The Moonshot program also announced new commitments from nongovernmental organizations to support people with cancer with out-of-pocket medication costs, stress management, smoking cessation, bring clinical trials to more diverse populations and help patients navigate the medical system, among other efforts.

Funding request

Government support has been crucial to the progress against cancer, but the cancer community worries Congress won't continue to generously fund scientific research. From 2010 to 2019, federal funding contributed to the development of 354 out of 356 newly approved drugs, many of which addressed cancer.

Thursday, the AACR and other advocates will lobby members of Congress to support continued financial support of cancer research. "We hate the idea of stalling the momentum," Greenberg said.

Money invested in research pays broader dividends, according to the AACR. Research funded by the National Institutes of Health stimulated $97 billion in economic activity and half a million jobs in fiscal year 2022. "It's a really good investment. It helped sustain the U.S. economy," he said.

The AACR in its report called on Congress to provide predictable annual funding growth over the next fiscal year, by adding $3.5 billion to the NIH budget and $2.6 billion to the National Cancer Institute's.

Bladder cancer patient Lesa Kirkman told the audience she planned to spend the day Thursday lobbying "anybody who will listen to me," about the progress in cancer treatments in her lifetime. "Because this is incredible."

When Kirkman, 61, of Niceville, Florida, was diagnosed in 2016, she was convinced it was a death sentence, because that's what cancer was when she was growing up.

She had two rounds of surgery and a standard treatment that unfortunately didn't work.

When her cancer came back in 2018, her oncologist referred her to a gene therapy trial that had so few side effects that she was able to launch and participate in a tennis team while in treatment. "I was able to live a full life throughout all my treatments," said Kirkman, who has been cancer-free since. "We're all thriving because of the research that has happened,"

Contact Karen Weintraub at [email protected].

Health and patient safety coverage at USA TODAY is made possible in part by a grant from the Masimo Foundation for Ethics, Innovation and Competition in Healthcare. The Masimo Foundation does not provide editorial input .

An official website of the United States government

The .gov means it’s official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Publications
Account settings

Preview improvements coming to the PMC website in October 2024. Learn More or Try it out now .

Advanced Search
Journal List
Cancer Manag Res

2024

Information

Author Services

Initiatives

You are accessing a machine-readable page. In order to be human-readable, please install an RSS reader.

All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess .

Feature papers represent the most advanced research with significant potential for high impact in the field. A Feature Paper should be a substantial original Article that involves several techniques or approaches, provides an outlook for future research directions and describes possible research applications.

Feature papers are submitted upon individual invitation or recommendation by the scientific editors and must receive positive feedback from the reviewers.

Editor’s Choice articles are based on recommendations by the scientific editors of MDPI journals from around the world. Editors select a small number of articles recently published in the journal that they believe will be particularly interesting to readers, or important in the respective research area. The aim is to provide a snapshot of some of the most exciting work published in the various research areas of the journal.

Original Submission Date Received: .

Active Journals
Find a Journal
Proceedings Series
For Authors
For Reviewers
For Editors
For Librarians
For Publishers
For Societies
For Conference Organizers
Open Access Policy
Institutional Open Access Program
Special Issues Guidelines
Editorial Process
Research and Publication Ethics
Article Processing Charges
Testimonials
Preprints.org
SciProfiles
Encyclopedia

Article Menu

Subscribe SciFeed
Recommended Articles
Google Scholar
on Google Scholar
Table of Contents

Find support for a specific problem in the support section of our website.

Please let us know what you think of our products and services.

Visit our dedicated information section to learn more about MDPI.

JSmol Viewer

Personalized medicine in pancreatic cancer: the promise of biomarkers and molecular targeting with dr. michael j. pishvaian.

Simple Summary

1. introduction, 1.1. pancreatic cancer epidemiology, 1.2. current standards of care, 1.3. biomarkers for pancreatic cancer, 1.4. cancer survival rates, 2. present and future of precision medicine in pancreatic cancer, 2.1. molecular classification and precision medicine, 2.2. next-generation sequencing efforts in pancreatic cancer, 2.3. remarkaable benefit.

Improved Survival with Surgery: Patients with pancreatic cancer who are eligible for surgery to remove the tumor can expect a significantly longer survival. Experts consider surgical resection as potentially curative, particularly when the tumor remains localized and has not spread beyond the pancreas [ 46 ]. According to recent studies, the median survival for patients undergoing successful surgical resection can be extended to approximately 20–23 months compared to a median of 6–11 months with non-surgical management. Moreover, advancements in surgical techniques and perioperative care have further improved outcomes, reducing postoperative complications and enhancing recovery rates [ 47 ].
Tailoring Therapies: While the majority of pancreatic cancer patients do not have germline mutations, using all available tools, including genetic testing, can help select therapies. Personalized treatment may not achieve a cure but can improve quality of life and extend survival [ 48 , 49 ]. For example, patients with BRCA mutations may benefit from PARP inhibitors, which have shown promise in prolonging progression-free survival. Additionally, tailored chemotherapeutic regimens based on genetic profiling can lead to better management outcomes. The implementation of molecular profiling in routine clinical practice allows for more precise targeting of therapies, potentially leading to better responses and fewer side effects compared to conventional treatments. The implementation of molecular profiling in routine clinical practice allows for more precise targeting of therapies, potentially leading to better responses and fewer side effects compared to conventional treatments. Precision medicine approaches, guided by biomarker or genetic testing, have demonstrated significant benefits in patient outcomes. Specifically, therapies matched to biomarkers or genetic profiles have been associated with extended survival rates (Pancreatic Cancer Action Network [PanCAN], 2024). PanCAN advocates for the adoption of genetic testing for inherited mutations at the time of diagnosis and recommends biomarker testing of tumor tissue for all patients, unless medically contraindicated. They provide comprehensive resources, including the Know Your Tumor ® precision medicine service, to facilitate informed treatment decisions and enhance patient care. Next-generation sequencing (NGS) is now widely utilized to detect diagnostic, prognostic, and predictive mutations across various cancers, contributing significantly to enhanced treatment efficacy [ 45 , 50 , 51 ]. In pancreatic cancer (PC), genomic profiling data have demonstrated potential benefits in guiding treatment decisions and improving patient survival [ 52 , 53 ]. Precision medicine, which tailors therapies based on molecular profiling of gene expressions and mutations, is anticipated to play a crucial role, especially in cases of unresectable pancreatic cancer. These mutations often involve genes such as KRAS, TP53, CDKN2A, and SMAD4, among others, which are known to play critical roles in pancreatic cancer pathogenesis and progression. The identification of these mutations through NGS holds promise for personalized treatment approaches, including targeted therapies and enrollment in clinical trials aimed at exploiting specific molecular vulnerabilities in pancreatic cancer cells. Despite challenges such as tumor heterogeneity and the complex genomic landscape of pancreatic cancer, NGS continues to emerge as a valuable tool in oncology.
Challenges: Regrettably, only approximately 10% of patients with pancreatic cancer receive an early diagnosis, thereby qualifying them for potentially curative surgical resection [ 50 ]. Most cases receive a diagnosis at a more advanced stage, which restricts the available treatment options. This highlights the need for improved early detection methods and public awareness to increase the rate of early diagnosis and intervention. Furthermore, the development of more effective systemic therapies for advanced-stage pancreatic cancer remains a critical area of ongoing research. Recent efforts in biomarker discovery and the utilization of liquid biopsies are promising steps toward earlier detection and better monitoring of treatment response.

2.4. Future Perspectives in Precision Medicine

3. advancing pancreatic cancer treatment: the power of targeted therapies and genetic insights, 4. emerging therapeutic targets in metastatic pancreatic cancer: mdm2, claudin 18.2, and mtap deletion, 5. ongoing advancements in pancreatic cancer management through biomarker-based clinical trials and precision medicine, 6. conclusions and future perspectives, author contributions, acknowledgments, conflicts of interest.

Pancreatic Cancer—Symptoms and Causes—Mayo Clinic. Available online: https://www.mayoclinic.org/diseases-conditions/pancreatic-cancer/symptoms-causes/syc-20355421 (accessed on 3 May 2024).
A-Kader, H.H.; Ghishan, F.K. The Pancreas. In Textbook of Clinical Pediatrics ; Springer: Berlin/Heidelberg, Germany, 2012; pp. 1925–1936. [ Google Scholar ] [ CrossRef ]
Pancreatic Cancer Types. Available online: https://www.hopkinsmedicine.org/health/conditions-and-diseases/pancreatic-cancer/pancreatic-cancer-types (accessed on 3 May 2024).
Rossiaky, D. What Are the Different Types of Pancreatic Cancer? Available online: https://www.healthline.com/health/pancreatic-cancer/types-of-pancreatic-cancer (accessed on 3 May 2024).
Magi, L.; Marasco, M.; Rinzivillo, M.; Faggiano, A.; Panzuto, F. Management of Functional Pancreatic Neuroendocrine Neoplasms. Curr. Treat. Options Oncol. 2023 , 24 , 725–741. [ Google Scholar ] [ CrossRef ] [ PubMed ]
Symptoms of Pancreatic Cancer. Available online: https://www.cancerresearchuk.org/about-cancer/pancreatic-cancer/symptoms (accessed on 3 May 2024).
Khalaf, N.; El-Serag, H.B.; Abrams, H.R.; Thrift, A.P. Burden of Pancreatic Cancer: From Epidemiology to Practice. Clin. Gastroenterol. Hepatol. 2021 , 19 , 876–884. [ Google Scholar ] [ CrossRef ] [ PubMed ]
Key Statistics for Pancreatic Cancer. Available online: https://www.cancer.org/cancer/types/pancreatic-cancer/about/key-statistics.html#:~:text=About%2066%2C440%20people%20%2834%2C530%20men%20and%2031%2C910%20women%29,men%20and%20about%201%20in%2060%20in%20women (accessed on 3 May 2024).
Ecancer Pancreatic Cancer Projected to Become Second Leading Cause of Cancer-Related Death in the United States by 2030. Available online: https://ecancer.org/en/news/5660-pancreatic-cancer-projected-to-become-second-leading-cause-of-cancer-related-death-in-the-united-states-by-2030#:~:text=An%20analysis%20projects%20pancreatic%20and%20liver%20cancers%20to,journal%20of%20the%20American%20Association%20for%20Cancer%20Research (accessed on 3 May 2024).
Chun, J.W.; Lee, S.H.; Kim, J.S.; Park, N.; Huh, G.; Cho, I.R.; Paik, W.H.; Ryu, J.K.; Kim, Y.-T. Comparison between FOLFIRINOX and Gemcitabine plus Nab-Paclitaxel Including Sequential Treatment for Metastatic Pancreatic Cancer: A Propensity Score Matching Approach. BMC Cancer 2021 , 21 , 537. [ Google Scholar ] [ CrossRef ]
Wainberg, Z.A.; Melisi, D.; Macarulla, T.; Cid, R.P.; Chandana, S.R.; De La Fouchardière, C.; Dean, A.; Kiss, I.; Lee, W.J.; Goetze, T.O.; et al. NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): A randomised, open-label, phase 3 trial. Lancet 2023 , 402 , 1272–1281. [ Google Scholar ] [ CrossRef ] [ PubMed ]
Herbst, B.; Zheng, L. Precision Medicine in Pancreatic Cancer: Treating Every Patient as an Exception. Lancet Gastroenterol. Hepatol. 2019 , 4 , 805–810. [ Google Scholar ] [ CrossRef ] [ PubMed ]
Perkhofer, L.; Golan, T.; Cuyle, P.-J.; Matysiak-Budnik, T.; Van Laethem, J.-L.; Macarulla, T.; Cauchin, E.; Kleger, A.; Beutel, A.K.; Gout, J.; et al. Targeting DNA Damage Repair Mechanisms in Pancreas Cancer. Cancers 2021 , 13 , 4259. [ Google Scholar ] [ CrossRef ] [ PubMed ]
Park, S.; Shin, K.; Kim, I.-H.; Hong, T.; Kim, Y.; Suh, J.; Lee, M. Clinicopathological Features and Prognosis of Resected Pancreatic Ductal Adenocarcinoma Patients with Claudin-18 Overexpression. J. Clin. Med. 2023 , 12 , 5394. [ Google Scholar ] [ CrossRef ]
Oliner, J.D.; Saiki, A.Y.; Caenepeel, S. The Role of MDM2 Amplification and Overexpression in Tumorigenesis. Cold Spring Harb. Perspect. Med. 2016 , 6 , a026336. [ Google Scholar ] [ CrossRef ] [ PubMed ]
Lee, M.K.C.; Grimmond, S.M.; McArthur, G.A.; Sheppard, K.E. PRMT5: An Emerging Target for Pancreatic Adenocarcinoma. Cancers 2021 , 13 , 5136. [ Google Scholar ] [ CrossRef ]
Ansari, D.; Andersson, R. Biomarkers in Pancreatic Cancer. In Textbook of Pancreatic Cancer ; Springer: Cham, Switzerland, 2021; pp. 467–487. [ Google Scholar ] [ CrossRef ]
Meng, Q.; Shi, S.; Liang, C.; Liang, D.; Xu, W.; Ji, S.; Zhang, B.; Ni, Q.; Xu, J.; Yu, X. Diagnostic and Prognostic Value of Carcinoembryonic Antigen in Pancreatic Cancer: A Systematic Review and Meta-Analysis. OncoTargets Ther. 2017 , 10 , 4591–4598. [ Google Scholar ] [ CrossRef ]
Seladi-Schulman, J. Pancreatic Cancer (Tumor) Markers: Uses and Accuracy. Available online: https://www.healthline.com/health/pancreatic-cancer/pancreatic-cancer-markers (accessed on 3 May 2024).
Khomiak, A.; Brunner, M.; Kordes, M.; Lindblad, S.; Miksch, R.C.; Öhlund, D.; Regel, I. Recent Discoveries of Diagnostic, Prognostic and Predictive Biomarkers for Pancreatic Cancer. Cancers 2020 , 12 , 3234. [ Google Scholar ] [ CrossRef ] [ PubMed ]
Madadjim, R.; An, T.; Cui, J. MicroRNAs in Pancreatic Cancer: Advances in Biomarker Discovery and Therapeutic Implications. Int. J. Mol. Sci. 2024 , 25 , 3914. [ Google Scholar ] [ CrossRef ] [ PubMed ]
Yang, M.; Zhang, C.-Y. Diagnostic Biomarkers for Pancreatic Cancer: An Update. World J. Gastroenterol. 2021 , 27 , 7862–7865. [ Google Scholar ] [ CrossRef ] [ PubMed ]
Wu, H.; Ou, S.; Zhang, H.; Huang, R.; Yu, S.; Zhao, M.; Tai, S. Advances in Biomarkers and Techniques for Pancreatic Cancer Diagnosis. Cancer Cell Int. 2022 , 22 , 220. [ Google Scholar ] [ CrossRef ] [ PubMed ]
Survival Rates for Pancreatic Cancer. Available online: https://www.cancer.org/cancer/types/pancreatic-cancer/detection-diagnosis-staging/survival-rates.html (accessed on 3 May 2024).
Pishvaian, M. Updates in Biomarker-Based Therapy for Pancreatic Cancer. Presented at the MedNews Week, Online. 27 February 2023. [ Google Scholar ]
Seppälä, T.T.; Zimmerman, J.W.; Suri, R.; Zlomke, H.; Ivey, G.D.; Szabolcs, A.; Shubert, C.R.; Cameron, J.L.; Burns, W.R.; Lafaro, K.J.; et al. Precision Medicine in Pancreatic Cancer: Patient-Derived Organoid Pharmacotyping Is a Predictive Biomarker of Clinical Treatment Response. Clin. Cancer Res. 2022 , 28 , 3296–3307. [ Google Scholar ] [ CrossRef ] [ PubMed ]
George, B. Precision Medicine and Pancreatic Cancer. Surg. Oncol. Clin. N. Am. 2021 , 30 , 693–708. [ Google Scholar ] [ CrossRef ]
Victor Navigating the Future of Precision Medicine: The Role of Genetic Testing. Available online: https://www.novo-dx.com/post/navigating-the-future-of-precision-medicine-the-role-of-genetic-testing#:~:text=Genetic%20testing%20lies%20at%20the%20core%20of%20precision,disease%20risk%20factors%2C%20and%20potential%20responses%20to%20treatment (accessed on 3 May 2024).
Zhang, Q.; Fu, Q.; Bai, X.; Liang, T. Molecular Profiling–Based Precision Medicine in Cancer: A Review of Current Evidence and Challenges. Front. Oncol. 2020 , 10 , 532403. [ Google Scholar ] [ CrossRef ] [ PubMed ]
Schleifer, K.-H.; Ludwig, W. Molecular Taxonomy: Classification and Identification. In Bacterial Diversity and Systematics ; Springer: Boston, MA, USA, 1994; pp. 1–15. [ Google Scholar ] [ CrossRef ]
Libretexts 10.3: Classification and Detection of Molecular Markers. Available online: https://bio.libretexts.org/Bookshelves/Genetics/Online_Open_Genetics_%28Nickle_and_Barrette-Ng%29/10%3A__Molecular_Markers_and_Quantitative_Traits/10.03%3A_Classification_and_Detection_of_Molecular_Markers (accessed on 3 May 2024).
Precision Medicine. Available online: https://www.fda.gov/medical-devices/in-vitro-diagnostics/precision-medicine (accessed on 3 May 2024).
Naithani, N.; Sinha, S.; Misra, P.; Vasudevan, B.; Sahu, R. Precision Medicine: Concept and Tools. Med. J. Armed Forces India 2021 , 77 , 249–257. [ Google Scholar ] [ CrossRef ]
Pishvaian, M.J.; Brody, J.R. Molecular Profiling and Precision Medicine for Pancreatic Cancer. In Pancreatic Cancer: A Multidisciplinary Approach ; Springer: Cham, Switzerland, 2022; pp. 255–267. [ Google Scholar ] [ CrossRef ]
Miyabayashi, K.; Nakagawa, H.; Koike, K. Molecular and Phenotypic Profiling for Precision Medicine in Pancreatic Cancer: Current Advances and Future Perspectives. Front. Oncol. 2021 , 11 , 682872. [ Google Scholar ] [ CrossRef ]
Shen, G.-Q.; Aleassa, E.M.; Walsh, R.M.; Morris-Stiff, G. Next-Generation Sequencing in Pancreatic Cancer. Pancreas 2019 , 48 , 739–748. [ Google Scholar ] [ CrossRef ]
Jung, K.; Lee, S.; Na, H.Y.; Kim, J.-W.; Lee, J.-C.; Hwang, J.-H.; Kim, J.W.; Kim, J. NGS-Based Targeted Gene Mutational Profiles in Korean Patients with Pancreatic Cancer. Sci. Rep. 2022 , 12 , 20937. [ Google Scholar ] [ CrossRef ] [ PubMed ]
Stover, E.H.; Konstantinopoulos, P.A.; Matulonis, U.A.; Swisher, E.M. Biomarkers of Response and Resistance to DNA Repair Targeted Therapies. Clin. Cancer Res. 2016 , 22 , 5651–5660. [ Google Scholar ] [ CrossRef ] [ PubMed ]
Rahnamay Farnood, P.; Danesh Pazhooh, R.; Asemi, Z.; Yousefi, B. DNA Damage Response and Repair in Pancreatic Cancer Development and Therapy. DNA Repair 2021 , 103 , 103116. [ Google Scholar ] [ CrossRef ] [ PubMed ]
Ghidini, M.; Lampis, A.; Mirchev, M.B.; Okuducu, A.F.; Ratti, M.; Valeri, N.; Hahne, J.C. Immune-Based Therapies and the Role of Microsatellite Instability in Pancreatic Cancer. Genes 2020 , 12 , 33. [ Google Scholar ] [ CrossRef ] [ PubMed ]
Sudhesh Dev, S.; Zainal Abidin, S.A.; Farghadani, R.; Othman, I.; Naidu, R. Receptor Tyrosine Kinases and Their Signaling Pathways as Therapeutic Targets of Curcumin in Cancer. Front. Pharmacol. 2021 , 12 , 772510. [ Google Scholar ] [ CrossRef ] [ PubMed ]
Daoud, A.Z.; Mulholland, E.J.; Cole, G.; McCarthy, H.O. MicroRNAs in Pancreatic Cancer: Biomarkers, Prognostic, and Therapeutic Modulators. BMC Cancer 2019 , 19 , 1130. [ Google Scholar ] [ CrossRef ] [ PubMed ]
Park, Y.; Heider, D.; Hauschild, A.-C. Integrative Analysis of Next-Generation Sequencing for Next-Generation Cancer Research toward Artificial Intelligence. Cancers 2021 , 13 , 3148. [ Google Scholar ] [ CrossRef ] [ PubMed ]
Jiang, Y.; Abboud, Y.; Liang, J.; Larson, B.; Osipov, A.; Gong, J.; Hendifar, A.E.; Atkins, K.; Liu, Q.; Nissen, N.N.; et al. The Disproportionate Rise in Pancreatic Cancer in Younger Women Is Due to a Rise in Adenocarcinoma and Not Neuroendocrine Tumors: A Nationwide Time-Trend Analysis Using 2001–2018 United States Cancer Statistics Databases. Cancers 2024 , 16 , 971. [ Google Scholar ] [ CrossRef ] [ PubMed ]
Hu, Z.I.; Shia, J.; Stadler, Z.K.; Varghese, A.M.; Capanu, M.; Salo-Mullen, E.; Lowery, M.A.; Diaz, L.A.; Mandelker, D.; Yu, K.H.; et al. Evaluating Mismatch Repair Deficiency in Pancreatic Adenocarcinoma: Challenges and Recommendations. Clin. Cancer Res. 2018 , 24 , 1326–1336. [ Google Scholar ] [ CrossRef ]
Corey, C. Long-Term Pancreatic Cancer Survivors Report Excellent Post-Surgery Quality of Life. Available online: https://newsnetwork.mayoclinic.org/discussion/long-term-pancreatic-cancer-survivors-report-excellent-post-surgery-quality-of-life/ (accessed on 3 May 2024).
Pancreatic Cancer Survival Rate—Pancreatic Cancer Action Network. Available online: https://pancan.org/facing-pancreatic-cancer/about-pancreatic-cancer/survival-rate/ (accessed on 3 May 2024).
Ferrara, N. People with Pancreatic Cancer Are Living Longer, Thanks to Improved Approaches—Mayo Clinic Comprehensive Cancer Center Blog. Available online: https://cancerblog.mayoclinic.org/2022/11/15/people-with-pancreatic-cancer-are-living-longer-thanks-to-improved-approaches/ (accessed on 3 May 2024).
Lee, M.S.; Pant, S. Targeted Therapies for Pancreatic Cancer. In Pancreatic Cancer ; Springer: Cham, Switzerland, 2023; pp. 67–95. [ Google Scholar ] [ CrossRef ]
Gheorghe, G.; Bungau, S.; Ilie, M.; Behl, T.; Vesa, C.M.; Brisc, C.; Bacalbasa, N.; Turi, V.; Costache, R.S.; Diaconu, C.C. Early Diagnosis of Pancreatic Cancer: The Key for Survival. Diagnostics 2020 , 10 , 869. [ Google Scholar ] [ CrossRef ]
Roy, R.; Chun, J.; Powell, S.N. BRCA1 and BRCA2: Different roles in a common pathway of genome protection. Nat. Rev. Cancer 2011 , 12 , 68–78. [ Google Scholar ] [ CrossRef ] [ PubMed ]
Rosen, M.N.; Goodwin, R.A.; Vickers, M.M. BRCA mutated pancreatic cancer: A change is coming. World J. Gastroenterol. 2021 , 27 , 1943–1958. [ Google Scholar ] [ CrossRef ] [ PubMed ]
Morales, J.; Li, L.; Fattah, F.J.; Dong, Y.; Bey, E.A.; Patel, M.; Gao, J.; Boothman, D.A. Review of poly (ADP-ribose) polymerase (PARP) mechanisms of action and rationale for targeting in cancer and other diseases. Crit. Rev. Eukaryot. Gene Expr. 2014 , 24 , 15–28. [ Google Scholar ] [ CrossRef ] [ PubMed ]
Anderson, R.K. Numerous Clinical Trials Investigate Next Generation of PARP Inhibitors. Available online: https://www.pharmacytimes.com/view/numerous-clinical-trials-investigate-next-generation-of-parp-inhibitors (accessed on 5 May 2024).
Taylor, A.K.; Kosoff, D.; Emamekhoo, H.; Lang, J.M.; Kyriakopoulos, C.E. PARP inhibitors in metastatic prostate cancer. Front. Oncol. 2023 , 13 , 1159557. [ Google Scholar ] [ CrossRef ] [ PubMed ]
Slootbeek, P.H.J.; Kloots, I.S.H.; van Oort, I.M.; Kroeze, L.I.; Schalken, J.A.; Bloemendal, H.J.; Mehra, N. Cross-Resistance between Platinum-Based Chemotherapy and PARP Inhibitors in Castration-Resistant Prostate Cancer. Cancers 2023 , 15 , 2814. [ Google Scholar ] [ CrossRef ] [ PubMed ]
Iannantuono, G.M.; Chandran, E.; Floudas, C.S.; Choo-Wosoba, H.; Butera, G.; Roselli, M.; Gulley, J.L.; Karzai, F. Efficacy and safety of PARP inhibitors in metastatic castration-resistant prostate cancer: A systematic review and meta-analysis of clinical trials. Cancer Treat Rev. 2023 , 120 , 102623. [ Google Scholar ] [ CrossRef ] [ PubMed ]
Azmi, A.S.; Philip, P.A.; Almhanna, K.; Beck, F.W.; Sarkar, F.H.; Mohammad, R.M. MDM2 Inhibitors for Pancreatic Cancer Therapy. Mini-Rev. Med. Chem , 2010; 10, 518–526. [ Google Scholar ] [ CrossRef ]
Azmi, A.S.; Philip, P.A.; Aboukameel, A.; Wang, Z.; Banerjee, S.; Zafar, S.F.; Goustin, A.S.; Almhanna, K.; Yang, D.; Sarkar, F.H.; et al. Reactivation of p53 by novel MDM2 inhibitors: Implications for pancreatic cancer therapy. Curr. Cancer Drug Targets. 2010 , 10 , 319–331. [ Google Scholar ] [ CrossRef ]
Traweek, R.S.; Cope, B.M.; Roland, C.L.; Keung, E.Z.; Nassif, E.F.; Erstad, D.J. Targeting the MDM2-p53 pathway in dedifferentiated liposarcoma. Front. Oncol. 2022 , 12 , 1006959. [ Google Scholar ] [ CrossRef ] [ PubMed ]
Shah, M.A.; Shitara, K.; Ajani, J.A.; Bang, Y.-J.; Enzinger, P.; Ilson, D.; Lordick, F.; Cutsem, E.V.; Plazas, J.G.; Huang, J.; et al. Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: The randomized, phase 3 GLOW trial. Nat. Med. 2023 , 29 , 2133–2141. [ Google Scholar ] [ CrossRef ]
Wang, W.; Albadari, N.; Du, Y.; Fowler, J.F.; Sang, H.T.; Xian, W.; McKeon, F.; Li, W.; Zhou, J.; Zhang, R. MDM2 Inhibitors for Cancer Therapy: The Past, Present, and Future. Pharmacol. Rev. 2024 , 76 , 414–453. [ Google Scholar ] [ CrossRef ]
Hou, H.; Sun, D.; Zhang, X. The role of MDM2 amplification and overexpression in therapeutic resistance of malignant tumors. Cancer Cell Int. 2019 , 19 , 216. [ Google Scholar ] [ CrossRef ] [ PubMed ]
Xu, Q.; Jia, C.; Ou, Y.; Zeng, C.; Jia, Y. Dark horse target Claudin18.2 opens new battlefield for pancreatic cancer. Front. Oncol. 2024 , 14 , 1371421. [ Google Scholar ] [ CrossRef ] [ PubMed ]
Zhou, B.; Flodby, P.; Luo, J.; Castillo, D.R.; Liu, Y.; Yu, F.X.; Mcconnell, A.; Varghese, B.; Li, G.; Chimge, N.-O.; et al. Claudin-18-mediated YAP activity regulates lung stem and progenitor cell homeostasis and tumorigenesis. J. Clin. Investig. 2018 , 128 , 970–984. [ Google Scholar ] [ CrossRef ] [ PubMed ]
Shimobaba, S.; Taga, S.; Akizuki, R.; Hichino, A.; Endo, S.; Matsunaga, T.; Watanabe, R.; Yamaguchi, M.; Yamazaki, Y.; Sugatani, J.; et al. Claudin-18 inhibits cell proliferation and motility mediated by inhibition of phosphorylation of PDK1 and Akt in human lung adenocarcinoma A549 cells. Biochim. Biophys. Acta 2016 , 1863 , 1170–1178. [ Google Scholar ] [ CrossRef ] [ PubMed ]
Luo, J.; Chimge, N.O.; Zhou, B.; Flodby, P.; Castaldi, A.; Firth, A.L.; Liu, Y.; Wang, H.; Yang, C.; Marconett, C.N.; et al. CLDN18.1 attenuates Malignancy and related signaling pathways of lung adenocarcinoma in vivo and in vitro. Int. J. Cancer 2018 , 143 , 3169–3180. [ Google Scholar ] [ CrossRef ] [ PubMed ]
Li, J. Context-Dependent Roles of Claudins in Tumorigenesis. Front. Oncol. 2021 , 11 , 676781. [ Google Scholar ] [ CrossRef ] [ PubMed ]
Hu, Q.; Qin, Y.; Ji, S.; Shi, X.; Dai, W.; Fan, G.; Li, S.; Xu, W.; Liu, W.; Liu, M.; et al. MTAP Deficiency–Induced Metabolic Reprogramming Creates a Vulnerability to Cotargeting De Novo Purine Synthesis and Glycolysis in Pancreatic Cancer. Metab. Chem. Biol. 2021 , 81 , 4964–4980. [ Google Scholar ] [ CrossRef ] [ PubMed ]
Bray, C.; Balcells, C.; McNeish, I.A.; Keun, H.C. The potential and challenges of targeting MTAP-negative cancers beyond synthetic lethality. Front. Oncol. 2023 , 13 , 1264785. [ Google Scholar ] [ CrossRef ] [ PubMed ]
Casolino, R.; Braconi, C.; Malleo, G.; Paiella, S.; Bassi, C.; Milella, M.; Dreyer, S.B.; Froeling, F.E.M.; Chang, D.K.; Biankin, A.V.; et al. Reshaping preoperative treatment of pancreatic cancer in the era of precision medicine. Ann. Oncol. 2021 , 32 , 183–196. [ Google Scholar ] [ CrossRef ]
Von Hoff, D.D.; Stephenson, J.J., Jr.; Rosen, P.; Loesch, D.M.; Borad, M.J.; Anthony, S.; Jameson, G.; Brown, S.; Cantafio, N.; Richards, D.A.; et al. Pilot study using molecular profiling of patients’ tumors to find potential targets and select treatments for their refractory cancers. J. Clin. Oncol. 2010 , 28 , 4877–4883. [ Google Scholar ] [ CrossRef ]
Le, D.T.; Uram, J.N.; Wang, H.; Bartlett, B.R.; Kemberling, H.; Eyring, A.D.; Skora, A.D.; Luber, B.S.; Azad, N.S.; Laheru, D.; et al. PD-1 blockade in tumors with mismatch-repair deficiency. N. Engl. J. Med. 2015 , 372 , 2509–2520. [ Google Scholar ] [ CrossRef ] [ PubMed ]
National Cancer Institute. NCI-MATCH Trial. Available online: https://www.cancer.gov/about-cancer/treatment/clinical-trials/nci-supported/nci-match (accessed on 6 May 2024).
American Society of Clinical Oncology. TAPUR Study. Available online: https://www.tapur.org (accessed on 6 May 2024).
Pancreatic Cancer Canada. COMPASS Trial. Available online: https://pancreaticcancercanada.ca/research/clinical-trials/compass-trial/ (accessed on 6 May 2024).
IMPaCT Trial. ClinicalTrials.gov. Available online: https://clinicaltrials.gov/ct2/show/NCT03337087 (accessed on 6 May 2024).
Marabelle, A.; Le, D.T.; Ascierto, P.A.; Giacomo, A.M.D.; Jesus-Acosta, A.D.; Delord, J.-P.; Geva, R.; Gottfried, M.; Penel, N.; Hansen, A.R.; et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: Results from the phase II KEYNOTE-158 study. J. Clin. Oncol. 2020 , 38 , 1–10. [ Google Scholar ] [ CrossRef ] [ PubMed ]
Skoulidis, F.; Li, B.T.; Dy, G.K.; Price, T.J.; Falchook, G.S.; Wolf, J.; Italiano, A.; Schuler, M.; Borghaei, H.; Barlesi, F.; et al. Sotorasib for lung cancers with KRAS p.G12C mutation. N. Engl. J. Med. 2021 , 384 , 2371–2381. [ Google Scholar ] [ CrossRef ] [ PubMed ]
Jänne, P.A.; Rybkin, I.I.; Spira, A.I.; Riley, G.J.; Papadopoulos, K.P.; Sabari, J.K.; Johnson, M.L.; Heist, R.S.; Bazhenova, L.; Barve, M.; et al. KRYSTAL-1: Adagrasib (MRTX849) in non-small cell lung cancer harboring a KRAS G12C mutation. Eur. J. Cancer 2020 , 138 , S1–S2. [ Google Scholar ] [ CrossRef ]
Schram, A.M.; Odintsov, I.; Espinosa-Cotton, M.; Khodos, I.; Sisso, W.J.; Mattar, M.S.; Lui, A.J.W.; Vojnic, M.; Shameem, S.H.; Chauhan, T.; et al. Zenocutuzumab in ERBB2-amplified and NRG1-rearranged cancers. Cancer Discov. 2022 , 12 , 1233–1247. [ Google Scholar ] [ CrossRef ]
Sacher, A.; LoRusso, P.; Patel, M.R.; Miller, W.H., Jr.; Garralda, E.; Forster, M.D.; Santoro, A.; Falcon, A.; Kim, T.W.; Paz-Ares, L.; et al. Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation. N. Engl. J. Med. 2023 , 389 , 710–721. [ Google Scholar ] [ CrossRef ] [ PubMed ]
Li, J.; Shen, L.; Gu, Y.; Calles, A.; Wu, L.; Ba, Y.; Li, Z.H.; Bai, C.; Yao, Y.; Hubert, A.; et al. Preliminary activity and safety results of KRAS G12C inhibitor glecirasib (JAB-21822) in patients with pancreatic cancer and other solid tumors. J. Clin. Oncol. 2024 , 42 , 604. [ Google Scholar ] [ CrossRef ]
National Cancer Institute. NCI-Supported Research Programs. Available online: https://www.cancer.gov/about-cancer/treatment/clinical-trials/nci-supported/pancreatic-cancer (accessed on 8 May 2024).
Schwaederle, M.; Zhao, M.; Lee, J.J.; Eggermont, A.M.; Schilsky, R.L.; Mendelsohn, J.; Lazar, V.; Kurzrock, R. Impact of precision medicine in diverse cancers: A meta-analysis of phase II clinical trials. J. Clin. Oncol. 2015 , 33 , 3817–3825. [ Google Scholar ] [ CrossRef ] [ PubMed ]
Hyman, D.M.; Puzanov, I.; Subbiah, V.; Farris, J.E.; Chau, I.; Blay, J.-Y.; Wolf, J.; Raje, N.S.; Diamond, E.L.; Hollebecque, A.; et al. Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations. N. Engl. J. Med. 2015 , 373 , 726–736. [ Google Scholar ] [ CrossRef ]
Hong, D.S.; Fakih, M.G.; Strickler, J.H.; Desai, J.; Durm, G.A.; Shapiro, G.I.; Falchook, G.S.; Price, T.J.; Sacher, A.; Denlinger, C.S.; et al. KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors. N. Engl. J. Med. 2020 , 383 , 1207–1217. [ Google Scholar ] [ CrossRef ] [ PubMed ] [ PubMed Central ]
Klomp, J.E.; Diehl, J.N.; Klomp, J.A.; Edwards, A.C.; Yang, R.; Morales, A.J.; Taylor, K.E.; Drizyte-Miller, K.; Bryant, K.L.; Schaefer, A.; et al. Determining the ERK-regulated phosphoproteome driving KRAS-mutant cancer. Science 2024 , 384 , eadk0850. [ Google Scholar ] [ CrossRef ]
Pishvaian, M.J.; Blais, E.M.; Brody, J.R.; Lyons, E.; DeArbeloa, P.; Hendifar, A.; Mikhail, S.; Chung, V.; Sahai, V.; Sohal, D.P.S.; et al. Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: A retrospective analysis of the Know Your Tumor registry trial. Lancet Oncol. 2020 , 21 , 508–518. [ Google Scholar ] [ CrossRef ]
Mahadevan, K.K.; LeBleu, V.S.; Ramirez, E.V.; Chen, Y.; Li, B.; Sockwell, A.M.; Gagea, M.; Sugimoto, H.; Sthanam, L.K.; Tampe, D.; et al. Elimination of oncogenic KRAS in genetic mouse models eradicates pancreatic cancer by inducing FAS-dependent apoptosis by CD8+ T cells. Dev. Cell. 2023 , 58 , 1562–1577.e8. [ Google Scholar ] [ CrossRef ]
Mahadevan, K.K.; McAndrews, K.M.; LeBleu, V.S.; Yang, S.; Lyu, H.; Li, B.; Sockwell, A.M.; Kirtley, M.L.; Morse, S.J.; Moreno Diaz, B.A.; et al. KRASG12D inhibition reprograms the microenvironment of early and advanced pancreatic cancer to promote FAS-mediated killing by CD8+ T cells. Cancer Cell 2023 , 41 , 1606–1620. [ Google Scholar ] [ CrossRef ]
Brozos-Vázquez, E.; Toledano-Fonseca, M.; Costa-Fraga, N.; Garcia-Ortiz, M.V.; Diaz-Lagares, A.; Rodriguez-Ariza, A.; Aranda, E.; Lopez-Lopez, R. Pancreatic cancer biomarkers: A pathway to advance in personalized treatment selection. Cancer Treat. Rev. 2024 , 125 , 102719. [ Google Scholar ] [ CrossRef ]
Lawlor, R.T.; Mattiolo, P.; Mafficini, A.; Hong, S.-M.; Piredda, M.L.; Taormina, S.V.; Malleo, G.; Marchegiani, G.; Pea, A.; Salvia, R.; et al. Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Pancreatic Cancer: Systematic Review and Still-Open Questions. Cancers 2021 , 13 , 3119. [ Google Scholar ] [ CrossRef ]
Koay, E.J.; Zaid, M.; Aliru, M.; Bagereka, P.; Wieren, A.V.; Rodriguez, M.J.; Jacobson, G.; Wolff, R.A.; Overman, M.; Varadhachary, G.; et al. Nab-Paclitaxel, Capecitabine, and Radiation Therapy After Induction Chemotherapy in Treating Patients With Locally Advanced and Borderline Resectable Pancreatic Cancer: Phase 1 Trial and Imaging-based Biomarker Validation. Int. J. Radiat. Oncol. Biol. Phys. 2022 , 114 , 444–453. [ Google Scholar ] [ CrossRef ]
Pant, S.; Martin, L.K.; Geyer, S.; Wei, L.; Loon, K.V.; Sommovilla, N.; Zalupski, M.; Iyer, R.; Fogelman, D.; Ko, A.H.; et al. Baseline serum albumin is a predictive biomarker for patients with advanced pancreatic cancer treated with bevacizumab: A pooled analysis of 7 prospective trials of gemcitabine-based therapy with or without bevacizumab. Cancer 2014 , 120 , 1780–1786. [ Google Scholar ] [ CrossRef ]
Abe, T.; Koi, C.; Kohi, S.; Song, K.-B.; Tamura, K.; Macgregor-Das, A.; Kitaoka, N.; Chuidian, M.; Ford, M.; Dbouk, M.; et al. Gene Variants That Affect Levels of Circulating Tumor Markers Increase Identification of Patients With Pancreatic Cancer. Clin. Gastroenterol. Hepatol. 2020 , 18 , 1161–1169. [ Google Scholar ] [ CrossRef ]
Agnihotri, N.; Ambavane, A.; Fan, L.; Li, W.; Yoo, H.; Joo, S.; Muston, D. Modeling health outcomes associated with BRCA testing and treatment strategies for patients with metastatic pancreatic cancer. Pancreatology 2024 , 24 , 271–278. [ Google Scholar ] [ CrossRef ]
Mukherji, R.; Debnath, D.; Hartley, M.L.; Noel, M.S. The Role of Immunotherapy in Pancreatic Cancer. Curr. Oncol. 2022 , 29 , 6864–6892. [ Google Scholar ] [ CrossRef ]
Yoon, J.H.; Jung, Y.-J.; Moon, S.-H. Immunotherapy for Pancreatic Cancer. World J. Clin. Cases 2021 , 9 , 2969–2982. [ Google Scholar ] [ CrossRef ]
Puccini, A.; Battaglin, F.; Iaia, M.L.; Lenz, H.-J.; Salem, M.E. Overcoming Resistance to Anti-PD1 and Anti-PD-L1 Treatment in Gastrointestinal Malignancies. J. Immunother. Cancer 2020 , 8 , e000404. [ Google Scholar ] [ CrossRef ]
Le, D.T.; Durham, J.N.; Smith, K.N.; Wang, H.; Bartlett, B.R.; Aulakh, L.K.; Lu, S.; Kemberling, H.; Wilt, C.; Luber, B.S.; et al. Mismatch Repair Deficiency Predicts Response of Solid Tumors to PD-1 Blockade. Science 2017 , 357 , 409–413. [ Google Scholar ] [ CrossRef ]
Xue, B.; Luo, X.; Liu, Y.; Ye, S.; Zhou, L.; Li, S.; Li, P.; Liang, A. CAR T-Cell Therapy Combined with PD-1 Inhibitors Significantly Improve the Efficacy and Prognosis of r/r DLBCL with TP53 Alterations. Blood 2023 , 142 , 3515. [ Google Scholar ] [ CrossRef ]
Yi, M.; Zheng, X.; Niu, M.; Zhu, S.; Ge, H.; Wu, K. Combination Strategies with PD-1/PD-L1 Blockade: Current Advances and Future Directions. Mol. Cancer 2022 , 21 , 28. [ Google Scholar ] [ CrossRef ]
Farhangnia, P.; Khorramdelazad, H.; Nickho, H.; Delbandi, A.-A. Current and Future Immunotherapeutic Approaches in Pancreatic Cancer Treatment. J. Hematol. Oncol. 2024 , 17 , 40. [ Google Scholar ] [ CrossRef ]
Maitra, A.; Topol, E.J. Early Detection of Pancreatic Cancer and AI Risk Partitioning. Lancet 2024 , 403 , 1438. [ Google Scholar ] [ CrossRef ]
Bhat, A.A.; Nisar, S.; Mukherjee, S.; Saha, N.; Yarravarapu, N.; Lone, S.N.; Masoodi, T.; Chauhan, R.; Maacha, S.; Bagga, P.; et al. Integration of CRISPR/Cas9 with Artificial Intelligence for Improved Cancer Therapeutics. J. Transl. Med. 2022 , 20 , 534. [ Google Scholar ] [ CrossRef ]
Qin, Q.; Yu, R.; Eriksson, J.E.; Tsai, H.-I.; Zhu, H. Cancer-Associated Fibroblasts in Pancreatic Ductal Adenocarcinoma Therapy: Challenges and Opportunities. Cancer Lett. 2024 , 591 , 216859. [ Google Scholar ] [ CrossRef ]
Glabman, R.A.; Choyke, P.L.; Sato, N. Cancer-Associated Fibroblasts: Tumorigenicity and Targeting for Cancer Therapy. Cancers 2022 , 14 , 3906. [ Google Scholar ] [ CrossRef ]
Chen, X.; Song, E. Turning Foes to Friends: Targeting Cancer-Associated Fibroblasts. Nat. Rev. Drug Discov. 2018 , 18 , 99–115. [ Google Scholar ] [ CrossRef ]
Maia, A.; Wiemann, S. Cancer-Associated Fibroblasts: Implications for Cancer Therapy. Cancers 2021 , 13 , 3526. [ Google Scholar ] [ CrossRef ]
Yang, D.; Liu, J.; Qian, H.; Zhuang, Q. Cancer-Associated Fibroblasts: From Basic Science to Anticancer Therapy. Exp. Mol. Med. 2023 , 55 , 1322–1332. [ Google Scholar ] [ CrossRef ]

Click here to enlarge figure

Clinical Trial Name	Aim and Description
NCI-MATCH (Molecular Analysis for Therapy Choice) [ ]	Targets therapy based on tumor mutations rather than their cancer type.
TAPUR (Targeted Agent and Profiling Utilization Registry) [ ]	Evaluates the safety and efficacy of FDA-approved targeted therapies in patients with advanced cancer harboring specific genetic alterations.
COMPASS (Comprehensive Molecular Characterization of Advanced Pancreatic Ductal Adenocarcinoma for Better Treatment Selection) [ ]	Uses molecular profiling for advanced pancreatic cancer treatment.
IMPaCT (Integrative Molecular Profiling of Pancreatic Cancer Therapy) [ ]	Matches patients with therapies based on tumor molecular characteristics.
KEYNOTE-158 (Phase II) [ ]	Pembrolizumab in MSI-H/dMMR tumors: 18.2% RR, 2.1m PFS, 4 m OS.
CODEBREAK-100 (Phase Ib/II) [ ]	Sotorasib in KRAS G12C mutations: 21% RR, 4 m PFS, 6.9 m OS.
KRYSTAL-1 (Phase II) [ ]	Adagrasib in KRAS G12C mutations: 33.3% RR, 5.4 m PFS, 8 m OS.
Schram’s 2021 Phase II [ ]	Zenocutuzumab in NRG1 fusions: 40% RR.
Sacher’s 2023 Phase I [ ]	Diravasib in KRAS G12C mutations: 36% RR.
Li’s 2024 Phase I/II [ ]	Olomorasib in KRAS G12C mutations: 33% RR.
Hollebecque’s 2024 Phase I/II [ ]	Glecirasib in KRAS G12C mutations: 46.4% RR, 5.5 m PFS.I
Pancreatic Cancer Cohort Consortium [ ]	Studies cause and natural history of pancreatic cancer (includes PanScan).
Pancreatic Cancer Detection Consortium (PCDC) [ ]	Develops/tests early detection biomarkers.
Pancreatic Ductal Adenocarcinoma (PDAC) Stromal Reprogramming Consortium (PSRC)	Studies tumor microenvironment in PDAC progression and therapy response.
Pancreatic Specialized Programs of Research Excellence (Pancreatic SPOREs)	Translates basic research into clinical settings.
RAS Initiative [ ]	Develops therapies for RAS mutations in pancreatic cancer.

The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

Cortiana, V.; Abbas, R.H.; Chorya, H.; Gambill, J.; Mahendru, D.; Park, C.H.; Leyfman, Y. Personalized Medicine in Pancreatic Cancer: The Promise of Biomarkers and Molecular Targeting with Dr. Michael J. Pishvaian. Cancers 2024 , 16 , 2329. https://doi.org/10.3390/cancers16132329

Cortiana V, Abbas RH, Chorya H, Gambill J, Mahendru D, Park CH, Leyfman Y. Personalized Medicine in Pancreatic Cancer: The Promise of Biomarkers and Molecular Targeting with Dr. Michael J. Pishvaian. Cancers . 2024; 16(13):2329. https://doi.org/10.3390/cancers16132329

Cortiana, Viviana, Rabab Hunaid Abbas, Harshal Chorya, Jade Gambill, Diksha Mahendru, Chandler H. Park, and Yan Leyfman. 2024. "Personalized Medicine in Pancreatic Cancer: The Promise of Biomarkers and Molecular Targeting with Dr. Michael J. Pishvaian" Cancers 16, no. 13: 2329. https://doi.org/10.3390/cancers16132329

Article Metrics

Article access statistics, further information, mdpi initiatives, follow mdpi.

Subscribe to receive issue release notifications and newsletters from MDPI journals

Why are gastrointestinal cancer patients getting younger?

Andrés Cervantes, ESMO President

Research is moving forward to adapt clinical practice to a new wave of early-onset cases of cancer in the digestive tract

Early-onset gastrointestinal (GI) cancers, occurring in people below the age of 50, are on the rise in high-income countries ( JAMA Netw Open 2023 Aug 1;6(8):e2328171 ) - a trend that is especially worrisome because, taken together, GI cancers account for a quarter of all new cancer cases and a third of cancer deaths worldwide ( Lancet Gastroenterol Hepatol 2024;9:229–37 ). Research is ongoing to understand the causes and inform prevention and management of these young patients, as a dedicated session at the ESMO Gastrointestinal Cancers Congress 2024 shows. Emerging data on the features and outcomes of early-onset disease lead us to a differentiated view of the phenomenon across different tumour types.

As presented in Munich, one study conducted at two institutions in Greece and Cyprus found that the clinical and molecular characteristics of colorectal cancer , the most common GI malignancy, are generally similar across patient age groups (Abstract 139P). Notable differences previously described pertain to the tumour location, which is more frequently the left colon in younger patients, and to an increased likelihood of early-onset disease being linked to a hereditary cancer risk such as Lynch syndrome ( N Engl J Med 2022;386:1547-58 ). Early-onset colorectal cancer is also more likely to be diagnosed at an advanced stage, possibly because younger patients do not pay as close attention to the relevant symptoms. In the metastatic setting, patients younger than 50 years may additionally have a poorer prognosis than their older counterparts (Abstract 80P).

Early-onset cancer of the pancreas similarly appeared to be associated with more aggressive disease at several institutions in Tunisia, where patients under 45 years of age were reported to have lower rates of curative surgery and higher rates of relapse after surgery (Abstract 365P). Patients diagnosed with biliary tract cancer by the age of 50, by contrast, may have a somewhat better prognosis in the metastatic setting than their elders, with more opportunities to receive personalised therapies thanks to a higher frequency of targetable alterations such as FGFR2 fusions (Abstract 291P).

The optimal management of younger patients , for example through more aggressive treatment approaches, remains in many respects to be determined, and is further complicated by the specific psychosocial issues surrounding rehabilitation, returning to work after completing treatment and survivorship issues that this age group faces. However, the knowledge we do have provides a strong rationale for immediate changes in practice such as lowering the starting age of colorectal cancer screening programmes and offering germline genetic testing to all patients diagnosed before the age of 50, followed by genetic counselling for them and their relatives as appropriate. In the medium term, measures are also needed to strengthen citizens’ health literacy and improve overall participation in screening campaigns , which remain largely underutilised across Europe.

Future epidemiological research should aim to define more precisely the risk factors for early-onset GI cancers , as similar incidence trends across countries in the developed world suggest environmental and lifestyle causes that could become the target of future prevention strategies. The Western-style diet, low physical activity, obesity, alcoholism, tobacco consumption and use of antibiotics have all been proposed as contributors to changes in the gut microbiome and gut inflammation that can lead to carcinogenesis ( Cancer Discov 2023;13:538–51 ), but their impact on cancer risk and its potential to be reversed still need to be confirmed. A society like ESMO will have its role to play in disseminating advances in our scientific understanding of this phenomenon and educating doctors and patients on health-promoting lifestyles that could help to break the trend.

Beyond Weight Management: 5 Other Potential Benefits of Semaglutide

Ozempic and Wegovy have been approved by the FDA to manage weight and control type 2 diabetes, but research has shown that it may have many other benefits.
New studies found that semaglutide, the active ingredient in Ozempic and Wegovy, may protect kidney health.
Other conditions semaglutide may be able to treat include dementia, pancreatitis, and polycystic ovary syndrome, or PCOS.

Semaglutide, the active ingredient in the diabetes and weight management drugs Ozempic and Wegovy, may offer yet another potential benefit: protecting kidney health.

Clinical trial results published recently in The New England Journal of Medicine revealed that, compared to people who took a placebo, those taking semaglutide had a 24% lower chance of having a major kidney disease event, such as needing dialysis , getting a kidney transplant, losing at least half of their kidney function, or dying from kidney-related or cardiovascular causes. The trial included about 3,500 people with kidney disease and type 2 diabetes.

Another recent study that included 17,600 people who were obese or overweight and who had cardiovascular disease found that 22% fewer people experienced kidney-related events in a group receiving a weekly semaglutide injection compared with a group taking a placebo.

The studies suggest that semaglutide shows promise for treating chronic kidney disease , which occurs when the kidneys become damaged and gradually lose the ability to filter blood the way they should. More than one in seven adults in the United States has the condition, which has no cure.

As it stands, the Food and Drug Administration has approved Wegovy for weight management and Ozempic to help control type 2 diabetes. After researchers discovered that the drugs lowered the risk of major adverse cardiovascular events by 20%, the FDA also approved them to lower the odds of cardiovascular death, heart attack, and stroke in adults with cardiovascular disease and overweight or obesity.

However, researchers have not only found that Ozempic and Wegovy—which belong to a class of drugs called glucagon-like peptide-1 ( GLP-1 ) receptor agonists—may have the potential to protect kidney health, but that the drugs may also have the potential to curb a slew of additional conditions.

“Obesity is associated with more than 200 comorbidities,” Priya Jaisinghani, MD , a clinical assistant professor at NYU Grossman School of Medicine in New York City, told Health . “Prevention and treatment of obesity will play a role in prevention, reversal, or remission of such comorbidities.”

Here are some other conditions that research shows semaglutide may improve or reduce the risk of a person developing.

NurPhoto / Contributor / Getty Images

Colorectal Cancer

A 2023 study showed that semaglutide lowered the rate of colorectal cancer —cancer affecting the large intestine or rectum—in people with type 2 diabetes.

For the study, researchers compared cancer diagnoses within 15 years of starting semaglutide and other diabetes treatments, including metformin and insulin, in more than 1.2 million people. Approximately 18,500 people who took GLP-1s for diabetes had a 25% lower rate of colorectal cancer compared to the same amount who took metformin. And the more than 22,000 people who took a GLP-1 had a 44% reduced risk of colorectal cancer compared to the same amount who took insulin.

It’s unclear exactly why semaglutide might affect colorectal cancer rates, but the authors said it could be because diabetes and obesity—two conditions that the drug helps manage—can increase the risk of developing this cancer.

Studies have suggested that people with type 2 diabetes who take GLP-1 receptor agonists, such as semaglutide, may have a lower rate of dementia compared to people given a placebo.

Because of this, researchers have begun trials to evaluate how the drug affects people with early Alzheimer’s disease.

One way that semaglutide might lower a person’s risk of Alzheimer’s is by improving diabetes, a risk factor for dementia.

Per the Alzheimer’s Association, diabetes raises the risk of heart disease, which damages blood vessels, including those in the brain. Damaged blood vessels may contribute to the development of Alzheimer’s. Too much sugar in the blood can also cause inflammation, which can also cause damage to the brain.

Pancreatitis

Research presented June 1 at the Endocrine Society’s meeting in Boston showed that semaglutide may lower the risk of acute pancreatitis , the sudden inflammation of the pancreas.

Investigators measured what happened when 638,501 people with a history of pancreatitis took either no medication, semaglutide, or other drugs for diabetes and obesity called SGLT2 inhibitors and DPP4s.

Within 15 years of starting semaglutide, 15% of participants developed pancreatitis again, compared to 24% who took SGLT2 inhibitors, 23% on DPP4s, and almost 52% of people not taking medication.

Substance Addiction

A small study published in 2023 suggested that semaglutide may lower symptoms of alcohol use disorder , which involves problems limiting alcohol intake.

“GLP-1s seem to alter some of the craving and reward drive in the brain, and we don’t completely understand how that’s happening at this point,” Jesse Richards, DO , an internal medicine physician at the University of Oklahoma, who led the study, told Health. “There seems to be a decrease in the cravings or the motivation to pursue.”

The research was only a “case series” study, which means it’s not robust enough to draw broad conclusions from. However, Richards said he’s leading a randomized controlled trial to monitor alcohol use in people on semaglutide or a placebo, with results expected next year.

Polycystic Ovary Syndrome

Semaglutide is used off-label—meaning it’s prescribed by doctors for a non-FDA approved purpose—to treat symptoms of polycystic ovary syndrome (PCOS) , a hormone imbalance that usually occurs when a person has high-than-normal levels of androgens. The condition affects the ovaries, causing them to develop multiple small cysts.

Anecdotal evidence and some small studies suggest that semaglutide may be helpful for people with PCOS.

Many people with PCOS are overweight or obese and may have insulin resistance, prediabetes, or diabetes, Marilyn Tan, MD , chief of the Endocrine Clinic at Stanford University School of Medicine, told Health .

“With weight loss and improved glucose control, menstrual cycles may become more regular, and sometimes hyperandrogenism (excess hair, acne) may improve,” Tan said.

However, randomized controlled trials are needed to confirm semaglutide’s positive effect on PCOS, she added.

The Downsides

Semaglutide might offer some people benefits, but the drugs aren’t for everyone.

If you have medullary thyroid cancer or a history of gallbladder disease or pancreatitis, your doctor may not recommend semaglutide. It may not be a good choice for underweight people, Richards added.

“These medications slow down the gastrointestinal tract, so I do not generally prescribe them if someone has uncontrolled gastroparesis or constipation,” Alyssa Lampe Dominguez, MD , an endocrinologist at the Keck School of Medicine at the University of Southern California in Los Angeles, told Health.

The drug does carry the risk of numerous side effects . Common ones include nausea, vomiting, diarrhea, stomach pain, and constipation.

It’s important to know that if you do go off the drug, you may gain about two-thirds of the weight back should you stop taking the medication, Dominguez said.

“Cost is another important consideration as many insurance plans do not yet cover these medications for obesity,” Dominguez added.

Perkovic V, Tuttle KR, Rossing P, et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes . N Engl J Med . Published online May 24, 2024. doi:10.1056/NEJMoa2403347

Colhoun HM, Lingvay I, Brown PM, et al. Effect of semaglutide on kidney outcomes in people with overweight or obesity and established cardiovascular disease in the SELECT trial . Nephrol Dial Transplant . 2024;39(Supplement_1):i1128-i1130. doi:10.1093/ndt/gfae069.692

National Institute of Diabetes and Digestive and Kidney Diseases. Kidney disease statistics for the United States .

Food and Drug Administration. FDA approves first treatment to reduce risk of serious heart problems specifically in adults with obesity or overweight .

Wang L, Wang W, Kaelber DC, Xu R, Berger NA. GLP-1 receptor agonists and colorectal cancer risk in drug-naive patients with type 2 diabetes, with and without overweight/obesity . JAMA Oncol . 2024;10(2):256-258. doi:10.1001/jamaoncol.2023.5573

UT Health San Antonio. Diabetes, obesity drug studied for affects on Alzheimer's .

Alzheimer's Association. Diabetes and cognitive decline .

Endocrine Society. GLP-1 medications for type 2 diabetes and obesity may lower risk of acute pancreatitis .

Richards JR, Dorand MF, Royal K, Mnajjed L, Paszkowiak M, Simmons WK. Significant decrease in alcohol use disorder symptoms secondary to semaglutide therapy for weight loss: a case series . J Clin Psychiatry . 2023;85(1):23m15068. doi:10.4088/JCP.23m15068

National Library of Medicine: MedlinePlus. Semaglutide injection .

Javascript is currently disabled in your browser. Several features of this site will not function whilst javascript is disabled.

Why Publish With Us?
Editorial Policies
Author Guidelines
Peer Review Guidelines
Open Outlook
Submit New Manuscript

Sustainability
Press Center
Testimonials
Favored Author Program
Permissions
Pre-Submission

open access to scientific and medical research

Expressions of interest for Editor-in-Chief - the International Medical Case Reports Journal Read more

Back to Journals » Cancer Management and Research » Volume 11

Cancer Management and Research

Issn: 1179-1322.

About Journal
Journal Metrics
Peer Reviewers
View all (4663)
Volume 16, 2024 (69)
Volume 15, 2023 (153)
Volume 14, 2022 (330)
Volume 13, 2021 (890)
Volume 12, 2020 (1256)
Volume 11, 2019 (969)
Volume 10, 2018 (645)
Volume 9, 2017 (89)
Volume 8, 2016 (17)
Volume 7, 2015 (33)
Volume 6, 2014 (43)
Volume 5, 2013 (41)
Volume 4, 2012 (47)
Volume 3, 2011 (32)
Volume 2, 2010 (32)
Volume 1, 2009 (17)

Archive: Volume 11, 2019

Deficient Regulatory Innate Lymphoid Cells and Differential Expression of miRNAs in Acute Myeloid Leukemia Quantified by Next Generation Sequence

Yu J, Li Y, Pan Y, Liu Y, Xing H, Xie X, Wan D, Jiang Z

Cancer Management and Research 2019 , 11:10969-10982

Published Date: 3 January 2020

circPCNX and Pecanex Promote Hepatocellular Carcinoma Cell Viability by Inhibiting miR-506

Sun P, Fan X, Hu X, Fu X, Wei Q, Zang Y

Cancer Management and Research 2019 , 11:10957-10967

Time-Varying Effects of Marital Status on Gastric Cancer: A Population-Based Study

Cancer Management and Research 2019 , 11:10949-10955

Circulating Tumor Cell Detection In Epithelial Ovarian Cancer Using Dual-Component Antibodies Targeting EpCAM And FRα

Li N, Zuo H, Chen L, Liu H, Zhou J, Yao Y, Xu B, Gong H, Weng Y, Hu Q, Song Q, Peng M, Cheng Y

Cancer Management and Research 2019 , 11:10939-10948

Pre/Post-Treatment Dynamic of Inflammatory Markers Has Prognostic Value in Patients with Small Hepatocellular Carcinoma Managed by Stereotactic Body Radiation Therapy

Zhuang Y, Yuan BY, Hu Y, Chen GW, Zhang L, Zhao XM, Chen YX, Zeng ZC

Cancer Management and Research 2019 , 11:10929-10937

New Preoperative Nomogram Using the Centrality Index to Predict High Nuclear Grade Clear Cell Renal Carcinoma

Feng Z, Lou S, Zhang L, Zhang L, Lan W, Wang M, Shen Q, Hu Z, Chen F

Cancer Management and Research 2019 , 11:10921-10928

Survival After Abdominal Q-M Type B versus C2 Radical Hysterectomy for Early-Stage Cervical Cancer

Chen C, Wang W, Liu P, Li P, Wang L, Jin S, Bin X, Lang J

Cancer Management and Research 2019 , 11:10909-10919

Published Date: 31 December 2019

Radiotherapy for patients with completely resected pathologic IIIA(N2) non–small-cell lung cancer: a retrospective analysis

Zhu Y, Fu L, Jing W, Kong L, Yu J

Cancer Management and Research 2019 , 11:10901-10908

MiR-935 Promotes Clear Cell Renal Cell Carcinoma Migration and Invasion by Targeting IREB2

Liu F, Chen Y, Chen B, Liu C, Xing J

Cancer Management and Research 2019 , 11:10891-10900

Published Date: 30 December 2019

Silencing of Peroxiredoxin 1 Inhibits the Proliferation of Esophageal Cancer Cells and Promotes Apoptosis by Inhibiting the Activity of the PI3K/AKT Pathway

Song Y, Liu H, Cui C, Peng X, Wang C, Tian X, Li W

Cancer Management and Research 2019 , 11:10883-10890

The Significance of Adjuvant Therapy for Extrahepatic Cholangiocarcinoma After Surgery

Wang G, Wang Q, Fan X, Ding L, Dong L

Cancer Management and Research 2019 , 11:10871-10882

Long Intergenic Non-Coding RNA 01121 Promotes Breast Cancer Cell Proliferation, Migration, and Invasion via the miR-150-5p/HMGA2 Axis

Wang Z, Wang P, Cao L, Li F, Duan S, Yuan G, Xiao L, Guo L, Yin H, Xie D, Zhu J, Chen X, Zhang M

Cancer Management and Research 2019 , 11:10859-10870

Application of Radiomics for Personalized Treatment of Cancer Patients

Meng Y, Sun J, Qu N, Zhang G, Yu T, Piao H

Cancer Management and Research 2019 , 11:10851-10858

LncRNA PCAT-1 Promoted ESCC Progression via Regulating ANXA10 Expression by Sponging miR-508-3p

Zang B, Zhao J, Chen C

Cancer Management and Research 2019 , 11:10841-10849

Development and Validation of Nomograms for Predicting the Prognosis of Triple-Negative Breast Cancer Patients Based on 379 Chinese Patients

Shi H, Wang XH, Gu JW, Guo GL

Cancer Management and Research 2019 , 11:10827-10839

Potential Antiangiogenic Treatment Eligibility of Patients with Squamous Non-Small–Cell Lung Cancer: EPISQUAMAB Study (GFPC 2015-01)

Vergnenègre A, Basse V, Le Garff G, Bylicki O, Dubos-Arvis C, Comet B, Marcq M, Le Treut J, Auliac JB, Madroszyk A, Fraboulet G, Crequit J, Thomas P, Paleiron N, Monnet I

Cancer Management and Research 2019 , 11:10821-10826

Published Date: 27 December 2019

Long Non-Coding RNA LINC00511 Mediates the Effects of ESR1 on Proliferation and Invasion of Ovarian Cancer Through miR-424-5p and miR-370-5p

Wang K, Zhu G, Bao S, Chen S

Cancer Management and Research 2019 , 11:10807-10819

A Case with Rectal Cancer Relapses After Clinical Complete Remission Following Neoadjuvant Chemoradiotherapy

Zhang PB, Huang ZL, Li JB, Huang XY

Cancer Management and Research 2019 , 11:10801-10806

Increased Stromal Infiltrating Lymphocytes are Associated with Circulating Tumor Cells and Metastatic Relapse in Breast Cancer Patients After Neoadjuvant Chemotherapy

Liu J, Xu Y, Yu M, Liu Z, Xu Y, Ma G, Zhou W, Kong P, Ling L, Wang S, Pan H, Zhao Y

Cancer Management and Research 2019 , 11:10791-10800

Beyond Ruxolitinib: Fedratinib and Other Emergent Treatment Options for Myelofibrosis

Bewersdorf JP, Jaszczur SM, Afifi S, Zhao JC, Zeidan AM

Cancer Management and Research 2019 , 11:10777-10790

Published Date: 24 December 2019

Thoracic Radiotherapy Benefits Elderly Extensive-Stage Small Cell Lung Cancer Patients with Distant Metastasis

Qi J, Xu L, Sun J, Wang X, Zhao L

Cancer Management and Research 2019 , 11:10767-10775

Malignant Triton Tumor in a Child: Case Report and Literature Review

Zhao A, Ding D, Li X, Wang J

Cancer Management and Research 2019 , 11:10759-10766

Clinicopathological Characteristics and Survival of Small Cell Carcinoma of the Salivary Gland: a Population-Based Study

Bai J, Zhao F, Pan S

Cancer Management and Research 2019 , 11:10749-10757

T-Regulatory Cells In Tumor Progression And Therapy

Verma A, Mathur R, Farooque A, Kaul V, Gupta S, Dwarakanath BS

Cancer Management and Research 2019 , 11:10731-10747

Downregulation of CDH16 in Papillary Thyroid Cancer and Its Potential Molecular Mechanism Analysed by qRT-PCR, TCGA and in silico Analysis

Li P, Wu Q, Sun Y, Pan X, Han Y, Ye B, Zhang Y, Dong J, Zheng Z

Cancer Management and Research 2019 , 11:10719-10729

Published Date: 23 December 2019

Super-Enhancer-Associated Hub Genes In Chronic Myeloid Leukemia Identified Using Weighted Gene Co-Expression Network Analysis

Ma H, Qu J, Luo J, Qi T, Tan H, Jiang Z, Zhang H, Qu Q

Cancer Management and Research 2019 , 11:10705-10718

Comparison of Microwave Ablation and Transarterial Chemoembolization for Single-Nodule Hepatocellular Carcinoma Smaller Than 5cm: A Propensity Score Matching Analysis

Cui R, Wang X, Ma C, Liu T, Cheng Z, Han Z, Liu F, Yu X, Yu J, Liang P

Cancer Management and Research 2019 , 11:10695-10704

A Novel Prognostic Scoring Model Based on Albumin and γ-Glutamyltransferase for Hepatocellular Carcinoma Prognosis

Wang L, Li Q, Zhang J, Lu J

Cancer Management and Research 2019 , 11:10685-10694

L61H46 Shows Potent Efficacy Against Human Pancreatic Cancer Through Inhibiting STAT3 Pathway [Erratum]

Bai E, Yang L, Xiang Y, Hu W, Li C, Lin J, Dai X, Liang G, Jin R, Zhao C

Cancer Management and Research 2019 , 11:10683-10684

MMP-2, MMP-9, TIMP-1, and TIMP-2 in the Peripheral Blood of Patients with Differentiated Thyroid Carcinoma

Zhang W, Song B, Yang T

Cancer Management and Research 2019 , 11:10675-10681

The Personalized Shoulder Reconstruction Assisted by 3D Printing Technology After Resection of the Proximal Humerus Tumours

Hu H, Liu W, Zeng Q, Wang S, Zhang Z, Liu J, Zhang Y, Shao Z, Wang B

Cancer Management and Research 2019 , 11:10665-10673

lncRNA DGCR5 Up-Regulates TGF-β1, Increases Cancer Cell Stemness and Predicts Survival of Prostate Cancer Patients

Li B, Guo Z, Liang Q, Zhou H, Luo Y, He S, Lin Z

Cancer Management and Research 2019 , 11:10657-10663

Amyloid Beta (A4) Precursor Protein: A Potential Biomarker for Recurrent Nasopharyngeal Carcinoma

Li XY, Meng HL, Li KG, Yang XH, Zhu XD, Li L, Liang ZG, Pan XB, Zeng FY, Qu S

Cancer Management and Research 2019 , 11:10651-10656

Published Date: 20 December 2019

A Novel Scoring System for Patients with Recurrence of Hepatocellular Carcinoma After Undergoing Minimal Invasive Therapies

Wang Q, Ma L, Li J, Yuan C, Sun J, Li K, Qin L, Zang C, Zhao Y, Zhao Y, Zhang Y

Cancer Management and Research 2019 , 11:10641-10649

LncRNA FOXD2-AS1 Regulates miR-25-3p/Sema4c Axis To Promote The Invasion And Migration Of Colorectal Cancer Cells

Zhang M, Jiang X, Jiang S, Guo Z, Zhou Q, He J

Cancer Management and Research 2019 , 11:10633-10639

Published Date: 19 December 2019

High Inflammatory Factor Grading Predicts Poor Disease-Free Survival in AJCC Stage I-II Hepatocellular Carcinoma Patients After R0 Resection

Zhang M, Chua MS, Hu J, Li H, Zhang S, Wu L, Han B

Cancer Management and Research 2019 , 11:10623-10632

Baohuoside I Inhibits the Proliferation of Pancreatic Cancer Cells via mTOR/S6K1-Caspases/Bcl2/Bax Apoptotic Signaling

Ni F, Tang H, Wang C, Zhang H, Zheng C, Zhang N, Chen B, Sun L

Cancer Management and Research 2019 , 11:10609-10621

miR-503 Inhibits Proliferation, Migration, And Angiogenesis Of Glioma By Acting On VEGFA Through Targeting LRIG2

Sun SL, Shu YG, Tao MY

Cancer Management and Research 2019 , 11:10599-10608

Risk Factors of Deterioration in Quality of Life Scores in Thyroid Cancer Patients After Thyroidectomy

Li J, Xue LB, Gong XY, Yang YF, Zhang BY, Jin J, Shi QF, Liu YH

Cancer Management and Research 2019 , 11:10593-10598

Decreased expression of miR-410-3p correlates with poor prognosis and tumorigenesis in human glioma

Wang C, Huang S, Rao S, Hu J, Zhang Y, Luo J, Wang H

Cancer Management and Research 2019 , 11:10581-10592

Published Date: 18 December 2019

Metastasectomy Improves the Survival of Gastric Cancer Patients with Krukenberg Tumors: A Retrospective Analysis of 182 patients

Ma F, Li Y, Li W, Kang W, Liu H, Ma S, Xie Y, Zhong Y, Xu Q, Wang B, Xue L, Tian Y

Cancer Management and Research 2019 , 11:10573-10580

Dynamic Changes Of Body Image And Quality Of Life In Breast Cancer Patients

Wu TY, Chang TW, Chang SM, Lin YY, Wang JD, Kuo YL

Cancer Management and Research 2019 , 11:10563-10571

Published Date: 17 December 2019

Serum Dickopff 1 as a Novel Biomarker in Hepatocellular Carcinoma Diagnosis and Follow Up After Ablative Therapy

Younis YS, Alegaily HS, Elagawy W, Semeya AA, Abo-Amer YEE, El-Abgeegy M, Mostafa SM, Elsergany HF, Abd-Elsalam S

Cancer Management and Research 2019 , 11:10555-10562

GALE Promotes the Proliferation and Migration of Glioblastoma Cells and Is Regulated by miR-let-7i-5p

Sun X, Xue H, Xiong Y, Yu R, Gao X, Qian M, Wang S, Wang H, Xu J, Chen Z, Deng L, Li G

Cancer Management and Research 2019 , 11:10539-10554

Published Date: 16 December 2019

Downregulation of lncRNA NCK1-AS1 Inhibits Cancer Cell Migration and Invasion in Nasopharyngeal Carcinoma by Upregulating miR-135a

Hu H, Li H, Feng X

Cancer Management and Research 2019 , 11:10531-10537

LncRNA TP73-AS1 Activates TGF-β1 to Promote the Migration and Invasion of Colorectal Cancer Cell

Li M, Jin Y, Li Y

Cancer Management and Research 2019 , 11:10523-10529

Current Understanding of Circular RNAs in Gastric Cancer

Tang X, Zhu J, Liu Y, Chen C, Liu T, Liu J

Cancer Management and Research 2019 , 11:10509-10521

Published Date: 13 December 2019

Oxymatrine Inhibits the Proliferation and Invasion of Breast Cancer Cells via the PI3K Pathway

Guo L, Yang T

Cancer Management and Research 2019 , 11:10499-10508

Prediction of Overall Survival of Patients with Completely Resected Non-Small Cell Lung Cancer: Analyses of Preoperative Spirometry, Preoperative Blood Tests, and Other Clinicopathological Data

Shi M, Zhan C, Shi J, Wang Q

Cancer Management and Research 2019 , 11:10487-10497

CDH1 (E-Cadherin) Mutation and Gastric Cancer: Genetics, Molecular Mechanisms and Guidelines for Management

Cancer Management and Research 2019 , 11:10477-10486

First-In-Human Phase I Study Of A Dual mTOR Kinase And DNA-PK Inhibitor (CC-115) In Advanced Malignancy

Munster P, Mita M, Mahipal A, Nemunaitis J, Massard C, Mikkelsen T, Cruz C, Paz-Ares L, Hidalgo M, Rathkopf D, Blumenschein Jr G, Smith DC, Eichhorst B, Cloughesy T, Filvaroff EH, Li S, Raymon H, de Haan H, Hege K, Bendell JC

Cancer Management and Research 2019 , 11:10463-10476

Long Non-Coding RNA HCP5 Facilitates Cell Invasion And Epithelial-Mesenchymal Transition In Oral Squamous Cell Carcinoma By miR-140-5p/SOX4 Axis

Zhao J, Bai X, Feng C, Shang X, Xi Y

Cancer Management and Research 2019 , 11:10455-10462

Published Date: 12 December 2019

Three-Dimensional CT Texture Analysis to Differentiate Colorectal Signet-Ring Cell Carcinoma and Adenocarcinoma

Yue Y, Hu F, Hu T, Sun Y, Tong T, Gu Y

Cancer Management and Research 2019 , 11:10445-10453

Suppressed Expression of CXCL14 in Hepatocellular Carcinoma Tissues and Its Reduction in the Advanced Stage of Chronic HBV Infection

Lin Y, Chen BM, Yu XL, Yi HC, Niu JJ, Li SL

Cancer Management and Research 2019 , 11:10435-10443

First-Line Doublet Chemotherapy for Metastatic Triple-Negative Breast Cancer: Circulating Tumor Cell Analysis of the tnAcity Trial

Liu MC, Janni W, Georgoulias V, Yardley DA, Harbeck N, Wei X, McGovern D, Beck R

Cancer Management and Research 2019 , 11:10427-10433

Cost-Effectiveness Analysis of First-Line Cetuximab Plus Leucovorin, Fluorouracil, and Oxaliplatin (FOLFOX-4) versus FOLFOX-4 in Patients with RAS Wild-Type Metastatic Colorectal Cancer

Bai L, Zhang P, Zhou K, Liao W, Li Q

Cancer Management and Research 2019 , 11:10419-10426

MiR-326: Promising Biomarker for Cancer

Pan YJ, Wan J, Wang CB

Cancer Management and Research 2019 , 11:10411-10418

Published Date: 11 December 2019

Stanniocalcin 2 (STC2) Expression Promotes Post-Radiation Survival, Migration and Invasion of Nasopharyngeal Carcinoma Cells [Corrigendum]

He H, Qie S, Guo Q, Chen S, Zou C, Lu T, Su Y, Zong J, Xu H, He D, Xu Y, Chen B, Pan J, Sang N, Lin S

Cancer Management and Research 2019 , 11:10409-10410

The Characteristics and Survival of Patients with Mesorectum Metastatic Lymph Nodes from Cervical Cancer

Wang W, Liu X, Zhang F, Hu K

Cancer Management and Research 2019 , 11:10401-10408

LncRNA PTCSC3 Inhibits Tumor Growth and Cancer Cell Stemness in Gastric Cancer by Interacting with lncRNA Linc-pint

Hong L, Wang H, Wang J, Wei S, Zhang F, Han J, Liu Y, Ma M, Liu C, Xu Y, Jiang D

Cancer Management and Research 2019 , 11:10393-10399

The Value of DNA Quantitative Cytology Test for the Screening of Endometrial Cancer

Yang B, Yu M, Xu J, Su Y, Ai Z

Cancer Management and Research 2019 , 11:10383-10391

Combined Use of Mean Platelet Volume/Platelet Count Ratio and Platelet Distribution Width to Distinguish Between Patients with Nasopharyngeal Carcinoma, Those with Benign Tumors of the Nasopharynx, and Healthy Subjects

Zhang X, Qin Y, Chen M, Wu Y, Lin F

Cancer Management and Research 2019 , 11:10375-10382

Decision of Adjuvant Systemic Treatment in HR+ HER2- Early Invasive Breast Cancer: Which Biomarkers Could Help?

Alexandre M, Maran-Gonzalez A, Viala M, Firmin N, D'Hondt V, Gutowski M, Bourgier C, Jacot W, Guiu S

Cancer Management and Research 2019 , 11:10353-10373

A Novel lncRNA MYOSLID/miR-1286/RAB13 Axis Plays a Critical Role in Osteosarcoma Progression

Yang S, Chen M, Lin C

Cancer Management and Research 2019 , 11:10345-10351

Published Date: 10 December 2019

Lack of Efficacy: When Opioids Do Not Achieve Analgesia from the Beginning of Treatment in Cancer Patients

Corli O, Damia G, Galli F, Verrastro C, Broggini M

Cancer Management and Research 2019 , 11:10337-10344

Overview of microRNA-199a Regulation in Cancer

Wang Q, Ye B, Wang P, Yao F, Zhang C, Yu G

Cancer Management and Research 2019 , 11:10327-10335

Spinal Intramedullary Solitary Fibrous Tumor: A Rare and Challenging Diagnosis

Yang C, Xu Y, Liu X

Cancer Management and Research 2019 , 11:10321-10326

Cervical Cancer Cells-Secreted Exosomal microRNA-221-3p Promotes Invasion, Migration and Angiogenesis of Microvascular Endothelial Cells in Cervical Cancer by Down-Regulating MAPK10 Expression

Zhang L, Li H, Yuan M, Li M, Zhang S

Cancer Management and Research 2019 , 11:10307-10319

Published Date: 9 December 2019

Validation of the Chinese Version of the Shame and Stigma Scale in Patients with Head and Neck Cancer

Tseng WT, Lee Y, Hung CF, Lin PY, Chien CY, Chuang HC, Fang FM, Li SH, Huang TL, Chong MY, Wang LJ

Cancer Management and Research 2019 , 11:10297-10305

CXCR7, a Prognostic Biomarker in Cervical Squamous Cell Carcinoma, May Be a Screening Index for Treatment Options at Stages IB1 and IIA1

Zhao D, Qin W, Zhao C, Long J, Li M

Cancer Management and Research 2019 , 11:10287-10296

ATG3, a Target of miR-431-5p, Promotes Proliferation and Invasion of Colon Cancer via Promoting Autophagy

Huang W, Zeng C, Hu S, Wang L, Liu J

Cancer Management and Research 2019 , 11:10275-10285

Head and Eye Trauma Before Retinoblastoma Diagnosis

Chen R, Ye H, Liu S, Lin Y, Xiao W, Bi S, Chen G, Zhang T, Chen J, Yang H

Cancer Management and Research 2019 , 11:10269-10274

Published Date: 6 December 2019

NLRP3 Inflammasome Mediated Interleukin-1β Production in Cancer-Associated Fibroblast Contributes to ALA-PDT for Cutaneous Squamous Cell Carcinoma

Nie S, Wang X, Wang H

Cancer Management and Research 2019 , 11:10257-10267

Clinical Management of Risk of Radiation Pneumonia with Serum Markers During the Radiotherapy for Patients with Thoracic Malignant Tumors

Deng Y, Qiu T, Patel N, Zhou S, Xue T, Zhang H

Cancer Management and Research 2019 , 11:10249-10256

Published Date: 5 December 2019

Cost-Effectiveness Analysis Of EGFR Mutation Testing And Afatinib Versus Gemcitabine-Cisplatin As First-Line Therapy For Advanced Non-Small-Cell Lung Cancer In China

You R, Liu J, Wu DBC, Qian X, Lyu B, Zhang Y, Luo N

Cancer Management and Research 2019 , 11:10239-10248

miR-194 Inhibits the Proliferation of SW620 Colon Cancer Stem Cells Through Downregulation of SSH2 Expression

Sun B, Fang YT, Jin DJ, Chen ZY, Li ZY, Gu XD, Xiang JB

Cancer Management and Research 2019 , 11:10229-10238

Published Date: 4 December 2019

The Role of Sharp Dissection in Nipple-Sparing Mastectomy: A Safe Procedure with No Necrosis of the Nipple-Areolar Complex

Yang CQ, Ji F, Gao HF, Zhang LL, Yang M, Zhu T, Chen M, Li J, Wang K

Cancer Management and Research 2019 , 11:10223-10228

CircCDYL Serves as a New Biomarker in Mantle Cell Lymphoma and Promotes Cell Proliferation

Mei M, Wang Y, Wang Q, Liu Y, Song W, Zhang M

Cancer Management and Research 2019 , 11:10215-10221

Published Date: 3 December 2019

B7-H3 Induces Ovarian Cancer Drugs Resistance Through An PI3K/AKT/BCL-2 Signaling Pathway

Zhou L, Zhao Y

Cancer Management and Research 2019 , 11:10205-10214

Decitabine-Containing Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Intermediate- and High-Risk Myelodysplastic Syndrome/Acute Myeloid Leukemia: Potential Decrease in the Incidence of Acute Graft versus Host Disease

Wang QY, Li Y, Liang ZY, Yin Y, Liu W, Wang Q, Dong YJ, Sun YH, Xu WL, Ren HY

Cancer Management and Research 2019 , 11:10195-10203

The Frequency of Circulating Tumour Cells and the Correlation with the Clinical Response to Standard Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma: A Prospective Study

Qian Y, Wu Y, Yuan Z, Niu X, He Y, Peng J, Zhou F, Wei S, Hu D, Zhou Y

Cancer Management and Research 2019 , 11:10187-10193

Published Date: 2 December 2019

Central Nervous System Involvement in Patients with Diffuse Large B Cell Lymphoma: Analysis of the Risk Factors and Prognosis from a Single-Center Retrospective Cohort Study

Ma J, Li Q, Shao J, Ma Y, Lin Z, Kang H, Chen B

Cancer Management and Research 2019 , 11:10175-10185

Comparison of Double Sleeve Lobectomy by Uniportal Video-Assisted Thoracic Surgery (VATS) and Thoracotomy for NSCLC Treatment

Wu L, Wang H, Cai H, Fan J, Jiang G, He Y, Jiang L

Cancer Management and Research 2019 , 11:10167-10174

Preoperative Bilirubin Level Predicts Overall Survival and Tumor Recurrence After Resection for Perihilar Cholangiocarcinoma Patients

Li CX, Zhang H, Wang K, Wang X, Li XC

Cancer Management and Research 2019 , 11:10157-10165

HIF1α/miR-520a-3p/AKT1/mTOR Feedback Promotes The Proliferation And Glycolysis Of Gastric Cancer Cells

Pan C, Liu Q, Wu X

Cancer Management and Research 2019 , 11:10145-10156

CSNK2A1 Promotes Gastric Cancer Invasion Through the PI3K-Akt-mTOR Signaling Pathway

Jiang C, Ma Z, Zhang G, Yang X, Du Q, Wang W

Cancer Management and Research 2019 , 11:10135-10143

The Effects of Matrine in Combination with Docetaxel on Castration-Resistant (Androgen-Independent) Prostate Cancer

Li Q, Xu J, He Z, Wen X, Wang F, Zhang P, Li J, Song B, Wang Q, Li R, Huang H

Cancer Management and Research 2019 , 11:10125-10133

LncRNA miR143HG Up-Regulates p53 In Endometrial Carcinoma By Sponging miR-125a

Shi F, Wang T, Liu Z, Zhang Y, Wang J, Zhang K, Su J

Cancer Management and Research 2019 , 11:10117-10123

PRPH2 Activates Hippo Signalling and Suppresses the Invasion and Anoikis Inhibition of Laryngeal Cancer

Dong K, Xue H, Cheng J, Su J, Li D, Zhang J, Zhang H

Cancer Management and Research 2019 , 11:10107-10115

SSBP1 Upregulation In Colorectal Cancer Regulates Mitochondrial Mass

Yang Y, Pan C, Yu L, Ruan H, Chang L, Yang J, Zheng Z, Zheng F, Liu T

Cancer Management and Research 2019 , 11:10093-10106

Bevacizumab in Combination with Pemetrexed and Platinum Significantly Improved the Clinical Outcome of Patients with Advanced Adenocarcinoma NSCLC and Brain Metastases

Tian Y, Zhai X, Tian H, Jing W, Zhu H, Yu J

Cancer Management and Research 2019 , 11:10083-10092

Published Date: 29 November 2019

Risk Assessment for Breast Cancer Development and Its Clinical Impact on Screening Performance in Iranian Women

Nikpour M, Hajian-Tilaki K, Bakhtiari A

Cancer Management and Research 2019 , 11:10073-10082

STIP1 Regulates Proliferation and Migration of Lung Adenocarcinoma Through JAK2/STAT3 Signaling Pathway

Guo X, Yan Z, Zhang G, Wang X, Pan Y, Huang M

Cancer Management and Research 2019 , 11:10061-10072

Stereotactic Radiotherapy for Parasagittal and Parafalcine Meningiomas: Patient Selection and Special Considerations

Pinzi V, Fariselli L, Marchetti M, Scorsetti M, Navarria P

Cancer Management and Research 2019 , 11:10051-10060

Serum Adipokines as Predictors for the Outcome of Prostate Biopsies at Early Stage Prostate Cancer Diagnosis

Ahmad AE, Mohammed A, Bhindi B, Richard PO, Fadaak K, Leão R, Finelli A, Fleshner NE, Kulkarni GS

Cancer Management and Research 2019 , 11:10043-10050

NECTIN4 Promotes Papillary Thyroid Cancer Cell Proliferation, Migration, and Invasion and Triggers EMT by Activating AKT [Corrigendum]

Hao RT, Zheng C, Wu CY, Xia EJ, Zhou XF, Quan RD, Zhang XH

Cancer Management and Research 2019 , 11:10041-10042

Published Date: 28 November 2019

A Nomogram To Predict The Overall Survival Of Breast Cancer Patients And Guide The Postoperative Adjuvant Chemotherapy In China

Wang X, Feng Z, Huang Y, Li H, Cui P, Wang D, Dai H, Song F, Zheng H, Wang P, Cao X, Gu L, Zhang J, Song F, Chen K

Cancer Management and Research 2019 , 11:10029-10039

Simvastatin Evokes An Unpredicted Antagonism For Tamoxifen In MCF-7 Breast Cancer Cells

Ibrahim AB, Zaki HF, Wadie W, Omran MM, Shouman SA

Cancer Management and Research 2019 , 11:10011-10028

Undifferentiated Pleomorphic Sarcoma: Long-Term Follow-Up from a Large Institution

Chen S, Huang W, Luo P, Cai W, Yang L, Sun Z, Zheng B, Yan W, Wang C

Cancer Management and Research 2019 , 11:10001-10009

Published Date: 27 November 2019

Perfusion, Diffusion, Or Brain Tumor Barrier Integrity: Which Represents The Glioma Features Best?

Yan LF, Sun YZ, Zhao SS, Hu YC, Han Y, Li G, Zhang X, Tian Q, Liu ZC, Yang Y, Nan HY, Yu Y, Sun Q, Zhang J, Chen P, Hu B, Li F, Han TH, Wang W, Cui GB

Cancer Management and Research 2019 , 11:9989-10000

Hepatic Arterial Chemoembolization With Arsenic Trioxide Eluting CalliSpheres Microspheres Versus Lipiodol Emulsion: Pharmacokinetics And Intratumoral Concentration In A Rabbit Liver Tumor Model

Duan X, Li H, Ren J, Han X, Chen P, Li F, Huang G, Ju S

Cancer Management and Research 2019 , 11:9979-9988

Published Date: 26 November 2019

ENO1 Acts as a Prognostic Biomarker Candidate and Promotes Tumor Growth and Migration Ability Through the Regulation of Rab1A in Colorectal Cancer

Cheng Z, Shao X, Xu M, Zhou C, Wang J

Cancer Management and Research 2019 , 11:9969-9978

A Novel Preoperative Nomogram for Predicting Lymph Node Invasion in Renal Cell Carcinoma Patients Without Metastasis

Li P, Peng C, Xie Y, Wang L, Gu L, Wu S, Shen D, Xuan Y, Ma X, Zhang X

Cancer Management and Research 2019 , 11:9961-9967

Synchronous Neoplastic Lesions In Referred Patients With Colorectal Cancer: A Retrospective Cohort Study

Li S, Zhu K, Yu W, Wang Y, Wang T, Guo S, Teng G, Guo J

Cancer Management and Research 2019 , 11:9951-9959

Transarterial Chemoembolization and Sorafenib Combined with Microwave Ablation for Advanced Primary Hepatocellular Carcinoma: A Preliminary Investigation of Safety and Efficacy

Ni JY, Sun HL, Luo JH, Jiang XY, Chen D, Wang WD, Chen YT, Huang JH, Xu LF

Cancer Management and Research 2019 , 11:9939-9950

Preoperative Albumin Level Is Superior To Albumin-Globulin Ratio As A Predicting Indicator In Gastric Cancer Patients Who Underwent Curative Resection

Xiao S, Feng F, Liu N, Liu Z, Guo Y, Lian X, Zhang H

Cancer Management and Research 2019 , 11:9931-9938

Published Date: 25 November 2019

Prognostic Role Of Computed Tomography Textural Features In Early-Stage Non-Small Cell Lung Cancer Patients Receiving Stereotactic Body Radiotherapy

Zhang R, Wang C, Cui K, Chen Y, Sun F, Sun X, Xing L

Cancer Management and Research 2019 , 11:9921-9930

AMPH-1 As A Critical Tumor Suppressor That Inhibits Osteosarcoma Progression

Zhang H, Liu Y, Xu K, Mao K, Han W, Xu F, Wan W, Sun Y

Cancer Management and Research 2019 , 11:9913-9919

Downregulation of Proline Hydroxylase 2 and Upregulation of Hypoxia-Inducible Factor 1α are Associated with Endometrial Cancer Aggressiveness

Zhu C, Ding H, Yang J, Zhou Y, Luo Y, Shi S, Zhang Y, Wei Y, Ni G

Cancer Management and Research 2019 , 11:9907-9912

Published Date: 22 November 2019

Retrospective Analysis Of Comparative Outcomes In Recurrent Platinum-Sensitive Ovarian Cancer Treated With Pegylated Liposomal Doxorubicin (Lipo-Dox) And Carboplatin Versus Paclitaxel And Carboplatin

Weng CS, Wu CC, Chen TC, Chen JR, Huang CY, Chang CL

Cancer Management and Research 2019 , 11:9899-9905

Published Date: 21 November 2019

Clinicopathological Characteristics And Treatment Outcomes Of Breast Cancer Among Adolescents And Young Adults In A Developing Country

Abdel-Razeq H, Almasri H, Abdel Rahman F, Abdulelah H, Abu Nasser M, Salam M, Al-Dairi A, Natour O, Rimawi D

Cancer Management and Research 2019 , 11:9891-9897

Multivariate Analysis Of The Diagnostic Yield Of Conventional Bronchoscopy In Peripheral Lung Adenocarcinoma

Gao W, Li C, Wang H, Han P, Nie Y

Cancer Management and Research 2019 , 11:9883-9889

Published Date: 20 November 2019

Lymph Node Yield Following Packet Submission After Isolation By Surgeon During Gastrectomy

Wang P, Zhang K, Xi H, Liang W, Xie T, Gao Y, Wei B, Chen L

Cancer Management and Research 2019 , 11:9871-9881

Published Date: 19 November 2019

Efficacy And Safety Of Raltitrexed Plus Oxaliplatin-Based Transarterial Chemoembolization In Patients With Unresectable Hepatocellular Carcinoma

Shao W, Li C, Tang J, Song J, Li Z, Sun J, Xu Y, Zheng Z, Cao J, Zhang L

Cancer Management and Research 2019 , 11:9863-9869

Benefits Of Timely Care In Pancreatic Cancer: A Systematic Review To Navigate Through The Contradictory Evidence

Lukács G, Kovács Á, Csanádi M, Moizs M, Repa I, Kaló Z, Vokó Z, Pitter JG

Cancer Management and Research 2019 , 11:9849-9861

Use Of Microwave Thermal Ablation In Management Of Skip Metastases In Extremity Osteosarcomas

Li N, Wei X, Zhang Z, Zhang Y

Cancer Management and Research 2019 , 11:9843-9848

Neuraxis Metastases Of Primary Central Nervous System Tumors: A Review Of Clinicopathological And Radiographic Characters Of 198 Cases In A Single Center

Liu H, Zhang J, Liu Y, Sun Y, Li C, Gu C, Wang H, Zhang H, Yu C, Zhang M

Cancer Management and Research 2019 , 11:9829-9841

Stage-specific concurrent chemoradiotherapy with or without induction chemotherapy for locoregionally advanced nasopharyngeal carcinoma: a retrospective, population-based study

Xia WX, Liang H, Lv X, Wang L, Ye YF, Ke LR, Xu LH, Guo X, Xiang YQ

Cancer Management and Research 2019 , 11:9813-9827

Image-Guided Percutaneous ‎Microwave Ablation Versus Cryoablation For Hepatocellular Carcinoma In High-Risk Locations: Intermediate-Term Results

Hu J, Chen S, Wang X, Lin N, Yang J, Wu S

Cancer Management and Research 2019 , 11:9801-9811

Published Date: 18 November 2019

Controlling Nutritional Status (CONUT) Score Is A Predictor Of Post-Operative Outcomes In Elderly Gastric Cancer Patients Undergoing Curative Gastrectomy: A Prospective Study

Huang Y, Huang Y, Lu M, Sun W, Sun X, Chen X, Li L, Chandoo A, Li L

Cancer Management and Research 2019 , 11:9793-9800

Low-Concentration PTX And RSL3 Inhibits Tumor Cell Growth Synergistically By Inducing Ferroptosis In Mutant p53 Hypopharyngeal Squamous Carcinoma

Ye J, Jiang X, Dong Z, Hu S, Xiao M

Cancer Management and Research 2019 , 11:9783-9792

Competing Morbidities In Advanced Head And Neck Squamous Cell Carcinoma Concurrent Chemoradiotherapy: A Strong Implication Of A Multidisciplinary Team Approach

Lazzari G, De Cillis MA, Buccoliero G, Silvano G

Cancer Management and Research 2019 , 11:9771-9782

Proton Pump Inhibitors Modulate Transport Of Doxorubicin And Its Liposomal Form Into 2D And 3D Breast Cancer Cell Cultures

Paškevičiūtė M, Petrikaitė V

Cancer Management and Research 2019 , 11:9761-9769

Reciprocal Role Of DNA Methylation And Sp1 Binding In Ki-67 Gene Transcription

Li LT, Wang X, Zhu WT, Qian GW, Pei DS, Zheng JN

Cancer Management and Research 2019 , 11:9749-9759

Synergistic Effect Between Full-Term Pregnancy/Breastfeeding And Familial Susceptibility On Breast Cancer Risk

Lin H, Wen J, Hong L, Chen Y, Wu Y, Zhong S

Cancer Management and Research 2019 , 11:9743-9748

Published Date: 15 November 2019

Prognostic Value Of The Preoperative Neutrophil To Lymphocyte Ratio In Patients With Sinonasal Squamous Cell Carcinoma

Zhong B, Deng D, Du JT, Chen F, Liu YF, Liu SX

Cancer Management and Research 2019 , 11:9733-9741

Advances In Research Of Spreading Through Air Spaces And The Effects On The Prognosis Of Lung Cancer

Cao D, Sha J, Cui R, Han S

Cancer Management and Research 2019 , 11:9725-9732

Intraoperative Prediction Of Non-Sentinel Lymph Node Metastasis Based On The Molecular Assay In Breast Cancer Patients

Sun X, Zhang Y, Wu S, Fu L, Yun JP, Wang YS

Cancer Management and Research 2019 , 11:9715-9723

Overexpressed miR-122-5p Promotes Cell Viability, Proliferation, Migration And Glycolysis Of Renal Cancer By Negatively Regulating PKM2

Wang S, Zheng W, Ji A, Zhang D, Zhou M

Cancer Management and Research 2019 , 11:9701-9713

The Prognosis Of Peroxiredoxin Family In Breast Cancer

Wang G, Zhong WC, Bi YH, Tao SY, Zhu H, Zhu HX, Xu AM

Cancer Management and Research 2019 , 11:9685-9699

Published Date: 14 November 2019

Downregulated Circular RNA hsa_circ_0000291 Suppresses Migration And Proliferation Of Gastric Cancer Via Targeting The miR-183/ITGB1 Axis

Cao C, Han S, Yuan Y, Wu Y, Lian W, Zhang X, Pan L, Li M

Cancer Management and Research 2019 , 11:9675-9683

Cancer Incidence Trends From 1999 to 2015 And Contributions Of Various Cancer Types To The Overall Burden: Projections To 2030 And Extrapolation Of Economic Burden In Saudi Arabia

Jazieh AR, Da'ar OB, Alkaiyat M, Zaatreh YA, Saad AA, Bustami R, Alrujaib M, Alkattan K

Cancer Management and Research 2019 , 11:9665-9674

Sentinel Lymph Node Biopsy Was Associated With Favorable Survival Outcomes For Patients With Clinically Node-Negative Asian Melanoma

Chang JWC, Huang YL, Chang YY, Lo YF, Ho TY, Huang YT, Chen HW, Wu CE

Cancer Management and Research 2019 , 11:9655-9664

PES1 In Liver Cancer: A Prognostic Biomarker With Tumorigenic Roles

Fu Z, Jiao Y, Li YQ, Ke JJ, Xu YH, Jia BX, Liu B

Cancer Management and Research 2019 , 11:9641-9653

Potential Diagnostic Value Of Combining Inflammatory Cell Ratios With Carcinoembryonic Antigen For Colorectal Cancer

Li X, Guo D, Chu L, Huang Y, Zhang F, Li W, Chen J

Cancer Management and Research 2019 , 11:9631-9640

Poor Prognosis With Coexistence Of EGFR T790M Mutation And Common EGFR-Activating Mutation In Non- Small Cell Lung Cancer

Gao X, Zhao Y, Bao Y, Yin W, Liu L, Liu R, Yu Z, Zhou X, Shuai J

Cancer Management and Research 2019 , 11:9621-9630

Published Date: 13 November 2019

Integrin α5/ITGA5 Promotes The Proliferation, Migration, Invasion And Progression Of Oral Squamous Carcinoma By Epithelial–Mesenchymal Transition

Deng Y, Wan Q, Yan W

Cancer Management and Research 2019 , 11:9609-9620

Clinical Outcomes And Cost-Effectiveness Of Different Staplers For Lung Lobectomy With Video-Assisted Thoracic Surgery

Xiao X, Chang R, Gao Y

Cancer Management and Research 2019 , 11:9599-9607

Knockdown Of CCDC132 Attenuates Gastric Cancer Cells Proliferation And Tumorigenesis By Facilitating DNA Damage Signaling

Xu X, Cao W, Sun W, Wang Z, Chen H, Zheng Z, Yang X

Cancer Management and Research 2019 , 11:9585-9597

Published Date: 12 November 2019

Digital Immune-Related Gene Expression Signatures In High-Grade Serous Ovarian Carcinoma: Developing Prediction Models For Platinum Response

Mairinger F, Bankfalvi A, Schmid KW, Mairinger E, Mach P, Walter RFH, Borchert S, Kasimir-Bauer S, Kimmig R, Buderath P

Cancer Management and Research 2019 , 11:9571-9583

Predictive Role Of Body Composition Parameters In Operable Breast Cancer Patients Treated With Neoadjuvant Chemotherapy

Omarini C, Palumbo P, Pecchi A, Draisci S, Balduzzi S, Nasso C, Barbolini M, Isca C, Bocconi A, Moscetti L, Galetti S, Tazzioli G, Torricelli P, Cascinu S, Piacentini F

Cancer Management and Research 2019 , 11:9563-9569

Aberrant Expression Of PDCD4/eIF4A1 Signal Predicts Postoperative Recurrence For Early-Stage Oral Squamous Cell Carcinoma

Zhao M, Ding L, Yang Y, Chen S, Zhu N, Fu Y, Ni Y, Wang Z

Cancer Management and Research 2019 , 11:9553-9562

Published Date: 11 November 2019

High-Risk Human Papillomavirus E7 Maintains Stemness Via APH1B In Cervical Cancer Stem-Cell Like Cells

Yang S, Chen T, Huang L, Xu S, Cao Z, Zhang S, Xu J, Li Y, Yue Y, Lu W, Cheng X, Xie X

Cancer Management and Research 2019 , 11:9541-9552

miR-1305 Inhibits The Progression Of Non-Small Cell Lung Cancer By Regulating MDM2

Cai Y, Hao Y, Ren H, Dang Z, Xu H, Xue X, Gao Y

Cancer Management and Research 2019 , 11:9529-9540

5-Aza-CdR Regulates RASSF1A By Inhibiting DNMT1 To Affect Colon Cancer Cell Proliferation, Migration And Apoptosis

Chen J, Wu L, Xu H, Cheng S

Cancer Management and Research 2019 , 11:9517-9528

Published Date: 8 November 2019

Sevoflurane Inhibited Osteosarcoma Cell Proliferation And Invasion Via Targeting miR-203/WNT2B/Wnt/β-Catenin Axis

Chen M, Zhou L, Liao Z, Ye X, Xuan X, Gu B, Lu F

Cancer Management and Research 2019 , 11:9505-9515

Impact Of ELN Risk Stratification, Induction Chemotherapy Regimens And Hematopoietic Stem Cell Transplantation On Outcomes In Hyperleukocytic Acute Myeloid Leukemia With Initial White Blood Cell Count More Than 100 × 109/L

Feng S, Zhou L, Zhang X, Tang B, Zhu X, Liu H, Sun Z, Zheng C

Cancer Management and Research 2019 , 11:9495-9503

Cost-Effectiveness Analysis Of Pembrolizumab In The Treatment Of Advanced Recurrent Metastatic Head And Neck Squamous Cell Carcinoma In China And The United States

Liu M, Han S, Zheng B, Cai H, Yang J, Zhuang Q, Li N

Cancer Management and Research 2019 , 11:9483-9493

A Molecular Epidemiological Analysis Of Programmed Cell Death Ligand-1 (PD-L1) Protein Expression, Mutations And Survival In Non-Small Cell Lung Cancer

Schabath MB, Dalvi TB, Dai HA, Crim AL, Midha A, Shire N, Gimbrone NT, Walker J, Greenawalt DM, Lawrence D, Rigas JR, Brody R, Potter D, Kumar NS, Huntsman SA, Gray JE

Cancer Management and Research 2019 , 11:9469-9481

Published Date: 7 November 2019

Nomogram-Integrated C-Reactive Protein/Albumin Ratio Predicts Efficacy And Prognosis In Patients With Thoracic Esophageal Squamous Cell Carcinoma Receiving Chemoradiotherapy

Zhang H, Guo XW, Yin XX, Liu YC, Ji SJ

Cancer Management and Research 2019 , 11:9459-9468

Published Date: 6 November 2019

Risk Stratification Of Diffuse Large B-Cell Lymphoma With Interim PET/CT By Combining Deauville Scores And International Prognostic Index

Sun H, Yu Z, Ma N, Zhou J, Tian R, Zhao M, Wang T

Cancer Management and Research 2019 , 11:9449-9457

Nomogram For The Prediction Of Malignancy In Small (8–20 mm) Indeterminate Solid Solitary Pulmonary Nodules In Chinese Populations

Chen XB, Yan RY, Zhao K, Zhang DF, Li YJ, Wu L, Dong XX, Chen Y, Gao DP, Ding YY, Wang XC, Li ZH

Cancer Management and Research 2019 , 11:9439-9448

The Prognostic Value Of Lymph Node Ratio In Patients With N2 Stage Lung Squamous Cell Carcinoma: A Nomogram And Heat Map Approach

Bi G, Lu T, Yao G, Bian Y, Zhao M, Huang Y, Zhang Y, Xue L, Zhan C, Fan H

Cancer Management and Research 2019 , 11:9427-9437

Glycodelin As A Biomarker Of Advanced Lung Adenocarcinoma Brain Metastases In Patients Treated With EGFR Tyrosine Kinase Inhibitors

Ni Z, Zhang L, Zheng J, Su X, Zhang S

Cancer Management and Research 2019 , 11:9421-9425

Prognostic Significance Of The Inflammatory Index-Based Scoring System In Patients Preliminarily Diagnosed With Multiple Myeloma In The Bortezomib-Based Chemotherapy Era

Liu S, Shi J, Guo H, Xu F, Wei M, Sun K, Chen Y

Cancer Management and Research 2019 , 11:9409-9420

Published Date: 5 November 2019

Single-Fraction Radiotherapy (SFRT) For Bone Metastases: Patient Selection And Perspectives

Loi M, Nuyttens JJ, Desideri I, Greto D, Livi L

Cancer Management and Research 2019 , 11:9397-9408

Local Tumor Ischemia-Reperfusion Mediated By Ultrasound-Targeted Microbubble Destruction Enhances The Anti-Tumor Efficacy Of Doxorubicin Chemotherapy

Wu M, Song Z, Zhang S, Dan Q, Tang C, Peng C, Liang Y, Zhang L, Wang H, Li Y

Cancer Management and Research 2019 , 11:9387-9395

Development And Validation Of A Simple Model For Detection Of Early Hepatocellular Carcinoma In A Liver Cirrhosis Cohort

Li T, Li H, Wang A, Su X, Zhao J, Cui Y, Liu J, Hu J

Cancer Management and Research 2019 , 11:9379-9386

LncRNA ASB16-AS1 Promotes Growth And Invasion Of Hepatocellular Carcinoma Through Regulating miR-1827/FZD4 Axis And Activating Wnt/β-Catenin Pathway

Yao X, You G, Zhou C, Zhang D

Cancer Management and Research 2019 , 11:9371-9378

MST4 Predicts Poor Prognosis And Promotes Metastasis By Facilitating Epithelial–Mesenchymal Transition In Gastric Cancer

Li T, Deng L, He X, Jiang G, Hu F, Ye S, You Y, Duanmu J, Dai H, Huang G, Tang C, Lei X

Cancer Management and Research 2019 , 11:9353-9369

The Cytoplasmic Expression Of CLDN12 Predicts An Unfavorable Prognosis And Promotes Proliferation And Migration Of Osteosarcoma

Tian X, He Y, Han Z, Su H, Chu C

Cancer Management and Research 2019 , 11:9339-9351

Published Date: 1 November 2019

Distribution Of Brain Metastasis From Lung Cancer

Wang G, Xu J, Qi Y, Xiu J, Li R, Han M

Cancer Management and Research 2019 , 11:9331-9338

Efficacy Of Apatinib In Transcatheter Arterial Chemoembolization (TACE) Refractory Intermediate And Advanced-Stage Hepatocellular carcinoma：A Propensity Score Matching Analysis

Qiu Z, Shen L, Chen S, Qi H, Cao F, Xie L, Fan W

Cancer Management and Research 2019 , 11:9321-9330

Population-Based Analysis Of The Use Of Radium-223 For Bone-Metastatic Castration-Resistant Prostate Cancer In Ontario, And Of Factors Associated With Treatment Completion And Outcome

Cheng S, Arciero V, Goldberg H, Tajzler C, Manganaro A, Kozlowski N, Rowbottom L, McDonald R, Chow R, Vasisht G, Shaji S, Wong ECL, Petrovic M, Zhang L, Phillips C, Zalewski P, Kapoor A, Fleshner NE, Chow E, Emmenegger U

Cancer Management and Research 2019 , 11:9307-9319

Published Date: 31 October 2019

Clinical Characteristics And Outcome Of Biphenotypic Acute Leukemia: 10 Case Reports And Literature Review

Yu J, Li Y, Xing H, Pan Y, Sun H, Wan D, Liu Y, Xie X, Wang C, Sun L, Sun K, Jiang Z

Cancer Management and Research 2019 , 11:9297-9306

The role of digital breast tomosynthesis in breast cancer screening: a manufacturer- and metrics-specific analysis

Hadjipanteli A, Kontos M, Constantinidou A

Cancer Management and Research 2019 , 11:9277-9296

Serum Apolipoprotein A-I Combined With C-Reactive Protein Serves As A Novel Prognostic Stratification System For Colorectal Cancer

Ye J, Luo Q, Wang X, Liu Z, Chen M, Huang H, Zhang L

Cancer Management and Research 2019 , 11:9265-9276

Published Date: 30 October 2019

Pancreatic Ductal Adenocarcinoma: Machine Learning–Based Quantitative Computed Tomography Texture Analysis For Prediction Of Histopathological Grade

Qiu W, Duan N, Chen X, Ren S, Zhang Y, Wang Z, Chen R

Cancer Management and Research 2019 , 11:9253-9264

Real-World Data Of Osimertinib In Patients With Pretreated Non-Small Cell Lung Cancer: A Retrospective Study

Mu Y, Xing P, Hao X, Wang Y, Li J

Cancer Management and Research 2019 , 11:9243-9251

Population-Based Incidence, Mortality, And Survival For Gastrointestinal Cancers During 2006–2016 In Wuhan, Central China

Cheng Y, Liu J, Liao Q, Hu X, Lv H, Ding P, Nie S, Tan L

Cancer Management and Research 2019 , 11:9233-9241

Published Date: 29 October 2019

Upregulation Of circMMP9 Promotes Osteosarcoma Progression Via Targeting miR-1265/CHI3L1 Axis

Pan G, Hu T, Chen X, Zhang C

Cancer Management and Research 2019 , 11:9225-9231

Development and validation of a novel diagnostic model for assessing lung cancer metastasis in a Chinese population based on multicenter real-world data

Yao Y, Yan C, Zhang W, Wu SG, Guan J, Zeng G, Du Q, Huang C, Zhang H, Wang H, Hou Y, Li Z, Wang L, Zheng Y, Li X

Cancer Management and Research 2019 , 11:9213-9223

Micheliolide Inhibits Liver Cancer Cell Growth Via Inducing Apoptosis And Perturbing Actin Cytoskeleton

Yu L, Chen W, Tang Q, Ji KY

Cancer Management and Research 2019 , 11:9203-9212

Cost-Effectiveness Analysis Of Ceritinib And Alectinib Versus Crizotinib In The Treatment Of Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer

Liu M, Zhang L, Huang Q, Li N, Zheng B, Cai H

Cancer Management and Research 2019 , 11:9195-9202

Published Date: 25 October 2019

The Diagnostic Value Of Using 18F-Fluorodeoxyglucose Positron Emission Tomography To Differentiate Between Low- And High-Grade Meningioma

Hua L, Hua F, Zhu H, Deng J, Wang D, Luan S, Tang H, Guan Y, Xie Q, Gong Y

Cancer Management and Research 2019 , 11:9185-9193

USP13 serves as a tumor suppressor via the PTEN/AKT pathway in oral squamous cell carcinoma

Qu Z, Zhang R, Su M, Liu W

Cancer Management and Research 2019 , 11:9175-9183

Transcriptional Characterization Of The Tumor Immune Microenvironment And Its Prognostic Value For Locally Advanced Lung Adenocarcinoma In A Chinese Population

Chen Y, Chen H, Mao B, Zhou Y, Shi X, Tang L, Jiang H, Wang G, Zhuang W

Cancer Management and Research 2019 , 11:9165-9173

Ras-ERK1/2 Signaling Promotes The Development Of Osteosarcoma By Regulating H2BK12ac Through CBP

Xu X, Yu H, Xu Y

Cancer Management and Research 2019 , 11:9153-9163

Published Date: 24 October 2019

OSacc: Gene Expression-Based Survival Analysis Web Tool For Adrenocortical Carcinoma

Xie L, Wang Q, Nan F, Ge L, Dang Y, Sun X, Li N, Dong H, Han Y, Zhang G, Zhu W, Guo X

Cancer Management and Research 2019 , 11:9145-9152

Silencing Of hsa_circ_0008450 Represses Hepatocellular Carcinoma Progression Through Regulation Of microRNA-214-3p/EZH2 Axis

Lin T, Dai Y, Guo X, Chen W, Zhao J, Cao L, Wu Z

Cancer Management and Research 2019 , 11:9133-9143

Imaging-Based Individualized Response Prediction Of Carbon Ion Radiotherapy For Prostate Cancer Patients

Wu S, Jiao Y, Zhang Y, Ren X, Li P, Yu Q, Zhang Q, Wang Q, Fu S

Cancer Management and Research 2019 , 11:9121-9131

Comparative performance of inflammation-based prognostic scores in patients operated for intrahepatic cholangiocarcinoma

Lin J, Fang T, Zhu M, Xu X, Zhang J, Zheng S, Jing C, Zhang M, Liu B, Zhang B

Cancer Management and Research 2019 , 11:9107-9119

Increased Expression Of SOX2 Predicts A Poor Prognosis And Promotes Malignant Phenotypes In Upper Tract Urothelial Carcinoma

Bao Z, Zhan Y, He S, Li Y, Guan B, He Q, Yang X, Li X, Fang D, Zhou L

Cancer Management and Research 2019 , 11:9095-9106

Baseline FDG Uptake And Peripheral Lymphocyte-Monocyte Ratio For Predicting Chemoradiotherapy Response In Patients With Esophageal Squamous Cell Carcinoma

Wang C, Zhao K, Huang Y, Ma L, Song Y, Li M

Cancer Management and Research 2019 , 11:9085-9093

Expression Of Cyclin D1 Protein Isoforms And Its Prognostic Significance In Cervical Cancer

Gu J, Zhang X, Yang Z, Wang N

Cancer Management and Research 2019 , 11:9073-9083

Platelet Volume Is Reduced In Metastasing Breast Cancer: Blood Profiles Reveal Significant Shifts

Li M, Yue C, Fu S, Zhang X, Zhao CJ, Wang R

Cancer Management and Research 2019 , 11:9067-9072

Fusobacterium nucleatum prevents apoptosis in colorectal cancer cells via the ANO1 pathway

Lu P, Xu M, Xiong Z, Zhou F, Wang L

Cancer Management and Research 2019 , 11:9057-9066

Comparison Of Long Term Results Between Matched Chemoradiotherapy And Surgery For Limited Stage Small Cell Lung Cancer

Chen M, Hu X, Bao Y, Wang J, Chen Y, Xu Y, Jin J, Chen M

Cancer Management and Research 2019 , 11:9049-9055

Published Date: 23 October 2019

Long Noncoding RNA GAS5 Acts As A Tumor Suppressor In Laryngeal Squamous Cell Carcinoma Via miR-21 [Corrigendum]

Lyu K, Xu Y, Yue H, Li Y, Zhao J, Chen L, Wu J, Zhu X, Chai L, Li C, Wen W, Lei W

Cancer Management and Research 2019 , 11:9047-9048

Nomogram For Preoperative Prediction Of Microvascular Invasion Risk In Hepatocellular Carcinoma

Deng G, Yao L, Zeng F, Xiao L, Wang Z

Cancer Management and Research 2019 , 11:9037-9045

Published Date: 22 October 2019

Prognostic Value Of Preoperative Systemic Inflammatory Biomarkers In Patients With Gallbladder Cancer And The Establishment Of A Nomogram

Deng Y, Zhang F, Yu X, Huo CL, Sun ZG, Wang S

Cancer Management and Research 2019 , 11:9025-9035

Published Date: 21 October 2019

Clinical And Imageological Features Of Lung Squamous Cell Carcinoma With EGFR Mutations

Gao X, Zhu J, Chen L, Jiang Y, Zhou X, Shuai J, Zhao Y

Cancer Management and Research 2019 , 11:9017-9024

Berberine induces apoptosis in non-small-cell lung cancer cells by upregulating miR-19a targeting tissue factor

Chen Q, Shi J, Ding Z, Xia Q, Zheng T, Ren Y, Li M, Fan L

Cancer Management and Research 2019 , 11:9005-9015

TCDD-Inducible Poly-ADP-Ribose Polymerase (TIPARP), A Novel Therapeutic Target Of Breast Cancer

Cheng L, Li Z, Huang YZ, Zhang X, Dai XY, Shi L, Xi PW, Wei JF, Ding Q

Cancer Management and Research 2019 , 11:8991-9004

Published Date: 18 October 2019

A Multi-Element Expression Score Is A Prognostic Factor In Glioblastoma Multiforme

Li JQ, Wang QT, Nie Y, Xiao YP, Lin T, Han RJ, Li Z, Fan YY, Yuan XH, Wang YM, Zhang J, He YW, Liao HX

Cancer Management and Research 2019 , 11:8977-8989

Published Date: 17 October 2019

Prognostic Significance Of Platelet-To-Lymphocyte Ratio (PLR) And Mean Platelet Volume (MPV) During Etoposide-Based First-Line Treatment In Small Cell Lung Cancer Patients

Shen XB, Wang Y, Shan BJ, Lin L, Hao L, Liu Y, Wang W, Pan YY

Cancer Management and Research 2019 , 11:8965-8975

Genetic And Epigenetic Regulation Of E-Cadherin Signaling In Human Hepatocellular Carcinoma

Fan X, Jin S, Li Y, Khadaroo PA, Dai Y, He L, Zhou D, Lin H

Cancer Management and Research 2019 , 11:8947-8963

Published Date: 16 October 2019

Novel Hsp90 Inhibitor C086 Potently Inhibits Non-Small Cell Lung Cancer Cells As A Single Agent Or In Combination With Gefitinib

Wang L, Fan Y, Mei H, Liu Y, Zhang L, Xu J, Huang X

Cancer Management and Research 2019 , 11:8937-8945

RETRACTED ARTICLE: Isovitexin Suppresses Cancer Stemness Property And Induces Apoptosis Of Osteosarcoma Cells By Disruption Of The DNMT1/miR-34a/Bcl-2 Axis

Liang X, Xu C, Cao X, Wang W

Cancer Management and Research 2019 , 11:8923-8936

Published Date: 15 October 2019

Metadherin Promotes Malignant Phenotypes And Induces Beta-Catenin Nuclear Translocation And Epithelial–Mesenchymal Transition In Gastric Cancer

Feng D, Yu X, Tian X, Meng H, Jiang Y, Song H, Li W, Zhang H, Geng J

Cancer Management and Research 2019 , 11:8911-8921

Published Date: 11 October 2019

Downregulation Of LncRNA PMS2L2 In Endometrial Adenocarcinoma Upon Carboplatin Treatment

Zhang D, Sun X, Zhang Y

Cancer Management and Research 2019 , 11:8905-8910

Published Date: 10 October 2019

Ten-Year Outcomes Of Intensity-Modulated Radiotherapy (IMRT) Combine With Chemotherapy Versus IMRT Alone For Stage II Nasopharyngeal Carcinoma In The Real-World Study (RWD)

Ding XC, Fan PP, Xie P, Fan BJ, Yang J, Jiang LY, Bai XB, Yu JM, Hu M

Cancer Management and Research 2019 , 11:8893-8903

Time Trends And Age-Period-Cohort Effects On The Incidence Of Gastric Cancer In Changle From 2003 To 2012

Lin Y, Lin S, Chen J, Chen L, Tao T, Wu S

Cancer Management and Research 2019 , 11:8885-8892

Serum Fibrinogen Is An Independent Prognostic Factor In Operable Esophageal Squamous Carcinoma: A Real-World Study

Zheng Y, Li Y, Xing W, Qin J, Liu X, Zhang R, Sun H, Chen X

Cancer Management and Research 2019 , 11:8877-8883

A Study Of Efficacy And Safety With Apatinib Or Apatinib Combined With Chemotherapy In Recurrent/advanced Ovarian Cancer Patients

Yang M, Liu X, Zhang C, Liao F, Li Z, Luo X, Sun Y, Chen C

Cancer Management and Research 2019 , 11:8869-8876

Published Date: 9 October 2019

Survival advantage and clinicopathological significance of microRNA-22 in cancers: a meta-analysis

Xiang Q, Xiang Z, Dou R, Xiong B

Cancer Management and Research 2019 , 11:8855-8868

Published Date: 8 October 2019

Effect Of Surgical Safety Checklists On Gastric Cancer Outcomes: A Single-Center Retrospective Study

Yu D, Zhao Q

Cancer Management and Research 2019 , 11:8845-8853

The Prediction Of Epidermal Growth Factor Receptor Mutation And Prognosis Of EGFR Tyrosine Kinase Inhibitor By Serum Ferritin In Advanced NSCLC

Wu Z, Dai Y, Chen LA

Cancer Management and Research 2019 , 11:8835-8843

Published Date: 7 October 2019

Physician And Patient Barriers To Radiotherapy Service Access: Treatment Referral Implications

Chierchini S, Ingrosso G, Saldi S, Stracci F, Aristei C

Cancer Management and Research 2019 , 11:8829-8833

Midostaurin In Acute Myeloid Leukemia: An Evidence-Based Review And Patient Selection

Abbas HA, Alfayez M, Kadia T, Ravandi-Kashani F, Daver N

Cancer Management and Research 2019 , 11:8817-8828

Published Date: 4 October 2019

Prognostic Usefulness Of Advanced Lung Cancer Inflammation Index In Locally-Advanced Pancreatic Carcinoma Patients Treated With Radical Chemoradiotherapy

Topkan E, Mertsoylu H, Ozdemir Y, Sezer A, Kucuk A, Besen AA, Ozyilkan O, Selek U

Cancer Management and Research 2019 , 11:8807-8815

Combination Of ALBI And APRI To Predict Post-Hepatectomy Liver Failure After Liver Resection For HBV-Related HCC Patients

Mai R, Wang Y, Bai T, Chen J, Xiang B, Wu G, Wu F, Li L, Ye J

Cancer Management and Research 2019 , 11:8799-8806

Published Date: 2 October 2019

The Long Noncoding RNA LINC00908 Facilitates Hepatocellular Carcinoma Progression Via Interaction With Sox-4

Hu X, Li Q, Zhang J

Cancer Management and Research 2019 , 11:8789-8797

Published Date: 30 September 2019

The CRP/Albumin Ratio Predicts Survival And Monitors Chemotherapeutic Effectiveness In Patients With Advanced Pancreatic Cancer

Fan Z, Fan K, Gong Y, Huang Q, Yang C, Cheng H, Jin K, Ni Q, Yu X, Luo G, Liu C

Cancer Management and Research 2019 , 11:8781-8788

Preoperative Hyponatremia And Hypocalcemia Predict Poor Prognosis In Elderly Gastric Cancer Patients

Xu J, Chen X, Wang X, Zhu C, Hu Y, Yang X, Xu C, Shen X

Cancer Management and Research 2019 , 11:8765-8780

Published Date: 27 September 2019

A Meta-Analysis And Systematic Review Of Accuracy Of Endoscopic Ultrasound For N Staging Of Gastric Cancers

Chen J, Zhou C, He M, Zhen Z, Wang J, Hu X

Cancer Management and Research 2019 , 11:8755-8764

Silencing of TAZ inhibits the motility of hepatocellular carcinoma cells through autophagy induction

Zhou W, Weng J, Wu K, Xu X, Wang H, Zhang J, Zhao C, Yang J, Zhang Y, Shen W

Cancer Management and Research 2019 , 11:8743-8753

Published Date: 26 September 2019

Development and validation of CT imaging–based preoperative nomogram in the prediction of unfavorable high-grade small renal masses

Xie H, Li G, Liu K, Wang Z, Shang Z, Liu Z, Xiong Z, Quan C, Niu Y

Cancer Management and Research 2019 , 11:8731-8741

Published Date: 25 September 2019

Prevalence, Risk Factors And Location Of Skip Metastasis In Papillary Thyroid Carcinoma: A Systematic Review And Meta-Analysis

Qiu Y, Fei Y, Liu J, Liu C, He X, Zhu N, Zhao W, Zhu J

Cancer Management and Research 2019 , 11:8721-8730

Bortezomib sensitivity is tissue dependent and high expression of the 20S proteasome precludes good response in malignant pleural mesothelioma

Walter RFH, Sydow SR, Berg E, Kollmeier J, Christoph DC, Christoph S, Eberhardt WEE, Mairinger T, Wohlschlaeger J, Schmid KW, Mairinger FD

Cancer Management and Research 2019 , 11:8711-8720

Published Date: 24 September 2019

Long non-coding RNA TUG1-mediated down-regulation of KLF4 contributes to metastasis and the epithelial-to-mesenchymal transition of colorectal cancer by miR-153-1

Shao H, Dong D, Shao F

Cancer Management and Research 2019 , 11:8699-8710

Common molecular markers between circulating tumor cells and blood exosomes in colorectal cancer: a systematic and analytical review

Vafaei S, Fattahi F, Ebrahimi M, Janani L, Shariftabrizi A, Madjd Z

Cancer Management and Research 2019 , 11:8669-8698

Pre-treatment inflammatory biomarkers predict early treatment response and favorable survival in patients with metastatic colorectal cancer who underwent first line cetuximab plus chemotherapy

Jiang J, Ma T, Xi W, Yang C, Wu J, Zhou C, Wang N, Zhu Z, Zhang J

Cancer Management and Research 2019 , 11:8657-8668

Comparison of outcomes of complete mesocolic excision with conventional radical resection performed by laparoscopic approach for right colon cancer

Ouyang M, Luo Z, Wu J, Zhang W, Tang S, Lu Y, Hu W, Yao X

Cancer Management and Research 2019 , 11:8647-8656

Columbamine suppresses the proliferation and malignization of colon cancer cells via abolishing Wnt/β-catenin signaling pathway

Lei C, Yao Y, Shen B, Liu J, Pan Q, Liu N, Li L, Huang J, Long Z, Shao L

Cancer Management and Research 2019 , 11:8635-8645

Published Date: 23 September 2019

A New Regulatory Mechanism Between P53 And YAP Crosstalk By SIRT1 Mediated Deacetylation To Regulate Cell Cycle And Apoptosis In A549 Cell Lines

Yuan F, Wang J, Li R, Zhao X, Zhang Y, Liu B, Lei Y, Hu Y

Cancer Management and Research 2019 , 11:8619-8633

Downregulated MCOLN1 Attenuates The Progression Of Non-Small-Cell Lung Cancer By Inhibiting Lysosome-Autophagy

Yin C, Zhang H, Liu X, Zhang H, Zhang Y, Bai X, Wang L, Li H, Li X, Zhang S, Zhang L, Zhang Y

Cancer Management and Research 2019 , 11:8607-8617

miR-140-5p Alleviates The Aggressive Progression Of Wilms’ Tumor Through Directly Targeting TGFBR I Gene [Retraction]

Wang H, Lou C, Ma N

Cancer Management and Research 2019 , 11:8605-8606

Long Noncoding RNA LINC00511 Promotes Cell Growth And Invasion In Triple-Negative Breast Cancer By Interacting With Snail [Retraction]

Liu R, Wang L, Gan T, Pan T, Huang J, Bai M

Cancer Management and Research 2019 , 11:8603-8604

Epigenetic regulation of IncRNA KCNKI5-ASI in gastric cancer

Zhang H, Zhang Z, Wang D

Cancer Management and Research 2019 , 11:8589-8602

Published Date: 20 September 2019

Clinical features, treatment and outcomes of colorectal mucosa-associated lymphoid tissue (MALT) lymphoma: literature reviews published in English between 1993 and 2017

Won JH, Kim SM, Kim JW, Park JH, Kim JY

Cancer Management and Research 2019 , 11:8577-8587

Atopobium vaginae And Porphyromonas somerae Induce Proinflammatory Cytokines Expression In Endometrial Cells: A Possible Implication For Endometrial Cancer?

Caselli E, Soffritti I, D'Accolti M, Piva I, Greco P, Bonaccorsi G

Cancer Management and Research 2019 , 11:8571-8575

Linc01278 inhibits the development of papillary thyroid carcinoma by regulating miR-376c-3p/DNM3 axis

Lin S, Tan L, Luo D, Peng X, Zhu Y, Li H

Cancer Management and Research 2019 , 11:8557-8569

Published Date: 19 September 2019

ADAR1 may be involved in the proliferation of acute myeloid leukemia cells via regulation of the Wnt pathway

Xiao H, Cheng Q, Wu X, Tang Y, Liu J, Li X

Cancer Management and Research 2019 , 11:8547-8555

Concurrent proton-pump inhibitors increase risk of death for lung cancer patients receiving 1st-line gefitinib treatment - a nationwide population-based study

Fang YH, Yang YH, Hsieh MJ, Hung MS, Lin YC

Cancer Management and Research 2019 , 11:8539-8546

Beyond The T/C Ratio: Old And New Anticancer Activity Scores In Vivo

Cancer Management and Research 2019 , 11:8529-8538

Long noncoding RNA PVT1 promotes hepatoblastoma cell proliferation through activating STAT3

Luo Z, Cao P

Cancer Management and Research 2019 , 11:8517-8527

Clinicopathological features and outcomes of esophageal lesions containing a basal layer type squamous cell carcinoma component

Zhuang X, Chen Z, Wang J, Chen J, Wu X, Wang Y, Chen C, Deng G, Qian K, Bai Y

Cancer Management and Research 2019 , 11:8507-8516

Published Date: 18 September 2019

Quality of life of patients with proximal humerus metastasis treated with cement spacer

Guo W, Gao X, Wang D, Wang T, Tang L, Wang Y, Liu B

Cancer Management and Research 2019 , 11:8499-8506

Published Date: 17 September 2019

Long Noncoding RNA GAS5 Acts As A Tumor Suppressor In Laryngeal Squamous Cell Carcinoma Via miR-21

Cancer Management and Research 2019 , 11:8487-8498

Impact of antiviral therapy with nucleos(t)ide analog on survival of patients with HBV-related small hepatocellular carcinomas

Wei Y, Yi Y, Tao C, Ye W, Zhao W

Cancer Management and Research 2019 , 11:8475-8486

Emodin sensitizes human pancreatic cancer cells to EGFR inhibitor through suppressing Stat3 signaling pathway

Wang Z, Chen H, Chen J, Hong Z, Liao Y, Zhang Q, Tong H

Cancer Management and Research 2019 , 11:8463-8473

The prognostic value of the lymphocyte-to-monocyte ratio for high-risk papillary thyroid carcinoma

Song L, Zhu J, Li Z, Wei T, Gong R, Lei J

Cancer Management and Research 2019 , 11:8451-8462

Anti-tumor effects of engineered mesenchymal stem cells in colon cancer model

Yang J, Lv K, Sun J, Guan J

Cancer Management and Research 2019 , 11:8443-8450

Characteristic And Novel Therapeutic Strategies Of Nasopharyngeal Carcinoma With Synchronous Metastasis

Liao W, Tian M, Chen N

Cancer Management and Research 2019 , 11:8431-8442

Published Date: 16 September 2019

RETRACTED ARTICLE: MicroRNA-506 regulates apoptosis in retinoblastoma cells by targeting sirtuin 1

Song Z, Wang H, Zong F, Zhu C, Tao Y

Cancer Management and Research 2019 , 11:8419-8429

Mechanisms Underlying Therapeutic Effects Of Traditional Chinese Medicine On Gastric Cancer

Yang L, Zhao L, Zeng T, Chen H, Shao J, Yang S, Tao Z, Yang J, Chen T, Lin X, Chen X, Tang M

Cancer Management and Research 2019 , 11:8407-8418

Berzosertib (VE-822) inhibits gastric cancer cell proliferation via base excision repair system

Ni F, Tang H, Wang C, Wang Z, Yu F, Chen B, Sun L

Cancer Management and Research 2019 , 11:8391-8405

Published Date: 13 September 2019

Risk factors of catheter-related thrombosis in early-stage breast cancer patients: a single-center retrospective study

Tan L, Sun Y, Zhu L, Lei X, Liang D, Rao N, Su F, Chen K, Li S

Cancer Management and Research 2019 , 11:8379-8389

rhTPO combined with chemotherapy and G-CSF for autologous peripheral blood stem cells in patients with refractory/relapsed non-Hodgkin’s lymphoma

Zhu J, Hao SG, Hu J, Zhuang JL, Wang C, Bai HT

Cancer Management and Research 2019 , 11:8371-8377

UBE2T promotes proliferation via G2/M checkpoint in hepatocellular carcinoma

Liu LL, Zhu JM, Yu XN, Zhu HR, Shi X, Bilegsaikhan E, Guo HY, Wu J, Shen XZ

Cancer Management and Research 2019 , 11:8359-8370

Histone deacetylase inhibitors reinforce the phenotypical markers of breast epithelial or mesenchymal cancer cells but inhibit their migratory properties

Wawruszak A, Gumbarewicz E, Okon E, Jeleniewicz W, Czapinski J, Halasa M, Okla K, Smok-Kalwat J, Bocian A, Rivero-Muller A, Stepulak A

Cancer Management and Research 2019 , 11:8345-8358

Spatial heterogeneity of KRAS mutations in colorectal cancers in northern France

Turpin A, Genin M, Hebbar M, Occelli F, Lanier C, Vasseur F, Descarpentries C, Pannier D, Ploquin A

Cancer Management and Research 2019 , 11:8337-8344

Carbon ion and proton beam irradiation of a normal human TK6 lymphoblastoid cell line within a magnetic field of 1.0 tesla

Yudhistiara B, Weber KJ, Huber PE, Ruehle A, Brons S, Haering P, Debus J, Hauswald H

Cancer Management and Research 2019 , 11:8327-8335

Published Date: 12 September 2019

Predictive And Prognostic Value Of Hepatic Steatosis In Conversion Therapy For Colorectal Liver-limited Metastases: A Propensity Score Matching Analysis

Jian M, Chang W, Ren L, Liu T, Chen Y, Wei Y, Lin Q, Xu J, Qin X

Cancer Management and Research 2019 , 11:8315-8326

Published Date: 11 September 2019

12-lipoxygenase promotes tumor progress by TGF-β1-mediated epithelial to mesenchymal transition and predicts poor prognosis in esophageal squamous cell carcinoma

Qu Y, Wen Z, Mi S, Chen P, Wang J, Jia Y, Cheng Y

Cancer Management and Research 2019 , 11:8303-8313

Analysis of the efficacy and safety of bortezomib for treating newly diagnosed multiple myeloma through different administration methods

Zhang HM, Liu XY, Liu YZ, Liu LN, Lin QD, Song YP, Fang BJ

Cancer Management and Research 2019 , 11:8295-8302

Published Date: 10 September 2019

Clinical results of intensity-modulated radiotherapy for 250 patients with cervical and upper thoracic esophageal carcinoma

Zhang J, Zhang W, Zhang B, Qian D, Li X, Zhang H, Wang Q, Zhao L, Pang Q, Wang P

Cancer Management and Research 2019 , 11:8285-8294

Gemcitabine, cisplatin, prednisone, and thalidomide for relapse and refractory peripheral T-cell lymphoma: a retrospective study from China

Liu X, Shang Y, Li L, Zhang X, Li Z, Zhang M

Cancer Management and Research 2019 , 11:8277-8284

Published Date: 9 September 2019

Neutrophil-to-lymphocyte ratio predicts the prognosis of stage II nasopharyngeal carcinoma

Pan XB, Huang ST, Zhu XD

Cancer Management and Research 2019 , 11:8269-8275

The relationship between pancreatic cancer and type 2 diabetes: cause and consequence

Li Y, Bian X, Wei S, He M, Yang Y

Cancer Management and Research 2019 , 11:8257-8268

Adverse effect of laparoscopic radical hysterectomy depends on tumor size in patients with cervical cancer

Hu TWY, Ming X, Yan HZ, Li ZY

Cancer Management and Research 2019 , 11:8249-8255

Added value of histogram analysis of apparent diffusion coefficient maps for differentiating triple-negative breast cancer from other subtypes of breast cancer on standard MRI

Liu HL, Zong M, Wei H, Wang C, Lou JJ, Wang SQ, Zou QG, Jiang YN

Cancer Management and Research 2019 , 11:8239-8247

Published Date: 6 September 2019

The synergistic antileukemic effects of eltrombopag and decitabine in myeloid leukemia cells

Shi M, Xu F, Yang X, Bai Y, Niu J, Drokow EK, Chen M, Chen Y, Sun K

Cancer Management and Research 2019 , 11:8229-8238

Increased expression of heat shock protein (HSP) 10 and HSP70 correlates with poor prognosis of nasopharyngeal carcinoma

Feng J, Zhan Y, Zhang Y, Zheng H, Wang W, Fan S

Cancer Management and Research 2019 , 11:8219-8227

Differential gene expression identifies KRT7 and MUC1 as potential metastasis-specific targets in sarcoma

Jiang L, Tolani B, Yeh CC, Fan Y, Reza JA, Horvai AE, Xia E, Kratz JR, Jablons DM, Mann MJ

Cancer Management and Research 2019 , 11:8209-8218

Correlation of body composition by computerized tomography and metabolic parameters with survival of nivolumab-treated lung cancer patients

Magri V, Gottfried T, Di Segni M, Urban D, Peled M, Daher S, Stoff R, Bar J, Onn A

Cancer Management and Research 2019 , 11:8201-8207

Published Date: 5 September 2019

Elevated levels of pre-treatment lactate dehydrogenase are an unfavorable predictor factor in patients with EML4-ALK rearrangement non-small cell lung cancer treated with crizotinib

Liang H, Ma D, Xu Y, Zhao J, Chen M, Liu X, Zhong W, Li J, Wang M

Cancer Management and Research 2019 , 11:8191-8200

The prognostic value of pretreatment Glasgow Prognostic Score in patients with esophageal cancer: a meta-analysis

Wang Y, Li P, Li J, Lai Y, Zhou K, Wang X, Che G

Cancer Management and Research 2019 , 11:8181-8190

Published Date: 4 September 2019

Overexpression of HOXC6 promotes cell proliferation and migration via MAPK signaling and predicts a poor prognosis in glioblastoma

Yang P, Kang W, Pan Y, Zhao X, Duan L

Cancer Management and Research 2019 , 11:8167-8179

Published Date: 3 September 2019

Clinical study of nimotuzumab combined with concurrent radiochemotherapy for treatment of locally advanced cervical cancer

Chen W, Li T, Wang J, Liang L, Huang D, Yan G, Tian Y, Zhang X, Zhang W

Cancer Management and Research 2019 , 11:8157-8165

Recent insights into breast cancer incidence trends among four Asian countries using age-period-cohort model

Mubarik S, Malik SS, Wang Z, Li C, Fawad M, Yu C

Cancer Management and Research 2019 , 11:8145-8155

Magnesemia: an independent risk factor of hypocalcemia after thyroidectomy

Wang W, Meng C, Ouyang Q, Xie J, Li X

Cancer Management and Research 2019 , 11:8135-8144

RETRACTED ARTICLE: Effect of SMYD3 on biological behavior and H3K4 methylation in bladder cancer

Wu X, Xu Q, Chen P, Yu C, Ye L, Huang C, Li T

Cancer Management and Research 2019 , 11:8125-8133

Published Date: 2 September 2019

ERRα is an aggressive factor in lung adenocarcinoma indicating poor prognostic outcomes

Li P, Wang J, Wu D, Ren X, Wu W, Zuo R, Zeng Q, Wang B, He X, Yuan J, Xie N

Cancer Management and Research 2019 , 11:8111-8123

Preoperative Cachexia predicts poor outcomes in young rather than elderly gastric cancer patients: a prospective study

Chen X, Zeng Y, Huang Y, Xu J, Meng W, Wang X, Zhu C, Zhu G, Mao C, Shen X

Cancer Management and Research 2019 , 11:8101-8110

Asunercept as an innovative therapeutic approach for recurrent glioblastoma and other malignancies

Krendyukov A, Gieffers C

Cancer Management and Research 2019 , 11:8095-8100

The role of low density lipoprotein receptor-related protein 11 as a tumor promoter in cervical cancer

Wang Y, Han S, You X, Shi X, Liu L, Sun Y, Ma Y, Qian Q, Liu H, Cui B, Zhang Y

Cancer Management and Research 2019 , 11:8081-8093

Published Date: 30 August 2019

Enasidenib in acute myeloid leukemia: clinical development and perspectives on treatment

Reed DR, Elsarrag RZ, Morris AL, Keng MK

Cancer Management and Research 2019 , 11:8073-8080

A prospective study on urine alkalization with an oral regimen consisting of sodium bicarbonate and acetazolamide in patients receiving high-dose methotrexate

Reed DR, Pierce EJ, Sen JM, Keng MK

Cancer Management and Research 2019 , 11:8065-8072

Long noncoding RNA MIR31HG abrogates the availability of tumor suppressor microRNA-361 for the growth of osteosarcoma

Sun Y, Jia X, Wang M, Deng Y

Cancer Management and Research 2019 , 11:8055-8064

Do early HER2-overexpression breast cancer patients benefit from undergoing neoadjuvant trastuzumab and mastectomy? A meta-analysis

He L, Wu Q, Xiong J, Su Z, Zhang B, Song Y

Cancer Management and Research 2019 , 11:8043-8054

Published Date: 29 August 2019

Factors associated with human papillomavirus infection – findings from a cervical cancer screening program for female employees in Beijing

Yang H, Zhong Y, Lv W, Yu H

Cancer Management and Research 2019 , 11:8033-8041

Published Date: 28 August 2019

Knockdown of EBV-encoded circRNA circRPMS1 suppresses nasopharyngeal carcinoma cell proliferation and metastasis through sponging multiple miRNAs

Liu Q, Shuai M, Xia Y

Cancer Management and Research 2019 , 11:8023-8031

Published Date: 27 August 2019

RETRACTED ARTICLE: iNOS is associated with tumorigenicity as an independent prognosticator in human intrahepatic cholangiocarcinoma

Liu S, Jiang J, Huang L, Jiang Y, Yu N, Liu X, Lv Y, Li H, Zou L, Peng C, Yu X, Jiang B

Cancer Management and Research 2019 , 11:8005-8022

Published Date: 26 August 2019

High preoperative serum prealbumin predicts long-term survival in resected esophageal squamous cell cancer

Wei J, Jin M, Shao Y, Ning Z, Huang J

Cancer Management and Research 2019 , 11:7997-8003

Skin lesions in chronic myeloid leukemia patients during dasatinib treatment

Tarantini F, Anelli L, Ingravallo G, Attolico I, Zagaria A, Russo Rossi A, Lospalluti L, Bufano T, Zanframundo G, Maiorano E, Specchia G, Albano F

Cancer Management and Research 2019 , 11:7991-7996

The prognostic value of pretreatment inflammatory biomarkers in primary angiosarcoma

Wang M, Wu S, Tong A, Cui X, Ma X

Cancer Management and Research 2019 , 11:7981-7989

Published Date: 22 August 2019

MicroRNA-195 as a prognostic factor for cancer survival outcome in China: a meta-analysis

Wang N, Cao Y, Ge X, Nie J, Yu Y, Li Q, Wang F, Miao L

Cancer Management and Research 2019 , 11:7967-7979

Antibiotic therapy augments the efficacy of gemcitabine-containing regimens for advanced cancer: a retrospective study

Imai H, Saijo K, Komine K, Otsuki Y, Ohuchi K, Sato Y, Okita A, Takahashi M, Takahashi S, Shirota H, Takahashi M, Ishioka C

Cancer Management and Research 2019 , 11:7953-7965

Protective autophagy or autophagic death: effects of BEZ235 on chronic myelogenous leukemia

Xin P, Xu W, Zhu X, Li C, Zheng Y, Zheng T, Cheng W, Peng Q

Cancer Management and Research 2019 , 11:7933-7951

Dynamic changes in T-cell subsets and C-reactive protein after radiation therapy in lung cancer patients and correlation with symptomatic radiation pneumonitis treated with steroid therapy

Bai L, Zhou BS, Zhao YX

Cancer Management and Research 2019 , 11:7925-7931

Downregulation of HDGF inhibits the tumorigenesis of bladder cancer cells by inactivating the PI3K-AKT signaling pathway

Zhang C, Chang X, Chen D, Yang F, Li Z, Li D, Yu N, Yan L, Liu H, Xu Z

Cancer Management and Research 2019 , 11:7909-7923

Evaluating vandetanib in the treatment of medullary thyroid cancer: patient-reported outcomes

Fallahi P, Ferrari SM, Elia G, Ragusa F, Paparo SR, Ruffilli I, Patrizio A, Materazzi G, Antonelli A

Cancer Management and Research 2019 , 11:7893-7907

Published Date: 21 August 2019

EIF3B is associated with poor outcomes in gastric cancer patients and promotes cancer progression via the PI3K/AKT/mTOR signaling pathway

Wang L, Wen X, Luan F, Fu T, Gao C, Du H, Guo T, Han J, Huangfu L, Cheng X, Ji J

Cancer Management and Research 2019 , 11:7877-7891

Comprehensive assessment of HER2 alteration in a colorectal cancer cohort: from next-generation sequencing to clinical significance

Yeh YM, Lee CH, Chen SH, Lee CT, Chen YL, Lin BW, Lin SC, Chan RH, Lee JC, Shen MR, Lin PC

Cancer Management and Research 2019 , 11:7867-7875

Published Date: 20 August 2019

Differentiation of chronic mass-forming pancreatitis from pancreatic ductal adenocarcinoma using contrast-enhanced computed tomography

Ren S, Chen X, Cui W, Chen R, Guo K, Zhang H, Chen S, Wang Z

Cancer Management and Research 2019 , 11:7857-7866

Programmed cell death 4 (PDCD4) as a novel prognostic marker for papillary thyroid carcinoma

Galuppini F, Fassan M, Bertazza L, Barollo S, Cascione L, Watutantrige-Fernando S, Lazzarin V, Simonato P, Vianello F, Rugge M, Mian C, Pennelli G

Cancer Management and Research 2019 , 11:7845-7855

Low expression of ZMYND8 correlates with aggressive features and poor prognosis in nasopharyngeal carcinoma

Chen J, Liu J, Chen X, Li Y, Li Z, Shen C, Chen K, Zhang X

Cancer Management and Research 2019 , 11:7835-7843

Radiomic signature: a non-invasive biomarker for discriminating invasive and non-invasive cases of lung adenocarcinoma

Yang B, Guo L, Lu G, Shan W, Duan L, Duan S

Cancer Management and Research 2019 , 11:7825-7834

Published Date: 19 August 2019

Overexpressed PKMYT1 promotes tumor progression and associates with poor survival in esophageal squamous cell carcinoma

Zhang Q, Zhao X, Zhang C, Wang W, Li F, Liu D, Wu K, Zhu D, Liu S, Shen C, Yuan X, Zhang K, Yang Y, Zhang Y, Zhao S

Cancer Management and Research 2019 , 11:7813-7824

Phyllodes tumor of the breast: diagnosis, management and outcome during a 10-year experience

Ditsatham C, Chongruksut W

Cancer Management and Research 2019 , 11:7805-7811

Fruquintinib: a novel antivascular endothelial growth factor receptor tyrosine kinase inhibitor for the treatment of metastatic colorectal cancer

Zhang Y, Zou JY, Wang Z, Wang Y

Cancer Management and Research 2019 , 11:7787-7803

Published Date: 16 August 2019

Impact of tivozanib on patient outcomes in treatment of advanced renal cell carcinoma

Yalcin S, Lacin S

Cancer Management and Research 2019 , 11:7779-7785

Intensity-modulated carbon-ion radiation therapy versus intensity-modulated photon-based radiation therapy in locally recurrent nasopharyngeal carcinoma: a dosimetric comparison

Wang L, Hu J, Liu X, Wang W, Kong L, Lu JJ

Cancer Management and Research 2019 , 11:7767-7777

Impact of sites versus number of metastases on survival of patients with organ metastasis from newly diagnosed cervical cancer

Yin Z, Tang H, Li L, Ni J, Yuan S, Lou H, Chen M

Cancer Management and Research 2019 , 11:7759-7766

Combined ultrasound/computed tomography guidance in percutaneous radiofrequency ablation after transarterial chemoembolization for hepatocellular carcinoma in the hepatic dome

Kan X, Wang Y, Han P, Yao Q, Qian K, Xiong B, Zheng C

Cancer Management and Research 2019 , 11:7751-7757

Published Date: 15 August 2019

Long non-coding RNA NNT-AS1 functions as an oncogenic gene through modulating miR-485/BCL9 in cholangiocarcinoma

Huang L, Jiang X, Kang P, Wang Z, Leng K, Ji D, Xu Y, Wang H, Cui Y

Cancer Management and Research 2019 , 11:7739-7749

OSM-induced CD44 contributes to breast cancer metastatic potential through cell detachment but not epithelial-mesenchymal transition

Covert H, Mellor LF, Wolf CL, Ankenbrandt N, Emathinger JM, Tawara K, Oxford JT, Jorcyk CL

Cancer Management and Research 2019 , 11:7721-7737

Prospect of immunotherapy combined with anti-angiogenic agents in patients with advanced non-small cell lung cancer

Liang H, Wang M

Cancer Management and Research 2019 , 11:7707-7719

Prognostic significance of FA score based on plasma fibrinogen and serum albumin in patients with epithelial ovarian cancer

Li Y, Yang JN, Cheng SS, Wang Y

Cancer Management and Research 2019 , 11:7697-7705

Published Date: 14 August 2019

The prognostic value and mechanisms of lncRNA UCA1 in human cancer

Yao F, Wang Q, Wu Q

Cancer Management and Research 2019 , 11:7685-7696

Correlation of NRF2 and progesterone receptor and its effects on ovarian cancer biology

Czogalla B, Kahaly M, Mayr D, Schmoeckel E, Niesler B, Hester A, Zeder-Göß C, Kolben T, Burges A, Mahner S, Jeschke U, Trillsch F

Cancer Management and Research 2019 , 11:7673-7684

BHLHE41 promotes U87 and U251 cell proliferation via ERK/cyclinD1 signaling pathway

Wang C, Zhao N, Zheng Q, Zhang D, Liu Y

Cancer Management and Research 2019 , 11:7657-7672

Infiltrating CD4 and CD8 lymphocytes in HPV infected uterine cervical milieu

Maskey N, Thapa N, Maharjan M, Shrestha G, Maharjan N, Cai H, Liu S

Cancer Management and Research 2019 , 11:7647-7655

Clinical characteristics of testicular seminoma in individuals in West China: a 10-year follow-up study

Chen Z, Qiu S, Cao D, Guo J, Chen B, Huang Y, Lai L, Bao Y, Dong Q, Liu L, Wei Q

Cancer Management and Research 2019 , 11:7639-7645

Prognostic significance of preoperative albumin-to-globulin ratio and prognostic nutritional index combined score in Siewert type 3 adenocarcinoma of esophagogastric junction

Wang Y, Zhu Z, Li C, Ma Y, You Q, Li Z, Zhang H, Song H, Xue Y

Cancer Management and Research 2019 , 11:7631-7638

The Hedgehog signal transducer Smoothened and microRNA-326: pathogenesis and regulation of drug resistance in pediatric B-cell acute lymphoblastic leukemia

Sheybani Z, Rahgozar S, Ghodousi ES

Cancer Management and Research 2019 , 11:7621-7630

Published Date: 12 August 2019

Role of surgery in patients with early stage small-cell lung cancer [Erratum]

Peng A, Li G, Xiong M, Xie S, Wang C

Cancer Management and Research 2019 , 11:7619-7620

Programmed cell death 1 expression and Epstein-Barr virus infection in chronic lymphocytic leukaemia: a prospective cohort study

Grywalska E, Pasiarski M, Sosnowska-Pasiarska B, Macek P, Rolińska A, Samardakiewicz M, Ludian J, Góźdź S, Roliński J

Cancer Management and Research 2019 , 11:7605-7618

Significance of the neutrophil-to-lymphocyte ratio in young patients with oral squamous cell carcinoma

Zhang B, Du W, Gan K, Fang Q, Zhang X

Cancer Management and Research 2019 , 11:7597-7603

Published Date: 9 August 2019

Morbidity and associated factors of depressive disorder in patients with lung cancer

Lee Y, Lin PY, Lin MC, Wang CC, Lu HI, Chen YC, Chong MY, Hung CF

Cancer Management and Research 2019 , 11:7587-7596

Role of Hippo/YAP signaling in irradiation-induced glioma cell apoptosis

Xu X, Chen Y, Wang X, Mu X

Cancer Management and Research 2019 , 11:7577-7585

The prognostic value of preoperative controlling nutritional status score in non-metastatic renal cell carcinoma treated with surgery: a retrospective single-institution study

Song H, Xu B, Luo C, Zhang Z, Ma B, Jin J, Zhang Q

Cancer Management and Research 2019 , 11:7567-7575

Sanguinarine exhibits potent efficacy against cervical cancer cells through inhibiting the STAT3 pathway in vitro and in vivo

Zhang H, Zhang J, Venkat PS, Gu C, Meng Y

Cancer Management and Research 2019 , 11:7557-7566

Spotlight on telotristat ethyl for the treatment of carcinoid syndrome diarrhea: patient selection and reported outcomes

Saavedra C, Barriuso J, McNamara MG, Valle JW, Lamarca A

Cancer Management and Research 2019 , 11:7537-7556

Published Date: 8 August 2019

Precision oncology: lessons learned and challenges for the future

Yang HT, Shah RH, Tegay D, Onel K

Cancer Management and Research 2019 , 11:7525-7536

Published Date: 7 August 2019

Predictive value of preoperative neutrophil-to-lymphocyte ratio in non-metastatic papillary renal cell carcinoma patients after receiving curative surgery

Tu X, Wang F, Chang T, Zhang C, Zhang M, Liu Z, Qiu S, Yang L, Wei Q

Cancer Management and Research 2019 , 11:7515-7524

c-MYC expression in T (III/IV) stage oral squamous cell carcinoma (OSCC) patients [Corrigendum]

Lin SH, Wang HK, Yeh KT, Tai HC, Wang HY, Huang LR, Chiu CW, Chung CM, Velmurugan BK

Cancer Management and Research 2019 , 11:7513-7514

The prognostic value of the postoperative serum CEA levels/preoperative serum CEA levels ratio in colorectal cancer patients with high preoperative serum CEA levels

Xie HL, Gong YZ, Kuang JA, Gao F, Tang SY, Gan JL

Cancer Management and Research 2019 , 11:7499-7511

Overexpression of KRT17 promotes proliferation and invasion of non-small cell lung cancer and indicates poor prognosis

Wang Z, Yang MQ, Lei L, Fei LR, Zheng YW, Huang WJ, Li ZH, Liu CC, Xu HT

Cancer Management and Research 2019 , 11:7485-7497

Identification of a novel DNA repair-related prognostic signature predicting survival of patients with hepatocellular carcinoma

Li N, Zhao L, Guo C, Liu C, Liu Y

Cancer Management and Research 2019 , 11:7473-7484

Published Date: 6 August 2019

The relevance between the immune response-related gene module and clinical traits in head and neck squamous cell carcinoma

Song Y, Pan Y, Liu J

Cancer Management and Research 2019 , 11:7455-7472

Down-regulation of CCL17 in cancer-associated fibroblasts inhibits cell migration and invasion of breast cancer through ERK1/2 pathway

Li J, Yang C, Yang J, Zou L

Cancer Management and Research 2019 , 11:7439-7453

Incident cancer risk in dipeptidyl peptidase-4 inhibitor-treated patients with type 2 diabetes mellitus

Choi YJ, Kim DJ, Shin S

Cancer Management and Research 2019 , 11:7427-7438

Postoperative metastasis prediction based on portal vein circulating tumor cells detected by flow cytometry in periampullary or pancreatic cancer

Tao L, Su L, Yuan C, Ma Z, Zhang L, Bo S, Niu Y, Lu S, Xiu D

Cancer Management and Research 2019 , 11:7405-7425

Integrative gene expression profiling reveals that dysregulated triple microRNAs confer paclitaxel resistance in non-small cell lung cancer via co-targeting MAPT

Cai Y, Jia R, Xiong H, Ren Q, Zuo W, Lin T, Lin R, Lei Y, Wang P, Dong H, Zhao H, Zhu L, Fu Y, Zeng Z, Zhang W, Wang S

Cancer Management and Research 2019 , 11:7391-7404

Published Date: 5 August 2019

F factor plasmid-mediated Epstein-Barr virus genome introduction establishes an EBV positive NPC cell model

Duan J, Yang Y, Wu Z, Lin S, Zhou C, Sheng G, Yang F, Bian L, Zhang X, Xiao S

Cancer Management and Research 2019 , 11:7377-7389

The role of circular RNA hsa_circ_0085616 in proliferation and migration of hepatocellular carcinoma cells

Li W, Zhou X, Wu X, Wei J, Huang Z

Cancer Management and Research 2019 , 11:7369-7376

EDNRB isoform 3 confers Temozolomide resistance in A375 melanoma cells by modulating membrane potential, reactive oxygen species and mitochondrial Ca2+

Chen YS, Liu F, Luo YH, Fan Y, Xu FG, Li P, Zhou B, Pan XY, Wang CC, Cui L

Cancer Management and Research 2019 , 11:7353-7367

Establishment and validation of an AJCC stage- and histologic grade-based nomogram for pancreatic neuroendocrine tumors after surgical resection

Zhang C, Wu Y, Zhuang H, Li D, Lin Y, Yin Z, Lu X, Hou B, Jian Z

Cancer Management and Research 2019 , 11:7345-7352

MAPT promoter CpG island hypermethylation is associated with poor prognosis in patients with stage II colorectal cancer

Wang C, Liu Y, Guo W, Zhu X, Ahuja N, Fu T

Cancer Management and Research 2019 , 11:7337-7343

Sorcin: a novel potential target in therapies of cancers

Zhou X, Wu X, Chen B

Cancer Management and Research 2019 , 11:7327-7336

Cellular magnetic resonance imaging: in vivo tracking of gastric cancer cells and detecting of lymph node metastases using microparticles of iron oxide in mice

Chen J, Ren G, Cai R, Wu X, Gui T, Zhao J, Li H, Guo C

Cancer Management and Research 2019 , 11:7317-7326

Published Date: 2 August 2019

LOX-1+ PMN-MDSC enhances immune suppression which promotes glioblastoma multiforme progression

Chai E, Zhang L, Li C

Cancer Management and Research 2019 , 11:7307-7315

Salvage living donor liver transplantation for posthepatectomy recurrence: a higher incidence of recurrence but promising strategy for long-term survival

Chan KM, Cheng CH, Wu TH, Lee CF, Wu TJ, Chou HS, Lee WC

Cancer Management and Research 2019 , 11:7295-7305

Immunological nomograms predicting prognosis and guiding adjuvant chemotherapy in stage II colorectal cancer

Feng Y, Li Y, Cai S, Peng J

Cancer Management and Research 2019 , 11:7279-7294

Published Date: 1 August 2019

Long noncoding RNA SNHG16 silencing inhibits the aggressiveness of gastric cancer via upregulation of microRNA-628-3p and consequent decrease of NRP1

Pang W, Zhai M, Wang Y, Li Z

Cancer Management and Research 2019 , 11:7263-7277

Treatment of non-metastatic castration-resistant prostate cancer: focus on apalutamide

Gul A, Garcia JA, Barata PC

Cancer Management and Research 2019 , 11:7253-7262

Prognostic value of lactate dehydrogenase to albumin ratio (LAR) in patients with resectable esophageal squamous cell carcinoma

Feng JF, Wang L, Yang X, Jiang YH

Cancer Management and Research 2019 , 11:7243-7251

Published Date: 31 July 2019

Statins induce cell apoptosis through a modulation of AKT/FOXO1 pathway in prostate cancer cells

Deng JL, Zhang R, Zeng Y, Zhu YS, Wang G

Cancer Management and Research 2019 , 11:7231-7242

Estimation of radiotherapy modalities for patients with stage I-II nasal natural killer T-Cell lymphoma

Liu X, Wu F, Guo Q, Wang Y, He Y, Luo H, Li Q, Zhong M, Li C, Yang H, Zhou J, Jin F

Cancer Management and Research 2019 , 11:7219-7229

Published Date: 30 July 2019

A multivariable model of BRAFV600E and ultrasonographic features for predicting the risk of central lymph node metastasis in cN0 papillary thyroid microcarcinoma

Chen BD, Zhang Z, Wang KK, Shang MY, Zhao SS, Ding WB, Du R, Yu Z, Xu XM

Cancer Management and Research 2019 , 11:7211-7217

HPV infection associated DNA damage correlated with cervical precancerous lesions and cancer in the highest area of cervical cancer mortality, Longnan, China

Zhao J, Guo Z, Wang Q, Si T, Pei S, Qu H, Shang L, Yang Y, Wang L

Cancer Management and Research 2019 , 11:7197-7210

Gain and loss from transcatheter intra-arterial limb infusion of cisplatin for extremity osteosarcoma: a retrospective study of 99 cases in the past six years

Xie L, Xu J, Dong S, Gao J, Tang X, Yan T, Yang R, Guo W

Cancer Management and Research 2019 , 11:7183-7195

Impact of bladder volume on treatment planning and clinical outcomes of radiotherapy for patients with cervical cancer

Ma S, Zhang T, Jiang L, Qin W, Lu K, Zhang Y, Wang R

Cancer Management and Research 2019 , 11:7171-7181

Published Date: 29 July 2019

Diagnostic value of angiopoietin-like protein 2 for CHB-related hepatocellular carcinoma

Zhou J, Yang W, Zhang S, He X, Lin J, Zhou T, Li Y, Wang G, Chen J

Cancer Management and Research 2019 , 11:7159-7169

Laparoscopic surgery facilitates administration of adjuvant chemotherapy in locally advanced colon cancer: propensity score analyses

Wasmann KATGM, Klaver CEL, van der Bilt JDW, van Dieren S, Nagtegaal ID, Punt CJA, van Ramshorst B, Wolthuis AM, de Wilt JHW, D'Hoore A, van Santvoort HC, Tanis PJ

Cancer Management and Research 2019 , 11:7141-7157

A multi-center, Phase II trial of nab-paclitaxel and gemcitabine in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy

Tachihara M, Kiriu T, Hata A, Hatakeyama Y, Nakata K, Nagano T, Yamamoto M, Kobayashi K, Ohnishi H, Katakami N, Nishimura Y

Cancer Management and Research 2019 , 11:7135-7140

Malignant ascite-derived extracellular vesicles inhibit T cell activity by upregulating Siglec-10 expression

Li Y, Zhou J, Zhuo Q, Zhang J, Xie J, Han S, Zhao S

Cancer Management and Research 2019 , 11:7123-7134

Silibinin restores the sensitivity of cisplatin and taxol in A2780-resistant cell and reduces drug-induced hepatotoxicity

Yang Z, Pan Q, Zhang D, Chen JQ, Qiu Y, Chen X, Zheng F, Lin F

Cancer Management and Research 2019 , 11:7111-7122

Published Date: 26 July 2019

Diabetes mellitus is a predictive factor for radiation pneumonitis after thoracic radiotherapy in patients with lung cancer

Kong M, Lim YJ, Kim Y, Chung MJ, Min S, Shin DO, Chung W

Cancer Management and Research 2019 , 11:7103-7110

Role of surgery in patients with early stage small-cell lung cancer

Cancer Management and Research 2019 , 11:7089-7101

PDX1, a key factor in pancreatic embryogenesis, can exhibit antimetastatic activity in pancreatic ductal adenocarcinoma

Kondratyeva LG, Safina DR, Chernov IP, Kopantzev EP, Kostrov SV, Sverdlov ED

Cancer Management and Research 2019 , 11:7077-7087

HOXA10 knockdown inhibits proliferation, induces cell cycle arrest and apoptosis in hepatocellular carcinoma cells through HDAC1

Zhang Y, Chen J, Wu SS, Lv MJ, Yu YS, Tang ZH, Chen XH, Zang GQ

Cancer Management and Research 2019 , 11:7065-7076

iTRAQ-based quantitative protein expression profiling of biomarkers in childhood B-cell and T-cell acute lymphoblastic leukemia

Yu R, Zhang J, Zang Y, Zeng L, Zuo W, Bai Y, Liu Y, Sun K, Liu Y

Cancer Management and Research 2019 , 11:7047-7063

Published Date: 25 July 2019

The oncological outcome and influence of neoadjuvant chemotherapy on the surgery in the resectable and locally advanced oral squamous cell carcinoma

Su X, Liu Q, Li J, Zhang C, Xue Z, He C, Liu W

Cancer Management and Research 2019 , 11:7039-7046

Multiple gastrointestinal stromal tumors: analysis of clinicopathologic characteristics and prognosis of 20 patients

Li K, Tjhoi WEH, Shou C, Yang W, Zhang Q, Liu X, Yu J

Cancer Management and Research 2019 , 11:7031-7038

Relationship of B7-H3 expression in tumor cells and tumor vasculature with FOXP3+ regulatory T cells in renal cell carcinoma

Inamura K, Amori G, Yuasa T, Yamamoto S, Yonese J, Ishikawa Y

Cancer Management and Research 2019 , 11:7021-7030

Intraperitoneal cytology after laparoscopic radical hysterectomy with vaginal closure without the use of a manipulator for cervical cancer: a retrospective observational study

Tanaka T, Miyamoto S, Terada S, Kogata Y, Sasaki H, Tsunetoh S, Yamada T, Ohmichi M

Cancer Management and Research 2019 , 11:7015-7020

Unexpected uterine sarcomas after hysterectomy and myomectomy for presumed leiomyoma: a retrospective study of 26,643 patients

Cao H, Li L, Yang B, Luo G, Lou J, Xi M

Cancer Management and Research 2019 , 11:7007-7014

Secreted TGF-beta-induced protein promotes aggressive progression in bladder cancer cells

Zou J, Huang R, Li H, Wang B, Chen Y, Chen S, Ou K, Wang X

Cancer Management and Research 2019 , 11:6995-7006

Downregulation of miR-216a-5p by long noncoding RNA PVT1 suppresses colorectal cancer progression via modulation of YBX1 expression

Zeng X, Liu Y, Zhu H, Chen D, Hu W

Cancer Management and Research 2019 , 11:6981-6993

Published Date: 24 July 2019

Surgical outcomes and prognostic factors for patients with gastric cancer spinal metastasis

Zhong N, Leng A, He S, Yang M, Zhang D, Jiao J, Xu W, Yang X, Xiao J

Cancer Management and Research 2019 , 11:6971-6979

Loss of Cirbp expression is correlated with the malignant progression and poor prognosis in nasopharyngeal carcinoma

Lin TY, Chen Y, Jia JS, Zhou C, Lian M, Wen YT, Li XY, Chen HW, Lin XL, Zhang XL, Xiao SJ, Sun Y, Xiao D

Cancer Management and Research 2019 , 11:6959-6969

Predictors of health care use in Australian cancer patients

Rana RH, Alam K, Gow J, Ralph N

Cancer Management and Research 2019 , 11:6941-6957

Feasibility and safety of neoadjuvant laparoscopic hyperthermic intraperitoneal chemotherapy in patients with advanced stage ovarian cancer: a single-center experience

Gao T, Huang X, Wang W, Wu M, Lin Z, Li J

Cancer Management and Research 2019 , 11:6931-6940

Nomograms for predicting overall survival and cancer-specific survival in patients with surgically resected intrahepatic cholangiocarcinoma

Ma K, Dong B, Wang L, Zhao C, Fu Z, Che C, Liu W, Yang Z, Liang R

Cancer Management and Research 2019 , 11:6907-6929

Association between single nucleotide polymorphisms of NOTCH signaling pathway-related genes and the prognosis of NSCLC

Xu Q, Lin D, Li X, Xiao R, Liu Z, Xiong W, Cai L, He F

Cancer Management and Research 2019 , 11:6895-6905

Circular RNA hsa_circRNA_102958 promotes tumorigenesis of colorectal cancer via miR-585/CDC25B axis

Li R, Wu B, Xia J, Ye L, Yang X

Cancer Management and Research 2019 , 11:6887-6893

Published Date: 23 July 2019

Prognostic values of baseline, interim and end-of therapy 18F-FDG PET/CT in patients with follicular lymphoma

Zhou Y, Zhao Z, Li J, Zhang B, Sang S, Wu Y, Deng S

Cancer Management and Research 2019 , 11:6871-6885

Inhibitor of DNA binding 1 (Id1) mediates stemness of colorectal cancer cells through the Id1-c-Myc-PLAC8 axis via the Wnt/β-catenin and Shh signaling pathways

Sun Y, Lai X, Yu Y, Li J, Cao L, Lin W, Huang C, Liao J, Chen W, Li C, Yang C, Ying M, Chen Q, Ye Y

Cancer Management and Research 2019 , 11:6855-6869

Exploration of exact significance of lymph node ratio and construction of a novel stage in colon cancer with no distant metastasis

Lv Y, Feng QY, Lin SB, Mao YH, Xu YQ, Zheng P, Yang LL, He GD, Xu JM

Cancer Management and Research 2019 , 11:6841-6854

MicroRNA 145 enhances chemosensitivity of glioblastoma stem cells to demethoxycurcumin

Qian C, Wang B, Zou Y, Zhang Y, Hu X, Sun W, Xiao H, Liu H, Shi L

Cancer Management and Research 2019 , 11:6829-6840

Evaluating the prognostic significance of tumor-infiltrating lymphocytes in solid tumor: practice of a standardized method from the International Immuno-Oncology Biomarkers Working Group

Liu JY, Yang GF, Chen FF, Peng CW

Cancer Management and Research 2019 , 11:6815-6827

Optimal management of thymic malignancies: current perspectives

Drevet G, Collaud S, Tronc F, Girard N, Maury JM

Cancer Management and Research 2019 , 11:6803-6814

Published Date: 22 July 2019

Cardiovascular disease-related chronic conditions among Veterans Affairs nonmetastatic colorectal cancer survivors: a matched case–control analysis

Zullig LL, Smith VA, Lindquist JH, Williams CD, Weinberger M, Provenzale D, Jackson GL, Kelley MJ, Danus S, Bosworth HB

Cancer Management and Research 2019 , 11:6793-6802

Upregulation of family with sequence similarity 83 member D expression enhances cell proliferation and motility via activation of Wnt/β-catenin signaling and predicts poor prognosis in gastric cancer

Wang F, Zhang S, Wei Y, Chen H, Jiao Z, Li Y

Cancer Management and Research 2019 , 11:6775-6791

Ultra-late recurrence of non-small cell lung cancer over 10 years after curative resection

Sonoda D, Matsuura Y, Ichinose J, Nakao M, Ninomiya H, Mun M, Ishikawa Y, Nakagawa K, Satoh Y, Okumura S

Cancer Management and Research 2019 , 11:6765-6774

Published Date: 19 July 2019

MicroRNA-206 inhibits metastasis of triple-negative breast cancer by targeting transmembrane 4 L6 family member 1

Fan C, Liu N, Zheng D, Du J, Wang K

Cancer Management and Research 2019 , 11:6755-6764

High dose vs low dose irradiation of the subventricular zone in patients with glioblastoma—a systematic review and meta-analysis

Şuşman S, Leucuţa DC, Kacso G, Florian ŞI

Cancer Management and Research 2019 , 11:6741-6753

Published Date: 18 July 2019

Expression of endoplasmic reticulum oxidoreductase 1-α in cholangiocarcinoma tissues and its effects on the proliferation and migration of cholangiocarcinoma cells

Yan W, Wang X, Liu T, Chen L, Han L, Xu J, Jin G, Harada K, Lin Z, Ren X

Cancer Management and Research 2019 , 11:6727-6739

Novel variants of unknown significance in the PMS2 gene identified in patients with hereditary colon cancer

Liccardo R, Della Ragione C, Mitilini N, De Rosa M, Izzo P, Duraturo F

Cancer Management and Research 2019 , 11:6719-6725

Relationships between expression of BCS1L, mitochondrial bioenergetics, and fatigue among patients with prostate cancer

Hsiao CP, Chen MK, Veigl ML, Ellis R, Cooney M, Daly B, Hoppel C

Cancer Management and Research 2019 , 11:6703-6717

IL-37 induces anti-tumor immunity by indirectly promoting dendritic cell recruitment and activation in hepatocellular carcinoma

Liu Y, Zhao JJ, Zhou ZQ, Pan QZ, Zhu Q, Tang Y, Xia JC, Weng DS

Cancer Management and Research 2019 , 11:6691-6702

High expression of proenkephalin is associated with favorable outcomes in patients with gastrointestinal stromal tumors

Tang D, Lin T, Wang Y, Cao H

Cancer Management and Research 2019 , 11:6681-6690

Published Date: 17 July 2019

Efficacy of complementary and integrative medicine on health-related quality of life in cancer patients: a systematic review and meta-analysis

Lin WF, Zhong MF, Zhou QH, Zhang YR, Wang H, Zhao ZH, Cheng BB, Ling CQ

Cancer Management and Research 2019 , 11:6663-6680

Influence of serum total cholesterol, LDL, HDL, and triglyceride on prostate cancer recurrence after radical prostatectomy

Cheng S, Zheng Q, Ding G, Li G

Cancer Management and Research 2019 , 11:6651-6661

Published Date: 16 July 2019

Paclitaxel-loaded nanobubble targeted to pro-gastrin-releasing peptide inhibits the growth of small cell lung cancer

Wang JP, Yan JP, Xu J, Yin TH, Zheng RQ, Wang W

Cancer Management and Research 2019 , 11:6637-6649

HOXA10 deteriorates gastric cancer through activating JAK1/STAT3 signaling pathway

Chen W, Wu G, Zhu Y, Zhang W, Zhang H, Zhou Y, Sun P

Cancer Management and Research 2019 , 11:6625-6635

Published Date: 15 July 2019

miR-625 reverses multidrug resistance in gastric cancer cells by directly targeting ALDH1A1

Gong X, Xu B, Zi L, Chen X

Cancer Management and Research 2019 , 11:6615-6624

The impact of the patient’s condition, diagnostic procedures and treatment on the survival of carcinoma of unknown primary site patients

Dorobisz K, Wlodarska-Polinska I, Pazdro-Zastawny K, Rutkowski T, Palka P, Dworzecki T, Zatonski T

Cancer Management and Research 2019 , 11:6603-6614

Expression and prognostic role of IKBKE and TBK1 in stage I non-small cell lung cancer

Wang X, Teng F, Lu J, Mu D, Zhang J, Yu J

Cancer Management and Research 2019 , 11:6593-6602

Long noncoding RNA DANCR in various cancers: a meta-analysis and bioinformatics

Wang L, Xie Y, Fang H, Zhang X, Pan H, Yan SX

Cancer Management and Research 2019 , 11:6581-6592

The antitumor properties of metformin and phenformin reflect their ability to inhibit the actions of differentiated embryo chondrocyte 1

Kuo CL, Hsieh Li SM, Liang SY, Liu ST, Huang LC, Wang WM, Yen LC, Huang SM

Cancer Management and Research 2019 , 11:6567-6579

Ezrin promotes pancreatic cancer cell proliferation and invasion through activating the Akt/mTOR pathway and inducing YAP translocation

Quan C, Sun J, Lin Z, Jin T, Dong B, Meng Z, Piao J

Cancer Management and Research 2019 , 11:6553-6566

Published Date: 12 July 2019

Intercalated combination of chemotherapy and erlotinib for stage IIIA non-small-cell lung cancer: a multicenter, open-label, single-arm, phase II study

Chen Z, Shen S, Shi W, Jiang G, Wang X, Jian H, Zhou Z, Ding Z, Lu S

Cancer Management and Research 2019 , 11:6543-6552

Ectopic expression of HSDL2 is related to cell proliferation and prognosis in breast cancer

Dong B, Yang Y, Han A, Zhang S, Lin Z, Wang Y, Piao J

Cancer Management and Research 2019 , 11:6531-6542

The validation of the 2014 International Society of Urological Pathology (ISUP) grading system for patients with high-risk prostate cancer: a single-center retrospective study

Liu J, Zhao J, Zhang M, Chen N, Sun G, Yang Y, Zhang X, Chen J, Shen P, Shi M, Zeng H

Cancer Management and Research 2019 , 11:6521-6529

MicroRNA-218 regulates the chemo-sensitivity of cervical cancer cells through targeting survivin

Yu M, Xu B, Yang H, Xue S, Zhang R, Zhang H, Ying X, Dai Z

Cancer Management and Research 2019 , 11:6511-6519

Circ-ITGA7 sponges miR-3187-3p to upregulate ASXL1, suppressing colorectal cancer proliferation

Yang G, Zhang T, Ye J, Yang J, Chen C, Cai S, Ma J

Cancer Management and Research 2019 , 11:6499-6509

Association of ki67 and tumor marker p53 in locally advanced breast cancer patients and evaluation of response to neoadjuvant chemotherapy: a survey in South Iran

Firouzabadi D, Rezvani A, Dehghanian A, Mahmoudi L

Cancer Management and Research 2019 , 11:6489-6497

Published Date: 11 July 2019

Comparison of long-term results between radiotherapy after breast-conserving surgery and postmastectomy radiotherapy in stage T1-2N1M0 breast cancer

Lan XW, Wen G, He Z, Huang JH, Zou XB, Lin X, Tan YT, Huang XB

Cancer Management and Research 2019 , 11:6477-6487

T cells targeting multiple tumor-associated antigens as a postremission treatment to prevent or delay relapse in acute myeloid leukemia

Xue L, Hu Y, Wang J, Liu X, Wang X

Cancer Management and Research 2019 , 11:6467-6476

FGF5 promotes osteosarcoma cells proliferation via activating MAPK signaling pathway

Han D, Wang M, Yu Z, Yin L, Liu C, Wang J, Liu Y, Jiang S, Ren Z, Yin J

Cancer Management and Research 2019 , 11:6457-6466

Published Date: 10 July 2019

TBH score: a new model to predict and prevent severe liver damage after chemotherapy for cancer patients

Zhang M, Bao Y, Chen W, Wei M, Pang H, Ren YF, Mei J, Ye S, Fu S, Peng ZW

Cancer Management and Research 2019 , 11:6443-6456

Predictors of inguinal lymph node metastasis in penile cancer patients: a meta-analysis of retrospective studies

Hu J, Cui Y, Liu P, Zhou X, Ren W, Chen J, Zu X

Cancer Management and Research 2019 , 11:6425-6441

Stanniocalcin 2 (STC2) expression promotes post-radiation survival, migration and invasion of nasopharyngeal carcinoma cells

Cancer Management and Research 2019 , 11:6411-6424

Integrated assessment of PD-L1 expression and molecular classification facilitates therapy selection and prognosis prediction in gastric cancer

Sun Y, Yu W, Guan W, Cai L, Qiao M, Zheng L, Jiang R, Wang R, Wang L

Cancer Management and Research 2019 , 11:6397-6410

DNMT3a promotes proliferation by activating the STAT3 signaling pathway and depressing apoptosis in pancreatic cancer

Jing W, Song N, Liu YP, Qu XJ, Qi YF, Li C, Hou KZ, Che XF, Yang XH

Cancer Management and Research 2019 , 11:6379-6396

TMED2 as a marker of prognosis in breast cancer [Letter]

Schwarz MC, Allikmets S

Cancer Management and Research 2019 , 11:6377-6378

Chinese expert consensus on diagnosis and treatment of nasopharyngeal carcinoma: evidence from current practice and future perspectives

Lang J, Hu C, Lu T, Pan J, Lin T

Cancer Management and Research 2019 , 11:6365-6376

Alcohol consumption, tobacco smoking, betel quid chewing and oral health associations with hypopharyngeal cancer among men in Central South China: a case–control study

Zeng J, Tang Y, Wu P, Fang X, Wang W, Fan Y, Li X, Zhao S

Cancer Management and Research 2019 , 11:6353-6364

Characterization of acquired receptor tyrosine–kinase fusions as mechanisms of resistance to EGFR tyrosine–kinase inhibitors

Xu H, Shen J, Xiang J, Li H, Li B, Zhang T, Zhang L, Mao X, Jian H, Shu Y

Cancer Management and Research 2019 , 11:6343-6351

Published Date: 9 July 2019

Downregulation of TfR1 promotes progression of colorectal cancer via the JAK/STAT pathway

Cui C, Cheng X, Yan L, Ding H, Guan X, Zhang W, Tian X, Hao C

Cancer Management and Research 2019 , 11:6323-6341

Screening miRNAs associated with resistance gemcitabine from exosomes in A549 lung cancer cells

Liang AL, Du SL, Zhang B, Zhang J, Ma X, Wu CY, Liu YJ

Cancer Management and Research 2019 , 11:6311-6321

Published Date: 8 July 2019

Radiation therapy-induced reactive oxygen species specifically eliminates CD19+ IgA+ B cells in nasopharyngeal carcinoma

Li W, Wang L, Shen C, Xu T, Chu Y, Hu C

Cancer Management and Research 2019 , 11:6299-6309

Correlation between pelvic bone marrow radiation dose and acute hematological toxicity in cervical cancer patients treated with concurrent chemoradiation

Kumar T, Schernberg A, Busato F, Laurans M, Fumagalli I, Dumas I, Deutsch E, Haie-Meder C, Chargari C

Cancer Management and Research 2019 , 11:6285-6297

Frequency of germline mutations in BRCA1 and BRCA2 in ovarian cancer patients and their effect on treatment outcome

Ashour M, Ezzat Shafik H

Cancer Management and Research 2019 , 11:6275-6284

Identifying risk factors for high-dose methotrexate-induced toxicities in children with acute lymphoblastic leukemia

Li X, Sui Z, Jing F, Xu W, Li X, Guo Q, Sun S, Bi X

Cancer Management and Research 2019 , 11:6265-6274

Published Date: 5 July 2019

The development of a nomogram to predict post-radiation necrosis in nasopharyngeal carcinoma patients: a large-scale cohort study

Li XY, Sun XS, Liu SL, Chen QY, Guo SS, Liu LT, Yan JJ, Xie HJ, Tang QN, Liang YJ, Guo L, Tang LQ, Mai HQ

Cancer Management and Research 2019 , 11:6253-6263

YAP/TAZ: a promising target for squamous cell carcinoma treatment

Dong X, Meng L, Liu P, Ji R, Su X, Xin Y, Jiang X

Cancer Management and Research 2019 , 11:6245-6252

Mechanisms of resistance to a PI3K inhibitor in gastrointestinal stromal tumors: an omic approach to identify novel druggable targets

Ravegnini G, Sammarini G, Moran S, Calice G, Indio V, Urbini M, Astolfi A, Zanotti F, Pantaleo MA, Hrelia P, Angelini S

Cancer Management and Research 2019 , 11:6229-6244

Analysis of the circular RNA transcriptome in the grade 3 endometrial cancer

Ye F, Tang QL, Ma F, Cai L, Chen M, Ran XX, Wang XY, Jiang XF

Cancer Management and Research 2019 , 11:6215-6227

LincRNA-p21 leads to G1 arrest by p53 pathway in esophageal squamous cell carcinoma

Zhang Y, Miao Y, Shang M, Liu M, Liu R, Pan E, Pu Y, Yin L

Cancer Management and Research 2019 , 11:6201-6214

Published Date: 4 July 2019

The β-galactoside α2,6-sialyltranferase 1 (ST6GAL1) inhibits the colorectal cancer metastasis by stabilizing intercellular adhesion molecule-1 via sialylation

Zhou L, Zhang S, Zou X, Lu J, Yang X, Xu Z, Shan A, Jia W, Liu F, Yan X, Su H, Liang T, Zheng M, Zhang Y, Feng B

Cancer Management and Research 2019 , 11:6185-6199

Plasma long noncoding RNAs PANDAR, FOXD2-AS1, and SMARCC2 as potential novel diagnostic biomarkers for gastric cancer

Yang Z, Sun Y, Liu R, Shi Y, Ding S

Cancer Management and Research 2019 , 11:6175-6184

Modified Glasgow prognostic score as a prognostic factor for renal cell carcinomas: a systematic review and meta-analysis

Hu X, Wang Y, Yang WX, Dou WC, Shao YX, Li X

Cancer Management and Research 2019 , 11:6163-6173

New serum biomarker identification and analysis by mass spectrometry in cervical precancerous lesion and acute cervicitis in South China

Qiu F, Su B, Li Z, Chen W, Cao L, Chen F, Liu D, He J, Lin N

Cancer Management and Research 2019 , 11:6151-6162

Prognostic analysis of patients with mutant and wild-type EGFR gene lung adenocarcinoma

Zheng H, Zhang Y, Zhan Y, Liu S, Lu J, Feng J, Wu X, Wen Q, Fan S

Cancer Management and Research 2019 , 11:6139-6150

M2 macrophage infiltration into tumor islets leads to poor prognosis in non-small-cell lung cancer

Cao L, Che X, Qiu X, Li Z, Yang B, Wang S, Hou K, Fan Y, Qu X, Liu Y

Cancer Management and Research 2019 , 11:6125-6138

Efficacy and safety of intraperitoneally administered resveratrol against rat orthotopic ovarian cancers

Zhong LX, Wu ML, Li H, Liu J, Lin LZ

Cancer Management and Research 2019 , 11:6113-6124

Arm port vs chest port: a systematic review and meta-analysis

Li G, Zhang Y, Ma H, Zheng J

Cancer Management and Research 2019 , 11:6099-6112

Published Date: 3 July 2019

Association of lung and heart dose with survival in patients with non-small cell lung cancer underwent volumetric modulated arc therapy

Shen L, Liu C, Jin J, Han C, Zhou Y, Zheng X, Gong C, Chen M, Xie C, Jin X

Cancer Management and Research 2019 , 11:6091-6098

Transcription factor Nrf2 induces the up-regulation of lncRNA TUG1 to promote progression and adriamycin resistance in urothelial carcinoma of the bladder

Sun Z, Huang G, Cheng H

Cancer Management and Research 2019 , 11:6079-6090

Integrative analysis of the lncRNA-associated ceRNA network reveals lncRNAs as potential prognostic biomarkers in human muscle-invasive bladder cancer

Lyu L, Xiang W, Zhu JY, Huang T, Yuan JD, Zhang CH

Cancer Management and Research 2019 , 11:6061-6077

Silencing of LINC01116 suppresses the development of oral squamous cell carcinoma by up-regulating microRNA-136 to inhibit FN1

Chen Z, Tao Q, Qiao B, Zhang L

Cancer Management and Research 2019 , 11:6043-6059

Benefit of adjuvant chemoradiotherapy in patients with pathological stage III gastric cancer

Ma GF, Zhang HG, Liu J, Chen YX, Xiao H, Wang XF, He J, Zeng ZC, Sun J, Liu TS

Cancer Management and Research 2019 , 11:6029-6041

Published Date: 2 July 2019

Heterogeneity of targeted lung lesion predicts platinum-based first-line therapy outcomes and overall survival for metastatic triple-negative breast cancer patients with lung metastasis: a “PET biopsy” method

Xie Y, Gu B, Hu X, Zhang Y, Zhang J, Wang Z, Zhao Y, Gong C, Li Y, Yang Z, Wang B

Cancer Management and Research 2019 , 11:6019-6027

Postoperative morbidity and mortality after neoadjuvant chemotherapy versus upfront surgery for locally advanced gastric cancer: a propensity score matching analysis

Wu L, Ge L, Qin Y, Huang M, Chen J, Yang Y, Zhong J

Cancer Management and Research 2019 , 11:6011-6018

Neutrophil–lymphocyte ratio dynamics are useful for distinguishing between recurrence and pseudoprogression in high-grade gliomas

Huang Y, Ding H, Wu Q, Li Z, Li H, Li S, Xie C, Zhong Y

Cancer Management and Research 2019 , 11:6003-6009

Published Date: 1 July 2019

Long noncoding RNA Linc00460 promotes breast cancer progression by regulating the miR-489-5p/FGF7/AKT axis

Zhu Y, Yang L, Chong QY, Yan H, Zhang W, Qian W, Tan S, Wu Z, Lobie PE, Zhu T

Cancer Management and Research 2019 , 11:5983-6001

Mechanism of trastuzumab resistance caused by HER-2 mutation in breast carcinomas

Kong X, Zhang K, Wang X, Yang X, Li Y, Zhai J, Xing Z, Qi Y, Gao R, Feng X, Wang J, Fang Y

Cancer Management and Research 2019 , 11:5971-5982

SNHG15: a promising cancer-related long noncoding RNA

Tong J, Ma X, Yu H, Yang J

Cancer Management and Research 2019 , 11:5961-5969

Clinical outcomes and survival analysis for petroclival meningioma patients receiving surgical resection: an analysis of 176 cases

Qiao L, Yu C, Zhang H, Zhang M, Qu Y, Ren M, Gu C, Wang H

Cancer Management and Research 2019 , 11:5949-5959

Comparison of short-term and survival outcomes for transanal natural orifice specimen extraction with conventional mini-laparotomy after laparoscopic anterior resection for colorectal cancer

Zhou S, Wang X, Zhao C, Pei W, Zhou H, Liu Q, Liang J, Zhou Z, Wang X

Cancer Management and Research 2019 , 11:5939-5948

Effects of dynein light chain Tctex-type 3 on the biological behavior of ovarian cancer

Zhou L, Ye M, Xue F, Lu E, Sun LZ, Zhu X

Cancer Management and Research 2019 , 11:5925-5938

The impact of panitumumab treatment on survival and quality of life in patients with RAS wild-type metastatic colorectal cancer

Battaglin F, Puccini A, Ahcene Djaballah S, Lenz HJ

Cancer Management and Research 2019 , 11:5911-5924

Published Date: 28 June 2019

The emerging roles of PIWI-interacting RNA in human cancers

Yu Y, Xiao J, Hann SS

Cancer Management and Research 2019 , 11:5895-5909

Atractylon induces apoptosis and suppresses metastasis in hepatic cancer cells and inhibits growth in vivo

Cheng Y, Chen T, Yang X, Xue J, Chen J

Cancer Management and Research 2019 , 11:5883-5894

ZNF488 is an independent prognostic indicator in nasopharyngeal carcinoma and promotes cell adhesion and proliferation via collagen IV/FAK/AKT/Cyclin D1 pathway

Zong D, Jiang N, Xu JH, Wang DJ, Zhu HF, Wu LR, Chen C, Yin L, He X

Cancer Management and Research 2019 , 11:5871-5882

Evaluation of therapeutic efficacy with CytoSorter® circulating tumor cell–capture system in patients with locally advanced head and neck squamous cell carcinoma

Zheng W, Zhang Y, Guo L, Wang S, Fang M, Mao W, Lou J

Cancer Management and Research 2019 , 11:5857-5869

Published Date: 27 June 2019

MicroRNA-3662 targets ZEB1 and attenuates the invasion of the highly aggressive melanoma cell line A375

Zhu L, Liu Z, Dong R, Wang X, Zhang M, Guo X, Yu N, Zeng A

Cancer Management and Research 2019 , 11:5845-5856

Sp1 contributes to radioresistance of cervical cancer through targeting G2/M cell cycle checkpoint CDK1

Deng YR, Chen XJ, Chen W, Wu LF, Jiang HP, Lin D, Wang LJ, Wang W, Guo SQ

Cancer Management and Research 2019 , 11:5835-5844

microRNA-548b suppresses aggressive phenotypes of hepatocellular carcinoma by directly targeting high-mobility group box 1 mRNA

Yun Z, Meng F, Jiang P, Yue M, Li S

Cancer Management and Research 2019 , 11:5821-5834

Published Date: 25 June 2019

Familial association of lung cancer with liver cancer in first-degree relatives

Xu CR, Lin H, Su J, Zhang XC, Huang YS, Yang XN, Zhou Q, Yang JJ, Zhong WZ, Wu YL

Cancer Management and Research 2019 , 11:5813-5819

siPRDX2-elevated DNM3 inhibits the proliferation and metastasis of colon cancer cells via AKT signaling pathway

Ma Y, Guan L, Han Y, Zhou Y, Li X, Liu Y, Zhang X, Zhang W, Li X, Wang S, Lu W

Cancer Management and Research 2019 , 11:5799-5811

Genome-wide DNA methylation and RNA expression profiles identified RIPK3 as a differentially methylated gene in Chlamydia pneumoniae infection lung carcinoma patients in China

Xiong WM, Xu QP, Xiao RD, Hu ZJ, Cai L, He F

Cancer Management and Research 2019 , 11:5785-5797

Prognostic significance of a novel indicator (PSApostd3/PSApre) for PSA recurrence in patients after radical prostatectomy

Zhou Z, Xu Y, Li Q, Yan W, Zhou Y, Zheng Z, Li H, Ji Z

Cancer Management and Research 2019 , 11:5777-5783

The prognosis comparison of different molecular subtypes of breast tumors after radiotherapy and the intrinsic reasons for their distinct radiosensitivity

He L, Lv Y, Song Y, Zhang B

Cancer Management and Research 2019 , 11:5765-5775

Safety and efficacy of amrubicin monotherapy in patients with platinum-refractory metastatic neuroendocrine carcinoma of the gastrointestinal tract: a single cancer center retrospective study

Kitagawa Y, Osumi H, Shinozaki E, Ota Y, Nakayama I, Suzuki T, Wakatsuki T, Ichimura T, Ogura M, Ooki A, Takahari D, Suenaga M, Chin K, Yamaguchi K

Cancer Management and Research 2019 , 11:5757-5764

Detection of a novel panel of somatic mutations in plasma cell-free DNA and its diagnostic value in hepatocellular carcinoma

Xiong Y, Xie CR, Zhang S, Chen J, Yin ZY

Cancer Management and Research 2019 , 11:5745-5756

Cancer-associated fibroblasts endow stem-like qualities to liver cancer cells by modulating autophagy

Zhao Z, Bai S, Wang R, Xiong S, Li Y, Wang X, Chen W, Cheng B

Cancer Management and Research 2019 , 11:5737-5744

Published Date: 24 June 2019

TRIM14 promotes cell proliferation and inhibits apoptosis by suppressing PTEN in colorectal cancer

Shen W, Jin Z, Tong X, Wang H, Zhuang L, Lu X, Wu S

Cancer Management and Research 2019 , 11:5725-5735

Laparoscopic hepatectomy versus radiofrequency ablation for hepatocellular carcinoma: a systematic review and meta-analysis

Li X, Wu YS, Chen D, Lin H

Cancer Management and Research 2019 , 11:5711-5724

Construction and validation of a seven-microRNA signature as a prognostic tool for lung squamous cell carcinoma

Gan Z, Zou Q, Lin Y, Huang X, Huang Z, Chen Z, Xu Z, Lv Y

Cancer Management and Research 2019 , 11:5701-5709

Published Date: 21 June 2019

Long noncoding RNA LINC00511 promotes cell growth and invasion in triple-negative breast cancer by interacting with Snail

Cancer Management and Research 2019 , 11:5691-5699

Conversion of immunohistochemical markers and breast density are associated with pathological response and prognosis in very young breast cancer patients who fail to achieve a pathological complete response after neoadjuvant chemotherapy

Zhao Y, Wang X, Huang Y, Zhou X, Zhang D

Cancer Management and Research 2019 , 11:5677-5690

Published Date: 20 June 2019

Concurrent TP53 mutations predict poor outcomes of EGFR-TKI treatments in Chinese patients with advanced NSCLC

Hou H, Qin K, Liang Y, Zhang C, Liu D, Jiang H, Liu K, Zhu J, Lv H, Li T, Zhang X

Cancer Management and Research 2019 , 11:5665-5675

Statin use and its potential therapeutic role in esophageal cancer: a systematic review and meta-analysis

Zhou C, Zhong X, Gao P, Wu Z, Shi J, Guo Z, Wang Z, Song Y

Cancer Management and Research 2019 , 11:5655-5663

Published Date: 19 June 2019

Serum pepsinogen assay is not recommended for the diagnosis of esophageal squamous cell carcinoma: a systematic review and meta-analysis

Liu XB, Gao ZY, Zhang QH, Jin S, Gao B, Yang GL, Li SB

Cancer Management and Research 2019 , 11:5643-5654

Prognostic value of long non-coding RNA CRNDE in gastrointestinal cancers: a meta-analysis

He TY, Li SH, Huang J, Gong M, Li G

Cancer Management and Research 2019 , 11:5629-5642

Systemic inflammation score: a novel risk stratification tool for postoperative outcomes after video-assisted thoracoscopic surgery lobectomy for early-stage non-small-cell lung cancer

Li S, Wang Z, Zhang W, Li J, Zhou K, Che G

Cancer Management and Research 2019 , 11:5613-5628

Early or deferred treatment of smoldering multiple myeloma: a meta-analysis on randomized controlled studies

Zhao AL, Shen KN, Wang JN, Huo LQ, Li J, Cao XX

Cancer Management and Research 2019 , 11:5599-5611

SNHG1 contributes to proliferation and invasion by regulating miR-382 in breast cancer

Zheng S, Li M, Miao K, Xu H

Cancer Management and Research 2019 , 11:5589-5598

Published Date: 18 June 2019

miR-1-3p suppresses the epithelial-mesenchymal transition property in renal cell cancer by downregulating Fibronectin 1

Liu J, Huang Y, Cheng Q, Wang J, Zuo J, Liang Y, Yuan G

Cancer Management and Research 2019 , 11:5573-5587

Candidate tumor suppressor gene IRF6 is involved in human breast cancer pathogenesis via modulating PI3K-regulatory subunit PIK3R2 expression

Xu HF, Huang TJ, Yang Q, Xu L, Lin F, Lang YH, Hu H, Peng LX, Meng DF, Xie YJ, Tan L, Qian CN, Huang BJ

Cancer Management and Research 2019 , 11:5557-5572

Sinonasal/nasopharyngeal pleomorphic adenoma and carcinoma ex pleomorphic adenoma: a report of 17 surgical cases combined with a literature review

Li W, Lu H, Zhang H, Lai Y, Zhang J, Ni Y, Wang D

Cancer Management and Research 2019 , 11:5545-5555

Published Date: 17 June 2019

Lipids in surgical aerosol as diagnosis biomarkers for discrimination of lung cancer

Zhang J, Zheng Q, Zhang W, Wang N, Xu J, Cheng X, Wei Y

Cancer Management and Research 2019 , 11:5537-5543

Distribution of circulating tumor cell phenotype in early cervical cancer

Pan L, Yan G, Chen W, Sun L, Wang J, Yang J

Cancer Management and Research 2019 , 11:5531-5536

Determination of portal vein tumor thrombus blood supply using in vivo cellular magnetic resonance imaging in a rabbit model

Zhang X, Wu B, Guo Z, Gao Y, Xi W, Yu H, Feng G, Zhang J, Shen W, Chen J

Cancer Management and Research 2019 , 11:5523-5529

Effects of anesthetic technique and surgery on myeloid-derived suppressor cells and prognosis in women who underwent breast cancer surgery: a prospective study

Yan T, Zhang GH, Cheng YZ, Wu LX, Liu XY, Sun YL, Zheng H, Sun L

Cancer Management and Research 2019 , 11:5513-5522

MAT2B expression correlates with poor prognosis in triple-negative breast cancer

Xu J, Wu D, Wang S, Wang Z

Cancer Management and Research 2019 , 11:5501-5511

Published Date: 14 June 2019

Clinical genetic features and related survival implications in patients with surgically resected large-cell lung cancer

Wang F, Lu JB, Wu XY, Feng YF, Shao Q, An X, Wang HY

Cancer Management and Research 2019 , 11:5489-5499

Vascular index measured by smart 3-D superb microvascular imaging can help to differentiate malignant and benign breast lesion

Zhang XY, Zhang L, Li N, Zhu QL, Li JC, Sun Q, Wang HY, Jiang YX

Cancer Management and Research 2019 , 11:5481-5487

Published Date: 13 June 2019

Prognostic value of the 2018 FIGO staging system for cervical cancer patients with surgical risk factors

Yan DD, Tang Q, Chen JH, Tu YQ, Lv XJ

Cancer Management and Research 2019 , 11:5473-5480

IGF1R facilitates epithelial-mesenchymal transition and cancer stem cell properties in neuroblastoma via the STAT3/AKT axis

Wang XH, Wu HY, Gao J, Wang XH, Gao TH, Zhang SF

Cancer Management and Research 2019 , 11:5459-5472

Published Date: 12 June 2019

MicroRNA-371-3 cluster as biomarkers for the diagnosis and prognosis of cancers

Pan B, He B, Xu X, Liu X, Xu T, Xu M, Chen X, Zeng K, Lin K, Hu X, Sun L, Pan Y, Sun H, Wang S

Cancer Management and Research 2019 , 11:5437-5457

Bioinformatics analysis of dysregulated microRNAs in exosomes from docetaxel-resistant and parental human breast cancer cells

Chen WX, Xu LY, Cheng L, Qian Q, He X, Peng WT, Zhu YL

Cancer Management and Research 2019 , 11:5425-5435

CircRNA hsa_circ_0004585 as a potential biomarker for colorectal cancer

Tian J, Xi X, Wang J, Yu J, Huang Q, Ma R, Zhang X, Li H, Wang L

Cancer Management and Research 2019 , 11:5413-5423

Published Date: 11 June 2019

Exercise during adjuvant treatment for colorectal cancer: treatment completion, treatment-related toxicities, body composition, and serum level of adipokines

Shim YJ, Kim HJ, Oh SC, Lee SI, Choi SW

Cancer Management and Research 2019 , 11:5403-5412

Genetic polymorphisms in IL-7 and IL-7R are correlated with lung cancer risk in the Chinese Han population

Zhang C, Su P, Chen W, Li Q, Dai R, Cheng Y, Yang J

Cancer Management and Research 2019 , 11:5393-5401

The novel lncRNA p4516 acts as a prognostic biomarker promoting gastric cancer cell proliferation and metastasis

Nie ML, Han J, Huang HC, Guo T, Huangfu LT, Cheng XJ, Li XM, Du H, Li QD, Wen XZ, Ji JF

Cancer Management and Research 2019 , 11:5375-5391

Prognostic value of pretreatment neutrophil count in metastatic renal cell carcinoma: a systematic review and meta-analysis

Shen J, Chen Z, Fan M, Lu H, Zhuang Q, He X

Cancer Management and Research 2019 , 11:5365-5374

Published Date: 10 June 2019

MicroRNA-193a-3p suppresses the colorectal cancer cell proliferation and progression through downregulating the PLAU expression

Lin M, Zhang Z, Gao M, Yu H, Sheng H, Huang J

Cancer Management and Research 2019 , 11:5353-5363

Urinary 8-hydroxydeoxyguanosine in relation to XRCC1 rs25487 G/A (Arg399Gln) and OGG1 rs1052133 C/G (Ser326Cys) DNA repair genes polymorphisms in patients with chronic hepatitis C and related hepatocellular carcinoma

Mahmoud AA, Hassan MH, Ghweil AA, Abdelrahman A, Mohammad AN, Ameen HH

Cancer Management and Research 2019 , 11:5343-5351

Gephyrin suppresses lung squamous cell carcinoma development by reducing mTOR pathway activation

Zhang X, Cheng D, Liu Y, Wu Y, He Z

Cancer Management and Research 2019 , 11:5333-5341

Published Date: 7 June 2019

miR-6716-5p promotes metastasis of colorectal cancer through downregulating NAT10 expression

Liu Z, Liu X, Li Y, Ren P, Zhang C, Wang L, Du X, Xing B

Cancer Management and Research 2019 , 11:5317-5332

Published Date: 6 June 2019

An integrated prediction model of recurrence in endometrial endometrioid cancers

Miller MD, Salinas EA, Newtson AM, Sharma D, Keeney ME, Warrier A, Smith BJ, Bender DP, Goodheart MJ, Thiel KW, Devor EJ, Leslie KK, Gonzalez-Bosquet J

Cancer Management and Research 2019 , 11:5301-5315

Safety and efficacy of combination therapy with apatinib and doxorubicin in metastatic soft tissue sarcomas: an observational study from multiple institutions

Tian Z, Wang X, Liu Z, Wang J, Yao W, Zhao Y, Gao S, Zhang P, Ge H

Cancer Management and Research 2019 , 11:5293-5300

Current status of liquid biopsies for the detection and management of prostate cancer

Lu YT, Delijani K, Mecum A, Goldkorn A

Cancer Management and Research 2019 , 11:5271-5291

MicroRNA-876 is sponged by long noncoding RNA LINC00707 and directly targets metadherin to inhibit breast cancer malignancy

Li T, Li Y, Sun H

Cancer Management and Research 2019 , 11:5255-5269

ELF-1 expression in nasopharyngeal carcinoma facilitates proliferation and metastasis of cancer cells via modulation of CCL2/CCR2 signaling

Chen CH, Su LJ, Tsai HT, Hwang CF

Cancer Management and Research 2019 , 11:5243-5254

RETRACTED ARTICLE: Tangeretin inhibits hepatocellular carcinoma proliferation and migration by promoting autophagy-related BECLIN1

Zheng J, Shao Y, Jiang Y, Chen F, Liu S, Yu N, Zhang D, Liu X, Zou L

Cancer Management and Research 2019 , 11:5231-5242

Definitive radiotherapy or chemoradiotherapy for distal rectal cancer with early stage of cT1-2N0

Peng HH, Liao ZW, Lin XD, Qiu XS, You KY

Cancer Management and Research 2019 , 11:5221-5229

Identification of hub genes and key pathways associated with angioimmunoblastic T-cell lymphoma using weighted gene co-expression network analysis

Li X, Liu Z, Mi M, Zhang C, Xiao Y, Liu X, Wu G, Zhang L

Cancer Management and Research 2019 , 11:5209-5220

The molecular mechanisms underlying BCR/ABL degradation in chronic myeloid leukemia cells promoted by Beclin1-mediated autophagy

Huang X, Li Y, Shou L, Li L, Chen Z, Ye X, Qian W

Cancer Management and Research 2019 , 11:5197-5208

Development and validation of a prognostic score predicting recurrence in resected combined hepatocellular cholangiocarcinoma

Tian MX, Luo LP, Liu WR, Deng W, Yin JC, Jin L, Jiang XF, Zhou YF, Qu WF, Tang Z, Wang H, Tao CY, Fang Y, Qiu SJ, Zhou J, Liu JF, Fan J, Shi YH

Cancer Management and Research 2019 , 11:5187-5195

Published Date: 5 June 2019

Neutrophils infiltration and its correlation with human papillomavirus status in the oral squamous cell carcinoma

Li C, Zhao L, Wang Q, Ma S, Sun J, Ma C, Liu J, Jing X, Ai D, Nan Z, Qu X

Cancer Management and Research 2019 , 11:5171-5185

c-MYC expression in T (III/IV) stage oral squamous cell carcinoma (OSCC) patients

Cancer Management and Research 2019 , 11:5163-5169

Preoperative neutrophil–lymphocyte and platelet–lymphocyte ratios as independent predictors of T stages in hilar cholangiocarcinoma

Huang H, Wan X, Bai Y, Bian J, Xiong J, Xu Y, Sang X, Zhao H

Cancer Management and Research 2019 , 11:5157-5162

Published Date: 4 June 2019

NETO2 promotes pancreatic cancer cell proliferation, invasion and migration via activation of the STAT3 signaling pathway

Li Y, Zhang Y, Liu J

Cancer Management and Research 2019 , 11:5147-5156

Connexin 32 downregulation is critical for chemoresistance in oxaliplatin-resistant HCC cells associated with EMT

Yang Y, Yao JH, Du QY, Zhou YC, Yao TJ, Wu Q, Liu J, Ou YR

Cancer Management and Research 2019 , 11:5133-5146

Published Date: 31 May 2019

Combination of the preoperative albumin to globulin ratio and neutrophil to lymphocyte ratio as a novel prognostic factor in patients with triple negative breast cancer

Xuan Q, Yang Y, Ji H, Tang S, Zhao J, Shao J, Wang J

Cancer Management and Research 2019 , 11:5125-5131

Immune inflammation indicators in anal cancer patients treated with concurrent chemoradiation: training and validation cohort with online calculator (ARC: Anal Cancer Response Classifier) [Corrigendum]

Casadei-Gardini A, Montagnani F, Casadei C

Cancer Management and Research 2019 , 11:5123-5124

Association of caveolin-1 protein expression with hepatocellular carcinoma: a meta-analysis and literature review

Zhang Y, Fan W, Wu J, Dong J, Cui Z

Cancer Management and Research 2019 , 11:5113-5122

Cancer prevalence among the rural poverty-stricken population in Northeast China

Liu B, Lao X, Feng Y, Liu J, Jiao M, Zhao M, Wang J, Zhang X, Liu J, Qi X, Liu H, Chen R, Wu Q, Hao Y

Cancer Management and Research 2019 , 11:5101-5112

Serum hepatitis B viral (HBV) DNA is a predictive biomarker for survival in non-small cell lung cancer patients with chronic HBV infection

Fu Y, Yang X, Liang H, Wu X

Cancer Management and Research 2019 , 11:5091-5100

HMGB3 silence inhibits breast cancer cell proliferation and tumor growth by interacting with hypoxia-inducible factor 1α

Gu J, Xu T, Huang QH, Zhang CM, Chen HY

Cancer Management and Research 2019 , 11:5075-5089

Definitive chemoradiotherapy and salvage chemotherapy for patients with isolated locoregional recurrence after radical resection of primary pancreatic cancer

Shi W, Jiang R, Liang F, Yu G, Long J, Zhao J

Cancer Management and Research 2019 , 11:5065-5073

Predictors of postoperative complications after robot-assisted radical cystectomy with extracorporeal urinary diversion

Lee CU, Kang M, Kim TJ, Na JP, Sung HH, Jeon HG, Seo SI, Jeon SS, Lee HM, Jeong BC

Cancer Management and Research 2019 , 11:5055-5063

Mucin phenotype of differentiated early gastric cancer: an immunohistochemistry study supporting therapeutic decision making

Cavalcanti E, De Michele F, Lantone G, Panarese A, Caruso ML

Cancer Management and Research 2019 , 11:5047-5054

Plausibility of trophoblastic-like regulation of cancer tissue

Piechowski J

Cancer Management and Research 2019 , 11:5033-5046

Assessment of microRNA expression in leukemic cells as predictors of sensitivity to purine nucleoside analogs, fludarabine and cladribine, in chronic lymphocytic leukemia patients

Szymczyk A, Chocholska S, Macheta A, Szczepanek D, Hus M, Podhorecka M

Cancer Management and Research 2019 , 11:5021-5031

Published Date: 30 May 2019

The efficacy and safety of apatinib in metastatic alveolar soft part sarcoma: a case series of six patients in one institution [Corrigendum]

Wang Y, Min L, Zhou Y, Tang F, Luo Y, Zhang W, Duan H, Tu C

Cancer Management and Research 2019 , 11:5019-5020

Dosimetry comparison between a 3D printed minimally invasive guidance template and free implantation in the brachytherapy treatment of postoperative recurrent cervical carcinoma

Yuan X, Zhang Y, Cui M, Miao J, Gao L, Hu J, Tian D, You J

Cancer Management and Research 2019 , 11:5013-5018

Analyzing biological and molecular characteristics and genomic damage induced by exposure to asbestos

Ospina D, Villegas VE, Rodríguez-Leguizamón G, Rondón-Lagos M

Cancer Management and Research 2019 , 11:4997-5012

kshv-mir-k12-1-5p promotes cell growth and metastasis by targeting SOCS6 in Kaposi’s sarcoma cells

Zhang J, Pu XM, Xiong Y

Cancer Management and Research 2019 , 11:4985-4995

Published Date: 29 May 2019

Comprehensive analysis of genes based on chr1p/19q co-deletion reveals a robust 4-gene prognostic signature for lower grade glioma

Zhang C, Yu R, Li Z, Song H, Zang D, Deng M, Fan Y, Liu Y, Zhang Y, Qu X

Cancer Management and Research 2019 , 11:4971-4984

Negative regulators of STAT3 signaling pathway in cancers

Wu M, Song D, Li H, Yang Y, Ma X, Deng S, Ren C, Shu X

Cancer Management and Research 2019 , 11:4957-4969

Nuclear GAPDH is vital for hypoxia-induced hepatic stellate cell apoptosis and is indicative of aggressive hepatocellular carcinoma behavior

Gong Y, Zou B, Peng S, Li P, Zhu G, Chen J, Chen J, Liu X, Zhou W, Ding L, Chen Y, Zeng L, Zhang B, Cai C, Li J

Cancer Management and Research 2019 , 11:4947-4956

Loss of ARID1A promotes proliferation, migration and invasion via the Akt signaling pathway in NPC

Yang Y, Wang X, Yang J, Duan J, Wu Z, Yang F, Zhang X, Xiao S

Cancer Management and Research 2019 , 11:4931-4946

Apolipoprotein C1 (APOC1) promotes tumor progression via MAPK signaling pathways in colorectal cancer

Ren H, Chen Z, Yang L, Xiong W, Yang H, Xu K, Zhai E, Ding L, He Y, Song X

Cancer Management and Research 2019 , 11:4917-4930

Apatinib enhances chemosensitivity of gastric cancer to paclitaxel and 5-fluorouracil

Xu Z, Hu C, Chen S, Zhang C, Yu J, Wang X, Lv H, Cheng X

Cancer Management and Research 2019 , 11:4905-4915

Nivolumab plus ipilimumab combination therapy for the first-line treatment NSCLC: evidence to date

Remon J, Esteller L, Taus Á

Cancer Management and Research 2019 , 11:4893-4904

Impact of EGFR genotype on the efficacy of osimertinib in EGFR tyrosine kinase inhibitor-resistant patients with non-small cell lung cancer: a prospective observational study

Igawa S, Ono T, Kasajima M, Ishihara M, Hiyoshi Y, Kusuhara S, Nishinarita N, Fukui T, Kubota M, Sasaki J, Hisashi M, Yokoba M, Katagiri M, Naoki K

Cancer Management and Research 2019 , 11:4883-4892

Published Date: 28 May 2019

Dihydrodiosgenin inhibits endothelial cell-derived factor VIII and platelet-mediated hepatocellular carcinoma metastasis

Zhuang M, Xin G, Wei Z, Li S, Xing Z, Ji C, Du J, Niu H, Huang W

Cancer Management and Research 2019 , 11:4871-4882

Adjuvant chemoradiotherapy versus adjuvant chemotherapy for patients with N3 gastric cancer after D2/R0 resection: a retrospective study based on propensity score analyses

Zhou ML, Yang W, Wang YQ, Mo M, Hu R, Wang Y, Yang JN, Li GC, Wang YN, Zhang Z

Cancer Management and Research 2019 , 11:4855-4870

Intra-rectal use of epinephrine in radiotherapy of prostate cancer

Qin SB, Gao XS, Li HZ, Liu CX, Hou DL, Nian WD, Li XY, Wang D

Cancer Management and Research 2019 , 11:4847-4854

Published Date: 27 May 2019

Safety of early oral feeding after total laparoscopic radical gastrectomy for gastric cancer (SOFTLY-1): a single-center randomized controlled trial

Wang Q, Yang KL, Guo BY, Shang LF, Yan ZD, Yu J, Zhang D, Ji G

Cancer Management and Research 2019 , 11:4839-4846

MiR-193a-3p inhibits pancreatic ductal adenocarcinoma cell proliferation by targeting CCND1

Chen ZM, Yu Q, Chen G, Tang RX, Luo DZ, Dang YW, Wei DM

Cancer Management and Research 2019 , 11:4825-4837

Selective use of concurrent chemotherapy in elderly cervical cancer patients treated with definitive radiotherapy: experience from two institutions

You Ky, Peng Hh, Jiang Yh, Bi Zf, Qiu Xs

Cancer Management and Research 2019 , 11:4815-4823

Prognostic impact of the pretreatment albumin to alkaline phosphatase ratio for nonmetastatic breast cancer patients

Long ZQ, Hua X, Zhang WW, Lv SW, Deng JP, Guo L, He ZY, Lin HX

Cancer Management and Research 2019 , 11:4809-4814

DCZ0814 induces apoptosis and G0/G1 phase cell cycle arrest in myeloma by dual inhibition of mTORC1/2

Kong Y, Li B, Chang S, Gao L, Xu Z, He W, Yang G, Xie B, Chen G, Hu L, Lu K, Wang Y, Wu X, Zhu W, Shi J

Cancer Management and Research 2019 , 11:4797-4808

Eupatilin inhibits glioma proliferation, migration, and invasion by arresting cell cycle at G1/S phase and disrupting the cytoskeletal structure

Fei X, Wang J, Chen C, Ding B, Fu X, Chen W, Wang C, Xu R

Cancer Management and Research 2019 , 11:4781-4796

Published Date: 24 May 2019

An efficient method that combines the ThinPrep cytologic test with E6/E7 mRNA testing for cervical cancer screening

Pan D, Zhang CQ, Liang QL, Hong XC

Cancer Management and Research 2019 , 11:4773-4780

A panel of collagen genes are associated with prognosis of patients with gastric cancer and regulated by microRNA-29c-3p: an integrated bioinformatics analysis and experimental validation

Zhang QN, Zhu HL, Xia MT, Liao J, Huang XT, Xiao JW, Yuan C

Cancer Management and Research 2019 , 11:4757-4772

TLR4 expression correlated with PD-L1 expression indicates a poor prognosis in patients with peripheral T-cell lymphomas

Zhao S, Sun M, Meng H, Ji H, Liu Y, Zhang M, Li H, Li P, Zhang Y, Zhang Q

Cancer Management and Research 2019 , 11:4743-4756

Published Date: 23 May 2019

miR-142-3p suppresses uveal melanoma by targeting CDC25C, TGFβR1, GNAQ, WASL, and RAC1

Peng D, Dong J, Zhao Y, Peng X, Tang J, Chen X, Wang L, Hu DN, Reinach PS, Qu J, Yan D

Cancer Management and Research 2019 , 11:4729-4742

A novel preoperative plasma indicator to predict prognoses for patients with esophageal squamous cell carcinoma after radical esophagectomy: fibrinogen-to-lymphocyte ratio

Fan N, Chen D, Zheng J, Wen Z, Lin P

Cancer Management and Research 2019 , 11:4719-4728

Voltage-dependent calcium channel α2δ1 subunit is a specific candidate marker for identifying gastric cancer stem cells

Zhang Z, Zhao W, Lin X, Gao J, Zhang Z, Shen L

Cancer Management and Research 2019 , 11:4707-4718

Trastuzumab treatment after progression in HER2-positive metastatic breast cancer following relapse of trastuzumab-based regimens: a meta-analysis

Han Y, Wang J, Liu W, Yuan P, Li Q, Zhang P, Ma F, Luo Y, Fan Y, Chen S, Cai R, Li Q, Xu B

Cancer Management and Research 2019 , 11:4699-4706

Elevated expression of CXCL16 correlates with poor prognosis in patients with colorectal cancer

Chen Z, Dai W, Yang L, Yang H, Ding L, He Y, Song X, Cui J

Cancer Management and Research 2019 , 11:4691-4697

Expression of CD133 and CD24 and their different phenotypes in urinary bladder carcinoma

Farid RM, Sammour SA, Shehab ElDin ZA, Salman MI, Omran TI

Cancer Management and Research 2019 , 11:4677-4690

Whole-brain helical tomotherapy with integrated boost for brain metastases in patients with malignant melanoma – final results of the BRAIN-RT trial

Hauswald H, Bernhardt D, Krug D, Katayama S, Habl G, Lorenzo Bermejo J, Debus J, Sterzing F

Cancer Management and Research 2019 , 11:4669-4676

Estrogen-dependent disruption of intracellular iron metabolism augments the cytotoxic effects of doxorubicin in select breast and ovarian cancer cells

Bajbouj K, Shafarin J, Hamad M

Cancer Management and Research 2019 , 11:4655-4668

Upregulation of long noncoding RNA LINC00152 promotes proliferation and metastasis of esophageal squamous cell carcinoma

Yang Y, Sun X, Chi C, Liu Y, Lin C, Xie D, Shen X, Lin X

Cancer Management and Research 2019 , 11:4643-4654

Published Date: 21 May 2019

Metabolic profile and structure–activity relationship of resveratrol and its analogs in human bladder cancer cells

Yang Y, Zhang G, Li C, Wang S, Zhu M, Wang J, Yue H, Ma X, Zhen Y, Shu X

Cancer Management and Research 2019 , 11:4631-4642

Efficacy and safety of programmed death 1 inhibitors in patients with advanced non-small cell lung cancer: a meta-analysis

Liu Y, Zhou S, Du Y, Sun L, Jiang H, Zhang B, Sun G, Wang R

Cancer Management and Research 2019 , 11:4619-4630

Disulfiram inhibits epithelial–mesenchymal transition through TGFβ–ERK–Snail pathway independently of Smad4 to decrease oral squamous cell carcinoma metastasis [Corrigendum]

Bu W, Wang Z, Meng L, Li X, Liu X, Chen Y, Xin Y, Li B, Sun H

Cancer Management and Research 2019 , 11:4617-4618

Published Date: 22 May 2019

Does the radiologist need to rescan the breast lesion to validate the final BI-RADS US assessment made on the static images in the diagnostic setting?

Hu Y, Mei J, Jiang X, Gu R, Liu F, Yang Y, Wang H, Shen S, Jia H, Liu Q, Gong C

Cancer Management and Research 2019 , 11:4607-4615

Expression of PD-L1 in cervical carcinoma and its impact on survival associated with T-cell infiltration and FoxP3 expression

Grochot RM, Brollo J, Neto FR, Tregnago AC, Scholze C, Norris R, Silva S, Weschenfelder DC, Reiriz AB, Michelin L, Pasqualotto FF

Cancer Management and Research 2019 , 11:4597-4605

Published Date: 17 May 2019

NSE from diffuse large B-cell lymphoma cells regulates macrophage polarization

Zhu MY, Liu WJ, Wang H, Wang WD, Liu NW, Lu Y

Cancer Management and Research 2019 , 11:4577-4595

The opposite role of alternatively spliced isoforms of LINC00477 in gastric cancer

Zhao H, He Y, Li H, Zhu A, Ye Y, Liu G, Zhao C, Zhang X

Cancer Management and Research 2019 , 11:4569-4576

Published Date: 16 May 2019

Clinicopathological features and prognosis of AFP-producing colorectal cancer: a single-center analysis of 20 cases

Ren F, Weng W, Zhang Q, Tan C, Xu M, Zhang M, Wang L, Sheng W, Ni S, Huang D

Cancer Management and Research 2019 , 11:4557-4567

The value of the plasma circulating cell-free DNA concentration and integrity index as a clinical tool for prostate cancer diagnosis: a prospective case–control cohort study in an Iranian population

Khani M, Hosseini J, Mirfakhraie R, Habibi M, Azargashb E, Pouresmaeili F

Cancer Management and Research 2019 , 11:4549-4556

Cardiac toxicity of immune-checkpoint inhibitors: a clinical case of nivolumab-induced myocarditis and review of the evidence and new challenges

Martin Huertas R, Saavedra Serrano C, Perna C, Ferrer Gómez A, Alonso Gordoa T

Cancer Management and Research 2019 , 11:4541-4548

The oncoprotein HBXIP facilitates metastasis of hepatocellular carcinoma cells by activation of MMP15 expression

Zheng S, Wu H, Wang F, Lv J, Lu J, Fang Q, Wang F, Lu Y, Zhang S, Xu Y, Bao Q, Xie C, Yin Z

Cancer Management and Research 2019 , 11:4529-4540

Profile of pembrolizumab in the treatment of patients with unresectable or metastatic urothelial carcinoma

Inokuchi J, Eto M

Cancer Management and Research 2019 , 11:4519-4528

Published Date: 15 May 2019

The lncRNA HOXA11-AS regulates Rab3D expression by sponging miR-125a-5p promoting metastasis of osteosarcoma

Cao K, Fang Y, Wang H, Jiang Z, Guo L, Hu Y

Cancer Management and Research 2019 , 11:4505-4518

Impact of taste and smell training on taste disorders during chemotherapy – TASTE trial

von Grundherr J, Koch B, Grimm D, Salchow J, Valentini L, Hummel T, Bokemeyer C, Stein A, Mann J

Cancer Management and Research 2019 , 11:4493-4504

Upregulation of LSD1 promotes migration and invasion in gastric cancer through facilitating EMT

Zhang J, Zhao D, Li Q, Du X, Liu Y, Dai X, Hong L

Cancer Management and Research 2019 , 11:4481-4491

Prognostic significance of systemic immune-inflammation index in triple-negative breast cancer

Liu J, Shi Z, Bai Y, Liu L, Cheng K

Cancer Management and Research 2019 , 11:4471-4480

Published Date: 14 May 2019

Prognostic significance of perineural invasion in vulvar squamous cell carcinoma

Long Y, Yao DS, Wei YS, Wei CH, Chen XY

Cancer Management and Research 2019 , 11:4461-4469

Safety, tolerability, and pharmacokinetics of simotinib, a novel specific EGFR tyrosine kinase inhibitor, in patients with advanced non-small cell lung cancer: results of a phase Ib trial

Hu XS, Han XH, Yang S, Li N, Wang L, Song YY, Mu H, Shi YK

Cancer Management and Research 2019 , 11:4449-4459

Published Date: 13 May 2019

Effective prevention of sorafenib-related vascular damage induced adverse events and maintenance of hepatic function by dried bonito broth and histidine

Sakai N, Kamimura K, Shinagawa-Kobayashi Y, Nagoya T, Niwa Y, Ko M, Setsu T, Sakamaki A, Yokoo T, Abe S, Kamimura H, Sugitani S, Yanagi M, Terai S

Cancer Management and Research 2019 , 11:4437-4448

Long noncoding RNA FEZF1-AS1 promotes the motility of esophageal squamous cell carcinoma through Wnt/β-catenin pathway

Yang L, Ye Y, Chu J, Jia J, Qu Y, Sun T, Yin H, Ming L, Wan J, He F

Cancer Management and Research 2019 , 11:4425-4435

Tissue-specific and exosomal miRNAs in lung cancer radiotherapy: from regulatory mechanisms to clinical implications

Long L, Zhang X, Bai J, Li Y, Wang X, Zhou Y

Cancer Management and Research 2019 , 11:4413-4424

Development and external validation of a nomogram for predicting the overall survival of patients with stage II nasopharyngeal carcinoma after curative treatment

He SS, Wang CT, Peng ZW, Ren YF, Lu LX, Chen RW, Liang SB, Wang Y, Chen Y

Cancer Management and Research 2019 , 11:4403-4412

Published Date: 10 May 2019

Elevated nuclear YBX1 expression and the clinicopathological characteristics of patients with solid tumors: a meta-analysis

Zhang C, Yin T, Tao R, Xiao B, Chen J, Li Z, Miao X, Peng Q, Sun L, Zhang W, Ren J, Zhang Z, Zhang Y, Li X, Zhang W

Cancer Management and Research 2019 , 11:4391-4402

Current status and future prospects of PARP inhibitor clinical trials in ovarian cancer

Jiang X, Li W, Li X, Bai H, Zhang Z

Cancer Management and Research 2019 , 11:4371-4390

Prognostic role of a new inflammatory index with neutrophil-to-lymphocyte ratio and lactate dehydrogenase (CII: Colon Inflammatory Index) in patients with metastatic colorectal cancer: results from the randomized Italian Trial in Advanced Colorectal Cancer (ITACa) study

Casadei-Gardini A, Scarpi E, Ulivi P, Palladino MA, Accettura C, Bernardini I, Spallanzani A, Gelsomino F, Corbelli J, Marisi G, Ruscelli S, Valgiusti M, Frassineti GL, Passardi A

Cancer Management and Research 2019 , 11:4357-4369

Prevalence and risk factors of anxiety and depression in Chinese patients with lung cancer: a cross-sectional study

Yan X, Chen X, Li M, Zhang P

Cancer Management and Research 2019 , 11:4347-4356

Published Date: 9 May 2019

Clinical relevance and significance of programmed death-ligand 1 expression, tumor-infiltrating lymphocytes, and p16 status in sinonasal squamous cell carcinoma

Quan H, Yan L, Wang S, Wang S

Cancer Management and Research 2019 , 11:4335-4345

Prevention effect of low-temperature atomization inhalation for radiation induced oral mucositis in patients with head and neck cancer undergoing radiotherapy

Bai XH, Chen ZM, Ma LH, He Z, Li G

Cancer Management and Research 2019 , 11:4327-4333

Circulating microRNA as diagnostic biomarkers for haematological cancers: a systematic review and meta-analysis

Drokow EK, Sun K, Ahmed HAW, Akpabla GS, Song J, Shi M

Cancer Management and Research 2019 , 11:4313-4326

Clinical utility of pembrolizumab in the management of advanced solid tumors: an evidence-based review on the emerging new data

du Rusquec P, de Calbiac O, Robert M, Campone M, Frenel JS

Cancer Management and Research 2019 , 11:4297-4312

Clinicopathological and prognostic significance of pretreatment thrombocytosis in patients with endometrial cancer: a meta-analysis

Bai YY, Du L, Jing L, Tian T, Liang X, Jiao M, Nan KJ, Guo H, Ruan ZP

Cancer Management and Research 2019 , 11:4283-4295

Published Date: 8 May 2019

Gonadotropin-releasing hormone agonists during chemotherapy for ovarian function and fertility preservation for patients with early-stage breast cancer

Abdel-Razeq H

Cancer Management and Research 2019 , 11:4273-4282

Survival and intracranial control outcomes of whole-brain radiotherapy (WBRT) alone versus WBRT plus a radiotherapy boost in non-small-cell lung cancer with brain metastases: a single-institution retrospective analysis

Lu F, Hou Y, Xia Y, Li L, Wang L, Cao K, Chen H, Chang L, Li W

Cancer Management and Research 2019 , 11:4255-4272

Prognostic significance of peripheral blood absolute lymphocyte count and derived neutrophil to lymphocyte ratio in patients with newly diagnosed extranodal natural killer/T-cell lymphoma

Zhou X, Sun X, Zhao W, Fang X, Wang X

Cancer Management and Research 2019 , 11:4243-4254

Published Date: 7 May 2019

Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for peritoneal mesothelioma: patient selection and special considerations

Enomoto LM, Shen P, Levine EA, Votanopoulos KI

Cancer Management and Research 2019 , 11:4231-4241

A comprehensive analysis of the factors of positive pelvic lymph nodes on survival of cervical cancer patients with 2018 FIGO stage IIIC1p

Yan DD, Tang Q, Tu YQ, Chen JH, Lv XJ

Cancer Management and Research 2019 , 11:4223-4230

Long noncoding RNA DLX6-AS1 promotes tumorigenesis by modulating miR-497-5p/FZD4/ FZD6/Wnt/β-catenin pathway in pancreatic cancer

Yang J, Ye Z, Mei D, Gu H, Zhang J

Cancer Management and Research 2019 , 11:4209-4221

Successful postoperative recovery management after thoracoscopic lobectomy and segmentectomy using an ERAS-based protocol of immediate ice cream intake and early ambulation: a 3-year study

Kuroda H, Sugita Y, Watanabe K, Nakanishi K, Sakakura N, Naito Y, Sakao Y

Cancer Management and Research 2019 , 11:4201-4207

Clinical significance of systemic immune-inflammation index (SII) and C-reactive protein-to-albumin ratio (CAR) in patients with esophageal cancer: a meta-analysis

Zhang Y, Xiao G, Wang R

Cancer Management and Research 2019 , 11:4185-4200

Clinicopathological and prognostic value of PD-L1 in urothelial carcinoma: a meta-analysis

Ding X, Chen Q, Yang Z, Li J, Zhan H, Lu N, Chen M, Yang Y, Wang J, Yang D

Cancer Management and Research 2019 , 11:4171-4184

A novel LARCassigner3 classification predicts outcomes in patients with locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy: a retrospective training and validation analysis

Zhang J, Shen L, Deng Y, Sun X, Wang Y, Yao Y, Zhang H, Zou W, Zhang Z, Wan J, Yang L, Zhu J, Zhang Z

Cancer Management and Research 2019 , 11:4153-4170

Short-term benefit of neoadjuvant hormone therapy in patients with localized high-risk or limited progressive prostate cancer

Ma BL, Yao L, Fan Y, Wang Y, Meng YS, Zhang Q, He ZS, Jin J, Zhou LQ

Cancer Management and Research 2019 , 11:4143-4151

Acute myeloid leukemia patient with FLT3-ITD and NPM1 double mutation should undergo allogeneic hematopoietic stem cell transplantation in CR1 for better prognosis

Huang Y, Hu J, Lu T, Luo Y, Shi J, Wu W, Han X, Zheng W, He J, Cai Z, Wei G, Huang H, Sun J

Cancer Management and Research 2019 , 11:4129-4142

Comparative efficacy of targeted maintenance therapy for newly diagnosed epithelial ovarian cancer: a network meta-analysis

Xu X, Yin S, Guo H, Li M, Qian Z, Tian X, Li T

Cancer Management and Research 2019 , 11:4119-4128

The safety and serious adverse events of approved ALK inhibitors in malignancies: a meta-analysis

Hou H, Sun D, Liu K, Jiang M, Liu D, Zhu J, Zhou N, Cong J, Zhang X

Cancer Management and Research 2019 , 11:4109-4118

The utility of folate receptor-positive circulating tumor cell in cancer diagnosis in the elderly population

Li N, Zhong D, Chen H, Huang T, Hou P, Zhang Y, Chen F, Wang X, Zhang H

Cancer Management and Research 2019 , 11:4097-4107

Published Date: 6 May 2019

Whole exome sequencing of multiple meningiomas with varying histopathological presentation in one patient revealed distinctive somatic mutation burden and independent clonal origins

Sheng HS, Shen F, Zhang N, Yu LS, Lu XQ, Zhang Z, Fang HY, Zhou LL, Lin J

Cancer Management and Research 2019 , 11:4085-4095

Impact of high-mobility-group A2 overexpression on epithelial-mesenchymal transition in pancreatic cancer

Gong J, Wang Y, Jiang B, Xu B, Hu C

Cancer Management and Research 2019 , 11:4075-4084

Published Date: 3 May 2019

Adjuvant trans-arterial chemoembolization after hepatectomy significantly improves the prognosis of low-risk patients with R0-stage hepatocellular carcinoma

Xie H, Tian S, Cui L, Yan J, Bai Y, Li X, Wang M, Zhang F, Duan F

Cancer Management and Research 2019 , 11:4065-4073

Intake consumption of ginsenoside Rg3, profiling of selected cytokines, and development of rectal polyps

Xie J, Luo S, Mi H, Du Y, Bao G, Zhou J, Xi Y, Li C

Cancer Management and Research 2019 , 11:4059-4064

Prognostic value of tumor-associated macrophages in pancreatic cancer: a meta-analysis

Yu M, Guan R, Hong W, Zhou Y, Lin Y, Jin H, Hou B, Jian Z

Cancer Management and Research 2019 , 11:4041-4058

Exosomal miRNA-107 induces myeloid-derived suppressor cell expansion in gastric cancer

Ren W, Zhang X, Li W, Feng Q, Feng H, Tong Y, Rong H, Wang W, Zhang D, Zhang Z, Tu S, Zhu X, Zhang Q

Cancer Management and Research 2019 , 11:4023-4040

Weight control is vital for patients with early-stage endometrial cancer or complex atypical hyperplasia who have received progestin therapy to spare fertility: a systematic review and meta-analysis

Li M, Guo T, Cui R, Feng Y, Bai H, Zhang Z

Cancer Management and Research 2019 , 11:4005-4021

A real-world evidence of efficacy of palliative gastrectomy plus chemotherapy in metastatic gastric cancer patients

Yang LP, Wang ZX, He MM, Wu HX, Yuan SQ, Wang W, Jin Y, Ren C, Wang ZQ, Wang FH, Li YH, Wang F, Xu RH

Cancer Management and Research 2019 , 11:3993-4003

Published Date: 2 May 2019

Development and validation of a nomogram to predict liver metastasis in patients with pancreatic ductal adenocarcinoma: a large cohort study

He C, Zhong L, Zhang Y, Cai Z, Lin X

Cancer Management and Research 2019 , 11:3981-3991

High systemic immune–inflammation index represents an unfavorable prognosis of malignant pleural mesothelioma

Ma M, Yu N, Wu B

Cancer Management and Research 2019 , 11:3973-3979

LncRNA LOC105372579 promotes proliferation and epithelial-mesenchymal transition in hepatocellular carcinoma via activating miR-4316/FOXP4 signaling [Corrigendum]

E C, Yang J, Li H, Li C

Cancer Management and Research 2019 , 11:3971-3972

Incidence risk of PD-1/PD-L1 related diarrhea in non-small cell lung cancer (NSCLC) patients: a systematic review and meta-analysis

Zhang C, Zhang S, Xu D, Liu R, Zhu Q, Zhao Y, Mao Y, Tian Y

Cancer Management and Research 2019 , 11:3957-3969

Small RNA sequencing reveals a novel tsRNA-26576 mediating tumorigenesis of breast cancer

Zhou J, Wan F, Wang Y, Long J, Zhu X

Cancer Management and Research 2019 , 11:3945-3956

T-lymphoid/myeloid mixed phenotype acute leukemia and early T-cell precursor lymphoblastic leukemia similarities with NOTCH1 mutation as a good prognostic factor

Noronha EP, Marques LVC, Andrade FG, Sardou-Cezar I, dos Santos-Bueno FV, Zampier CDP, Terra-Granado E, Pombo-de-Oliveira MS

Cancer Management and Research 2019 , 11:3933-3943

Expression profiles and prognostic significance of RNA N6-methyladenosine-related genes in patients with hepatocellular carcinoma: evidence from independent datasets

Zhou Y, Yin Z, Hou BH, Yu M, Chen R, Jin H, Jian Z

Cancer Management and Research 2019 , 11:3921-3931

Published Date: 1 May 2019

Relationship between Helicobacter pylori and expression of programmed death-1 and its ligand in gastric intraepithelial neoplasia and early-stage gastric cancer

Shen B, Qian A, Lao W, Li W, Chen X, Zhang B, Wang H, Yuan F, Sun Y

Cancer Management and Research 2019 , 11:3909-3919

Total pancreatectomy compared with pancreaticoduodenectomy: a systematic review and meta-analysis

Yang DJ, Xiong JJ, Liu XT, Li J, Dhanushka Layanthi Siriwardena KM, Hu WM

Cancer Management and Research 2019 , 11:3899-3908

Disulfiram inhibits epithelial–mesenchymal transition through TGFβ–ERK–Snail pathway independently of Smad4 to decrease oral squamous cell carcinoma metastasis

Cancer Management and Research 2019 , 11:3887-3898

The influence of sex on the prognostic value of body mass index in non-metastasis renal cell carcinoma

Zheng Y, Bao L, Chen J, Pan Y, Wang Q, Chen L, Gao X

Cancer Management and Research 2019 , 11:3869-3886

Functional variants of lncRNA LINC00673 and gastric cancer susceptibility: a case-control study in a Chinese population

Zhao K, Zhang R, Li T, Xiong Z

Cancer Management and Research 2019 , 11:3861-3868

Lenvatinib, a molecule with versatile application: from preclinical evidence to future development in anti-cancer treatment

Capozzi M, De Divitiis C, Ottaiano A, von Arx C, Scala S, Tatangelo F, Delrio P, Tafuto S

Cancer Management and Research 2019 , 11:3847-3860

KDR inferred haplotype is associated with upper limb dysfunction in breast cancer survivors of mixed ancestry

Mafu TS, September AV, Shamley D

Cancer Management and Research 2019 , 11:3829-3845

lncRNA CADM1-AS1 inhibits cell-cycle progression and invasion via PTEN/AKT/GSK-3β axis in hepatocellular carcinoma

Wang F, Qi X, Li Z, Jin S, Xie Y, Zhong H

Cancer Management and Research 2019 , 11:3813-3828

Published Date: 30 April 2019

MicroRNA-145 inhibits growth of laryngeal squamous cell carcinoma by targeting the PI3K/Akt signaling pathway

Ye D, Zhou C, Deng H, Lin L, Zhou S

Cancer Management and Research 2019 , 11:3801-3812

Survival benefit of higher fraction dose delivered by three-dimensional conformal radiotherapy in hepatocellular carcinoma smaller than 10 cm in size

Su F, Chen K, Liang Z, Qu S, Li L, Chen L, Yang Y, Wu C, Liang X, Zhu X

Cancer Management and Research 2019 , 11:3791-3799

FOXM1 promotes the growth and metastasis of colorectal cancer via activation of β-catenin signaling pathway

Yang K, Jiang B, Lu Y, Shu Q, Zhai P, Zhi Q, Li Q

Cancer Management and Research 2019 , 11:3779-3790

Functional analysis and clinical significance of the isocitrate dehydrogenase 2 gene in papillary thyroid carcinoma

Zhang J, Hu L, Wang H, Zhi J, Hou X, Wu Y, Zheng X, Gao M

Cancer Management and Research 2019 , 11:3765-3777

A new predictor is comparable to the updated nomogram in predicting the intermediate- and high-risk prostate cancer but outperforms nomogram in reducing the overtreatment for the low-risk Pca

Wang H, Tai S, Zhang L, Zhou J, Liang C

Cancer Management and Research 2019 , 11:3753-3763

CLDN8 promotes colorectal cancer cell proliferation, migration, and invasion by activating MAPK/ERK signaling

Cheng B, Rong A, Zhou Q, Li W

Cancer Management and Research 2019 , 11:3741-3751

Mutation spectrum of germline cancer susceptibility genes among unselected Chinese colorectal cancer patients

Gong R, He Y, Liu XY, Wang HY, Sun LY, Yang XH, Li B, Cao XK, Ye ZL, Kong LH, Zhang DD, Li YH, Xu RH, Shao JY

Cancer Management and Research 2019 , 11:3721-3739

Published Date: 29 April 2019

A serum piRNA signature as promising non-invasive diagnostic and prognostic biomarkers for colorectal cancer

Qu A, Wang W, Yang Y, Zhang X, Dong Y, Zheng G, Wu Q, Zou M, Du L, Wang Y, Wang C

Cancer Management and Research 2019 , 11:3703-3720

Apolipoprotein M could inhibit growth and metastasis of SMMC7721 cells via vitamin D receptor signaling

Yu M, Pan L, Sang C, Mu Q, Zheng L, Luo G, Xu N

Cancer Management and Research 2019 , 11:3691-3701

Baseline platelet counts and derived inflammatory biomarkers: prognostic relevance in metastatic melanoma patients receiving Endostar plus dacarbazine and cisplatin

Yang L, Xu Y, Luo P, Chen S, Zhu H, Wang C

Cancer Management and Research 2019 , 11:3681-3690

Synergistic interaction of gemcitabine and paclitaxel by modulating acetylation and polymerization of tubulin in non-small cell lung cancer cell lines

Effendi WI, Nagano T, Tachihara M, Umezawa K, Kiriu T, Dokuni R, Katsurada M, Yamamoto M, Kobayashi K, Nishimura Y

Cancer Management and Research 2019 , 11:3669-3679

Multiphoton microscopy in the diagnostic assessment of pediatric solid tissue in comparison to conventional histopathology: results of the first international online interobserver trial

Goedeke J, Schreiber P, Seidmann L, Li G, Birkenstock J, Simon F, König J, Muensterer OJ

Cancer Management and Research 2019 , 11:3655-3667

Human papillomavirus DNA in surgical smoke during cervical loop electrosurgical excision procedures and its impact on the surgeon

Zhou Q, Hu X, Zhou J, Zhao M, Zhu XJ, Zhu X

Cancer Management and Research 2019 , 11:3643-3654

Immune inflammation indicators in anal cancer patients treated with concurrent chemoradiation: training and validation cohort with online calculator (ARC: Anal Cancer Response Classifier)

Casadei-Gardini A, Montagnani F, Casadei C, Arcadipane F, Andrikou K, Aloi D, Prete AA, Zampino MG, Argentiero A, Pugliese G, Martini S, Iorio GC, Scartozzi M, Mistrangelo M, Fornaro L, Cassoni P, Marisi G, Dell’Acqua V, Ravenda PS, Lonardi S, Silvestris N, De Bari B, Ricardi U, Cascinu S, Franco P

Cancer Management and Research 2019 , 11:3631-3642

Published Date: 26 April 2019

Nutritional and clinical outcomes of chemoradiotherapy for clinical T1N0M0 esophageal carcinoma

Sakanaka K, Fujii K, Ishida Y, Miyamoto S, Horimatsu T, Muto M, Mizowaki T

Cancer Management and Research 2019 , 11:3623-3630

Identification of potential key genes associated with ovarian clear cell carcinoma [Retraction]

Xu Y, Shen K

Cancer Management and Research 2019 , 11:3621-3622

Prognostic significance of serum lactate dehydrogenase in patients with breast cancer: a meta-analysis

Liu D, Wang D, Wu C, Zhang L, Mei Q, Hu G, Long G, Sun W

Cancer Management and Research 2019 , 11:3611-3619

Impact of pelvic MRI in routine clinical practice on staging of IB1–IIA2 cervical cancer

Zhang W, Chen C, Liu P, Li W, Hao M, Zhao W, Lu A, Ni Y

Cancer Management and Research 2019 , 11:3603-3609

Downregulation of CD166 inhibits invasion, migration, and EMT in the radio-resistant human nasopharyngeal carcinoma cell line CNE-2R

Sun Y, Lin H, Qu S, Li L, Chen K, Yu B, Lin G, Wan F, Zhu X

Cancer Management and Research 2019 , 11:3593-3602

The efficacy and safety of apatinib in metastatic alveolar soft part sarcoma: a case series of six patients in one institution

Cancer Management and Research 2019 , 11:3583-3591

Fibrin-thrombin sealant does not reduce lymphocele formation in patients with inguinofemoral lymphadenectomy for vulvar cancer

Saner FAM, Schötzau A, Mackay G, Heinzelmann-Schwarz V, Montavon Sartorius C

Cancer Management and Research 2019 , 11:3575-3582

lncRNA BANCR suppresses cell viability and invasion and promotes apoptosis in non-small-cell lung cancer cells in vitro and in vivo

Yang L, Liu G

Cancer Management and Research 2019 , 11:3565-3574

Clinical efficacy of cisplatin, dexamethasone, gemcitabine and pegaspargase (DDGP) in the initial treatment of advanced stage (stage III–IV) extranodal NK/T-cell lymphoma, and its correlation with Epstein-Barr virus

Zhao Q, Fan S, Chang Y, Liu X, Li W, Ma Q, Li Y, Wang Y, Zhang L, Zhang M

Cancer Management and Research 2019 , 11:3555-3564

Published Date: 24 April 2019

The prognostic value of serum albumin–globulin ratio in early-stage non-small cell lung cancer: a retrospective study

Wang Y, Li S, Hu X, Wang Y, Wu Y, Li P, Che G

Cancer Management and Research 2019 , 11:3545-3554

Nomograms for estimating survival in patients with papillary thyroid cancer after surgery

Liu G, Liu Q, Sun SR

Cancer Management and Research 2019 , 11:3535-3544

MicroRNA-17 promotes cell proliferation and migration in human colorectal cancer by downregulating SIK1

Huang C, Liu J, Xu L, Hu W, Wang J, Wang M, Yao X

Cancer Management and Research 2019 , 11:3521-3534

The predictive value of high-density lipoprotein for ocular metastases in colorectal cancer patients

Zhu PW, Gong YX, Min YL, Lin Q, Li B, Shi WQ, Yuan Q, Ye L, Shao Y

Cancer Management and Research 2019 , 11:3511-3519

High expression of SMARCE1 predicts poor prognosis and promotes cell growth and metastasis in gastric cancer

Liu H, Zhao YR, Chen B, Ge Z, Huang JS

Cancer Management and Research 2019 , 11:3493-3509

Published Date: 23 April 2019

The role of visfatin in cancer proliferation, angiogenesis, metastasis, drug resistance and clinical prognosis

Cancer Management and Research 2019 , 11:3481-3491

Antitumor effects of Endostar(rh-endostatin) combined with gemcitabine in different administration sequences to treat Lewis lung carcinoma

Li Y, Huang P, Peng H, Yue H, Wu M, Liu S, Qin R, Fan J, Han Y

Cancer Management and Research 2019 , 11:3469-3479

MicroRNA-181c suppresses growth and metastasis of hepatocellular carcinoma by modulating NCAPG

Ai J, Gong C, Wu J, Gao J, Liu W, Liao W, Wu L

Cancer Management and Research 2019 , 11:3455-3467

Assessment of potential predictive value of peripheral blood inflammatory indexes in 26 cases with soft tissue sarcoma treated by pazopanib: a retrospective study

Mirili C, Paydas S, Guney IB, Ogul A, Gokcay S, Buyuksimsek M, Yetisir AE, Karaalioglu B, Tohumcuoglu M, Seydaoglu G

Cancer Management and Research 2019 , 11:3445-3453

Upfront whole brain radiotherapy for multiple brain metastases in patients with EGFR-mutant lung adenocarcinoma

Li C, Guo J, Zhao L, Hu F, Nie W, Wang H, Zheng X, Shen Y, Gu P, Zhang Y, Zhang X

Cancer Management and Research 2019 , 11:3433-3443

Statins may have double-edged effects in patients with lung adenocarcinoma after lung resection

Nishikawa S, Menju T, Takahashi K, Miyata R, Chen-Yoshikawa TF, Sonobe M, Yoshizawa A, Sabe H, Sato T, Date H

Cancer Management and Research 2019 , 11:3419-3432

Published Date: 18 April 2019

The crucial role of primary care providers in the long-term follow-up of adult survivors of childhood cancer

Jain J, Qorri B, Szewczuk MR

Cancer Management and Research 2019 , 11:3411-3418

FRMPD1 activates the Hippo pathway via interaction with WWC3 to suppress the proliferation and invasiveness of lung cancer cells

Rong X, Han Q, Lin X, Kremerskothen J, Wang E

Cancer Management and Research 2019 , 11:3395-3410

Prognostic significance of the ratio of fibrinogen and albumin in human malignancies: a meta-analysis

Zhang Y, Xiao G

Cancer Management and Research 2019 , 11:3381-3393

A high absolute lymphocyte count predicts a poor prognosis in HER-2- positive breast cancer patients treated with trastuzumab

Hong J, Chen X, Gao W, Zhu S, Wu J, Huang O, He J, Zhu L, Chen W, Li Y, Fei X, Lin L, Shen K

Cancer Management and Research 2019 , 11:3371-3379

Primary tumor regression patterns in esophageal squamous cell cancer treated with definitive chemoradiotherapy and implications for surveillance schemes

Chen M, Liu P, Chen Y, Chen Z, Shen M, Liu X, Li X, Lin Y, Yang R, Ni W, Zhou X, Zhang L, Tian Y, Chen J

Cancer Management and Research 2019 , 11:3361-3369

Published Date: 17 April 2019

Tumor-educated platelet miR-34c-3p and miR-18a-5p as potential liquid biopsy biomarkers for nasopharyngeal carcinoma diagnosis

Wang H, Wei X, Wu B, Su J, Tan W, Yang K

Cancer Management and Research 2019 , 11:3351-3360

Approaches to interpret the outcomes of a network meta-analysis on comparative efficacy of different targeted therapies plus fulvestrant for advanced breast cancer following progression on prior endocrine therapy

Jayaraj R, Kumarasamy C, Sabarimurugan S, Samiappan S

Cancer Management and Research 2019 , 11:3349-3350

Association between quantitative parameters of CEUS and Sall4/Wnt/β-catenin signaling in patients with hepatocellular carcinoma

Wang J, Huang J, Ma Q, Liu G

Cancer Management and Research 2019 , 11:3339-3347

The systemic inflammation response index predicts survival and recurrence in patients with resectable pancreatic ductal adenocarcinoma

Li S, Xu H, Wang W, Gao H, Li H, Zhang S, Xu J, Zhang W, Xu S, Li T, Ni Q, Yu X, Wu C, Liu L

Cancer Management and Research 2019 , 11:3327-3337

Identification of a transcription factor-microRNA network in esophageal adenocarcinoma through bioinformatics analysis and validation through qRT-PCR

Chen D, Lu T, Tan J, Zhao K, Li Y, Zhao W, Li H, Wang Q, Wang Y, Wei L

Cancer Management and Research 2019 , 11:3315-3326

The beneficial effects of metformin on cancer prevention and therapy: a comprehensive review of recent advances

Saraei P, Asadi I, Kakar MA, Moradi-Kor N

Cancer Management and Research 2019 , 11:3295-3313

Oncolytic viro-chemotherapy exhibits antitumor effect in laryngeal squamous cell carcinoma cells and mouse xenografts

Wang Y, Wang B, Liang J, Cui C, Ying C, Huang F, Ma B, Zhou X, Chu L

Cancer Management and Research 2019 , 11:3285-3294

Published Date: 15 April 2019

Knockdown of CHPF suppresses cell progression of non-small-cell lung cancer

Hou XM, Baloch Z, Zheng ZH, Zhang WH, Feng Y, Li DD, Wu XA, Yang SH

Cancer Management and Research 2019 , 11:3275-3283

Prognostic values of preoperative platelet-to-lymphocyte ratio, albumin and hemoglobin in patients with non-metastatic colon cancer

Li Z, Xu Z, Huang Y, Zhao R, Cui Y, Zhou Y, Wu X

Cancer Management and Research 2019 , 11:3265-3274

Published Date: 16 April 2019

CDKN3 promotes tumor progression and confers cisplatin resistance via RAD51 in esophageal cancer

Wang J, Che W, Wang W, Su G, Zhen T, Jiang Z

Cancer Management and Research 2019 , 11:3253-3264

RETRACTED ARTICLE: NPTX1 promotes metastasis via integrin/FAK signaling in gastric cancer

Yan HF, Zheng CL, Li Z, Bao BW, Yang BW, Hou KZ, Qu XJ, Xiao JW, Che XF, Liu YP

Cancer Management and Research 2019 , 11:3237-3251

Isocitrate dehydrogenase 1 mutation is associated with reduced levels of inflammation in glioma patients

Auezova R, Ivanova N, Akshulakov S, Zhetpisbaev B, Kozhakhmetova A, Ryskeldiyev N, Mustafin K, Teltayev D, Auezova L

Cancer Management and Research 2019 , 11:3227-3236

Novel nomograms individually predict the survival of patients with soft tissue sarcomas after surgery

Zhang SL, Wang ZM, Wang WR, Wang X, Zhou YH

Cancer Management and Research 2019 , 11:3215-3225

Evaluating venetoclax and its potential in treatment-naïve acute myeloid leukemia

Knight T, Edwards H, Taub JW, Ge Y

Cancer Management and Research 2019 , 11:3197-3213

Assessment of the presence and anti-tumor potential of tumor-infiltrating lymphocytes in patients with acute myeloid leukemia

Wei L, Wang Z, Zhang Z, Li Y, Fan S, Zhao Y, Liu Z, Ye X, Zhang F, Yu Y, Liu X, Cao F, Zhou J

Cancer Management and Research 2019 , 11:3187-3196

Published Date: 12 April 2019

SLC5A1 promotes growth and proliferation of pancreatic carcinoma via glucose-dependent AMPK/mTOR signaling

Gao HF, Chen LY, Cheng CS, Chen H, Meng ZQ, Chen Z

Cancer Management and Research 2019 , 11:3171-3185

A simplified T classification based on the 8th edition of the UICC/AJCC staging system for nasopharyngeal carcinoma

Pan XX, Tong LH, Chen YF, Li FL, Tang WB, Liu YJ, Yang W

Cancer Management and Research 2019 , 11:3163-3169

Published Date: 11 April 2019

Increased systemic immune-inflammation index independently predicts poor survival for hormone receptor-negative, HER2-positive breast cancer patients

Sun Y, Li W, Li AJ, Su H, Yue J, Yu J

Cancer Management and Research 2019 , 11:3153-3162

Overexpression of the phospholipase A2 group V gene in glioma tumors is associated with poor patient prognosis

Wu C, Su J, Wang X, Wang J, Xiao K, Li Y, Xiao Q, Ling M, Xiao Y, Qin C, Long W, Zhang F, Pan Y, Xiang F, Liu Q

Cancer Management and Research 2019 , 11:3139-3152

Apparent diffusion coefficient in extraprostatic extension of prostate cancer: a systematic review and diagnostic meta-analysis

Bai K, Sun Y, Li W, Zhang L

Cancer Management and Research 2019 , 11:3125-3137

MicroRNA-665 inhibits the oncogenicity of retinoblastoma by directly targeting high-mobility group box 1 and inactivating the Wnt/β-catenin pathway

Wang S, Du S, Lv Y, Zhang F, Wang W

Cancer Management and Research 2019 , 11:3111-3123

miR-526b-3p serves as a prognostic factor and regulates the proliferation, invasion, and migration of glioma through targeting WEE1

Wu M, Li X, Liu Q, Xie Y, Yuan J, Wanggou S

Cancer Management and Research 2019 , 11:3099-3110

Early detection of prostate cancer using prostate-specific antigen testing: an empirical evaluation among general practitioners and urologists

Kappen S, Jürgens V, Freitag MH, Winter A

Cancer Management and Research 2019 , 11:3079-3097

Efficacy and safety of olaparib maintenance therapy in platinum-sensitive ovarian cancer patients with BRCA mutations: a meta-analysis on randomized controlled trials

Ma J, Deng H, Li J, Hu S, Yang Y, Liu S, Han X

Cancer Management and Research 2019 , 11:3061-3078

High expression of dedicator of cytokinesis 1 adversely influences the prognosis of acute myeloid leukemia patients undergoing allogeneic hematopoietic stem cell transplantation

Zhang G, Zhang J, Yang X, Zhang X, Yang S, Wang J, Hu K, Shi J, Ke X, Fu L

Cancer Management and Research 2019 , 11:3053-3060

Mortality trends of bladder cancer in China from 1991 to 2015: an age-period-cohort analysis

Yang Y, Cheng Z, Jia X, Shi N, Xia Z, Zhang W, Shi X

Cancer Management and Research 2019 , 11:3043-3051

Published Date: 10 April 2019

Prognostic significance of combined pretreatment body mass index (BMI) and BMI loss in patients with esophageal cancer

Gu WS, Fang WZ, Liu CY, Pan KY, Ding R, Li XH, Duan CH

Cancer Management and Research 2019 , 11:3029-3041

RRBP1 is highly expressed in prostate cancer and correlates with prognosis

Li T, Wang Q, Hong X, Li H, Yang K, Li J, Lei B

Cancer Management and Research 2019 , 11:3021-3027

Docetaxel, oxaliplatin, leucovorin, and 5-fluorouracil (FLOT) as preoperative and postoperative chemotherapy compared with surgery followed by chemotherapy for patients with locally advanced gastric cancer: a propensity score-based analysis

Wang K, Ren Y, Ma Z, Li F, Cheng X, Xiao J, Zhang S, Yu Z, Yang H, Zhou H, Li Y, Liu H, Jiao ZY

Cancer Management and Research 2019 , 11:3009-3020

BCL11A enhances stemness and promotes progression by activating Wnt/β-catenin signaling in breast cancer

Zhu L, Pan R, Zhou D, Ye G, Tan W

Cancer Management and Research 2019 , 11:2997-3007

High CD3D/CD4 ratio predicts better survival in muscle-invasive bladder cancer

Shi MJ, Meng XY, Wu QJ, Zhou XH

Cancer Management and Research 2019 , 11:2987-2995

Chrysin inhibits sphere formation in SMMC-7721 cells via modulation of SHP-1/STAT3 signaling pathway

Zhang Y, Chen F, Xiao X, Pan W, Yuan Q, Cao J

Cancer Management and Research 2019 , 11:2977-2985

MicroRNA-34a suppresses aggressiveness of hepatocellular carcinoma by modulating E2F1, E2F3, and Caspase-3

Han R, Chen X, Li Y, Zhang S, Li R, Lu L

Cancer Management and Research 2019 , 11:2963-2976

Meta-analysis of comparing part-solid and pure-solid tumors in patients with clinical stage IA non-small-cell lung cancer in the eighth edition TNM classification

Jiang T, Li M, Lin M, Zhao M, Zhan C, Feng M

Cancer Management and Research 2019 , 11:2951-2961

Skin graft using MatriDerm® for plantar defects after excision of skin cancer

Kang SW, Park JK, Shon HC, Choi ES, Kim DS, Min KT

Cancer Management and Research 2019 , 11:2947-2950

The serum proteomics tracking of hepatocellular carcinoma early recurrence following radical resection

Liu H, Chen H, Wu X, Sun Y, Wang Y, Zeng Y, Chen G, Liu X, Xing X, Zhao B, Liu J

Cancer Management and Research 2019 , 11:2935-2946

Overexpressed pepsinogen C is associated with poor prognosis in human hepatocellular carcinoma: a tissue microarray study

Chen H, Zhu HR, Yu XN, Shi X, Bilegsaikhan E, Guo HY, Huang RZ, Liu TT, Shen XZ, Zhu JM

Cancer Management and Research 2019 , 11:2927-2934

Tumor location of the central and nipple portion is associated with impaired survival for women with breast cancer

Ji F, Xiao W, Yang C, Yang M, Zhang L, Gao HF, Lin Y, Zhu T, Cheng M, Li W, Pan W, Zhuang X, Wang K

Cancer Management and Research 2019 , 11:2915-2925

Published Date: 9 April 2019

A quantified risk-scoring system including the visceral fat area for peritoneal metastasis of gastric cancer

Chen X, Chen W, Huang Y, Xu J, Zeng Y, Shi M, Xu L, Zhang W, Zhu G, Mao C, Shen X

Cancer Management and Research 2019 , 11:2903-2913

Peri-tumor fibroblasts promote tumorigenesis and metastasis of hepatocellular carcinoma via Interleukin6/STAT3 signaling pathway

Zhao Z, Xiong S, Wang R, Li Y, Wang X, Wang Y, Bai S, Chen W, Zhao Y, Cheng B

Cancer Management and Research 2019 , 11:2889-2901

Apolipoprotein A1 and B as risk factors for development of intraocular metastasis in patients with breast cancer

Liu JX, Yuan Q, Min YL, He Y, Xu QH, Li B, Shi WQ, Lin Q, Li QH, Zhu PW, Shao Y

Cancer Management and Research 2019 , 11:2881-2888

LncRNA LOC105372579 promotes proliferation and epithelial-mesenchymal transition in hepatocellular carcinoma via activating miR-4316/FOXP4 signaling

Cancer Management and Research 2019 , 11:2871-2879

Diabetes mellitus predicts inferior survival in diffuse large B-cell lymphoma: a propensity score-matched analysis

Gao R, Liang JH, Man TS, Wang L, Zhu HY, Wu W, Fan L, Li JY, Yang T, Xu W

Cancer Management and Research 2019 , 11:2849-2870

Suppressing growth and invasion of human hepatocellular carcinoma cells by celecoxib through inhibition of cyclooxygenase-2

Tai Y, Zhang LH, Gao JH, Zhao C, Tong H, Ye C, Huang ZY, Liu R, Tang CW

Cancer Management and Research 2019 , 11:2831-2848

Dynamic impact of inﬂammation-based indices in colorectal cancer patients receiving FOLFOX-based chemotherapy

Tao Y, Yuan D, Pang H, Wu H, Liu D, Jin N, Wu N, Qiu J, Cao Y

Cancer Management and Research 2019 , 11:2817-2829

Wnt5a induces ROR1 and ROR2 to activate RhoA in esophageal squamous cell carcinoma cells

Wu X, Yan T, Hao L, Zhu Y

Cancer Management and Research 2019 , 11:2803-2815

High miR-454-3p expression predicts poor prognosis in hepatocellular carcinoma

Li Y, Jiao Y, Fu Z, Luo Z, Su J, Li Y

Cancer Management and Research 2019 , 11:2795-2802

Published Date: 8 April 2019

Upregulation of FOXP4 in breast cancer promotes migration and invasion through facilitating EMT

Ma T, Zhang J

Cancer Management and Research 2019 , 11:2783-2793

microRNA-877 inhibits malignant progression of colorectal cancer by directly targeting MTDH and regulating the PTEN/Akt pathway

Zhang L, Li C, Cao L, Li H, Zou H, Li H, Pei H

Cancer Management and Research 2019 , 11:2769-2781

Incidence, risk factors, and prognosis in patients with primary hepatocellular carcinoma and lung metastasis: a population-based study

Wu C, Ren X, Zhang Q

Cancer Management and Research 2019 , 11:2759-2768

Chromogranin A is a predictor of prognosis in patients with prostate cancer: a systematic review and meta-analysis

Guo Z, Wang Y, Xiang S, Wang S, Chan FL

Cancer Management and Research 2019 , 11:2747-2758

Published Date: 5 April 2019

miR-101 regulates cell proliferation and apoptosis by targeting KDM1A in diffuse large B cell lymphoma

Huang Y, Zou Y, Lin L, Ma X, Zheng R

Cancer Management and Research 2019 , 11:2739-2746

The role of long non-coding RNA GAS5 in cancers

Ji J, Dai X, Yeung SC, He X

Cancer Management and Research 2019 , 11:2729-2737

Correlations of health-related quality of life with serum inflammatory indicators IL-8 and mIBI in patients with hepatocellular carcinoma

Li L, Chan SL, Mo F, Hui EP, Koh J, Chan AKC, Tang NLS, Lee KF, Lai PBS, Yu SCH, Yeo W

Cancer Management and Research 2019 , 11:2719-2727

Published Date: 4 April 2019

Self-expanding metallic stent as a bridge to surgery versus emergency surgery for acute obstructive colorectal cancer: a retrospective study

Wang Y, Hu H, Wang M, Han X, Zhang Q, Yu L, Chen Y, Wang G

Cancer Management and Research 2019 , 11:2709-2718

Development and external validation of prognostic nomograms in hepatocellular carcinoma patients: a population based study

Xiao Z, Yan Y, Zhou Q, Liu H, Huang P, Zhou Q, Lai C, Zhang J, Wang J, Mao K

Cancer Management and Research 2019 , 11:2691-2708

Differential effects of adjuvant EGFR tyrosine kinase inhibitors in patients with different stages of non-small-cell lung cancer after radical resection: an updated meta-analysis

Lu D, Wang Z, Liu X, Feng S, Dong X, Shi X, Wang H, Wu H, Xiong G, Wang HF, Cai K

Cancer Management and Research 2019 , 11:2677-2690

Published Date: 2 April 2019

Carfilzomib for relapsed and refractory multiple myeloma

Groen K, van de Donk NWCJ, Stege CAM, Zweegman S, Nijhof IS

Cancer Management and Research 2019 , 11:2663-2675

Growth and differentiation factor 15 regulates PD-L1 expression in glioblastoma

Peng H, Li Z, Fu J, Zhou R

Cancer Management and Research 2019 , 11:2653-2661

Inhibition of human glioblastoma cell invasion involves PION@E6 mediated autophagy process

Ren Z, Liang J, Zhang P, Chen J, Wen J

Cancer Management and Research 2019 , 11:2643-2652

Published Date: 29 March 2019

Biliary tract cancers: current knowledge, clinical candidates and future challenges

Tariq N, McNamara MG, Valle JW

Cancer Management and Research 2019 , 11:2623-2642

Repeat procedures for recurrent colorectal liver metastases: analysis of long-term liver regeneration and outcome

Valdimarsson VT, Hellberg K, Brismar TB, Sparrelid E, Sturesson C

Cancer Management and Research 2019 , 11:2617-2622

HLA-DQB1 expression on tumor cells is a novel favorable prognostic factor for relapse in early-stage lung adenocarcinoma

Zhang L, Li M, Deng B, Dai N, Feng Y, Shan J, Yang Y, Mao C, Huang P, Xu C, Wang D

Cancer Management and Research 2019 , 11:2605-2616

Published Date: 1 April 2019

Comparison of irisin hormone expression between thyroid cancer tissues and oncocytic variant cells

Ugur K, Aydin S, Kuloglu T, Artas G, Kocdor MA, Sahin İ, Yardim M, Hanifi Ozercan I

Cancer Management and Research 2019 , 11:2595-2603

Published Date: 28 March 2019

CIP2A overexpression in Taiwanese oral cancer patients

Velmurugan BK, Wang HK, Chung CM, Lee CH, Huang LR, Yeh KT, Lin SH

Cancer Management and Research 2019 , 11:2589-2594

L3 skeletal muscle index (L3SMI) is a surrogate marker of sarcopenia and frailty in non-small cell lung cancer patients

Portal D, Hofstetter L, Eshed I, Dan-Lantsman C, Sella T, Urban D, Onn A, Bar J, Segal G

Cancer Management and Research 2019 , 11:2579-2588

NECTIN4 promotes papillary thyroid cancer cell proliferation, migration, and invasion and triggers EMT by activating AKT

Cancer Management and Research 2019 , 11:2565-2578

Clinical features and prognostic factors of primary bone marrow lymphoma

Wang G, Chang Y, Wu X, Li X, Li L, Zhang L, Fu X, Sun Z, Zhang X, Zhang M

Cancer Management and Research 2019 , 11:2553-2563

Clinical value of ROMA index in diagnosis of ovarian cancer: meta-analysis

Cui RL, Wang YC, Li Y, Li YG

Cancer Management and Research 2019 , 11:2545-2551

microRNA-944 inhibits the malignancy of hepatocellular carcinoma by directly targeting IGF-1R and deactivating the PI3K/Akt signaling pathway

Lv L, Wang X, Ma T

Cancer Management and Research 2019 , 11:2531-2543

Cadherin-11 is inactivated due to promoter methylation and functions in colorectal cancer as a tumour suppressor

Yuan S, Li L, Xiang S, Jia H, Luo T

Cancer Management and Research 2019 , 11:2517-2529

Positive or close margins: reoperation rate and second conservative resection or total mastectomy?

Houvenaeghel G, Lambaudie E, Bannier M, Rua S, Barrou J, Heinemann M, Buttarelli M, Thomassin Piana J, Cohen M

Cancer Management and Research 2019 , 11:2507-2516

Effect of ultrasound-guided proximal and distal approach for obturator nerve block in transurethral resection of bladder cancer under spinal anesthesia

Han C, Ma T, Lei D, Xie S, Ge Z

Cancer Management and Research 2019 , 11:2499-2505

Published Date: 27 March 2019

LAPTM4B facilitates tumor growth and induces autophagy in hepatocellular carcinoma

Wang F, Wu H, Zhang S, Lu J, Lu Y, Zhan P, Fang Q, Wang F, Zhang X, Xie C, Yin Z

Cancer Management and Research 2019 , 11:2485-2497

Nomogram for predicting disease-free survival among a multicenter cohort of Chinese patients with locally advanced rectal cancer

Li ZH, Xie PY, Zhang DF, Li YJ, Wu L, Dong J, Xiao J, Liu ZY

Cancer Management and Research 2019 , 11:2471-2483

JAM3 functions as a novel tumor suppressor and is inactivated by DNA methylation in colorectal cancer

Zhou D, Tang W, Zhang Y, An HX

Cancer Management and Research 2019 , 11:2457-2470

S100A16 regulated by Snail promotes the chemoresistance of nonmuscle invasive bladder cancer through the AKT/Bcl-2 pathway

Wang C, Zhu X, Li A, Yang S, Qiao R, Zhang J

Cancer Management and Research 2019 , 11:2449-2456

Does every classical type of well-differentiated thyroid cancer have excellent prognosis? A case series and literature review

Kaliszewski K

Cancer Management and Research 2019 , 11:2441-2448

Epigallocatechin-3-gallate-induced vascular normalization in A549-cell xenograft-bearing nude mice: therapeutic efficacy in combination with chemotherapy

Deng P, Hu C, Xiong Z, Li Y, Jiang J, Yang H, Tang Y, Cao L, Lu R

Cancer Management and Research 2019 , 11:2425-2439

WFDC2 contributes to epithelial–mesenchymal transition (EMT) by activating AKT signaling pathway and regulating MMP-2 expression

Chen Y, Huang L, Wang S, Li JL, Li M, Wu Y, Liu T

Cancer Management and Research 2019 , 11:2415-2424

The role of Clusterin in cancer metastasis

Peng M, Deng J, Zhou S, Tao T, Su Q, Yang X, Yang X

Cancer Management and Research 2019 , 11:2405-2414

Chimeric antigen receptor (CAR) T-cell therapy as a treatment option for patients with B-cell lymphomas: perspectives on the therapeutic potential of Axicabtagene ciloleucel

Viardot A, Wais V, Sala E, Koerper S

Cancer Management and Research 2019 , 11:2393-2404

Published Date: 25 March 2019

ITLN1 identified by comprehensive bioinformatic analysis as a hub candidate biological target in human epithelial ovarian cancer

Liu JH, Li SY, Liang JY, Jiang Y, Wan YC, Zhou SL, Cheng WJ

Cancer Management and Research 2019 , 11:2379-2392

Clinicopathological characteristics and recurrence risk of papillary thyroid microcarcinoma in the elderly

Wang X, Lei J, Wei T, Zhu J, Li Z

Cancer Management and Research 2019 , 11:2371-2377

Comparison of transcriptional profiles in human lymphocyte cells irradiated with 12C ion beams at 0–2.0 Gy

Zhang RF, Dang XH, Zhang ZX, Yuan YY, Ren Y, Duan ZK, Zuo YH

Cancer Management and Research 2019 , 11:2363-2369

Published Date: 22 March 2019

Linc01194 acts as an oncogene in colorectal carcinoma and is associated with poor survival outcome

Wang X, Liu Z, Tong H, Peng H, Xian Z, Li L, Hu B, Xie S

Cancer Management and Research 2019 , 11:2349-2362

UNBS5162 and amonafide inhibits tumor progression in human melanoma by the AKT/mTOR pathway

Ye Y, Huang S, Wu Y

Cancer Management and Research 2019 , 11:2339-2348

A systematic review of international guidelines and recommendations for the genetic screening, diagnosis, genetic counseling, and treatment of BRCA-mutated breast cancer

Forbes C, Fayter D, de Kock S, Quek RGW

Cancer Management and Research 2019 , 11:2321-2337

The impact of the interval between the induction of chemotherapy and radiotherapy on the survival of patients with nasopharyngeal carcinoma

Yang S, Fu X, Huang G, Chen J, Luo S, Wang Z, Kong F, Wu G, Lin S, Wang F, Chen L

Cancer Management and Research 2019 , 11:2313-2320

PF4V1, an miRNA-875-3p target, suppresses cell proliferation, migration, and invasion in prostate cancer and serves as a potential prognostic biomarker

Li D, Hao X, Dong Y, Zhang M, Song Y

Cancer Management and Research 2019 , 11:2299-2312

Published Date: 21 March 2019

Natural gypenosides: targeting cancer through different molecular pathways

Ahmad B, Khan S, Nabi G, Gamallat Y, Su P, Jamalat Y, Duan P, Yao L

Cancer Management and Research 2019 , 11:2287-2297

Role of the pretreatment neutrophil-to-lymphocyte ratio in the survival of primary parotid cancer patients

Cheng G, Liu F, Niu X, Fang Q

Cancer Management and Research 2019 , 11:2281-2286

Primary tumor location is an important predictor of survival in pulmonary adenocarcinoma

Wang Z, Li M, Teng F, Kong L, Yu J

Cancer Management and Research 2019 , 11:2269-2280

Is ramucirumab and paclitaxel therapy beneficial for second-line treatment of metastatic gastric or junctional adenocarcinoma for patients with ascites? Analysis of RAINBOW phase 3 trial data

Muro K, Jen MH, Cheng R

Cancer Management and Research 2019 , 11:2261-2267

Published Date: 20 March 2019

Influence of thoracic drainage fluid on proliferation, migration, apoptosis, and drug resistance in lung cancer cell lines

Mao Y, Yu Y, Han Y

Cancer Management and Research 2019 , 11:2253-2259

Management of mycosis fungoides-type cutaneous T-cell lymphoma (MF-CTCL): focus on chlormethine gel

Denis D, Beneton N, Laribi K, Maillard H

Cancer Management and Research 2019 , 11:2241-2251

Low-dose of olanzapine has ameliorating effects on cancer-related anorexia

Okamoto H, Shono K, Nozaki-Taguchi N

Cancer Management and Research 2019 , 11:2233-2239

Published Date: 19 March 2019

Nutritional status and related factors of patients with advanced lung cancer in northern China: a retrospective study

Ge T, Lin T, Yang J, Wang M

Cancer Management and Research 2019 , 11:2225-2231

Suppressed OGT expression inhibits cell proliferation and modulates EGFR expression in renal cell carcinoma

Wang L, Chen S, Zhang J, Mao S, Mao W, Zhang W, Guo Y, Wu Y, Wang R, Yan Y, Yao X

Cancer Management and Research 2019 , 11:2215-2223

Increased expression of TMED2 is an unfavorable prognostic factor in patients with breast cancer

Lin X, Liu J, Hu SF, Hu X

Cancer Management and Research 2019 , 11:2203-2214

Published Date: 18 March 2019

Defining unmet clinical need across the pathway of brain tumor care: a patient and carer perspective

Sage W, Fernández-Méndez R, Crofton A, Gifford MJ, Bannykh A, Chrysaphinis C, Tingley E, Bulbeck H, Brahmbhatt M, Pickard JD, Walter FM, Brodbelt A, Price SJ, Joannides AJ

Cancer Management and Research 2019 , 11:2189-2202

The oncogenic role of GNL3 in the progression and metastasis of osteosarcoma

Li TY, Li L, Wu XY, Tian KX, Wang YZ

Cancer Management and Research 2019 , 11:2179-2188

Published Date: 15 March 2019

Etiology and management of nasopharyngeal hemorrhage after radiotherapy for nasopharyngeal carcinoma

Zhan J, Zhang S, Wei X, Fu Y, Zheng J

Cancer Management and Research 2019 , 11:2171-2178

A multicenter study of a contrast-enhanced ultrasound diagnostic classification of breast lesions

Tang L, Chen Y, Du Z, Zhong Z, Chen Q, Yang L, Shen R, Cheng Y, Zhang Z, Han E, Lv Z, Yuan L, Yang Y, Cheng Y, Yang L, Wang S, Bai B, Luo J

Cancer Management and Research 2019 , 11:2163-2170

State of the art for gastric signet ring cell carcinoma: from classification, prognosis, and genomic characteristics to specified treatments

Machlowska J, Pucułek M, Sitarz M, Terlecki P, Maciejewski R, Sitarz R

Cancer Management and Research 2019 , 11:2151-2161

Oncogenic role of ABHD5 in endometrial cancer

Zhou Q, Wang F, Zhou K, Huang K, Zhu Q, Luo X, Yu J, Shi Z

Cancer Management and Research 2019 , 11:2139-2150

Published Date: 14 March 2019

Comparing the efficacy of concurrent EGFR-TKI and whole-brain radiotherapy vs EGFR-TKI alone as a first-line therapy for advanced EGFR-mutated non-small-cell lung cancer with brain metastases: a retrospective cohort study

He ZY, Li MF, Lin JH, Lin D, Lin RJ

Cancer Management and Research 2019 , 11:2129-2138

Evolution of the chemotherapeutic landscape and survival outcome in patients with metastatic pancreatic cancer: a four-institute cohort study in Taiwan, 2010–2016

Chou WC, Chen YY, Hung CY, Chen JS, Lu CH, Chang PH

Cancer Management and Research 2019 , 11:2119-2127

DR7 encoded by human herpesvirus 6 promotes glioma development and progression

Gu B, Li M, Zhang Y, Li L, Yao K, Wang S

Cancer Management and Research 2019 , 11:2109-2118

Published Date: 12 March 2019

Decentralized colorectal cancer care in Germany over the last decade is associated with high in-hospital morbidity and mortality

Ghadban T, Reeh M, Bockhorn M, Grotelueschen R, Bachmann K, Grupp K, Uzunoglu FG, Izbicki JR, Perez DR

Cancer Management and Research 2019 , 11:2101-2107

Axillary management still needed for patients with sentinel node micrometastases

Cong BB, Yu JM, Wang YS

Cancer Management and Research 2019 , 11:2097-2100

Published Date: 8 March 2019

Construction of a GLUT-1 and HIF-1α gene knockout cell model in HEp-2 cells using the CRISPR/Cas9 technique

Lu ZJ, Yu Q, Zhou SH, Fan J, Shen LF, Bao YY, Wu TT, Zhou ML, Huang YP

Cancer Management and Research 2019 , 11:2087-2096

Nonspecific immunoglobulin G is effective in preventing and treating cancer in mice

Xu Q, Zhang Z, Chen Z, Zhang B, Zhao C, Zhang Y, Zhao C, Deng X, Zhou Y, Wu Y, Gu J

Cancer Management and Research 2019 , 11:2073-2085

Published Date: 7 March 2019

Long noncoding RNA H19 is a critical oncogenic driver and contributes to epithelial-mesenchymal transition in papillary thyroid carcinoma

Liang WQ, Zeng D, Chen CF, Sun SM, Lu XF, Peng CY, Lin HY

Cancer Management and Research 2019 , 11:2059-2072

Published Date: 6 March 2019

Cervical cancer in women aged 25 years or younger: a retrospective study

Kong Y, Zong L, Yang J, Wu M, Xiang Y

Cancer Management and Research 2019 , 11:2051-2058

MicroRNA-21 and microRNA-30c as diagnostic biomarkers for prostate cancer: a meta-analysis

Zhou H, Zhu X

Cancer Management and Research 2019 , 11:2039-2050

Meta-analysis of the prognostic value of lncRNA DANCR for cancer patients in China

Fan Y, He Y, Zhou X, Liu Y, Wang F

Cancer Management and Research 2019 , 11:2027-2037

Published Date: 5 March 2019

CIRP regulates BEV-induced cell migration in gliomas

Liu Y, Zhou JN, Liu K, Fu X, Zhang Z, Zhang QH, Yue W

Cancer Management and Research 2019 , 11:2015-2025

Published Date: 11 March 2019

Outcomes of gastrectomy following upfront chemotherapy in advanced gastric cancer patients with a single noncurable factor: a cohort study

Li W, Jiang H, Yu Y, Wang Y, Wang Z, Cui Y, Shen K, Shen Z, Fang Y, Liu T

Cancer Management and Research 2019 , 11:2007-2013

Upregulated circ RNA hsa_circ_0000337 promotes cell proliferation, migration, and invasion of esophageal squamous cell carcinoma

Song H, Xu D, Shi P, He B, Li Z, Ji Y, Agbeko CK, Wang J

Cancer Management and Research 2019 , 11:1997-2006

Published Date: 4 March 2019

A novel 4-gene prognostic signature for hypermutated colorectal cancer

Ge W, Cai W, Bai R, Hu W, Wu D, Zheng S, Hu H

Cancer Management and Research 2019 , 11:1985-1996

Second primary malignancy in patients with cholangiocarcinoma: a population-based study

Zhuang L, Yan X, Meng Z

Cancer Management and Research 2019 , 11:1969-1983

Published Date: 1 March 2019

Increased cancer risk after myocardial infarction: fact or fiction? A systemic review and meta-analysis

Li N, Huang Z, Zhang Y, Sun H, Wang J, Zhao J

Cancer Management and Research 2019 , 11:1959-1968

EGFR mutations are significantly associated with visceral pleural invasion development in non-small-cell lung cancer patients

Shi J, Yang Y, Zhao Y, Zhu J, Song X, Jiang G

Cancer Management and Research 2019 , 11:1945-1957

Pancreatic neuroendocrine tumor: prediction of the tumor grade using magnetic resonance imaging findings and texture analysis with 3-T magnetic resonance

Guo C, Ren S, Chen X, Wang Q, Xiao W, Zhang J, Duan S, Wang Z

Cancer Management and Research 2019 , 11:1933-1944

The role and diagnostic potential of gastrokine 1 in gastric cancer

Koper-Lenkiewicz OM, Kamińska J, Gawrońska B, Matowicka-Karna J

Cancer Management and Research 2019 , 11:1921-1931

Pretreatment lymphocyte-to-monocyte ratio as a predictor of survival among patients with ovarian cancer: a meta-analysis

Gao XP, Liu YH, Liu ZY, Wang LJ, Jing CX, Zhu S, Zeng FF

Cancer Management and Research 2019 , 11:1907-1920

Published Date: 27 February 2019

Interferon α-inducible protein 27 is an oncogene and highly expressed in cholangiocarcinoma patients with poor survival

Chiang K, Huang S, Wu RC, Huang SC, Yeh T, Chen M, Hsu JT, Chen L, Kuo SF, Chueh H, Juang H, Hung S, Yeh C, Pang JS

Cancer Management and Research 2019 , 11:1893-1905

Published Date: 28 February 2019

Meta-analysis of the prognostic value of C-C chemokine receptor type 7 in patients with solid tumors

Zu G, Luo B, Yang Y, Tan Y, Tang T, Zhang Y, Chen X, Sun D

Cancer Management and Research 2019 , 11:1881-1892

Published Date: 26 February 2019

INTS8 accelerates the epithelial-to-mesenchymal transition in hepatocellular carcinoma by upregulating the TGF-β signaling pathway

Tong H, Liu X, Li T, Qiu W, Peng C, Shen BY, Zhu Z

Cancer Management and Research 2019 , 11:1869-1879

KIF15 promotes bladder cancer proliferation via the MEK–ERK signaling pathway

Zhao H, Bo Q, Wu Z, Liu Q, Li Y, Zhang N, Guo H, Shi B

Cancer Management and Research 2019 , 11:1857-1868

The unique invasiveness of glioblastoma and possible drug targets on extracellular matrix

Hatoum A, Mohammed R, Zakieh O

Cancer Management and Research 2019 , 11:1843-1855

Published Date: 25 February 2019

Oncometabolites as biomarkers in thyroid cancer: a systematic review

Khatami F, Payab M, Sarvari M, Gilany K, Larijani B, Arjmand B, Tavangar SM

Cancer Management and Research 2019 , 11:1829-1841

Progress in immunocytochemical staining for cervical cancer screening

Sun H, Shen K, Cao D

Cancer Management and Research 2019 , 11:1817-1827

Published Date: 22 February 2019

miR-491-5p functions as a tumor suppressor by targeting IGF2 in colorectal cancer

Lu L, Cai M, Peng M, Wang F, Zhai X

Cancer Management and Research 2019 , 11:1805-1816

E3 ubiquitin ligase Smurf2: a prognostic factor in microsatellite stable colorectal cancer

Klupp F, Giese C, Halama N, Franz C, Lasitschka F, Warth A, Schmidt T, Kloor M, Ulrich A, Schneider M

Cancer Management and Research 2019 , 11:1795-1803

Meta-analysis of the prognostic role of HE4 expression in cancer patients: clinical insights into interpretation of clinical outcomes

Jayaraj R, Kumarasamy C

Cancer Management and Research 2019 , 11:1791-1794

Published Date: 21 February 2019

lncRNA LINC00460 promoted colorectal cancer cells metastasis via miR-939-5p sponging

Zhang Y, Liu XC, Li Q, Zhang Y

Cancer Management and Research 2019 , 11:1779-1789

Impact of preoperative exercise therapy on surgical outcomes in lung cancer patients with or without COPD: a systematic review and meta-analysis

Li X, Li S, Yan S, Wang Y, Wang X, Sihoe ADL, Yang Y, Wu N

Cancer Management and Research 2019 , 11:1765-1777

Published Date: 20 February 2019

Cystic brain metastases had slower speed of tumor shrinkage but similar prognosis compared with solid tumors that underwent radiosurgery treatment

Wang H, Liu X, Jiang X, Song Y, Wang X, Wang J, Dong Y, Li F, Wu Z, Zhang Y, Yuan Z

Cancer Management and Research 2019 , 11:1753-1763

The prognostic value of Tiam1 correlates with its roles in epithelial–mesenchymal transition progression and angiogenesis in lung adenocarcinoma

Zhu G, Zhang Y, Wang Q, Che S, Yang Y, Chen L, Lin Z

Cancer Management and Research 2019 , 11:1741-1752

Promising diagnostic and prognostic value of E2Fs in human hepatocellular carcinoma

Huang Y, Ning G, Chen L, Lian Y, Gu Y, Wang J, Chen D, Wei H, Huang Y

Cancer Management and Research 2019 , 11:1725-1740

Published Date: 19 February 2019

C14orf159 suppresses gastric cancer cells’ invasion and proliferation by inactivating ERK signaling

Zhu YM, Li Q, Gao XZ, Meng X, Sun LL, Shi Y, Lu ET, Zhang Y

Cancer Management and Research 2019 , 11:1717-1723

Optimizing sequential treatment with anti-EGFR and VEGF mAb in metastatic colorectal cancer: current results and controversies

Chen DT, Gu KK, Wang HY

Cancer Management and Research 2019 , 11:1705-1716

Laparoscopic uncut Roux-en-Y for radical distal gastrectomy: the study protocol for a multirandomized controlled trial

Wang Q, Ni QR, Yang KL, Ji SQ, Fan Y, Wang C, Zhang WB, Yan S, Ma Q, Wei QY, Zhang D, Yu J, Ji G

Cancer Management and Research 2019 , 11:1697-1704

Forskolin exerts anticancer roles in non-Hodgkin’s lymphomas via regulating Axin/β-catenin signaling pathway

Cancer Management and Research 2019 , 11:1685-1696

Apoptotic and antimetastatic activities of betulin isolated from Quercus incana against non-small cell lung cancer cells

Zehra B, Ahmed A, Sarwar R, Khan A, Farooq U, Abid Ali S, Al-Harrasi A

Cancer Management and Research 2019 , 11:1667-1683

FGG promotes migration and invasion in hepatocellular carcinoma cells through activating epithelial to mesenchymal transition

Zhang X, Wang F, Huang Y, Ke K, Zhao B, Chen L, Liao N, Wang L, Li Q, Liu X, Wang Y, Liu J

Cancer Management and Research 2019 , 11:1653-1665

miR-140-5p alleviates the aggressive progression of Wilms’ tumor through directly targeting TGFBR1 gene

Cancer Management and Research 2019 , 11:1641-1651

Mismatch repair status and high expression of PD-L1 in nasopharyngeal carcinoma

Zhao L, Liao X, Hong G, Zhuang Y, Fu K, Chen P, Wang Y, Chen H, Lin Q

Cancer Management and Research 2019 , 11:1631-1640

Complete response associated with immune checkpoint inhibitors in advanced non-small-cell lung cancer: a meta-analysis of nine randomized controlled trials

Li J, He Q, Yu X, Khan K, Weng X, Guan M

Cancer Management and Research 2019 , 11:1623-1629

Published Date: 18 February 2019

Prognostic value of mean platelet volume to plateletcrit ratio in patients with osteosarcoma

Gou B, Cao H, Cheng XH, Shang W, Xu MQ, Qian W

Cancer Management and Research 2019 , 11:1615-1621

Protocadherin 17 is a tumor suppressor and is frequently methylated in nasopharyngeal carcinoma

He Y, Wang Z, Liu C, Gong Z, Li Y, Lu T, Hu G

Cancer Management and Research 2019 , 11:1601-1613

Comparison of analgesia, adverse effects, and quality of life in cancer patients during treatment of procedural pain with intravenous morphine, fentanyl nasal spray, and fentanyl buccal tablets

Piotrowska W, Leppert W, Majkowicz M

Cancer Management and Research 2019 , 11:1587-1600

Concomitant dose escalation with image–guided Tomotherapy in locally advanced mid–low rectal cancer: a single-center study

Zhao J, Liu X, Wang W, Hu K, Zhang F, Hou X, Meng Q

Cancer Management and Research 2019 , 11:1579-1586

Published Date: 15 February 2019

A tumor map generated from three-dimensional visualization of image fusion for the assessment of microwave ablation of hepatocellular carcinoma: a preliminary study

An C, Li X, Liang P, Yu J, Cheng Z, Han Z, Liu F, Dong L

Cancer Management and Research 2019 , 11:1569-1578

Identification of chromosomal abnormalities and genomic features in near-triploidy/tetraploidy-acute leukemia by fluorescence in situ hybridization

Yang R, Jiang M, Zhao J, Chen H, Gong J, You Y, Song L, Li Z, Li Q

Cancer Management and Research 2019 , 11:1559-1567

Safety and efficacy assessment of transarterial chemoembolization using drug-eluting beads in patients with hepatocellular carcinoma and arterioportal shunt: a single-center experience

Xiao YD, Ma C, Zhang ZS, Liu J

Cancer Management and Research 2019 , 11:1551-1557

Trametes robiniophila Murr: a traditional Chinese medicine with potent anti-tumor effects

Pan J, Yang C, Jiang Z, Huang J

Cancer Management and Research 2019 , 11:1541-1549

Published Date: 14 February 2019

A modified method for isolating human quiescent pancreatic stellate cells

Meng FT, Huang M, Fan FF, Shao F, Wang C, Huang Q

Cancer Management and Research 2019 , 11:1533-1539

Treatment-related adverse effects with TKIs in patients with advanced or radioiodine refractory differentiated thyroid carcinoma: a systematic review and meta-analysis

Yu S, Ge J, Luo J, Wei Z, Sun B, Lei S

Cancer Management and Research 2019 , 11:1525-1532

Polo-like kinase 3 is associated with poor prognosis and regulates proliferation and metastasis in prostate cancer

Lin C, Bai S, Du T, Lai Y, Chen X, Peng S, Ma X, Wu W, Guo Z, Huang H

Cancer Management and Research 2019 , 11:1517-1524

Significant prognostic values of aquaporin mRNA expression in breast cancer

Zhu L, Ma N, Wang B, Wang L, Zhou C, Yan Y, He J, Ren Y

Cancer Management and Research 2019 , 11:1503-1515

Early and sustained deep molecular response achieved with nilotinib in high Sokal risk chronic myeloid leukemia patients

Zaidi U, Kaleem B, Borhany M, Maqsood S, Fatima N, Sufaida G, Ansari SH, Farzana T, Shamsi TS

Cancer Management and Research 2019 , 11:1493-1502

The distinct clinicopathological and prognostic implications of PIK3CA mutations in breast cancer patients from Central China

Wu H, Wang W, Du J, Li H, Wang H, Huang L, Xiang H, Xie J, Liu X, Li H, Lin W

Cancer Management and Research 2019 , 11:1473-1492

P53-positive expression in dysplastic surgical margins is a predictor of tumor recurrence in patients with early oral squamous cell carcinoma

Yang XH, Ding L, Fu Y, Chen S, Zhang L, Zhang XX, Huang XF, Lu ZY, Ni YH, Hu QG

Cancer Management and Research 2019 , 11:1465-1472

Published Date: 13 February 2019

Relationship between bone mineral density and the risk of breast cancer: a systematic review and dose–response meta-analysis of ten cohort studies

Chen JH, Yuan Q, Ma YN, Zhen SH, Wen DL

Cancer Management and Research 2019 , 11:1453-1464

Non-tight junction-related function of claudin-7 in interacting with integrinβ1 to suppress colorectal cancer cell proliferation and migration

Li W, Xu C, Wang K, Ding Y, Ding L

Cancer Management and Research 2019 , 11:1443-1451

Comparison of the 7th and 8th edition of American Joint Committee on Cancer (AJCC) staging systems for breast cancer patients: a Surveillance, Epidemiology and End Results (SEER) Analysis

Shao N, Xie C, Shi Y, Ye R, Long J, Shi H, Shan Z, Thompson AM, Lin Y

Cancer Management and Research 2019 , 11:1433-1442

Preoperative fasting hyperglycemia is an independent prognostic factor for postoperative survival after gallbladder carcinoma radical surgery

Zheng P, Wang X, Hong Z, Shen F, Zhang Q

Cancer Management and Research 2019 , 11:1425-1432

Published Date: 12 February 2019

Circular RNA circHIPK3 promotes cell proliferation and invasion of prostate cancer by sponging miR-193a-3p and regulating MCL1 expression

Chen D, Lu X, Yang F, Xing N

Cancer Management and Research 2019 , 11:1415-1423

Preoperative aspartate aminotransferase-to-platelet-ratio index as a predictor of posthepatectomy liver failure for resectable hepatocellular carcinoma

Mai RY, Ye JZ, Long ZR, Shi XM, Bai T, Chen J, Li LQ, Wu GB, Wu FX

Cancer Management and Research 2019 , 11:1401-1414

The prognostic and predictive value of the combination of the neutrophil-to-lymphocyte ratio and the platelet-to-lymphocyte ratio in patients with hepatocellular carcinoma who receive transarterial chemoembolization therapy

He C, Zhang Y, Cai Z, Lin X

Cancer Management and Research 2019 , 11:1391-1400

DNA methylation-mediated Klotho silencing is an independent prognostic biomarker of head and neck squamous carcinoma

Zhu Y, Cao X, Zhang X, Chen Q, Wen L, Wang P

Cancer Management and Research 2019 , 11:1383-1390

Role of local treatment including radiotherapy in Barcelona Clinic of Liver Cancer stage C patients: a nationwide cohort analysis in South Korea

Lee J, Yoon WS, Koom WS, Rim CH

Cancer Management and Research 2019 , 11:1373-1382

Published Date: 11 February 2019

Efficacy of dose-adjusted EPOCH plus rituximab/R-CHOP regimens and the prognosis analysis in patients with MYC, BCL2/BCL6 gene copy number gain lymphoma and double-hit lymphoma: results from a single institution retrospective clinical study

Ma Q, Chang Y, Li L, Li X, Wang X, Wu J, Fu X, Sun Z, Yu H, Zhang X, Zhou Z, Nan F, Li Z, Liu X, Zhao Q, Li Y, Zhang L, Zhang M, Zhang L

Cancer Management and Research 2019 , 11:1363-1372

Activated Wnt signaling promotes growth and progression of AFP-producing gastric cancer in preclinical models

Chen D, Lin X, Zhang C, An G, Li Z, Dong B, Shen L, Gao J, Zhang X

Cancer Management and Research 2019 , 11:1349-1362

Claudin gene expression profiles and clinical value in colorectal tumors classified according to their molecular subtype

Cherradi S, Martineau P, Gongora C, Del Rio M

Cancer Management and Research 2019 , 11:1337-1348

Novel genetic alterations and their impact on target therapy response in head and neck squamous cell carcinoma

Jiang X, Ye J, Dong Z, Hu S, Xiao M

Cancer Management and Research 2019 , 11:1321-1336

Published Date: 8 February 2019

PTPN9 induces cell apoptosis by mitigating the activation of Stat3 and acts as a tumor suppressor in colorectal cancer

Wang D, Cheng Z, Zhao M, Jiao C, Meng Q, Pan H, Xie Y, Li L, Zhu Y, Wang W, Qu C, Liang D

Cancer Management and Research 2019 , 11:1309-1319

Long-term survival of patients with locally advanced esophageal squamous cell carcinoma receiving esophagectomy following neoadjuvant chemotherapy: a cohort study

Huang Z, Li S, Yang X, Lu F, Huang M, Zhang S, Xiong Y, Zhang P, Si J, Ma Y, Yang Y

Cancer Management and Research 2019 , 11:1299-1308

Real-world cost-effectiveness of targeted therapy in metastatic renal cell carcinoma in Sweden: a population-based retrospective analysis

Redig J, Dalén J, Harmenberg U, Lindskog M, Ljungberg B, Lundstam S, Sandin R, Wahlgren T, Åkerborg Ö, Jakobsson M

Cancer Management and Research 2019 , 11:1289-1297

Establishment and characterization of the GC-030-35 cell line derived from gastric hepatoid adenocarcinoma

Wei J, Xue Y, Huo X, Han R, Su X, Jin Y, Zhao W, Chen Y, Zhang H, Dai J, Chen J

Cancer Management and Research 2019 , 11:1275-1287

Overexpression of COL5A1 promotes tumor progression and metastasis and correlates with poor survival of patients with clear cell renal cell carcinoma

Feng G, Ma HM, Huang HB, Li YW, Zhang P, Huang JJ, Cheng L, Li GR

Cancer Management and Research 2019 , 11:1263-1274

Published Date: 7 February 2019

DNA methylation-mediated silencing of miR-204 is a potential prognostic marker for papillary thyroid carcinoma

Xia F, Wang W, Jiang B, Chen Y, Li X

Cancer Management and Research 2019 , 11:1249-1262

Pretreatment detection of circulating and tissue CD133+ CD44+ cancer stem cells as a prognostic factor affecting the outcomes in Egyptian patients with colorectal cancer

Zahran AM, Amal Rayan, Fakhry H, Attia AM, Ashmawy AM, Soliman A, Elkady A, Hetta HF

Cancer Management and Research 2019 , 11:1237-1248

Ultrasound-guided fine-needle aspiration biopsy of thyroid nodules <10 mm in the maximum diameter: does size matter?

Lyu Y, Shen F, Yan Y, Situ M, Wu W, Jiang G, Chen Y

Cancer Management and Research 2019 , 11:1231-1236

The Nrf2/HO-1 axis can be a prognostic factor in clear cell renal cell carcinoma

Deng Y, Wu Y, Zhao P, Weng W, Ye M, Sun H, Xu M, Wang C

Cancer Management and Research 2019 , 11:1221-1230

Loss of KCNJ15 expression promotes malignant phenotypes and correlates with poor prognosis in renal carcinoma

Liu Y, Wang H, Ni B, Zhang J, Li S, Huang Y, Cai Y, Mei H, Li Z

Cancer Management and Research 2019 , 11:1211-1220

Attenuated ZHX3 expression serves as a potential biomarker that predicts poor clinical outcomes in breast cancer patients

You Y, Ma Y, Wang Q, Ye Z, Deng Y, Bai F

Cancer Management and Research 2019 , 11:1199-1210

Published Date: 5 February 2019

Statin and metformin therapy in prostate cancer patients with hyperlipidemia who underwent radiotherapy: a population-based cohort study

Li K, Si-Tu J, Qiu J, Lu L, Mao Y, Zeng H, Chen M, Lai C, Chang HJ, Wang D

Cancer Management and Research 2019 , 11:1189-1197

Published Date: 4 February 2019

miR-600 inhibits lung cancer via downregulating the expression of METTL3

Wei W, Huo B, Shi X

Cancer Management and Research 2019 , 11:1177-1187

Published Date: 1 February 2019

Rhein shows potent efficacy against non-small-cell lung cancer through inhibiting the STAT3 pathway

Yang L, Li J, Xu L, Lin S, Xiang Y, Dai X, Liang G, Huang XY, Zhu J, Zhao C

Cancer Management and Research 2019 , 11:1167-1176

Carbon-ion radiotherapy in accelerated hypofractionated active raster-scanning technique for malignant lacrimal gland tumors: feasibility and safety

Akbaba S, Lang K, Held T, Herfarth K, Rieber J, Plinkert P, Auffarth GU, Rieken S, Debus J, Adeberg S

Cancer Management and Research 2019 , 11:1155-1166

Dexamethasone inhibits the proliferation of tumor cells

Wu Y, Xia R, Dai C, Yan S, Xie T, Liu B, Gan L, Zhuang Z, Huang Q

Cancer Management and Research 2019 , 11:1141-1154

Performance characteristics of prostate-specific antigen density and biopsy primary Gleason score to predict biochemical failure in patients with intermediate prostate cancer who underwent radical prostatectomy

Peng C, Zhang J, Hou JQ

Cancer Management and Research 2019 , 11:1133-1139

Modeling risk assessment for breast cancer in symptomatic women: a Saudi Arabian study

Ahmed AE, McClish DK, Thamer Alghamdi, Alshehri A, Aljahdali Y, Aburayah K, Almaymoni A, Albaijan M, Al-Jahdali H, Jazieh AR

Cancer Management and Research 2019 , 11:1125-1132

SERS-based detection of haptoglobin in ovarian cyst fluid as a point-of-care diagnostic assay for epithelial ovarian cancer

Perumal J, Mahyuddin AP, Balasundaram G, Goh D, Fu CY, Kazakeviciute A, Dinish US, Choolani M, Olivo M

Cancer Management and Research 2019 , 11:1115-1124

Published Date: 31 January 2019

Pathological risk factors for lymph node metastasis in patients with submucosal invasive colorectal carcinoma

Zhang Q, Wang L, Huang D, Xu M, Weng W, Ni S, Tan C, Sheng W

Cancer Management and Research 2019 , 11:1107-1114

Published Date: 30 January 2019

Postmastectomy radiotherapy using three different techniques: a retrospective evaluation of the incidental dose distribution in the internal mammary nodes

Wang W, Zhang Y, Xu M, Shao Q, Sun T, Yu T, Liu X, Li J

Cancer Management and Research 2019 , 11:1097-1106

Identifying the reasons for delayed presentation of Pakistani breast cancer patients at a tertiary care hospital

Gulzar F, Akhtar MS, Sadiq R, Bashir S, Jamil S, Baig SM

Cancer Management and Research 2019 , 11:1087-1096

Published Date: 29 January 2019

Oncologic outcome of parotid mucoepidermoid carcinoma in pediatric patients

Fang Q, Liu F, Seng D

Cancer Management and Research 2019 , 11:1081-1085

Expression and biological function of rhotekin in gastric cancer through regulating p53 pathway

Sun MY, Zhang H, Tao J, Ni ZH, Wu QX, Tang QF

Cancer Management and Research 2019 , 11:1069-1080

Published Date: 25 January 2019

Letter to the editor regarding the publication “Association between matrix-metalloproteinase polymorphisms and prostate cancer risk: a meta-analysis and systematic review”

Cancer Management and Research 2019 , 11:1067-1068

Published Date: 24 January 2019

Competing risk analysis of primary tracheal carcinoma based on SEER database

Gao HX, He X, Du JF, Yang SH, Wang Y, Zhang JW, Zhao CN

Cancer Management and Research 2019 , 11:1059-1065

Prognostic value of miR17-92 family in patients with digestive system cancers: a systematic review and meta-analysis

Zhang X, Zhang S, He Q, Gao X, Yang L, Xu P, Zhao R, Wang Q, Zhang L, Zhao P

Cancer Management and Research 2019 , 11:1043-1058

Published Date: 22 January 2019

Circular RNA hsa_circ_0072309 inhibits proliferation and invasion of breast cancer cells via targeting miR-492

Yan L, Zheng M, Wang H

Cancer Management and Research 2019 , 11:1033-1041

Synergistic cytotoxicity of homoharringtonine and etoposide in acute myeloid leukemia cells involves disrupted antioxidant defense

Zhang J, Geng H, Liu L, Zhang H

Cancer Management and Research 2019 , 11:1023-1032

Implementation of sorafenib treatment for advanced hepatocellular carcinoma: an illustration of current practice in Taiwan

Chan KM, Wu TH, Cheng CH, Lee CF, Wu TJ, Chou HS, Lee WC

Cancer Management and Research 2019 , 11:1013-1021

Clear cell adenocarcinoma of the lung: a population-based study

Ke SJ, Wang P, Xu B

Cancer Management and Research 2019 , 11:1003-1012

Clinical characteristics of extranodal NK/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis

Liu YZ, Bi LQ, Chang GL, Guo Y, Sun S

Cancer Management and Research 2019 , 11:997-1002

Published Date: 23 January 2019

Transcatheter arterial embolization combined with hypoxia-replicative oncolytic adenovirus perfusion enhances the therapeutic effect of hepatic carcinoma

Zhang H, Xiong F, Qian K, Liu Y, Liang B, Xiong B, Yang F, Zheng C

Cancer Management and Research 2019 , 11:981-996

Function of microRNA-145 and mechanisms underlying its role in malignant tumor diagnosis and treatment

Ye D, Shen ZS, Zhou SH

Cancer Management and Research 2019 , 11:969-979

Suppression of miR-21-3p enhances TRAIL-mediated apoptosis in liver cancer stem cells by suppressing PI3K/Akt/Bad cascade via regulating PTEN

Zhu Y, Tang H, Zhang L, Gong L, Wu G, Ni J, Tang X

Cancer Management and Research 2019 , 11:955-968

Trends in the incidence, treatment, and survival of patients with lung cancer in the last four decades

Lu T, Yang X, Huang Y, Zhao M, Li M, Ma K, Yin J, Zhan C, Wang Q

Cancer Management and Research 2019 , 11:943-953

Published Date: 21 January 2019

Lipase member H is a downstream molecular target of hypoxia inducible factor-1α and promotes papillary thyroid carcinoma cell migration in BCPAP and KTC-1 cell lines

Li Y, Zhou X, Zhang Q, Chen E, Sun Y, Ye D, Wang O, Zhang X, Lyu J

Cancer Management and Research 2019 , 11:931-941

Feasibility of computer-assisted diagnosis for breast ultrasound: the results of the diagnostic performance of S-detect from a single center in China

Zhao C, Xiao M, Jiang Y, Liu H, Wang M, Wang H, Sun Q, Zhu Q

Cancer Management and Research 2019 , 11:921-930

Systemic inflammation response index predicts prognosis in patients with clear cell renal cell carcinoma: a propensity score-matched analysis

Chen Z, Wang K, Lu H, Xue D, Fan M, Zhuang Q, Yin S, He X, Xu R

Cancer Management and Research 2019 , 11:909-919

Published Date: 18 January 2019

Outcomes of health-related quality of life after open, laparoscopic, or robot-assisted radical prostatectomy in China

Huang W, Zhang Y, Shen BH, Wang S, Meng HZ, Jin XD

Cancer Management and Research 2019 , 11:899-907

Integrated analysis of lncRNA-associated ceRNA network reveals potential biomarkers for the prognosis of hepatitis B virus-related hepatocellular carcinoma

Li H, Zhao X, Li C, Sheng C, Bai Z

Cancer Management and Research 2019 , 11:877-897

Published Date: 17 January 2019

The novel sugar transporter SLC50A1 as a potential serum-based diagnostic and prognostic biomarker for breast cancer

Wang Y, Shu Y, Gu C, Fan Y

Cancer Management and Research 2019 , 11:865-876

Clinicopathological and prognostic significance of CDH1 hypermethylation in hepatocellular carcinoma: a meta-analysis

Wu X, Yao X, Cao Q, Wu Z, Wang Z, Liu F, Shen L

Cancer Management and Research 2019 , 11:857-864

TMEFF1 overexpression and its mechanism for tumor promotion in ovarian cancer

Nie X, Liu C, Guo Q, Zheng M, Gao L, Li X, Liu D, Zhu L, Liu J, Lin B

Cancer Management and Research 2019 , 11:839-855

High-grade endometrial stromal sarcoma: a retrospective study of factors influencing prognosis

Zhang YY, Li Y, Qin M, Cai Y, Jin Y, Pan LY

Cancer Management and Research 2019 , 11:831-837

PUF60 accelerates the progression of breast cancer through down-regulation of PTEN expression

Sun D, Lei W, Hou X, Li H, Ni W

Cancer Management and Research 2019 , 11:821-830

Systemic immune-inflammation index and ultrasonographic classification of breast imaging-reporting and data system predict outcomes of triple-negative breast cancer

Wang P, Yue W, Li W, Luo Y, Li Z, Shao Y, He Z

Cancer Management and Research 2019 , 11:813-819

MNX1-AS1 is a functional oncogene that induces EMT and activates the AKT/mTOR pathway and MNX1 in breast cancer

Cheng Y, Pan Y, Pan Y, Wang O

Cancer Management and Research 2019 , 11:803-812

Outcome and prognostic factors following palliative craniospinal irradiation for leptomeningeal carcinomatosis

El Shafie RA, Böhm K, Weber D, Lang K, Schlaich F, Adeberg S, Paul A, Haefner MF, Katayama S, Sterzing F, Hörner-Rieber J, Löw S, Herfarth K, Debus J, Rieken S, Bernhardt D

Cancer Management and Research 2019 , 11:789-801

Dysregulation of ncRNAs located at the DLK1-DIO3 imprinted domain: involvement in urological cancers

Li J, Shen H, Xie H, Ying Y, Jin K, Yan H, Wang S, Xu M, Wang X, Xu X, Xie L

Cancer Management and Research 2019 , 11:777-787

Published Date: 15 January 2019

TINAGL1 promotes hepatocellular carcinogenesis through the activation of TGF-β signaling-medicated VEGF expression

Sun L, Dong Z, Gu H, Guo Z, Yu Z

Cancer Management and Research 2019 , 11:767-775

Determining the optimal cutoff point for lymph node density and its impact on overall survival in children with Wilms’ tumor

Pan Z, Bu Q, You H, Yang J, Liu Q, Lyu J

Cancer Management and Research 2019 , 11:759-766

Neoadjuvant chemoradiation for locally advanced rectal cancer: a systematic review of the literature with network meta-analysis

Chen M, Chen L, Xu L, Zhang J, Song X

Cancer Management and Research 2019 , 11:741-758

Comparative study of adjuvant chemotherapeutic efficacy of docetaxel plus cyclophosphamide and doxorubicin plus cyclophosphamide in female breast cancer

Adeel M, Asif M, Naeem Faisal M, Hasanain Chaudary M, Sheraz Malik M, Khalid M

Cancer Management and Research 2019 , 11:727-739

Aberrant CEACAM19 expression is associated with metastatic phenotype in penile cancer

Hu X, Chen M, Li Y, Wang Y, Wen S, Jun F

Cancer Management and Research 2019 , 11:715-725

Published Date: 14 January 2019

Type 2 diabetes mellitus increases the risk of hepatocellular carcinoma in subjects with chronic hepatitis B virus infection: a meta-analysis and systematic review

Tan Y, Wei S, Zhang W, Yang J, Yang J, Yan L

Cancer Management and Research 2019 , 11:705-713

A sample model established by S-index predicting overall survival after curative resection of primary hepatocellular carcinoma

Chen L, Cai BB, Zhou CJ, Hou XQ, Hu SP, Fang G, Chen WC, Li LH, Yang WJ

Cancer Management and Research 2019 , 11:693-703

Securidaca–saponins are natural inhibitors of AKT, MCL-1, and BCL2L1 in cervical cancer cells [Corrigendum]

Obasi TC, Braicu C, Iacob BC, Bodoki E, Jurj A, Raduly L, Oniga I, Berindan-Neagoe I, Oprean R

Cancer Management and Research 2019 , 11:691-692

Metformin induces apoptotic cytotoxicity depending on AMPK/PKA/GSK-3β-mediated c-FLIPL degradation in non-small cell lung cancer

Luo Z, Zhu T, Luo W, Lv Y, Zhang L, Wang C, Li M, Wu W, Shi S

Cancer Management and Research 2019 , 11:681-689

Published Date: 11 January 2019

Effect of bisphosphonates on local recurrence of giant cell tumor of bone: a meta-analysis

Shi M, Chen L, Wang Y, Wang W, Zhang Y, Yan S

Cancer Management and Research 2019 , 11:669-680

lncRNA WT1-AS inhibits the aggressiveness of cervical cancer cell via regulating p53 expression via sponging miR-330-5p

Cui LJ, Nai MM, Zhang K, Li L, Li RM

Cancer Management and Research 2019 , 11:651-667

MicroRNA-4458 suppresses migration and epithelial–mesenchymal transition via targeting HMGA1 in non-small-cell lung cancer cells

Ma Y, Li X, Chen S, Du B, Li Y

Cancer Management and Research 2019 , 11:637-649

Published Date: 10 January 2019

Peptidylarginine deiminase 4 overexpression resensitizes MCF-7/ADR breast cancer cells to adriamycin via GSK3β/p53 activation

Zhou Q, Song C, Liu X, Qin H, Miao L, Zhang X

Cancer Management and Research 2019 , 11:625-636

RETRACTED ARTICLE: Long noncoding RNA SNHG6 functions as a competing endogenous RNA by sponging miR-181a-5p to regulate E2F5 expression in colorectal cancer

Yu C, Sun J, Leng X, Yang J

Cancer Management and Research 2019 , 11:611-624

Genetic analysis of subsequent second primary malignant neoplasms in long-term pancreatic cancer survivors suggests new potential hereditary genetic alterations

Lovecek M, Janatova M, Skalicky P, Zemanek T, Havlik R, Ehrmann J, Strouhal O, Zemankova P, Lhotova K, Borecka M, Soukupova J, Svebisova H, Soucek P, Hlavac V, Kleibl Z, Neoral C, Melichar B, Mohelnikova-Duchonova B

Cancer Management and Research 2019 , 11:599-609

High prevalence of secondary bladder cancer in men on radiotherapy for prostate cancer: evidence from a meta-analysis

Zhao S, Xie Q, Yang R, Wang J, Zhang C, Luo L, Zhu Z, Liu Y, Li E, Zhao Z

Cancer Management and Research 2019 , 11:587-598

ATR activated by EB virus facilitates chemotherapy resistance to cisplatin or 5-fluorouracil in human nasopharyngeal carcinoma

Zhang B, Cui B, Du J, Shen X, Wang K, Chen J, Xiao L, Sun C, Li Y

Cancer Management and Research 2019 , 11:573-585

Published Date: 9 January 2019

Efficacy and safety of celecoxib on the incidence of recurrent colorectal adenomas: a systematic review and meta-analysis

Veettil SK, Nathisuwan S, Ching SM, Jinatongthai P, Lim KG, Kew ST, Chaiyakunapruk N

Cancer Management and Research 2019 , 11:561-571

Overexpression of Notch3 is associated with metastasis and poor prognosis in osteosarcoma patients

Tang XF, Cao Y, Peng DB, Zhao GS, Zeng Y, Gao ZR, Lv YF, Guo QN

Cancer Management and Research 2019 , 11:547-559

Published Date: 8 January 2019

Pathological nodal staging score for rectal cancer patients treated with radical surgery with or without neoadjuvant therapy: a postoperative decision tool

Dai W, Li Y, Wu Z, Feng Y, Cai S, Xu Y, Li Q, Cai G

Cancer Management and Research 2019 , 11:537-546

Published Date: 7 January 2019

FOXN2 is downregulated in breast cancer and regulates migration, invasion, and epithelial–mesenchymal transition through regulation of SLUG

Ye H, Duan M

Cancer Management and Research 2019 , 11:525-535

Published Date: 4 January 2019

Addressing physician barriers to administering cyclin-dependent kinases 4 and 6 inhibitors in first-line treatment of hormone receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer

Mahtani RL, Vogel CL

Cancer Management and Research 2019 , 11:513-524

Evolutionary role of chemotherapy in advanced nasopharyngeal carcinoma: a literature-based network meta-analysis

Li L, Liang W, Zhu JX, Dong CJ, Zou YM, Ye BC, Gao L

Cancer Management and Research 2019 , 11:501-512

Hedychium coronarium extract arrests cell cycle progression, induces apoptosis, and impairs migration and invasion in HeLa cervical cancer cells

Ray A, Jena S, Dash B, Sahoo A, Kar B, Patnaik J, Panda PC, Nayak S, Mahapatra N

Cancer Management and Research 2019 , 11:483-500

Published Date: 3 January 2019

Indoleamine 2,3-dioxygenase expression and overall survival in patients diagnosed with breast cancer in Pakistan

Asghar K, Loya A, Ali Rana I, Tahseen M, Ishaq M, Farooq A, Abu Bakar M, Masood I

Cancer Management and Research 2019 , 11:475-481

Mindfulness-based stress reduction in patients with differentiated thyroid cancer receiving radioactive iodine therapy: a randomized controlled trial

Liu T, Zhang W, Xiao S, Xu L, Wen Q, Bai L, Ma Q, Ji B

Cancer Management and Research 2019 , 11:467-474

NIMA-related kinase 2 overexpression is associated with poor survival in cancer patients: a systematic review and meta-analysis

Yao Y, Su J, Zhao L, Luo N, Long L, Zhu X

Cancer Management and Research 2019 , 11:455-465

A circular RNA hsa_circ_0079929 inhibits tumor growth in hepatocellular carcinoma

Zheng H, Chen T, Li C, Xu C, Ding C, Chen J, Ju S, Zhang Z, Liang Z, Cui Z, Zhao J

Cancer Management and Research 2019 , 11:443-454

A nomogram for endoscopic screening in a high esophageal squamous cell cancer risk area: results from a population-based study

Xing J, Min L, Zhang H, Li P, Li W, Lv F, Wang Y, Zhang Z, Li H, Guo Q, Wang S, Zhao Y, Wang J, Shi X, Zhu S, Ji M, Wu Y, Zhang S

Cancer Management and Research 2019 , 11:431-442

Identification of key genes and specific pathways potentially involved in androgen-independent, mitoxantrone-resistant prostate cancer

Zhu S, Jiang LL, Wang LY, Wang LL, Zhang C, Ma Y, Huang T

Cancer Management and Research 2019 , 11:419-430

Intraoperative monitoring of pelvic autonomic nerves during laparoscopic low anterior resection of rectal cancer

Zhou MW, Huang XY, Chen ZY, Li ZY, Zhou YM, Yang Y, Wang ZH, Xiang JB, Gu XD

Cancer Management and Research 2019 , 11:411-417

Published Date: 31 December 2018

Helical tomotherapy in patients with leptomeningeal metastases

Schiopu SRI, Habl G, Haefner M, Katayama S, Herfarth K, Debus J, Sterzing F

Cancer Management and Research 2019 , 11:401-409

RETRACTED ARTICLE: OCT4 accelerates tumorigenesis through activating JAK/STAT signaling in ovarian cancer side population cells

Ruan Z, Yang X, Cheng W

Cancer Management and Research 2019 , 11:389-399

Published Date: 28 December 2018

Biliary tract cancer: current challenges and future prospects

Ghidini M, Pizzo C, Botticelli A, Hahne JC, Passalacqua R, Tomasello G, Petrelli F

Cancer Management and Research 2019 , 11:379-388

IRF1 inhibits the proliferation and metastasis of colorectal cancer by suppressing the Ras-Rac1 pathway

Hong M, Zhang Z, Chen Q, Lu Y, Zhang J, Lin C, Zhang F, Zhang W, Li X, Zhang W, Li X

Cancer Management and Research 2019 , 11:369-378

Sequential therapy with bevacizumab and EGFR inhibitors for metastatic colorectal carcinoma: a national registry-based analysis

Buchler T, Chloupkova R, Poprach A, Fiala O, Kiss I, Kopeckova K, Dusek L, Veskrnova V, Slavicek L, Kohoutek M, Finek J, Svoboda M, Petruzelka L, Melichar B

Cancer Management and Research 2019 , 11:359-368

Robust analysis of novel mRNA–lncRNA cross talk based on ceRNA hypothesis uncovers carcinogenic mechanism and promotes diagnostic accuracy in esophageal cancer

Chen LP, Wang H, Zhang Y, Chen QX, Lin TS, Liu ZQ, Zhou YY

Cancer Management and Research 2019 , 11:347-358

Published Date: 27 December 2018

Surgery of primary tumor improves the survival of newly diagnosed metastatic melanoma: a population-based, propensity-matched study

Zhang D, Dong Y, Sun X, Yuan S, Yu J

Cancer Management and Research 2019 , 11:339-346

Identification of hub genes and outcome in colon cancer based on bioinformatics analysis

Yang W, Ma J, Zhou W, Li Z, Zhou X, Cao B, Zhang Y, Liu J, Yang Z, Zhang H, Zhao Q, Hong L, Fan D

Cancer Management and Research 2019 , 11:323-338

Long-term survival after percutaneous irreversible electroporation of inoperable colorectal liver metastases

Schicho A, Niessen C, Haimerl M, Wiesinger I, Stroszczynski C, Beyer LP, Wiggermann P

Cancer Management and Research 2019 , 11:317-322

Sex-related differences in urothelial cell carcinoma of the bladder in Germany

Scheller T, Hofmann R, Hegele A

Cancer Management and Research 2019 , 11:309-316

Switching to anastrozole plus goserelin vs continued tamoxifen for adjuvant therapy of premenopausal early-stage breast cancer: preliminary results from a randomized trial

Li J, Liu G, Ji Y, Yan X, Pang D, Jiang Z, Chen D, Zhang B, Xu B, Shao Z

Cancer Management and Research 2019 , 11:299-307

Polymorphisms in DNA repair pathway genes and ABCG2 gene in advanced colorectal cancer: correlation with tumor characteristics and clinical outcome in oxaliplatin-based chemotherapy

Hu X, Qin W, Li S, He M, Wang Y, Guan S, Zhao H, Yao W, Wei M, Liu M, Wu H

Cancer Management and Research 2019 , 11:285-297

Importance of gene expression signatures in pancreatic cancer prognosis and the establishment of a prediction model

Yan XK, Wan HF, Hao XY, Lan T, Li W, Xu L, Yuan KF, Wu H

Cancer Management and Research 2019 , 11:273-283

Higher plasma concentration of TP53-induced glycolysis and apoptosis regulator is associated with a lower risk of colorectal cancer metastasis

Lin L, Mi Y, Li X, Peng C, Shangguan Z, Li Z, Liu S

Cancer Management and Research 2019 , 11:263-272

Published Date: 24 December 2018

Overexpression of PDK4 is associated with cell proliferation, drug resistance and poor prognosis in ovarian cancer

Wang J, Qian Y, Gao M

Cancer Management and Research 2019 , 11:251-262

Prognostic value of the Glasgow prognostic score in colorectal cancer: a meta-analysis of 9,839 patients

Lu X, Guo W, Xu W, Zhang X, Shi Z, Zheng L, Zhao W

Cancer Management and Research 2019 , 11:229-249

Potential therapeutic value of primary tumor resection in ampullary cancer patients with distant metastases at initial diagnosis: a population-based study

Wang J, Bo X, Lu P, Suo T, Ni X, Liu H, Pan H, Shen S, Li M, Zhang D, Wang Y, Liu HB

Cancer Management and Research 2019 , 11:217-228

MARCH5 overexpression contributes to tumor growth and metastasis and associates with poor survival in breast cancer

Tang H, Peng S, Dong Y, Yang X, Yang P, Yang L, Yang B, Bao G

Cancer Management and Research 2019 , 11:201-215

Association of markers of systemic and local inflammation with prognosis of patients with rectal cancer who received neoadjuvant radiotherapy

Zhang X, Li J, Peng Q, Huang Y, Tang L, Zhuang Q, Lin F, Lin X, Du K, Wu J

Cancer Management and Research 2019 , 11:191-199

Transcriptomic analyses identify key differentially expressed genes and clinical outcomes between triple-negative and non-triple-negative breast cancer

Chen B, Tang H, Chen X, Zhang G, Wang Y, Xie X, Liao N

Cancer Management and Research 2019 , 11:179-190

Published Date: 21 December 2018

Radiation-induced skin reactions: mechanism and treatment

Wei J, Meng L, Hou X, Qu C, Wang B, Xin Y, Jiang X

Cancer Management and Research 2019 , 11:167-177

Incidences and oncological outcomes of urothelial carcinoma in kidney transplant recipients

Yu J, Lee CU, Kang M, Jeon HG, Jeong BC, Seo SI, Jeon SS, Lee HM, Sung HH

Cancer Management and Research 2019 , 11:157-166

Knockdown of nucleophosmin 1 suppresses proliferation of triple-negative breast cancer cells through activating CDH1/Skp2/p27kip1 pathway

Zeng D, Xiao YS, Zhu JL, Peng CY, Liang WQ, Lin HY

Cancer Management and Research 2019 , 11:143-156

A six-mRNA prognostic model to predict survival in head and neck squamous cell carcinoma

Tian S, Meng G, Zhang W

Cancer Management and Research 2019 , 11:131-142

Published Date: 20 December 2018

Evidence mapping and quality assessment of systematic reviews on therapeutic interventions for oral cancer

Madera Anaya M, Franco JVA, Ballesteros M, Solà I, Urrútia Cuchí G, Bonfill Cosp X

Cancer Management and Research 2019 , 11:117-130

Importance of avoiding surgery delays after initial discovery of suspected non-small-cell lung cancer in clinical stage IA patients

Kuroda H, Sugita Y, Ohya Y, Yoshida T, Arimura T, Sakakura N, Hida T, Yatabe Y, Sakao Y

Cancer Management and Research 2019 , 11:107-115

Deguelin induces apoptosis in colorectal cancer cells by activating the p38 MAPK pathway

Chen L, Jiang K, Chen H, Tang Y, Zhou X, Tan Y, Yuan Y, Xiao Q, Ding K

Cancer Management and Research 2019 , 11:95-105

Chronic cadmium exposure aggravates malignant phenotypes of nasopharyngeal carcinoma by activating the Wnt/β-catenin signaling pathway via hypermethylation of the casein kinase 1α promoter

Peng L, Huang YT, Zhang F, Chen JY, Huo X

Cancer Management and Research 2019 , 11:81-93

Published Date: 19 December 2018

Aspartate aminotransferase-to-platelet ratio index predicts prognosis of hepatocellular carcinoma after postoperative adjuvant transarterial chemoembolization

Zhu GQ, Wang K, Wang B, Zhou YJ, Yang Y, Chen EB, Zhou ZJ, Zhou SL, Shi YH, Zhou J, Dai Z

Cancer Management and Research 2019 , 11:63-79

Pristimerin protects against doxorubicin-induced cardiotoxicity and fibrosis through modulation of Nrf2 and MAPK/NF-kB signaling pathways

El-Agamy DS, El-Harbi KM, Khoshhal S, Ahmed N, Elkablawy MA, Shaaban AA, Abo-Haded HM

Cancer Management and Research 2019 , 11:47-61

The history of cancer pain and bone-targeted agents: 10 most commonly asked questions

Vieira CMP, Fragoso M, Ferreira M, Pereira FF, Pereira D, Medeiros R

Cancer Management and Research 2019 , 11:37-46

Published Date: 18 December 2018

Low periostin expression predicts poor survival in intestinal type gastric cancer patients

Zhang T, Han Z, Chandoo A, Huang X, Sun X, Ye L, Hu C, Xue X, Huang Y, Shen X, Chang W, Lin X

Cancer Management and Research 2019 , 11:25-36

miR-29a-3p inhibits growth, proliferation, and invasion of papillary thyroid carcinoma by suppressing NF-κB signaling via direct targeting of OTUB2

Ma Y, Sun Y

Cancer Management and Research 2019 , 11:13-23

Published Date: 17 December 2018

The construction and analysis of ceRNA networks in invasive breast cancer: a study based on The Cancer Genome Atlas

Gao C, Li H, Zhuang J, Zhang H, Wang K, Yang J, Liu C, Liu L, Zhou C, Sun C

Cancer Management and Research 2019 , 11:1-11

Contact Us • Privacy Policy • Associations & Partners • Testimonials • Terms & Conditions • Recommend this site • Cookies • Top

IMAGES

An Overview of Cancer Research
Cancer Management and Research
Cancer Management and Research
Institute of Cancer Research
Cancer Management and Research
Cancer Management and Research

COMMENTS

Cancer Management and Research
An open access journal publishing original research and reviews on cancer prevention, diagnosis, treatment and quality of life. Find articles on various types of cancer, prognostic models, biomarkers, imaging and more.
Cancer Management and Research
Cancer Management and Research is an international, peer reviewed, open access journal focusing on cancer research and the optimal use of preventative and integrated treatment interventions to achieve improved outcomes, enhanced survival, and quality of life for cancer patients. Cancer Management and Research will no longer consider meta ...
Cancer Management and Research Aims & Scope
Cancer Management and Research is an international, peer reviewed, open access journal focusing on cancer research and the optimal use of preventative and integrated treatment interventions to achieve improved outcomes, enhanced survival, and quality of life for cancer patients. Cancer Management and Research will no longer consider meta ...
Cancer Management and Research: Vol 13, No
Cancer Management and Research, Volume 13, Issue (2021) See all volumes and issues. Vol 16, 2024 Vol 15, 2023 Vol 14, 2022 Volume 13, 2021 Vol 12, 2020 Vol 11, 2019 Vol 10, 2018 Vol 9, 2017 Vol 8, 2016 Vol 7, 2015 Vol 6, 2014 Vol 5, 2013 Vol 4, 2012 Vol 3, 2011 Vol 2, 2010 Vol 1, 2009. Select to download all citations or PDFs.
Cancer Treatment Research
New research suggests that fungi in the gut may affect how tumors respond to cancer treatments. In mice, when bacteria were eliminated with antibiotics, fungi filled the void and impaired the immune response after radiation therapy, the study found. FDA Approves Belumosudil to Treat Chronic Graft-Versus-Host Disease.
Cancer Management and Research
A peer-reviewed journal that publishes original research, reviews, and case reports on various aspects of cancer management and research. Browse the latest articles on topics such as breast cancer, lung cancer, colorectal cancer, and more.
New approaches and procedures for cancer treatment: Current
Cancer is a global health problem responsible for one in six deaths worldwide. Treating cancer has been a highly complex process. Conventional treatment approaches, such as surgery, chemotherapy, and radiotherapy, have been in use, while significant advances are being made in recent times, including stem cell therapy, targeted therapy, ablation therapy, nanoparticles, natural antioxidants ...
Cancer Management and Research
An international, peer-reviewed, open access journal focusing on cancer research and the optimal use of preventative and integrated treatment interventions to achieve improved outcomes, enhanced survival and quality of life for the cancer patient. ... Cancer Management and Research 2023, 15:1271-1281 . Published Date: 11 November 2023.
Medical Xpress
An open access journal focusing on cancer research and treatment interventions. Find the latest news and articles on various topics related to oncology and cancer, such as depression, survival, surgery, and immune system.
The National Cancer Institute's Center For Cancer Research
Clinical Trials. Our highly trained physicians offer clinical trials for patients with cancer, HIV or immunodeficiency disorders. All trials take place at the NIH Clinical Center in Bethesda, MD, and through telehealth. Once you are enrolled in a clinical trial at the Clinical Center, medical care is free.
Cancer Management and Research
Cancer Management and Research is an international, peer reviewed, open access journal focusing on cancer research and the optimal use of preventative and integrated treatment interventions to ...
Cancer Management and Research
A peer-reviewed journal in epidemiology, cancer, anticancer agents, cancer screening and palliative care. It publishes original research articles, reviews, case reports and letters online and charges article processing fees.
Cancer and Oncology Research
Collaborative oncology research endeavors aim to alleviate this global burden, offering hope through treatment breakthroughs and advancements in assessment and screening. This freely available research explores diverse treatment methods, therapeutic breakthroughs, cancer management strategies, and more.
Nanocarrier-based immunotherapy in cancer management and research
This review covers cancer immunotherapy, with special focus on the nanocarrier system-based targeted approach for cancer. It is divided into two sections, ie, prophylaxis and therapeutic immunotherapy. A detailed analysis of a number of studies, with respect to underlying principles of immunology, is provided.
Cancer Management and Research
Cancer Management and Research is an international, peer reviewed, open access journal focusing on cancer research and the optimal use of preventative and integrated treatment interventions to achieve improved outcomes, enhanced survival, and quality of life for cancer patients. Specific topics covered in the journal include: Epidemiology ...
Cancer Management and Research: Vol 16, No (Current issue)
Cancer Management and Research, Volume 16, Issue (2024) See all volumes and issues. Volume 16, 2024 Vol 15, 2023 Vol 14, 2022 Vol 13, 2021 Vol 12, 2020 Vol 11, 2019 Vol 10, 2018 Vol 9, 2017 Vol 8, 2016 Vol 7, 2015 Vol 6, 2014 Vol 5, 2013 Vol 4, 2012 Vol 3, 2011 Vol 2, 2010 Vol 1, 2009. Download citations Download PDFs.
Management of Treatment-Related Infectious Complications in High-Risk
The most important is the electronic Symptom Management using the Advanced Symptom Management System (ASyMS) Remote Technology (eSMART; NCT02356081), an international, randomized controlled trial that evaluated the use of mobile phone technology to manage chemotherapy-related toxicities in people with breast cancer, colorectal cancer, Hodgkin ...
Why do patients with cancer die?
The phrase 'metastasis accounts for 90% of cancer deaths' is one of the most widely used in cancer research, yet it is overly simplistic, imprecise and it is difficult to find any primary ...
Cancer Management and Research
Cancer Management and Research 2023-11-10. Axicabtagene Ciloleucel in the Management of Follicular Lymphoma: Current Perspectives on Clinical Utility, Patient Selection and Reported O. Cancer Management and Research 2023-04-25. Ad. 0.0071930885314941. The Observatory of International Research. Home
Study reveals new opportunities to develop cancer treatments
Study reveals new opportunities to develop cancer treatments. Date: June 24, 2024. Source: Baylor College of Medicine. Summary: Researchers uncovered new potential therapeutic targets for cancer ...
Progress against cancer has been remarkable, but more needs to be done
Government support has been crucial to the progress against cancer, but the cancer community worries Congress won't continue to generously fund scientific research. From 2010 to 2019, federal ...
Archive of "Cancer Management and Research".
Cancer Management and ResearchVols. 1 to 16; 2009 to 2024. Articles from Cancer Management and Research are provided here courtesy of Dove Press.
Cancer Management and Research
An international, peer-reviewed, open access journal focusing on cancer research and the optimal use of preventative and integrated treatment interventions to achieve improved outcomes, enhanced survival and quality of life for the cancer patient. ... Cancer Management and Research 2024, 16:639-640 . Published Date: 19 June 2024.
Multidisciplinary patient‐centered approach to the management of skin
In recent years, new approaches for optimal patient management of cancer have focused on patient-centered care, with integration of tumour-directed treatment and patient-directed supportive and palliative care throughout the disease journey from prevention through screening, diagnosis, treatment, and follow-up.
Cancer Management and Research
An international, peer-reviewed, open access journal focusing on cancer research and the optimal use of preventative and integrated treatment interventions to achieve improved outcomes, enhanced survival and quality of life for the cancer patient. ... Cancer Management and Research 2012, 4:431-445 . Published Date: 18 December 2012.
Cancers
Pancreatic cancer, with its alarming rising incidence, is predicted to become the second deadliest type of solid tumor by 2040, highlighting the urgent need for improved diagnostic and treatment strategies. Despite medical advancements, the five-year survival rate for pancreatic cancer remains about 14%, dropping further when metastasized. This review explores the promise of biomarkers for ...
Why are gastrointestinal cancer patients getting younger?
Research is ongoing to understand the causes and inform prevention and management of these young patients, as a dedicated session at the ESMO Gastrointestinal Cancers Congress 2024 shows. Emerging data on the features and outcomes of early-onset disease lead us to a differentiated view of the phenomenon across different tumour types.
Cancer Management and Research
Associate Editor in Chief. Professor Singh. Department of Pathology, Mitchell Cancer Institute, University of South Alabama, Mobile, AL, USA. Professor Singh's primary research expertise is in the field of breast cancer, pancreatic cancer and melanoma. Specifically, her lab is interested in understanding the biological connection of ...
Beyond Weight Management: 5 Other Potential Benefits of ...
For the study, researchers compared cancer diagnoses within 15 years of starting semaglutide and other diabetes treatments, including metformin and insulin, in more than 1.2 million people.
Cancer Management and Research
An international, peer-reviewed, open access journal focusing on cancer research and the optimal use of preventative and integrated treatment interventions to achieve improved outcomes, enhanced survival and quality of life for the cancer patient. ... Cancer Management and Research 2019, 11:10463-10476 . Published Date: 13 December 2019.

Treatment Research

Cancer Management and Research

High levels of depression found among Canadian older adults with cancer during the COVID-19 pandemic

Nomogram may help predict survival in primary intestinal non-Hodgkin lymphoma

Ovarian cancer surgery outcomes studied

Researchers make breakthrough on immune system and brain tumors

E-mail newsletter

The Directory of Open Access Journals

Publishing with this journal

Best practice

Journal metadata

WeChat QR code

Cancer Management and Research

Subject Area and Category

Publication type

Leave a comment

Why do patients with cancer die?

Access options

Similar content being viewed by others

The changing landscape of cancer in the USA — opportunities for advancing prevention and treatment

Causes of death among people living with metastatic cancer

Deceptive measures of progress in the NHS long-term plan for cancer: case-based vs. population-based measures

Acknowledgements

Author information

Authors and Affiliations

Contributions

Corresponding authors

Ethics declarations

Peer review

Additional information

Rights and permissions

About this article

Share this article

This article is cited by

Quick links

Cancer Management and Research

Cancer treatment has come far, fast: Better prevention, early detection, new treatment

Using the immune system to fight cancer

Persistent challenges

Cancer Moonshot

Funding request

Information

Initiatives

Article Menu

JSmol Viewer

Simple Summary

2.4. Future Perspectives in Precision Medicine

Share and Cite

Article Metrics

Why are gastrointestinal cancer patients getting younger?

Related content

Beyond Weight Management: 5 Other Potential Benefits of Semaglutide

Colorectal Cancer

Pancreatitis

Substance Addiction

Polycystic Ovary Syndrome

The Downsides

Related Articles

Cancer Management and Research

Archive: Volume 11, 2019

Deficient Regulatory Innate Lymphoid Cells and Differential Expression of miRNAs in Acute Myeloid Leukemia Quantified by Next Generation Sequence

circPCNX and Pecanex Promote Hepatocellular Carcinoma Cell Viability by Inhibiting miR-506

Time-Varying Effects of Marital Status on Gastric Cancer: A Population-Based Study

Circulating Tumor Cell Detection In Epithelial Ovarian Cancer Using Dual-Component Antibodies Targeting EpCAM And FRα

Pre/Post-Treatment Dynamic of Inflammatory Markers Has Prognostic Value in Patients with Small Hepatocellular Carcinoma Managed by Stereotactic Body Radiation Therapy

New Preoperative Nomogram Using the Centrality Index to Predict High Nuclear Grade Clear Cell Renal Carcinoma

Survival After Abdominal Q-M Type B versus C2 Radical Hysterectomy for Early-Stage Cervical Cancer

Radiotherapy for patients with completely resected pathologic IIIA(N2) non–small-cell lung cancer: a retrospective analysis

MiR-935 Promotes Clear Cell Renal Cell Carcinoma Migration and Invasion by Targeting IREB2

Silencing of Peroxiredoxin 1 Inhibits the Proliferation of Esophageal Cancer Cells and Promotes Apoptosis by Inhibiting the Activity of the PI3K/AKT Pathway

The Significance of Adjuvant Therapy for Extrahepatic Cholangiocarcinoma After Surgery

Long Intergenic Non-Coding RNA 01121 Promotes Breast Cancer Cell Proliferation, Migration, and Invasion via the miR-150-5p/HMGA2 Axis

Application of Radiomics for Personalized Treatment of Cancer Patients

LncRNA PCAT-1 Promoted ESCC Progression via Regulating ANXA10 Expression by Sponging miR-508-3p

Development and Validation of Nomograms for Predicting the Prognosis of Triple-Negative Breast Cancer Patients Based on 379 Chinese Patients

Potential Antiangiogenic Treatment Eligibility of Patients with Squamous Non-Small–Cell Lung Cancer: EPISQUAMAB Study (GFPC 2015-01)

Long Non-Coding RNA LINC00511 Mediates the Effects of ESR1 on Proliferation and Invasion of Ovarian Cancer Through miR-424-5p and miR-370-5p

A Case with Rectal Cancer Relapses After Clinical Complete Remission Following Neoadjuvant Chemoradiotherapy

Increased Stromal Infiltrating Lymphocytes are Associated with Circulating Tumor Cells and Metastatic Relapse in Breast Cancer Patients After Neoadjuvant Chemotherapy

Beyond Ruxolitinib: Fedratinib and Other Emergent Treatment Options for Myelofibrosis